0001683168-24-001818.txt : 20240328 0001683168-24-001818.hdr.sgml : 20240328 20240328160540 ACCESSION NUMBER: 0001683168-24-001818 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 24798799 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 332-216-1147 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-K 1 sunshine_i10k-123123.htm FORM 10-K FOR FYE END DEC 2023 SUNSHINE BIOPHARMA, INC. 10-K
false 2023 FY 0001402328 0001402328 2023-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001402328 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001402328 2023-06-30 0001402328 2024-03-28 0001402328 2023-12-31 0001402328 2022-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001402328 2022-01-01 2022-12-31 0001402328 2021-12-31 0001402328 us-gaap:CommonStockMember 2021-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001402328 us-gaap:PreferredStockMember 2021-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2021-12-31 0001402328 us-gaap:RetainedEarningsMember 2021-12-31 0001402328 us-gaap:CommonStockMember 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001402328 us-gaap:PreferredStockMember 2022-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2022-12-31 0001402328 us-gaap:RetainedEarningsMember 2022-12-31 0001402328 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001402328 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2022-01-01 2022-12-31 0001402328 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001402328 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2023-01-01 2023-12-31 0001402328 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001402328 us-gaap:PreferredStockMember 2023-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2023-12-31 0001402328 us-gaap:RetainedEarningsMember 2023-12-31 0001402328 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember SBFM:GenericPharmaceuticalsMember 2023-01-01 2023-12-31 0001402328 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember SBFM:OTCProductsMember 2023-01-01 2023-12-31 0001402328 us-gaap:OfficeEquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:ComputerEquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:EquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:VehiclesMember 2023-01-01 2023-12-31 0001402328 SBFM:LicensesMember 2023-01-01 2023-12-31 0001402328 SBFM:WebsiteMember 2023-01-01 2023-12-31 0001402328 SBFM:NoraPharmaMember 2022-10-19 2022-10-20 0001402328 SBFM:NoraPharmaMember SBFM:MalekChamounMember 2022-10-20 0001402328 SBFM:NoraPharmaMember SBFM:MalekChamounMember 2023-01-01 2023-12-31 0001402328 SBFM:NoraPharmaMember SBFM:MalekChamounMember 2023-12-31 0001402328 SBFM:NoraPharmaMember 2022-10-20 0001402328 us-gaap:EquipmentMember 2023-12-31 0001402328 us-gaap:EquipmentMember 2022-12-31 0001402328 us-gaap:ComputerEquipmentMember 2023-12-31 0001402328 us-gaap:ComputerEquipmentMember 2022-12-31 0001402328 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001402328 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001402328 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001402328 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001402328 us-gaap:VehiclesMember 2023-12-31 0001402328 us-gaap:VehiclesMember 2022-12-31 0001402328 SBFM:FirstReverseStockSplitMember 2022-02-08 2022-02-09 0001402328 srt:DirectorMember 2023-12-31 0001402328 us-gaap:SeriesBPreferredStockMember srt:ChiefExecutiveOfficerMember 2023-12-31 0001402328 SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 us-gaap:CommonStockMember SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 SBFM:TradeableWarrantsMember SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-21 2022-02-22 0001402328 SBFM:TradeableWarrantsMember SBFM:PublicOfferingMember 2022-02-22 0001402328 us-gaap:PrivatePlacementMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember SBFM:CommonStockMemberAndInvestorWarrantsMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-04-27 2022-04-28 0001402328 us-gaap:PrivatePlacementMember SBFM:CommonStockMemberAndAprilWarrantsMember 2022-04-27 2022-04-28 0001402328 SBFM:NoraPharmaIncMember 2022-10-19 2022-10-20 0001402328 2023-01-19 0001402328 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001402328 SBFM:SingleInstitutionalInvestorMember 2023-05-15 2023-05-16 0001402328 SBFM:SingleInstitutionalInvestorMember us-gaap:CommonStockMember 2023-05-15 2023-05-16 0001402328 SBFM:SingleInstitutionalInvestorMember SBFM:MayPreFundedWarrantsMember 2023-05-15 2023-05-16 0001402328 SBFM:SingleInstitutionalInvestorMember SBFM:MayInvestorWarrantsMember 2023-05-15 2023-05-16 0001402328 SBFM:WarrantsExercisedMember 2022-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-07-01 2023-07-31 0001402328 SBFM:ExerciseOfMayPreFundedWarrantsMember 2023-11-15 2023-11-16 0001402328 SBFM:MayPreFundedWarrantsMember 2023-11-15 2023-11-16 0001402328 SBFM:MayPreFundedWarrantsMember 2023-11-16 0001402328 SBFM:PreFundedWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:PreFundedWarrantsMember 2023-12-31 0001402328 SBFM:TradeableWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:TradeableWarrantsMember 2023-12-31 0001402328 SBFM:InvestorWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:InvestorWarrantsMember 2023-12-31 0001402328 SBFM:AprilWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:AprilWarrantsMember 2023-12-31 0001402328 SBFM:MayPreFundedWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:MayPreFundedWarrantsMember 2023-12-31 0001402328 SBFM:MayInvestorWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:MayInvestorWarrantsMember 2023-12-31 0001402328 SBFM:AllWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:TradeableWarrantMember 2023-12-31 0001402328 SBFM:AdvanomicsCorporationMember 2023-01-01 2023-12-31 0001402328 SBFM:AdvanomicsCorporationMember 2022-01-01 2022-12-31 0001402328 2023-10-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CAD

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

(Mark one)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from            to           

 

Commission File Number 001-41282

 

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   20-5566275
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

1177 Avenue of the Americas

5th Floor

New York, NY 10036

(Address of principal executive offices)

 

(332) 216-1147

(Registrant’s Telephone Number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:   None

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered

Common Stock, par value $0.001

Warrants

  

SBFM

SBFMW

  

Nasdaq Capital Market

Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

None.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐   No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold on June 30, 2023 was $10,708,072.

 

As of March 28, 2024, the Registrant had 99,452,865 shares of common stock, par value $0.001 issued and outstanding.

 

Documents Incorporated by reference: None

 

   

 

 

TABLE OF CONTENTS

 

  Page
Defined Terms i
Forward Looking Statements ii
   
PART I 1
Item 1. Business 1
Item 1A. Risk Factors 7
Item 1B. Unresolved Staff Comments 17
Item 1C. Cybersecurity 17
Item 2. Properties 17
Item 3. Legal Proceedings 17
Item 4. Mine Safety Disclosures 17
     
PART II 18
Item 5. Market for the Registrant’s Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities 18
Item 6. Reserved. 18
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 21
Item 8. Financial Statements and Supplementary Data 22
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 41
Item 9A. Controls and Procedures 41
Item 9B. Other Information 41
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 41
     
PART III 42
Item 10. Directors, Executive Officers and Corporate Governance 42
Item 11. Executive Compensation 45
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 46
Item 13. Certain Relationships and Related Transactions, and Director Independence 48
Item 14. Principal Accounting Fees and Services 48
     
PART IV 49
Item 15. Exhibits, Financial Statement Schedules 50
     
Signatures 51

  

 

   

 

 

DEFINED TERMS

 

Unless the context requires otherwise, references to “Sunshine,” “the Company,” “we,” “us” or “our” in this Form 10-K refer to Sunshine Biopharma, Inc. and its subsidiaries. The following are definitions for terms or abbreviations used in this Form 10-K:

 

Adva-27a The laboratory designation of the Company’s chemotherapy small molecule under development
ASC Accounting Standards Codification
ASU Accounting Standards Update issued by FASB
CAD Canadian Dollar
COSO Committee of Sponsoring Organizations of the Treadway Commission
COVID-19 Novel coronavirus disease of 2019
DIN Drug Identification Number, an eight-digit number issued by Health Canada authorizing the sale of a drug in Canada
EPS Earnings per share
EUA Emergency Use Authorization
FASB Financial Accounting Standards Board
FDA U.S. Food and Drug Administration

FDIC

Federal Deposit Insurance Corporation

FTC Federal Trade Commission
G&A General and administrative

GAAP

Generally Accepted Accounting Principles

GMP Good Manufacturing Practice
GST Goods and Services Tax (Canada)
Health Canada The Canadian drug regulatory body
IND Investigational New Drug
IT Information Technology
LNP Lipid Nano Particle
K1.1 mRNA The laboratory designation of the Company’s mRNA based anticancer therapy under development
MD&A Management’s Discussion and Analysis of Financial Condition and Results of Operations
MERS-CoV Middle East Respiratory Syndrome Coronavirus
Mpro Coronavirus main protease
mRNA Messenger ribonucleic acid
NDA New Drug Application
NOC A Notice of Compliance issued by Health Canada to a drug manufacturing facility
Nora Pharma Nora Pharma Inc., a wholly-owned subsidiary of the Company acquired on October 20, 2022
NPN Natural Product Number, an eight-digit number issued by Health Canada authorizing the sale of a natural product or a supplement in Canada
OTC Over-The-Counter
pCPA pan-Canadian Pharmaceutical Alliance, an alliance of the provincial, territorial and federal governments that determines generic drugs pricing based on a percentage of the brand-name reference products

PCT

Patent Cooperation Treaty

PLpro Coronavirus papain-like protease
QST Quebec Sales Tax (Canada)
R&D Research and Development
ROU Right of Use
SARS Coronavirus Severe Acute Respiratory Syndrome Coronavirus, the group of coronaviruses that includes SARS-CoV-2, MERS-CoV, and SARS-CoV
SARS-CoV Severe Acute Respiratory Syndrome Coronavirus that first appeared in 2003
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2, the virus that causes COVID-19
SBFM-PL4 Laboratory designation of the Company’s COVID-19 treatment under development
SEC U.S. Securities and Exchange Commission
SOC Security Operations Center
street name Securities held in the name of a brokerage firm on behalf of a client
Sunshine Canada Sunshine Biopharma Canada Inc., a wholly owned subsidiary of the Company
U.S. United States of America
USD U.S. Dollars. All applicable references in this report refer to US Dollars and not Canadian Dollars (CAD) unless otherwise specifically stated.

 

 

 i 

 

 

FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine Biopharma Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.

 

Important factors known to us that could cause such material differences are identified in this Report. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

 

 

 

 

 ii 

 

 

PART I

 

ITEM 1. BUSINESS

 

About Sunshine Biopharma

 

We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We operate two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio consisting of 52 prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells OTC supplements.

 

In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. Development of the latter has been paused pending further analysis of unfavorable in vitro results obtained in the second half of 2023. See “Drugs in Development,” below.

 

History

 

We were incorporated in the State of Colorado on August 31, 2006, and on October 15, 2009, we acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, we changed our name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug. In December 2015, we acquired all worldwide issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound and terminated the License Agreement. Development of Adva-27a has been paused pending further analysis of unexpected in vitro results obtained in the latter part of 2023. See “Drugs in Development,” below.

 

In early 2020, we initiated a new R&D project focused on the development of a treatment for COVID-19 and on May 22, 2020, we filed a provisional patent application in the United States for the new coronavirus treatment. The patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro. On April 30, 2021, we filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro.

 

In June 2021, we initiated another R&D project in which we set out to determine if certain mRNA molecules can be used as anticancer agents. The data obtained for mRNA molecules bearing the laboratory name K1.1 became the subject of a new patent application filed in April 2022.

 

On October 20, 2022, we acquired Nora Pharma Inc. (“Nora Pharma”), a Canadian generic pharmaceuticals company based in the greater Montreal area. Nora Pharma has 44 employees and operates in a 23,500 square foot facility certified by Health Canada. Nora Pharma currently has 52 generic prescription drugs on the market in Canada.

 

 

 

 1 

 

 

Products on the Market

 

Through Nora Pharma we currently have the following generic prescription drugs on the market in Canada:

 

Drug   Action/Indication   Reference Brand
Alendronate   Osteoporosis   Fosamax®
Amlodipine   Cardiovascular   Norvasc®
Apixaban   Cardiovascular   Eliquis®
Aripiprazole   Antipsychotic   Abilify®
Atorvastatin   Cardiovascular   Lipitor®
Azithromycin   Antibacterial   Zithromax®
Candesartan   Hypertension   Atacand®
Candesartan HCTZ   Hypertension   Atacand Plus®
Celecoxib   Anti-inflammatory   Celebrex®
Cetirizine   Allergy   Reactine®
Ciprofloxacin   Antibiotic   Cipro®
Citalopram   Central nervous system   Celexa®
Clindamycin   Antibiotic   Dalacin®
Clopidogrel   Cardiovascular   Plavix®
Dapagliflozin   Diabetes   Forxiga®
Donepezil   Central nervous system   Aricept®
Duloxetine   Central nervous system   Cymbalta®
Dutasteride   Urology   Avodart®
Escitalopram   Central nervous system   Cipralex®
Ezetimibe   Cardiovascular   Ezetrol®
Finasteride   Urology   Proscar®
Flecainide   Cardiovascular   Tambocor®
Fluconazole   Antifungal   Diflucan®
Fluoxetine   Central nervous system   Prozac®
Hydroxychloroquine   Antimalarial   Plaquenil®
Lacosamide   Central nervous system   Vimpat®
Letrozole   Oncology   Femara®
Levetiracetam   Central nervous system   Keppra®
Mirtazapine   Central nervous system   Remeron®
Metformin   Diabetes   Glucophage®
Montelukast   Allergy   Singulair®
Olmesartan   Cardiovascular   Olmetec®
Olmesartan HCTZ   Cardiovascular   Olmetec Plus®
Pantoprazole   Gastroenterology   Pantoloc®
Paroxetine   Central nervous system   Paxil®
Perindopril   Cardiovascular   Coversyl®
Pravastatin   Cardiovascular   Pravachol®
Pregabalin   Central nervous system   Lyrica®
Quetiapine   Central nervous system   Seroquel®
Quetiapine XR   Central nervous system   Seroquel XR®
Ramipril   Cardiovascular   Altace®
Rizatriptan ODT   Central nervous system   Maxalt® ODT
Rosuvastatin   Cardiovascular   Crestor®
Sertraline   Central nervous system   Zoloft®
Sildenafil   Urology   Viagra®
Tadalafil   Urology   Cialis®
Telmisartan   Cardiovascular   Micardis®
Telmisartan HCTZ   Cardiovascular   Micardis Plus®
Topiramate   Anticonvulsant   Topamax®
Tramadol Acetaminophen   Central nervous system   Tramacet®
Zolmitriptan   Central nervous system   Zomig®
Zopiclone   Central nervous system   Imovane®

 

 

 

 2 

 

 

In addition to the 52 drugs currently on the market, we have 32 additional drugs scheduled to be launched in 2024 and 2025. These new drugs will address various human health areas including cardiovascular, oncology, gastroenterology, central nervous system, diabetes, urology, endocrinology, anti-infective, and anti-inflammatory.

 

We believe the addition of these products to our existing portfolio will strengthen our presence in the Canadian $9.7 billion a year generic drugs market and provide us with greater access to pharmacies as we become more of a go-to supplier for every-day and specialty medicines.

 

Products in Development

 

The following table summarizes our proprietary drugs in development:

 

Drug Candidate   Therapeutic Area   Development Stage  
Adva-27a (Small Molecule)   Oncology (Pancreatic Cancer)   Paused*  
K1.1 (mRNA LNP)   Oncology (Liver Cancer)   Animal Testing  
SBFM-PL4 (Small Molecule)   Antiviral (SARS Coronavirus)   Animal Testing  

*See “Adva-27a Anticancer Compound,” below

 

Adva-27a Anticancer Compound

 

Adva-27a is a small molecule designed for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). We are the direct owner of all patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.

 

In December 2022, we entered into a research agreement with the Jewish General Hospital (“JGH”), to conduct the IND-enabling studies of Adva-27a (the “Research Agreement”). In August 2023, we were informed by the JGH that the laboratory results on testing of the Adva-27a molecule were not favorable. After conclusion of an internal review of the laboratory results on November 2, 2023, we provided notice to JGH of termination of the Research Agreement. We have now paused the IND-enabling studies of Adva-27a pending a review of the results and the possibility of chemical modification of the compound to address the suboptimal performance of the molecule in certain studies.

 

K1.1 Anticancer mRNA

 

In June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology. In April 2022, we filed a provisional patent application in the United States covering the subject mRNA molecules.

 

In November 2022, we concluded an agreement with a specialized commercial partner for the purposes of formulating our K1.1 mRNA molecules into lipid nanoparticles (“LNP”) for use to conduct xenograft mice studies. The initial results of our xenograft mice studies indicate that our K1.1 mRNA-LNP is effective at reducing the size of liver cancer xenograft tumors in mice. We are currently seeking to confirm these results by conducting additional xenograft experiments on a broader scale and in more detailed dose-response studies.

 

 

 3 

 

 

SBFM-PL4 SARS Coronavirus Treatment

 

The initial genome expression products following infection by Betacoronavirus, the causative agent of COVID-19, are two large polyproteins, referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases, called Mpro and PLpro, to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent attractive anti-viral drug development targets as they play a central role in the early stages of viral replication. PLpro is of particular interest as a therapeutic target in that, in addition to processing essential viral proteins, it is also responsible for suppression of the human immune system making the virus more life-threatening. PLpro is present only in Betacoronaviruses, the subgroup of Coronaviruses represented by the highly pathogenic SARS-CoV, MERS-CoV, and SARS-CoV-2.

 

Our Anti-Coronavirus research effort has been focused on developing an inhibitor of PLpro and, on May 22, 2020, we filed a patent application in the United States covering composition subject matter pertaining to small molecules for inhibition of the Coronavirus PLpro as well as Mpro.

 

In February 2022, we expanded our PLpro inhibitors research effort by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the agreement, the University of Arizona granted us a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the Research Project. In addition, we and the University of Arizona have entered into an option agreement (the “Option Agreement”) whereby we were granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. On September 13, 2022, we exercised our options, and on February 24, 2023, we entered into an exclusive worldwide license agreement with the University of Arizona for all of the technology related to the Research Project.

 

We have recently broadened our objective to include the development of an injectable drug candidate of first-in-class PLpro inhibitor to treat SARS-CoV2 and potentially SARS-CoV and MERS-CoV infection in patients who could not use Paxlovid, Molnupiravir, or Remdesivir, due to concerns about drug interactions and possible ‘rebound’ infections and other side effects.

 

Intellectual Property

 

We are the sole owner of all rights pertaining to Adva-27a. These patent rights are covered by PCT/FR2007/000697 and PCT/CA2014/000029. The patent applications filed under these two PCT's have been issued in the United States under US Patent Number 8,236,935 and 10,272,065.

 

On May 22, 2020, we filed a provisional patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, we filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application.

 

On April 20, 2022, we filed a provisional patent application in the United States covering mRNA molecules capable of destroying cancer cells in vitro. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.

 

Effective February 24, 2023, we became the exclusive, worldwide licensee of the University of Arizona for three (3) patents related to small molecules which inhibit the Coronavirus protease, PLpro.

 

Our wholly owned subsidiary, Nora Pharma, owns 152 DIN’s issued by Health Canada for prescription drugs currently on the market in Canada. These DIN’s were secured through in-licenses or cross-licenses from international manufacturers of generic pharmaceutical products.

 

 

 

 4 

 

 

In addition, we are the owner of four (4) NPN’s issued by Health Canada including (i) NPN 80089663 which authorizes us to manufacture and sell our in-house developed OTC product, Essential 9™, (ii) NPN 80093432 which authorizes us to manufacture and sell the OTC product, Calcium-Vitamin D under the brand name Essential Calcium-Vitamin D™, (iii) NPN 80125047 which authorizes us to manufacture and sell the OTC product, L-Citrulline, and (iv) NPN 80127436 which authorizes us to manufacture and sell the OTC product, Taurine.

 

Manufacturing

 

Our generic drugs are manufactured by several different international partners under long-term contracts.

 

We currently do not have any proprietary drugs on the market. Research quantities of our proprietary drug candidates are currently manufactured at the University of Arizona located in Tucson, Arizona (Anti-Coronavirus compounds), WuXi App Tech located in Hong Kong, China (Adva-27a compound), and Arranta Bio MA LLC located in Watertown, Massachusetts (K1.1 mRNA).

 

Our OTC products are manufactured under contract by INOV Pharma Inc. located in Montreal, Canada.

 

Marketing and Sales

 

Our generic drugs are currently being sold across Canada. All of our generic drug sales are conducted by Nora Pharma’s sales representatives based in key Provinces across Canada. A segment of our marketing team provides human resources, commercial and technical assistance, as well as training and education support to pharmacy owners.

 

Our OTC products are currently sold in the U.S. and Canada through Amazon.com and Amazon.ca, respectively. Our personnel, together with outside consultants develop and place ads on various media platforms and manage our accounts with Amazon.

 

Government Regulations

 

All of our business operations, including our generic drugs, proprietary drugs, and OTC products operations, are subject to extensive and frequently changing federal, state, provincial and local laws and regulations.

 

In the United States, the Federal Government agency responsible for regulating prescription drugs and nonprescription OTC supplements is the U.S. Food and Drug Administration (“FDA”). The Canadian counterpart to the FDA is Health Canada. Though the FDA and Health Canada have generally similar requirements for drugs and OTC supplements to be approved or allowed to be marketed, approval in one jurisdiction does not automatically result in approval in the other. In Canada, prescription drugs and nonprescription OTC supplements are authorized through the issuance by Health Canada of a Drug Identification Number (DIN) for the former and a Natural Product Number (NPN) for the latter. In the United States, OTC supplements are required to be registered with the FDA prior to marketing. In both the U.S. and Canada, the ingredients, manufacturing processes and facilities for all drugs and OTC supplements must meet the guidelines for Good Manufacturing Practices (“GMP”). Moreover, all drug manufacturers must perform a series of tests, both during and after production, to show that every drug or supplement batch made meets the regulatory requirements for that product.

 

Our generic prescription medicines are produced following the same Good Manufacturing Practices (GMP) guidelines as for brand-name drugs. Prescription drugs dossiers are filed with Health Canada in order to obtain a manufacturing Notice of Compliance (NOC) and a Drug Identification Number (DIN). The same grant the applicant marketing authorization in Canada. In the case of Nora Pharma’s products, Nora Pharma secures cross-licenses from supply partners holding NOC’s and in turn applies to Health Canada to obtain DIN’s issued in Nora Pharma’s name in order to commercialize in Canada. In Canada, the pan-Canadian Pharmaceutical Alliance (pCPA), an alliance of the provincial, territorial and federal governments that collaborates on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments, determines generic drugs pricing based on a percentage of the brand-name reference products.

 

 

 5 

 

 

In the area of proprietary drug development where our Anti-Coronavirus and Anti-Cancer compounds fall, we will be subject to significant regulations in the U.S. in order to obtain approval of the FDA to offer our products for sale. The approximate procedure for obtaining FDA approval involves an initial filing of an IND application following which the FDA would review and allow for the drug developer to proceed with Phase I clinical trials. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly, following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion of Phase III, a new drug application, or NDA is submitted and a request is made for marketing approval. Depending on various issues and considerations, the FDA could provide “emergency use authorization” or limited approval for “compassionate-use” if the drug treats terminally ill patients with limited or no other treatment options available. As of the date of the filing of this report, we have not made any filings with the FDA or other regulatory bodies in other jurisdictions.

 

In connection with OTC supplements, the FDA regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution, and sale of such products, while the Federal Trade Commission (“FTC”) regulates marketing and advertising claims. In August 2007, a rule issued by the FDA went into effect requiring companies that manufacture, package, label, distribute or hold OTC supplements to meet certain GMP requirements to ensure such products are of the quality specified and are properly packaged and labeled. We are committed to meeting or exceeding the standards set by the FDA and the FTC and we believe we are currently operating within both the FDA and FTC mandates.

 

Employees

 

As of the date of this report we have a total of 44 employees.

 

Women compose approximately 57% of our workforce. Going forward, we are committed to maintaining fully balanced workforce that includes persons of diverse sexual orientation and ethnic backgrounds.

 

Presently, our proprietary drug development activities are subcontracted out to specialized service providers in the U.S., Canada and overseas. We also use consultants for various other activities including marketing, accounting, and IT.

 

Labors laws in Quebec provide for certain guaranteed minimum entitlements, including minimum wages, maternity leave, medical leave, employee termination conditions, and other similar benefits. Moreover, the Province of Quebec has various language laws governing language use. These laws require corporate operations carried out in the Province of Quebec to be conducted to a large extent, and in some cases entirely, in French. We and our Canadian subsidiaries operating in the Province of Quebec are fully compliant with these laws.

 

Competition

 

The Canadian generic pharmaceuticals market was valued at approximately $9.7 billion USD in 2023. Generic pharmaceutical companies produce and deliver more than 70% of the prescribed medicines with high quality at affordable prices. There are more than 35 active generic players in the market, of which, the top 3 hold approximately a 50% share of the market. Nora Pharma is relatively new in this space but has demonstrated one of the fastest year-over-year sales increase amongst its peers.

 

 

 

 6 

 

 

Our Anti-Coronavirus drug development project is in direct competition with several companies in the U.S. that have developed effective vaccines or treatment options for Covid-19. The companies focused on treatments include Pfizer, Merck, Gilead, Eli Lilly, and Regeneron. Today two leading vaccines (Pfizer’s, and Moderna’s) and two antibody treatments (Regeneron’s, and Eli Lilly’s) are in use. Gilead’s Remdesivir, an antiviral injectable, was approved by the FDA for treatment of Covid-19 in October 2020. In addition, in December 2021, Pfizer received Emergency Use Authorization (“EUA”), for its antiviral pill, Paxlovid, and, in the same month, the FDA granted Merck EUA for its antiviral pill, Molnupiravir. While the approved vaccines, pills and injectable treatments are effective, we believe that additional treatment options such as the one we are developing which targets a different part of the virus could potentially form an important component of the range of anti-coronavirus treatment options available to attending physicians.

 

In the area of anticancer drug development, we compete with large publicly and privately held companies engaged in developing new cancer therapies. There are numerous other entities engaged in oncology therapeutics development that have greater resources than the resources presently available to us. Nearly all major pharmaceutical companies including Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name a few, have on-going anticancer drug development programs and some of the drugs they may develop could be in direct competition with our own. In addition, a number of smaller companies are working in the area of cancer therapy and could develop drugs that may be in competition with ours.

 

Similarly, our OTC products fall directly within a very crowded and highly competitive product sector. As of the date of this report, we believe Essential 9™ is the only Essential Amino Acid product that comprises all 9 essential amino acids in capsule form. We believe this may provide us with a competitive advantage, at least for the near future but there are no assurances that this will occur.

 

ITEM 1A. RISK FACTORS

 

Investing in our securities includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed below, together with all of the other information contained in this report. Our business, financial condition, results of operations and prospects could be materially and adversely affected by these risks. 

 

Risks Related to Our Business

 

We have incurred losses and may never achieve profitability

 

We have an accumulated deficit of $63,905,658 as of December 31, 2023. We incurred a net loss of $4,506,044 for the year ended December 31, 2023, and a net loss of $26,744,440 for the year ended December 31, 2022. We may never achieve profitability.

 

We are subject to the significant risks associated with the generic pharmaceutical business

 

Since our acquisition of Nora Pharma in October 2022, we have generated revenues primarily through sales of generic pharmaceutical products in Canada, and we expect this to remain the case for the foreseeable future. Generic pharmaceuticals are, as a general matter, significantly less profitable than innovative medicines.

 

In recent years, the generic pharmaceutical business has experienced increased volatility in volumes due in large part to global supply chain issues and the COVID-19 pandemic. In 2022, the global economy was continuing to recover from the impacts of the COVID-19 pandemic and also began experiencing additional macroeconomic pressures such as rising inflation and disruptions to the global supply chain, in part resulting from the ongoing conflict between Russia and Ukraine. We may experience supply discontinuities due to macroeconomic issues, regulatory actions, including sanctions and trade restrictions, labor disturbances and approval delays, which may impact our ability to timely meet demand in certain instances. These adverse market forces have a direct impact on our overall performance. Any such disruptions could have a material adverse impact on our business and our results of operation and financial condition.

 

 

 7 

 

 

Other risks associated with our generic pharmaceutical business include:

 

·Current macroeconomic conditions are becoming increasingly less stable due to the war in Ukraine, and tensions in the Middle and Far East. Destabilized macroeconomics conditions pose a serious threat to supply chains around the world including those for the generic pharmaceutical business. Nearly all of Nora Pharma’s generic drugs are manufactured outside Canada and the United States and could experience disruptions which would adversely affect our main source of revenue.

 

·Supply chains discontinuities due to other issues, including unforeseen regulatory actions, economic sanctions, trade restrictions, labor disturbances and approval delays, may impact our ability to timely meet customer demand in certain instances. These adverse market forces would have a direct impact on our ability to achieve our sales projections.

 

·A significant portion of Nora Pharma’s revenues are derived from relatively few key customers, and any financial difficulties experienced by a single key customer, or any delay in receiving payments from such a customer, could have a material adverse effect on Nora Pharma’s business, financial condition, and results of operations.

 

·If Nora Pharma encounters difficulties in executing launches of new products, it may not be able to offset the increasing price erosion on existing products resulting from pricing pressures and accelerated generics approvals for competitors. Such unsuccessful launches can be caused by many factors, including delays in regulatory approvals, lack of operational or clinical readiness or patent litigation. Failure or delays to execute launches of new generic products could have a material adverse effect on Nora Pharma’s business and its ability to realize projected sales.

 

Sales of our generic products may be adversely affected by the drug regulatory environment in Canada

 

Currently we sell our generic drugs only in Canada. Our net sales may be affected by fluctuations in the buying patterns of our customers resulting from government lead pricing pressures and other factors. Our generic sales in Canada are done via retail pharmacies, pharmacy channels, distributors, and wholesalers. Pricing pressures in Canada represent the highest risk due to ongoing and unresolved negotiations between the pharmaceutical industry and the federal government. These together with the fact that a significant portion of our revenues is derived from relatively few key customers, any financial difficulties experienced by a single key customer, or any delay in receiving payments from such a customer, could have a material adverse effect on our business, financial condition, and results of operations.

 

Our revenues and profits from generic products may decline as a result of competition from other pharmaceutical companies and changes in regulatory policy

 

Our generic drugs face intense competition. Prices of generic drugs may, and often do, decline, sometimes dramatically, especially as additional generic pharmaceutical companies receive approvals and enter the market for a given product and competition intensifies. Consequently, our ability to sustain our sales and profitability on any given product over time is affected by the number of companies selling such product, including new market entrants, and the timing of their approvals.

 

Furthermore, brand pharmaceutical companies continue to manage products in a challenging environment through marketing agreements with payers, pharmacy benefits managers and generic manufacturers. For example, brand companies often sell or license their own generic versions of their products, either directly or through other generic pharmaceutical companies (so-called “authorized generics”). No significant regulatory approvals are required for authorized generics, and brand companies do not face any other significant barriers to entry into such market. Brand companies may seek to delay introductions of generic equivalents through a variety of commercial and regulatory tactics. These actions may increase the costs and risks of our efforts to introduce generic products and may delay or prevent such introduction altogether.

 

 

 8 

 

 

We may experience delays in launching our new generic products

 

If we cannot execute timely launches of new products, we may not be able to offset the increasing price erosion on existing products resulting from pricing pressures and accelerated generics approvals for competing products. Such unsuccessful launches can be caused by many factors, including delays in regulatory approvals, lack of operational or clinical readiness or patent litigation. Failure or delays to execute launches of new generic products could have a material adverse effect on our business, financial condition, and results of operations.

 

We may not receive required regulatory approval for any of our non-generic pharmaceutical product candidates

 

We have not received approval for any of our proprietary (non-generic) drug development operations product candidates from the FDA. Any compounds we discover or in-license will require extensive and costly development, preclinical testing and clinical trials prior to seeking regulatory approval for commercial sales. Our most advanced product candidate, K1.1 mRNA and our potential Covid-19 treatment in development may never be approved for commercial sale. We have not made any filings to date with the FDA or other regulatory bodies in other jurisdictions. The time required to attain product sales and profitability is lengthy and highly uncertain. If we fail to obtain required regulatory approvals for our pharmaceutical product candidates, our business will be materially harmed.

   

As we have no approved non-generic pharmaceutical products on the market, we do not expect to generate significant revenues from non-generic pharmaceutical product sales in the foreseeable future, if at all

 

To date, we have no approved non-generic pharmaceutical products on the market and have generated product revenues solely from our OTC supplements operations and generic pharmaceutical product sales. We have funded our operations primarily from sales of our securities. We have not received, and do not expect to receive for at least the next three to four years, if at all, any revenues from the commercialization of our non-generic pharmaceutical product candidates. To obtain revenues from sales of such pharmaceutical product candidates we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for manufacturing, marketing and distributing drugs with commercial potential. We may never succeed in these activities, and we may not generate sufficient revenues to continue our business operations or achieve profitability.

 

We will require additional funding to satisfy our future capital needs, which may not be available

 

We will require significant additional funding in large part due to our research and development expenses, future preclinical and clinical testing costs, and insufficient sales revenues in the near future. We do not know whether additional financing will be available to us on favorable terms or at all. If we cannot raise additional funds, we may be required to reduce our capital expenditures, scale back product development programs, reduce our workforce and license to others products or technologies that we may otherwise be able to commercialize. We are currently unable to project when or whether our operations will generate positive cash flow.

 

Any additional equity securities we issue or issuances of debt we may enter into or undertake may have rights, preferences or privileges senior to those of existing holders of common stock. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some rights to our technologies or product candidates or grant licenses on terms that are not favorable to us.

 

The FDA may change its approval policies or requirements, or apply interpretations to its policies or requirements, in a manner that could delay or prevent commercialization of K1.1 mRNA or our potential Covid-19 treatment in development

 

Regulatory requirements may change in a manner that requires us to conduct additional clinical trials, which may delay or prevent commercialization of our K1.1 mRNA and potential Covid-19 treatment in development. We cannot provide any assurance that the FDA will not require us to repeat existing studies or conduct new or unforeseen experiments in order to demonstrate the safety and efficacy of any product candidate before considering the approval of such product candidates.

  

 

 9 

 

 

Our business would be materially harmed if we fail to obtain FDA approval for our pharmaceutical product candidates

 

We anticipate that our ability to generate significant product revenues from our drug development business will depend on the successful development and commercialization of K1.1 mRNA or our potential Covid-19 treatment in development. The FDA may not approve in a timely manner, or at all, any of our drug candidates. If we are unable to submit a new drug application for our product candidates, we will be unable to commercialize such products and our business will be materially harmed. The FDA imposes substantial requirements on the introduction of pharmaceutical products through lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Satisfaction of these requirements typically takes several years and may vary substantially based upon the type and complexity of the pharmaceutical product. Our product candidates are novel compounds or new chemical entities, which may further increase the time required for satisfactory testing procedures.

 

We may be sued or become a party to litigation, which could require significant management time and attention and result in significant legal expenses and may result in an unfavorable outcome which could have a material adverse effect on our business, financial condition, results of operations and cash flow

 

We may be forced to incur costs and expenses in connection with defending ourselves with respect to litigation and the payment of any settlement or judgment in connection therewith if there is an unfavorable outcome. The expense of defending litigation may be significant. The amount of time to resolve lawsuits is unpredictable and defending ourselves may divert management’s attention from the day-to-day operations of our business, which could adversely affect our business, results of operations and cash flows. In addition, an unfavorable outcome in any such litigation could have a material adverse effect on our business, results of operations and cash flows.

   

If we are unable to attract and retain qualified scientific, technical, and key management personnel, or if our key executive, Dr. Steve N. Slilaty, discontinues his employment with us, it may delay our research and development efforts

 

We rely on the services of Dr. Slilaty for strategic and operational management, as well as for scientific and/or medical expertise in the development of our products. The loss of Dr. Slilaty would result in a significant negative impact on our ability to implement our business plan. The loss of Dr. Slilaty will also significantly delay or prevent the achievement of our business objectives.

  

Our business exposes us to potential product liability risks and we may be unable to acquire and maintain sufficient insurance to provide adequate coverage against potential liabilities

 

Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. The use of our products by our customers exposes us to the possibility of product liability claims and possible adverse publicity. These risks will increase to the extent our pharmaceutical product candidates receive regulatory approval and are commercialized. We currently have product liability insurance for our generic drugs and OTC products and we plan to obtain product liability insurance in connection with clinical trials of our pharmaceutical product candidates in the near future. However, our current and future product liability insurance may not provide adequate protection against potential liabilities. On occasion, juries have awarded large judgments in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim, or series of claims brought against us would decrease our cash reserves and could cause our stock price to fall significantly.

 

 

 

 10 

 

 

We face regulation and risks related to hazardous materials and environmental laws, violations of which may subject us to claims for damages or fines that could materially affect our business, cash flows, financial condition and results of operations

 

Our research and development activities involve the use of controlled and/or hazardous materials and chemicals. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of an accident, we could be held liable for any damages or fines that result, and the liability could have a material adverse effect on our business, financial condition, and results of operations. We are also subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and waste products. If we fail to comply with these laws and regulations or with the conditions attached to our operating licenses, the licenses could be revoked, and we could be subjected to criminal sanctions and substantial liability or be required to suspend or modify our operations. In addition, we may have to incur significant costs to comply with future environmental laws and regulations. We do not currently have a pollution and remediation insurance policy.

 

Third party manufacturers may not be able to manufacture our pharmaceutical product candidates, which would prevent us from commercializing our product candidates

 

If any of our pharmaceutical product candidates is approved by the FDA or other regulatory agencies for commercial sale, we will need third parties to manufacture the product in larger quantities. If we are able to reach an agreement with any collaborator or third-party manufacturer in the future, of which there can be no assurance due to factors beyond our control, these collaborators and/or third-party manufacturers may not be able to increase their manufacturing capacity for any of our product candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve. If we are unable to increase the manufacturing capacity for a product candidate successfully, the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product candidate. Our product candidates require precise, high-quality manufacturing. The failure of collaborators or third-party manufacturers to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously harm our business.

 

If we are unable to establish sales and marketing capabilities for our pharmaceutical product candidates or enter into agreements with third parties to sell and market any such products we may develop, we may be unable to generate revenues from our non-generic pharmaceutical business

 

We do not currently have product sales and marketing capabilities for our non-generic pharmaceutical operations. If we receive regulatory approval to commence commercial sales of any of our pharmaceutical product candidates, we will have to establish a sales and marketing organization with appropriate technical expertise and distribution capabilities or make arrangements with third parties to perform these services in other jurisdictions. If we receive approval in applicable jurisdictions to commercialize any of our pharmaceutical products candidates, we intend to engage additional pharmaceutical or health care companies with existing distribution systems and direct sales organizations to assist us in North America and throughout the world. We may not be able to negotiate favorable distribution partnering arrangements, if at all. To the extent we enter into co-promotion or other licensing arrangements, any revenues we receive will depend on the efforts of third parties and will not be under our control. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, our ability to generate product revenues, and become profitable, would be severely limited.

  

Even if we obtain required US and foreign regulatory approvals, as applicable, factors that may inhibit our efforts to commercialize our pharmaceutical product candidates without strategic partners or licensees include:

 

  · difficulty recruiting and retaining adequate numbers of effective sales and marketing personnel;
  · the inability of sales personnel to obtain access to, or persuade adequate numbers of, physicians to prescribe our products;
  · the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage against companies with broader product lines; and
  · unforeseen costs associated with creating an independent sales and marketing organization.

 

 

 11 

 

 

Even if we successfully develop and obtain approval for our proprietary drug product candidates, our business will not be profitable if such products do not achieve and maintain market acceptance

 

Even if our proprietary drug product candidates are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of our approved product candidates by physicians, healthcare professionals, patients and third-party payors, and our resulting profitability and growth, will depend on a number of factors, including:

 

  · our ability to provide acceptable evidence of safety and efficacy;
  · relative convenience and ease of administration;
  · the prevalence and severity of any adverse side effects;
  · the availability of alternative treatments;
  · the details of FDA labeling requirements, including the scope of approved indications and any safety warnings;
  · pricing and cost effectiveness;
  · the effectiveness of our or our collaborators' sales and marketing strategy;
  · our ability to obtain sufficient third-party insurance coverage or reimbursement; and
  · our ability to have the product listed on insurance company formularies.

 

If our proprietary drug product candidates achieve market acceptance, we may not maintain that market acceptance over time if new products or technologies are introduced that are received more favorably or are more cost effective. Complications may also arise, such as development of new know-how or new medical or therapeutic capabilities by other parties that render our product obsolete.

  

Because the results of preclinical studies for our preclinical product candidates are not necessarily predictive of future results, our pharmaceutical product candidates may not have favorable results in later clinical trials or ultimately receive regulatory approval

 

Our proprietary drug product candidates have not been tested in clinical trials. Positive results from preclinical studies are no assurance that later clinical trials will succeed. Preclinical studies are not designed to establish the clinical efficacy of our preclinical product candidates. We will be required to demonstrate through clinical trials that our product candidates are safe and effective for use before we can seek regulatory approvals for commercial sale. There is typically an extremely high rate of failure as product candidates proceed through the various phases of clinical trials. If our product candidates fail to demonstrate sufficient safety and efficacy in any clinical trial, we would experience potentially significant delays in, or be required to abandon, development of that product candidate. This would adversely affect our ability to generate revenues and may damage our reputation in the industry and in the investment community.

 

The future clinical testing of our proprietary drug product candidates could be delayed, resulting in increased costs to us and a delay in our ability to generate revenues

 

Our proprietary drug product candidates will require additional preclinical testing and extensive clinical trials prior to submission of a regulatory application for commercial sales. We do not know whether clinical trials will begin on time, if at all. Delays in the commencement of clinical testing could significantly increase our product development costs and delay product commercialization. In addition, many of the factors that may cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to denial of regulatory approval of a product candidate. Each of these results would adversely affect our ability to generate revenues.

 

The commencement of clinical trials can be delayed for a variety of reasons, including delays in:

 

  · demonstrating sufficient safety to obtain regulatory approval to commence a clinical trial;
  · reaching agreement on acceptable terms with prospective research organizations and trial sites;
  · manufacturing sufficient quantities of a product candidate;
  · obtaining institutional review board approvals to conduct clinical trials at prospective sites; and
  · procuring adequate financing to fund the work.

 

 

 12 

 

 

In addition, the commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. If we are unable to enroll a sufficient number of evaluable patients, the clinical trials for our product candidates could be delayed until sufficient numbers are achieved.

  

We face or will face significant competition from other biotechnology, pharmaceutical and OTC supplements companies, and our operating results will suffer if we fail to compete effectively

 

Most of our pharmaceutical company competitors, such as Merck, Bristol-Myers Squibb, Pfizer, Amgen, and others, are large pharmaceutical companies with substantially greater financial, technical, and human resources than we have. The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. The drugs that we are attempting to develop will compete with existing therapies if we receive marketing approval. Because of their significant resources, our competitors may be able to use discovery technologies and techniques, or partnerships with collaborators, to develop competing products that are more effective or less costly than the product candidate we are developing. This may render our technology or product candidate obsolete and noncompetitive. Academic institutions, government agencies, and other public and private research organizations may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.

 

Our competitors may succeed in obtaining FDA or other regulatory approvals for product candidates more rapidly than us. Companies that complete clinical trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including certain FDA marketing exclusivity rights that would delay or prevent our ability to market certain products. Any approved drugs resulting from our research and development efforts, or from our joint efforts with our existing or future collaborative partners, might not be able to compete successfully with our competitors' existing or future products.

 

We also face competition in our OTC supplements business. The business of marketing OTC supplements is highly competitive. This market segment includes numerous manufacturers, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad. The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. Sales of similar products by competitors may materially and adversely affect our business, financial condition, and results of operations.

 

 

 

 13 

 

 

Because our proprietary drug product candidates and our development and collaboration efforts depend on our intellectual property rights, adverse events affecting our intellectual property rights will harm our ability to commercialize products

 

Our success will depend to a large degree on our own and our licensors’ ability to obtain and defend patents for each party's respective technologies and the compounds and other products, if any, resulting from the application of such technologies. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and technical questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that will be allowed or maintained, after challenge, in our or other companies' patents.

 

The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:

 

  · we were the first to make the inventions covered by each of our pending patent applications;
  · we were the first to file patent applications for these inventions;
  · others will not independently develop similar or alternative technologies or duplicate any of our technologies;
  · any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not be challenged by third parties;
  · our pending patent applications will result in issued patents;
  · we will develop additional proprietary technologies that are patentable;
  · the patents of others will not have a negative effect on our ability to do business; or
  · our issued patents will have sufficient useful life remaining for commercial viability of our product candidate.  

 

If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, then our ability to receive patent protection or protect our proprietary information will be impaired. In addition, some of the technology we have developed or licensed relies on inventions developed using U.S. and other governments’ resources. Under applicable law, the U.S. government has the right to require us to grant a nonexclusive, partially exclusive or exclusive license for such technology to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, if the government determines that such action is necessary.

 

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property

 

We rely on trade secrets to protect our technology, particularly when we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. In order to protect our proprietary technology and processes, we rely in part on confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information, and in such case we could not assert any trade secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

  

The implementation of our business plan may result in a period of rapid growth that will impose a significant burden on our current administrative and operational resources

 

Our ability to effectively manage our growth will require us to substantially expand the capabilities of our administrative and operational resources by attracting, training, managing, and retaining additional qualified personnel, including additional members of management, technicians, and others. To successfully develop our products, we will need to manage operating, producing, marketing and selling our products. There can be no assurances that we will be able to do so. Our failure to successfully manage our growth will have a negative impact on our anticipated results of operations.

 

 

 14 

 

 

A significant or prolonged economic downturn could have a material adverse effect on our results of operations

 

A significant or prolonged economic downturn may adversely affect the disposable income of many consumers and may lower demand for some of our products. Any decline in economic conditions could negatively impact our business. A significant decline in consumer demand, even if only due in part to general economic conditions could have a material adverse effect on our revenues and profit margins.

 

The failure of our service providers and suppliers to supply quality services and materials in sufficient quantities, at a favorable price, and in a timely fashion could adversely affect the results of our operations

 

Our outside manufacturers buy raw materials from a limited number of suppliers. The loss of any of our major suppliers or of any supplier who, through our contract manufacturer, provides us materials that are hard to obtain elsewhere at the same quality could adversely affect our business operations. Although we believe we could establish alternate manufacturers and sources for most of our raw materials, any delay in locating and establishing relationships with other sources could result in shortages of products we manufacture from such raw materials, with a resulting loss of sales and customers.

 

A shortage of raw materials or an unexpected interruption of supply could also result in higher prices for those materials. We have experienced increases in various raw material costs, transportation costs and the cost of petroleum-based raw materials and packaging supplies used in our business. Increasing cost pricing pressures on raw materials and other products occurred throughout fiscal 2023 as a result of limited supplies of various ingredients, the effects of higher labor and transportation costs, and the impact of Covid-19. We expect these upward pressures to continue through fiscal 2024. Although we may be able to raise our prices in response to significant increases in the cost of raw materials, we may not be able to raise prices sufficiently or quickly enough to offset the negative effects such cost increases could have on our results of operations or financial condition.

 

There can be no assurance suppliers will provide the quality raw materials we need in the quantities requested or at a price we are willing to pay. Because we do not control the actual production of these raw materials, we are also subject to delays caused by interruption in production of materials including but not limited to those resulting from conditions outside of our control, such as pandemics, weather, transportation interruptions, strikes, terrorism, geopolitics, natural disasters, and other catastrophic events.

 

Our business is subject to the effects of adverse publicity, which could negatively affect our sales and revenues

 

Our business can be affected by adverse publicity or negative public perception about us, our competitors, our products, or our industry or competitors generally. Adverse publicity may include publicity about the efficacy, safety and quality of health care products or ingredients in general or our products or ingredients specifically, and regulatory investigations, regardless of whether these investigations involve us or the business practices or products of our competitors, or our customers. Any adverse publicity or negative public perception could have a material adverse effect on our business, financial condition and results of operations. Our business, financial condition and results of operations could be adversely affected if any of our products or any similar products distributed by other companies are alleged to be or are proved to be harmful to consumers or to have unanticipated and unwanted health consequences.

  

Our manufacturing and third-party fulfillment activities are subject to certain risks

 

Our products are manufactured at third party manufacturing facilities in Canada and overseas. As a result, we are dependent on the uninterrupted and efficient operation of these facilities. Such manufacturing operations, and those of their suppliers, are subject to power failures, blackouts, border shutdowns, telecommunications failures, computer viruses, cybersecurity vulnerabilities, human error, breakdown, failure or substandard performance. The occurrence of these or any other operational problems, including the improper installation or operation of equipment, terrorism, pandemics (including Covid-19), natural or other disasters, intentional acts of violence, and the need to comply with the requirements or directives of governmental agencies, including the FDA and Health Canada may have a material adverse effect on our business, financial condition and results of operations.

 

 

 15 

 

 

Risks Related to Our Common Stock

 

There is significant volatility in the price and trading volume of our common stock, and investors may find it difficult to buy and sell our shares

 

Our common stock has been listed on the Nasdaq Capital Market since February 15, 2022. The price and daily trading volume of our common stock have been very volatile and may continue to be so, and any significant trading volume in our common stock may not be maintained. These factors may have an adverse impact on the trading and price of our common stock.

 

If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted

 

Our common stock currently trades on Nasdaq, where it is subject to various listing requirements. On March 24, 2023, we received a notification letter from Nasdaq’s Listing Qualifications Department notifying us that, because the closing bid price of our common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, we no longer meet the minimum bid price requirement for continued listing under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). On September 21, 2023, we received another notification letter from Nasdaq advising that Nasdaq’s staff has determined that we are eligible for an extension of an additional 180 calendar day period, or until March 18, 2024, to cure the bid price deficiency. On February 28, 2024, we received a notification letter from Nasdaq advising that Nasdaq’s staff had determined that as of February 27, 2024, our common stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, we were subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii). As a result, Nasdaq determined that our securities would be removed from listing and registration on The Nasdaq Stock Market, subject to the procedures set forth in the Nasdaq Listing Rule 5800 Series which provide for the opportunity to appeal such determination. On February 28, 2024, we applied for such appeal, and a hearing has been scheduled for April 25, 2024. Accordingly, the delisting action referenced in the Nasdaq staff’s determination letter has been stayed, pending a final written decision by the Nasdaq Hearings Panel. In December 2023, we had obtained shareholder approval for and intend to complete a reverse stock split to regain compliance with the Minimum Bid Price Requirement. If we are unable to achieve and maintain compliance with such listing standards or other Nasdaq listing requirements in the future, we could be subject to suspension and delisting proceedings. A delisting of our common stock and our inability to list on another national securities market could negatively impact us by: (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradeable securities, thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.

    

We do not intend to pay dividends on our common stock for the foreseeable future

 

We have paid no dividends on our common stock to date and we do not anticipate paying any dividends to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of the business, we currently anticipate that we will retain any earnings to finance our future expansion and for the implementation of our business plan. Investors should take note of the fact that a lack of a dividend can further affect the market value of our common stock and could significantly affect the value of any investment in our Company.

  

Our articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock

 

Our board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to issue up to 30,000,000 shares of our preferred stock without further stockholder approval. 1,000,000 shares of preferred stock are designated Series B Preferred Stock and as of the date of this Report, 130,000 of such shares are outstanding and held by our Chief Executive Officer. Our board of directors could authorize the creation of additional series of preferred stock that would grant to holders of preferred stock the right to our assets upon liquidation, or the right to receive dividend payments before dividends are distributed to the holders of common stock. In addition, subject to the rules of any securities exchange on which our stock is then listed, our board of directors could authorize the creation of additional series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.

  

 

 

 16 

 

 

Additional stock offerings in the future or the issuance of stock upon exercise of outstanding warrants may dilute then-existing shareholders’ percentage ownership in our Company

 

Given our plans and expectations that we will need additional capital and personnel, we anticipate that we will need to issue additional shares of common stock or securities convertible or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. In addition, as of December 31, 2023, we have 23,395,046 common shares issuable upon exercise of outstanding warrants with a weighted average exercise price of $1.94. The issuance of additional securities in the future will dilute the percentage ownership of our then current stockholders.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 1C. CYBERSECURITY

 

Risk Management and Strategy

 

We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.

 

Managing Material Risks & Integrated Overall Risk Management

 

We have strategically integrated cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are an integral part of our decision-making processes at every level. Our management team works closely with our IT department to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.

 

Oversee Third-party Risk

 

Because we are aware of the risks associated with third-party service providers, we have implemented stringent processes to oversee and manage these risks. We conduct thorough security assessments of all third-party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes annual assessments of the SOC reports of our providers and implementing complementary controls. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.

 

Risks from Cybersecurity Threats

 

We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing.

 

ITEM 2. PROPERTIES

 

Our principal place of business is located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036. We also have a satellite office in the greater Montreal area located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. We are not party to lease agreements in connection with these two office locations. We pay rent month-to-month and have access to additional space on a pay-per-use basis.

 

Our wholly owned subsidiary, Nora Pharma, currently occupies a 23,500 square foot facility located at 1565 Boulevard Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7 pursuant to a lease agreement that expires in January 2030, with an option to extend for 5 years. This site is composed of 18,500 square feet of warehouse space and 5,000 square feet of executive office space. The facility houses all administrative, marketing, quality control, regulatory affairs, and other operations personal, as well as a Health Canada licensed warehouse space. We pay a monthly rent of $27,250 CAD (approximately $19,900 USD), including taxes. We estimate that this facility is adequate for annual sales of approximately $50 to $75 million, past which we will need to find additional space.

 

ITEM 3. LEGAL PROCEEDINGS

 

We are not party to, and our property is not the subject of, any legal proceedings nor are we aware of any threats of such actions against us.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

 17 

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is listed on the Nasdaq Capital Market under the symbol “SBFM”. As of March 28, 2024, we had a total of 99,452,865 shares of our common stock issued and outstanding. We also have tradeable warrants exercisable to purchase shares of our common stock listed on the Nasdaq Capital Market under the symbol “SBFMW.” As of March 28, 2024, we had a total of 963,693 tradeable warrants outstanding.

 

As of March 28, 2024, there were approximately 149 holders of record of our common stock, not including those holding their shares in “street name.”

 

Equity Compensation Plan Information

 

The following table sets forth information regarding our equity compensation plans as of December 31, 2023:

 

  

 

 

Plan Category

Number of Securities to be Issued Upon Exercise of Outstanding Options,
Warrants and Rights

 

Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights

Number of Securities
Remaining Available for

Future Issuance Under
Equity Compensation Plans

Equity compensation plans approved by security holders(1)

–

–

3,320,988

Equity compensation plans not approved by security holders

–

–

–

(1) Represents our 2023 Equity Incentive Plan.

 

Dividend Policy

 

We have not paid any dividends since our incorporation and do not anticipate paying any dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop and market our products. Our payment of dividends in the future will depend upon, among other factors, our earnings, capital requirements, and operating financial conditions.

  

Recent Sales of Unregistered Securities

 

None.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described. This discussion should be read in conjunction with our financial statements and the related notes included in this report. This discussion contains forward-looking statements. Please see “Cautionary Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements.

 

 

 18 

 

 

Results of Operations

 

Comparison of Results of Operations for the fiscal years ended December 31, 2023 and 2022

 

During our fiscal year ended December 31, 2023, we generated revenues of $24,092,787, compared to revenues of $4,345,603 in 2022. The increase was the result of twelve months of Nora Pharma sales included in the 2023 results compared to only seventy-two days of sales in 2022 (October 20, 2022, the date of acquisition of Nora Pharma, through December 31, 2022). The cost of sales in 2023 and 2022 for generating these revenues was $15,753,616 and $2,649,028, respectively.

 

General and administrative (“G&A”) expenses for our fiscal year ended December 31, 2023, were $13,124,470, compared to $28,697,325 during our fiscal year ended December 31, 2022, a decrease of $15,572,855. However, excluding the one-time impairment of goodwill in the amount of $18,326,719 from the 2022 G&A expenses, reveals an increase in G&A expenses of $2,753,864 in 2023. This increase is due to G&A expenses incurred by Nora Pharma during all of 2023, compared to only 72 days of G&A expenses included in 2022.

 

We had interest income of $811,974 in 2023, compared to interest income of $518,650 in 2022. We incurred $137,308 in interest expense in 2023, compared to $39,412 in interest expense in 2022.

 

As a result, we incurred a net loss of $4,506,044 for the year ended December 31, 2023, compared to a net loss of $26,744,440 for the year ended December 31, 2022.

 

Liquidity and Capital Resources

  

As of December 31, 2023, we had cash and cash equivalents of $16,292,347.

 

On February 17, 2022, we completed an underwritten public offering of common stock and warrants for gross proceeds of $8 million. We received net proceeds of approximately $6.8 million from the offering.

 

On March 14, 2022, we completed a private placement of common stock and warrants for gross proceeds of $8 million. We received net proceeds of approximately $6.8 million from the private placement.

 

On April 28, 2022, we completed a private placement of common stock and warrants for gross proceeds of approximately $19.5 million. We received net proceeds of approximately $16.8 million from the private placement.

 

During the fiscal years ended December 31, 2022 and 2023, we received aggregate proceeds of $13,196,681 in connection with warrant exercises.

 

On May 16, 2023, we completed a private placement of common stock and warrants for gross proceeds of approximately $5 million. We received net proceeds of approximately $4.1 million from the private placement.

 

Cash flows used in investing activities were $656,150 during the year ended December 31, 2023, compared to $14,619,390 during our fiscal year ended December 31, 2022. The reason for the decrease was due to the acquisition of Nora Pharma which took place on October 20, 2022. Net cash flows provided by financing activities were $3,425,587 in 2023, compared to $39,465,107 in 2022. The decrease was primarily a result of three (3) rounds of financing which took place in February, March, and April 2022 and only one (1) relatively small financing in 2023. Net cash used in operations was $8,775,111 in 2023, compared to $5,248,358 in 2022. The increase was due to expansion of Nora Pharma drugs portfolio.

 

 

 19 

 

 

We are not generating adequate revenues from our operations to fully implement our business plan as set forth herein. We believe our existing cash will be sufficient to fund our pharmaceuticals sales operations and research and development activities for the next 24 months. There is no assurance our estimates will be accurate. We have no committed sources of capital and we anticipate that we will need to raise additional capital in the future, including for further research and development activities and possibly clinical trials, as well as expansion of our generic pharmaceuticals operations. Additional capital may not be available on terms acceptable to us, or at all.

 

Critical Accounting Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Leases

 

We follow the guidance in ASC 842 “Accounting for Leases,” as amended, which requires us to evaluate the lease agreements we enter into to determine whether they represent operating or capital leases at the inception of the lease.

 

Our wholly owned subsidiary, Nora Pharma, currently occupies a 23,500 square foot facility located at 1565 Boulevard Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7 pursuant to a lease agreement that expires in January 2030, with an option to extend for 5 years. This site is composed of 18,500 square feet of warehouse space and 5,000 square feet of executive office space. The facility houses all administrative, marketing, quality control, regulatory affairs, and other operations personal, as well as a Health Canada licensed warehouse space. We pay a monthly rent of $27,250 CAD (approximately $19,900 USD), including taxes.

  

Recently Adopted Accounting Standards

 

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited consolidated financial statements.

 

 

 20 

 

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for a smaller reporting company.

 

 

 

 

 

 

 

 21 

 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the board of directors of Sunshine Biopharma, Inc.:

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Sunshine Biopharma, Inc. as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

 

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

 

We determined that there are no critical audit matters.

 

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company's auditor since 2013

Lakewood, CO

March 28, 2024

 

 

 

 22 

 

 

Sunshine Biopharma, Inc.

Consolidated Balance Sheets

 

           
   As of December 31, 
   2023   2022 
ASSETS          
Current Assets:          
Cash and cash equivalents  $16,292,347   $21,826,437 
Accounts receivable   2,552,362    1,912,153 
Inventory   5,734,755    3,289,945 
Prepaid expenses   310,591    283,799 
Total Current Assets   24,890,055    27,312,334 
Property and equipment   365,868    394,249 
Intangible assets   1,444,259    776,856 
Right-of-use-asset   646,779    760,409 
TOTAL ASSETS  $27,346,961   $29,243,848 
           
LIABILITIES          
Current Liabilities:          
Accounts payable and accrued expenses  $2,585,466   $2,802,797 
Earnout payable   2,547,831    3,632,000 
Income tax payable   299,869    373,191 
Right-of-use-liability   118,670    123,026 
Total Current Liabilities   5,551,836    6,931,014 
Long-Term Liabilities:          
Deferred tax liability   48,729    43,032 
Right-of-use-liability   539,035    642,232 
Total Long-Term Liabilities   587,764    685,264 
TOTAL LIABILITIES   6,139,600    7,616,278 
           
SHAREHOLDERS' EQUITY          
Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 10,000 shares issued and outstanding   1,000    1,000 
Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 28,024,290 and 22,585,632 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively   28,024    22,585 
Capital paid in excess of par value   84,387,890    80,841,752 
Accumulated comprehensive income   696,105    161,847 
Accumulated (Deficit)   (63,905,658)   (59,399,614)
TOTAL SHAREHOLDERS' EQUITY   21,207,361    21,627,570 
           
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY  $27,346,961   $29,243,848 

 

See Accompanying Notes To These Financial Statements

 

 

 23 

 

 

Sunshine Biopharma, Inc.

Consolidated Statements of Operations and Comprehensive Loss

 

           
   Year Ended December 31, 
   2023   2022 
         
Sales  $24,092,787   $4,345,603 
Cost of sales   15,753,616    2,649,028 
Gross profit   8,339,171    1,696,575 
           
General and Administrative Expenses:          
Accounting   463,705    341,139 
Consulting   850,173    842,894 
Director fees   400,000    300,000 
Goodwill impairment   –    18,326,719 
Legal   512,199    550,117 
Marketing   734,248    578,085 
Office   2,142,355    796,007 
Patent fees   14,108    15,148 
R&D   1,855,830    811,858 
Salaries   5,712,968    6,054,962 
Taxes   289,737    55,233 
Depreciation & amortization   149,147    25,163 
Total General and Administrative Expenses   13,124,470    28,697,325 
           
(Loss) From Operations   (4,785,299)   (27,000,750)
           
Other Income (Expense):          
Foreign exchange (loss)   (245)   (476)
Interest income   811,974    518,650 
Interest expense   (137,308)   (39,412)
Debt release   –    10,852 
Total Other Income (Expense)   674,421    489,614 
           
Net (loss) before income taxes   (4,110,878)   (26,511,136)
Provision for income taxes   395,166    233,304 
Net (Loss   (4,506,044)   (26,744,440)
           
Foreign exchange translation   534,258    184,986 
Comprehensive Income (Loss)  $(3,971,786)  $(26,559,454)
           
Basic and diluted (Loss) per common share  $(0.19)  $(1.76)
           
Weighted average common shares outstanding (basic & diluted)   24,331,908    15,180,868 

 

See Accompanying Notes To These Financial Statements.

 

 

 24 

 

 

Sunshine Biopharma, Inc.

Consolidated Statements of Cash Flows

 

           
   Year Ended December 31,
   2023   2022
Cash Flows From Operating Activities:          
Net (Loss)  $(4,506,044)  $(26,744,440)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   149,147    25,163 
Goodwill impairment   –    18,326,719 
Foreign exchange   –    548 
Debt release   –    (10,852)
Accounts receivable   (594,141)   (524,486)
Inventory   (2,365,549)   42,983 
Prepaid expenses   (21,143)   82,846 
Accounts payable and accrued expenses   (1,364,134)   3,359,141 
Deferred tax liability   –    3,628 
Income tax payable   (73,247)   238,679 
Interest payable   –    (48,287)
Net Cash Flows (Used In) Operating Activities   (8,775,111)   (5,248,358)
           
Cash Flows From Investing Activities:          
Reduction in Right-of-use asset   131,949    33,379 
Nora Pharma acquisition   –    (14,346,637)
Cash from Nora Pharma acquisition   –    (1,135)
Purchase of intangible assets   (705,848)   (111,015)
Purchase of equipment   (82,251)   (193,982)
Net Cash Flows (Used In) Investing Activities   (656,150)   (14,619,390)
           
Cash Flows From Financing Activities:          
Sale of common stock in private placements   4,089,218    30,367,185 
Exercise of warrants   3,502    13,193,177 
Purchase of treasury stock   (541,143)   (99,000)
Lease liability   (125,990)   (31,924)
Advances to Nora Pharma - pre acquisition   –    (2,064,331)
Payments of notes payable   –    (1,900,000)
Net Cash Flows Provided by Financing Activities   3,425,587    39,465,107 
           
Cash and Cash Equivalents at Beginning of Period   21,826,437    2,045,167 
Net increase (decrease) in cash and cash equivalents   (6,005,674)   19,597,359 
Effect of exchange rate changes on cash   (62,674)   (1,075)
Foreign currency translation adjustment   534,258    184,986 
Cash and Cash Equivalents at End of Period  $16,292,347   $21,826,437 
           
Supplementary Disclosure of Cash Flow Information:          
Cash paid for interest  $–   $48,287 
Stock issued for acquisition of Nora Pharma  $–   $4,514,000 

 

See Accompanying Notes To These Financial Statements.

 

 

 25 

 

 

Sunshine Biopharma, Inc.

Consolidated Statements of Shareholders' Equity

 

                                         
   Number of Common Shares   Common   Capital Paid in Excess of Par   Number of Preferred Shares   Preferred  

Compre-

hensive

   Accumulated     
   Issued   Stock   Value   Issued   Stock   Income   Deficit   Total 
                                 
Balance at December 31, 2021   2,591,240    2,591    32,787,384    1,000,000    100,000    (23,139)   (32,655,174)   211,662 
Fractional shares issued for reverse stock split   4,380    4    (4)   –    –    –    –    – 
Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs   6,656,526    6,657    30,360,528    –    –    –    –    30,367,185 
Exercise of warrants   9,633,486    9,633    13,183,544    –    –    –    –    13,193,177 
Preferred stock purchased from related party   –    –    –    (990,000)   (99,000)   –    –    (99,000)
Common stock issued as part of Nora Pharma acquisition   3,700,000    3,700    4,510,300    –    –    –    –    4,514,000 
Net (loss)   –    –    –    –    –    184,986    (26,744,440)   (26,559,454)
Balance at December 31, 2022   22,585,632   $22,585   $80,841,752    10,000   $1,000   $161,847   $(59,399,614)   21,627,570 
                                         
Repurchase of treasury stock   (513,723)   (514)   (540,629)   –    –    –    –    (541,143)
Common stock and pre-funded warrants issued in a private offering net of expenses   2,450,000    2,451    4,086,767    –    –    –    –    4,089,218 
Exercise of warrants   3,502,381    3,502    –    –    –    –    –    3,502 
Net (loss)   –    –    –    –    –    534,258    (4,506,044)   (3,971,786)
Balance at December 31, 2023   28,024,290   $28,024   $84,387,890    10,000   $1,000   $696,105   $(63,905,658)   21,207,361 

 

See Accompanying Notes To These Financial Statements.

 

 

 26 

 

 

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2023 and 2022

 

Note 1 – Description of Business

 

The Company was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company.

 

Sunshine Biopharma operates two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio of pharmaceutical products consisting of 52 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells nonprescription over-the-counter (“OTC”) products.

 

The Company has determined that it has two reportable segments:

 

•Prescription Generic Pharmaceuticals (“Generic Pharmaceuticals”)
•Nonprescription Over-The-Counter Products (“OTC Products”)

 

Through December 31, 2023, sales from the Generic Pharmaceuticals segment represented approximately 97% of total revenues of the Company while the remaining approximately 3% was generated from the sale of OTC Products. Based on these results, the Company deems segmentation reporting to be immaterial at December 31, 2023.

 

The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, in Canada Provincial governments reimburse patients for their prescription drugs expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on governmental policies which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance (“pCPA”) and the Canadian Generic Pharmaceutical Association have resulted in updated generic pricing for certain products which took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February 29, 2024, the Canadian federal government tabled new drug reimbursement legislation, a bill known as PharmaCare which, if passed, would result in a single-payer program whereby the Canadian federal government would pay for the drugs sold in Canada rather than the Provinces.

 

In addition, the Company is engaged in the development of the following proprietary drugs:

 

•Adva-27a, a small chemotherapy molecule for treatment of pancreatic cancer (IND-enabling studies were paused in November 2023 due to unfavorable results. See “Products in Development,” above.
•K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer
•SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections

 

Note 2 – Summary of Significant Accounting Policies

 

This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.

 

 

 27 

 

 

PRINCIPLES OF CONSOLIDATION

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

 

USE OF ESTIMATES

 

The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

  

TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

 

Trade accounts receivable are stated at net realizable value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis, management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts or if any accounts should be written off based on a past history of write-offs, collections and current credit conditions. A receivable is considered past due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral to support its receivables.

 

INVENTORY VALUATION

 

Inventory is valued at the lower of cost and net realizable value. Cost is determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business, less the costs of completion and costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to the acquisition of finished goods.

 

CASH AND CASH EQUIVALENTS

 

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $16,292,347 and $21,826,437 as of December 31, 2023 and December 31, 2022, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 in the U.S. or the equivalent in Canada.

 

PROPERTY AND EQUIPMENT

 

Property and equipment are reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2023 and 2022, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

 

 

 28 

 

 

Property and equipment are stated at cost. Depreciation is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows: 

   
Office Equipment: Straight-line and Declining balance method 5-7 Years / 20%
Computer Equipment: Declining balance method 55%
Laboratory Equipment: Straight-line method 5 Years
Vehicles: Straight-line and Declining balance method 5 Years / 30%

 

INTANGIBLE ASSETS

 

Intangible assets are amortized over their estimated useful lives according to the following methods at the following annual rates and period: 

   
Licenses: Straight-line method 5 Years
Website: Declining balance method 55%

 

Intangible assets are tested for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal. In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over its fair value.

 

INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES

 

The cost of patents and licenses acquired is capitalized and is amortized over the remaining life of the patents or licenses.

 

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future cash flows associated with it.

 

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

 

The Company computes gain or loss per share in accordance with ASC 260 – Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

 

Basic net income (loss) per share is calculated by dividing net gain (loss) by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2023, no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

 

INCOME TAXES

 

In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

 

 

 29 

 

 

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2023 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

 

For Canadian and US tax purposes, the Company’s 2020 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

 

FUNCTIONAL CURRENCY

 

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

 

The Company translates its Canadian subsidiaries' financial statements into U.S. dollars as follows:

 

  · Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.
  · Income statement accounts are translated using the weighted average exchange rate for the period.

 

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.

 

CONCENTRATION OF CREDIT RISKS

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

 

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company applies the provisions of accounting guidance, ASC 825 – Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023 and 2022, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

 

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

 

 

 30 

 

 
  · Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
     
  · Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.
     
  · Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

  

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

 

NOTES PAYABLE

 

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company had no notes payable as of December 31, 2023 and 2022.

 

REVENUE RECOGNITION

 

Over 97% of the Company’s revenues are derived from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies, purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company’s products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion) accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the Company.

 

No significant judgments are made in connection with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine the price of its products.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed at the Company’s current price list on the date of shipping and known in advance by the customer and does not vary.

 

The Company is involved in a singular activity which is to sell pharmaceutical finished goods. The Company fulfills its performance obligation when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured and the transfer of ownership to the customer takes place when the customer receives goods. At this point, the Company issues an invoice for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. It is when the invoice is issued that the revenue is recognized. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days of the date of the invoice. The collection is reasonably assured because of the nature of the Company’s customers. The Company is conducting sales only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.

 

 

 31 

 

 

In the event of any breach by the Company of any product warranty (whether by reason of defective materials, production faults or otherwise), the Company’s liability shall be limited to, at Company’s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company carries product insurance and is not liable for products’ failure to comply with the warranty of products if the failure or damage arises because of the customer’s negligence, deliberate damage, misuse or failure to store the products in conditions per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These conditions also apply to any replacement products supplied by the Company.

 

The Company warrants to the customer that, at the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements. In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable laws to purchase, store, distribute, sell and use the Company’s products. Visible defects or damages must be reported to the Company in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company shall not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters, terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts, shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not within the Company’s control.

 

LEASES

 

The Company recognizes and measures its leases in accordance with FASB ASC 842, Leases. The Company is a lessee in a non-cancellable operating lease for office space. The Company determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases. The Company’s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured throughout the lease term at the remaining amount (i.e., present value of the remaining lease payments), plus unamortized initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.

 

The Company has elected, for all underlying classes of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.

 

Under the available practical expedient, we account for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further, we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less).

 

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

  

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

 

 32 

 

 

Note 3 – Acquisition of Nora Pharma Inc.

 

On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (“Nora Pharma), a Canadian privately held pharmaceutical company. The purchase price for the shares was $18,860,637 which was paid in cash ($14,346,637) and by the issuance of 3,700,000 shares of the Company’s common stock valued at $4,514,000 or $1.22 per share on the acquisition date. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma’s operations are authorized by a Drug Establishment License issued by Health Canada.

 

The following table summarizes the allocation of the purchase price as of October 20, 2022, the acquisition date using Nora Pharma’s balance sheet assets and liabilities: 

     
Accounts receivable  $1,358,121 
Inventory   3,181,916 
Intangible assets   659,571 
Equipment & furniture   210,503 
Other assets   1,105,093 
Total assets   6,515,204 
Liabilities assumed   (5,981,286)
Net assets   533,918 
Goodwill   18,326,719 
Total Consideration  $18,860,637 

 

The value of the 3,700,000 common shares issued as part of the consideration paid for Nora Pharma was determined based on the closing market price of the Company’s common shares on the acquisition date, October 20, 2022 ($1.22 per share).

 

As part of the consideration paid for Nora Pharma, the Company agreed to a $5,000,000 CAD ($3,632,000 USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During the twelve-month period ended December 31, 2023, the Company paid an earn-out amount of $1,084,169 leaving a balance earn-out to be paid of $2,547,831 at December 31, 2023.

 

Note 4 – Goodwill

 

The Company acquired Nora Pharma on October 20, 2022. Allocation of the purchase price per ASC 805-20-25-1 yielded a goodwill amount of $18,326,719. The Company’s used a discounted cash flow model which requires estimating future cash flows expected to be generated from the acquired entity, discounted to their present value using a risk-adjusted discount rate and terminal values.

 

Assessing the recoverability of goodwill requires the Company to make estimates and assumptions about sales, operating margins, growth rates and discount rates based on its budgets, business plans, economic projections, anticipated future cash flows and marketplace data. Management determined that there are inherent uncertainties related to these factors as well as significant risks to cash flows due to ongoing geopolitical and geo-economics conflicts, making the discounted cash flow model unreliable.

 

 

 

 33 

 

 

The following table presents the changes in the carrying amount of goodwill of the Company as of December 31, 2022 and 2023. The provisions of ASC 350-20-50-1 require the disclosure of cumulative impairment. As a result of the acquisition, a new basis in goodwill was recorded in accordance with ASC 805-10. All impairments shown in the table below have been recorded subsequent to the acquisition. The Company had no goodwill on its balance sheet prior to the acquisition:

Schedule of goodwill     
Balance as of December 31, 2021  $– 
Acquisition of Nora Pharma (October 20, 2022)   18,326,719 
Impairment   (18,326,719)
Balance as of December 31, 2022   – 
Additions in 2023   – 
Balance as of December 31, 2023  $– 

 

Note 5 – Intangible Assets

 

Intangible assets, net, consisted of the following at December 31, 2022 and 2023:

Schedule of intangible assets     
Balance as of December 31, 2021  $– 
Finite-Lived intangible assets   659,571 
Dossier fee additions   121,807 
Balance at December 31, 2022   781,378 
Less accumulated amortization   (4,522)
Finite-lived intangible assets, net at December 31, 2022  $776,856 
      
Balance as of December 31, 2022  $776,856 
Dossier fee additions   710,372 
Balance at December 31, 2023   1,487,228 
Less accumulated amortization   (42,969)
Finite-lived intangible assets, net at December 31, 2023  $1,444,259 

 

As of December 31, 2023, the estimated amortization expense of the Company’s intangible assets for each of the next five years is as follows:

     
2024  $59,745 
2025   59,745 
2026   58,541 
2027   19,041 
2028   9,985 

 

 34 

 

 

Note 6 – Plant, Property and Equipment

 

Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:

Schedule of property and equipment          
   Year Ended December 31, 
   2023   2022 
Equipment  $171,859   $162,534 
Computer equipment   7,368    16,418 
Furniture and fixtures   34,132    33,329 
Leasehold improvements   17,664    – 
Vehicles   324,841    265,774 
Total   555,864    478,055 
Less: Accumulated depreciation   (189,996)   (83,806)
Plant, property and equipment, net  $365,868   $394,249 

 

Depreciation expense for the years ended December 31, 2023 and 2022 amounted to $110,701 and $20,641, respectively.

 

Note 7 – Reverse Stock Splits

 

Effective February 9, 2022, the Company completed a 1 for 200 reverse split of its common stock. The Company had previously completed two 20 to 1 reverse stock splits, one in 2019 and the other in 2020. The Company’s financial statements reflect all three reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

 

Note 8 – Capital Stock

 

The Company’s authorized capital is comprised of 3,000,000,000 shares of common stock, par value $0.001, and 30,000,000 shares of preferred stock, $0.10 par value. As of December 31, 2023, the Company had authorized 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible and non-redeemable. It has a liquidation preference to the common stock equal to the stated value of $0.10, relative to the rights to the common stock, and gives the holder the right to 1,000 votes per share. As of December 31, 2023, 10,000 shares of Series B Preferred Stock were outstanding and held by the Company’s Chief Executive Officer.

 

On February 17, 2022, the Company completed a public offering and received net proceeds of $6,833,071 from the offering. Pursuant to the public offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 warrants to purchase shares of common stock (the “Tradeable Warrants”).

 

On February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share. The remaining 10,000 shares of Series B Preferred Stock could not be voted pursuant to a warrant agent agreement relating to the Tradeable Warrants (the “Warrant Agent Agreement”). On October 12, 2023, the Company held a special meeting of the holders of the outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to the Warrant Agent Agreement to eliminate the provision that prohibited the Company’s CEO from exercising his voting rights under the Series B Preferred Stock, as well as to lower the exercise price of the Tradeable Warrants to $0.11. The Company entered into the amendment to the Warrant Agent Agreement on October 18, 2023.

 

 
 35 

 

 

On March 14, 2022, the Company completed a private placement and received net proceeds of $6,781,199. In connection with this private placement, the Company issued (i) 2,301,353 shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant was sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On October 20, 2022, the Company issued 3,700,000 shares of common stock as part of the acquisition of Nora Pharma. These shares were valued at $4,514,000, or $1.22 per share.

 

On January 19, 2023, the Company announced a stock repurchase program of up to $2 million (“Stock Repurchase Program”). During the six months ended June 30, 2023, the Company repurchased a total of 445,711 shares of common stock at an average price of $1.1371 per share for a total cost of $506,822. The 445,711 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 22,585,632 to 22,139,921.

 

On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with an institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were $4,089,218. In connection with the private placement, the Company issued (i) 2,450,000 shares of common stock, (ii) 3,502,381 pre-funded warrants (the “May Pre-Funded Warrants”), and (iii) investor warrants (the “May Warrants”) to purchase up to 11,904,762 shares of common stock at $0.59 per share. Each share of common stock and accompanying two May Warrants were sold together at a combined offering price of $0.84 and each May Pre-Funded Warrant and accompanying two May Warrants were sold together at a combined offering price of $0.839. The May Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Warrants have an exercise price of $0.59 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance.

 

In 2022 and 2023, the Company issued a total of 10,793,369 shares of common stock in connection with warrant exercises for aggregate net proceeds of $13,196,681.

 

 

 36 

 

 

In July 2023, the Company repurchased a total of 68,012 shares of common stock on the open market under the Stock Repurchase Program announced on January 19, 2023, at an average price of $0.5046 per share for a total cost of $34,321. In October 2023, the 68,012 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 25,746,302 to 25,678,290.

 

On November 16, 2023, the Company issued 2,346,000 shares of common stock and received net proceeds of $2,346 in connection with the exercise of all 2,346,000 remaining May Pre-Funded Warrants at the nominal exercise price of $0.001 per share.

 

As of December 31, 2023 and December 31, 2022, the Company has a total of 28,024,290 and 22,585,632 shares of common stock issued and outstanding, respectively.

 

The Company has declared no dividends since inception.

 

Note 9 – Warrants

 

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

 

In 2022 and 2023, the Company completed four financing events, and in connection therewith, it issued warrants as follows: 

           
Type   Number   Exercise Price   Expiry Date
Pre-Funded Warrants   3,692,276   $0.001   Unlimited
Tradeable Warrants   4,102,200   $2.22*   February 2027
Investor Warrants   3,603,604   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Pre-Funded Warrants   3,502,381   $0.001   Unlimited
May Warrants   11,904,762   $0.59   November 2028

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.

 

As of December 31, 2023, all of the Pre-Funded Warrants and a total of 3,138,507 Tradeable Warrants, 2,802,703 Investor Warrants, and all of the May Pre-Funded Warrants were exercised resulting in aggregate proceeds of $13,196,681 received by the Company.

 

 

 

 37 

 

 

The Company’s outstanding warrants at December 31, 2023 consisted of the following: 

           
Type   Number   Exercise Price   Expiry Date
Tradeable Warrants   963,693   $0.11*   February 2027
Investor Warrants   800,901   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Warrants   11,904,762   $0.59   November 2028

* On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.

 

Note 10 – Earnings Per Share

 

The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

        
   2023   2022 
Net gain (loss) attributable to common stock  $(4,506,044)  $(26,744,440)
Basic weighted average outstanding shares of common stock   24,331,908    15,180,868 
Dilutive common share equivalents   –    – 
Dilutive weighted average outstanding shares of common stock   24,331,908    15,180,868 
Net gain (loss) per share attributable to common stock  $(0.19)  $(1.76)

 

Note 11 – Income Taxes

 

The components of the provision for income taxes were as follows:

    
Current:     
Federal  $– 
State   50 
Foreign   379,246 
    

379,296

 
Deferred:     
Federal   – 
State   – 
Foreign   15,870 
    15,870 
Total  $395,166 

 

 

 

 38 

 

 

The Company’s effective tax rate differs from the federal statutory rate as follows:

Schedule of income tax expense          
Pre-Tax Book Income  $(826,953)  $20.14% 
State Taxes   50    0.00% 
Permanent Adjustments   56,812    -1.38% 
Change in Valuation Allowance   860,705    -20.96% 
Foreign Tax Rate Differential   –    0.00% 
Rate Change   167,676    -4.08% 
Provision to Return Adjustments   67,144    -1.63% 
Other   69,732    -1.70% 
Total  $395,166   $-9.62% 

 

The components of the net deferred tax assets and liabilitie were as follows:

    
Deferred Tax Assets:    
Net Operating Loss, Credits and Carryforwards  $5,277,829 
Fixed Assets   – 
Intangibles   641,800 
Research and Development   25,327 
Other DTA   454,890 
Lease Liability   174,292 
Valuation Allowance   (6,397,374)
Deferred Tax Assets   176,764 
Deferred Tax Liabilities:     
Fixed Assets   

(54,095

)
Intangibles   – 
Right-of-Use Asset   (171,396)
Deferred Tax Liabilities   (225,491)
Net Deferred Tax Liability  $(48,727)

 

Note 12 – Leases

 

The Company has obligations as a lessee for office space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company’s lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable Payment. The Company’s office space lease requires it to make variable payments for the Company’s proportionate share of building’s property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred.

 

Amounts reported on the balance sheet as of December 31, 2023 were as follows: 

   
Operating lease ROU asset $646,779
Operating Lease liability - Short-term $118,670
Operating lease liability - Long-term $539,035
Remaining lease term 6 years
Discount rate 6%

  

Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.

 

 

 39 

 

 

Maturities of lease liabilities under non-cancellable operating leases at December 31, 2023 are as follows:

 
2024 $118,670
2025 $118,862
2026 $112,582
2027 $106,042
2028 $99,881
Thereafter $101,667

  

Note 13 – Management and Director Compensation

 

The Company paid its officers cash compensation totaling $1,515,000 and $1,785,000 for the years ended December 31, 2023 and 2022, respectively. Of these amounts attributable to the Company’s CEO, $0 and $60,000, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

 

The Company paid its directors cash compensation totaling $400,000 and $300,000 for the years ended December 31, 2023 and 2022, respectively.

 

Note 14 – Subsequent Events

 

On February 15, 2024, the Company closed a firm commitment underwritten public offering with gross proceeds to the Company of approximately $10.0 million. The offering consisted of 71,428,571 Units, consisting of (a) 26,428,571 Common Units, with each Common Unit consisting of one share of our common stock, one-tenth (1/10) of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths (2/10) of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (b) 45,000,000 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock, one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The Pre-Funded Warrants are immediately exercisable at $0.001 per share and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant is $2.10 per share of common stock or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant is $2.38 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date.

 

On February 11, 2024, the Company bought back the 11,904,762 May Warrants from the holder, a single entity, for an aggregate purchase price of $2,361,596. Upon the closing of the transaction, the May Warrants were deemed cancelled and terminated in all respects.

 

On February 11, 2024, the Company entered into securities purchase agreements (the “April Warrants Purchase Agreements”) with the holders of warrants, dated April 28, 2022 (the “April Warrants”) to purchase an aggregate of 9,725,690 shares of common stock of the Company. Pursuant to the April Warrant Purchase Agreements, the Company bought back from the holders the April Warrants for a purchase price of $0.08 per April Warrant, for an aggregate purchase price of $778,055. Upon the closing of the April Warrant Purchase Agreements, which occurred on February 12, 2024, the Company paid the purchase price to the holders, and the April Warrants were deemed cancelled and terminated in all respects.

 

On February 8, 2024, the Company sold 20,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.

 

On March 4, 2024, the Company sold 100,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.

 

On March 4, 2024, the Company’s board of directors, and Company’s chief executive officer, as the holder of the majority of the voting power of the Company’s stockholders, approved an up to 1-for-200 reverse split of the Company’s common stock in order for the Company to become compliant with Nasdaq’s $1.00 minimum bid price for the listed common shares.

 

 

 

 

 40 

 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this report.

 

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

 

Based on this evaluation, our management, including our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2023, at reasonable assurance levels.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate “internal control over financial reporting,” as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act. Our system of internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with US GAAP.

 

Our internal control over financial reporting includes those policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized use, acquisition, or disposition of our assets that could have a material effect on the consolidated financial statements.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as of December 31, 2023, and they concluded that our internal control over financial reporting was effective as of December 31, 2023. In making this assessment, we utilized the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control — Integrated Framework (2013).

 

No Attestation Report by Independent Registered Accountant

 

The effectiveness of our internal control over financial reporting as of December 31, 2023, has not been audited by our independent registered public accounting firm by virtue of our exemption from such requirement as a smaller reporting company.

 

Changes in Internal Controls over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended December 31, 2023.

 

ITEM 9B. OTHER INFORMATION

 

During the quarter ended December 31, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

  

 

 41 

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 

The following individuals currently serve as our Board of Directors and executive officers.

 

Name   Age   Position(s)
         
Dr. Steve N. Slilaty   71   President, Chief Executive Officer and Chairman
         
Dr. Abderrazzak Merzouki   60   Chief Science Officer and Director
         
Mr. Camille Sebaaly   62   Chief Financial Officer and Secretary
         
Dr. Rabi Kiderchah   51   Director
         
Mr. David Natan   70   Director
         
Dr. Andrew Keller   70   Director
         
Mr. Malek Chamoun   39   Chief Development Officer
         
Mr. Marc Beaudoin   58   Chief Operating Officer

 

Dr. Steve N. Slilaty was appointed as our chief executive officer and chairman of our board of directors on October 15, 2009. Dr. Slilaty is an accomplished scientist and business executive. His scientific publications are widely cited. Sunshine Biopharma is the third in a line of biotechnology companies that Dr. Slilaty founded and managed. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and is now a member of a family of companies owned by MP Biomedicals, one of the largest international suppliers of biotechnology reagents. The second company which Dr. Slilaty founded, Genomics One Corporation, conducted an initial public offering of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty’s patented TrueBlue® Technology, Genomics One became one of the key participants in the Human Genome Project and reached a market capitalization of $1 billion in 2000. Formerly, Dr. Slilaty was a research team leader at the Biotechnology Research Institute (Montreal), a division of the National Research Council of Canada. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first gene delivery system applicable to humans in 1983 [Science 220: 725-727 (1983)]. Dr. Slilaty's other distinguished scientific career accomplishments included (i) the discovery of a new class of enzymes, the S24 Family of Proteases (IUBMB Enzyme: EC 3.4.21.88) [Proc. Natl. Acad. Sci. U.S.A. 84: 3987-3991 (1987)]. In addition, Dr. Slilaty (i) developed the first site-directed mutagenesis system applicable to double-stranded DNA [Analyt. Biochem. 185: 194-200 (1990)], (ii) cloned the gene for the first yeast-lytic enzyme (lytic b-1,3-glucanase) [J. Biol. Chem. 266: 1058-1063 (1991)], (iii) developed a new molecular strategy for increasing the rate of enzyme reactions [Protein Engineering 4: 919-922 (1991)], and (iv) constructed a powerful new cloning system for genomic sequencing (TrueBlue® Technology) [Gene 213: 83-91 (1998)]. Most recently, Dr. Slilaty, in collaboration with Institut National des Sciences Appliquée (France), State University of New York at Binghamton (USA) and École Polytechnique, Université de Montréal (Canada), designed, patented, and advanced the development the first, and currently the only known anticancer compound (Adva-27a) capable of destroying multidrug resistant cancer cells [Anticancer Res. 32: 4423 (2011) and US Patent Numbers: 8,236,935 and 10,272,065]. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty is the author of 18 original research papers and 10 issued and pending. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty received his Ph.D. degree in Molecular Biology from the University of Arizona in 1983 and Bachelor of Science degree in Genetics and Biochemistry from Cornell University in 1976. Dr. Slilaty has received research grants from the NIH and NSF and he is the recipient of the 1981 University of Arizona Foundation award for Meritorious Performance in Teaching.

 

 

 42 

 

 

Dr. Abderrazzak Merzouki was appointed as a director and our Chief Operating Officer in February 2016. In January 2024, he resigned from his position as Chief Operating Officer and became our Chief Science Officer but remained a director. From July 2007 through December 2016, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. Dr. Merzouki is a molecular biologist and an immunologist with extensive experience in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology.

  

Mr. Camille Sebaaly was appointed as our chief financial officer, secretary and a director of our Company on October 15, 2009. He resigned as a director of the Company in October 2021. Mr. Sebaaly held a number of senior executive positions in various areas including financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987.

 

Dr. Rabi Kiderchah has served as a director of our Company since October 2021. Dr. Kiderchah is a licensed physician in Canada. From 2000 until August 2021, he was working at Argenteuil Hospital, Lachute, Quebec, Canada, as an emergency room physician. He has also worked as what is referred to in Canada as a “medecins depanneurs”, working in rural areas where there are not enough ER doctors. Since August 2011 he has worked at Rabi Kiderchah Medecin Inc. as a freelance physician in the Quebec, Canada area. He received a Bachelor of Science degree in 1994 and an MD degree in 1998 from the University of Montreal.

 

Mr. David Natan has served as a director of our Company since February 2022. He currently serves as CEO of Natan & Associates, LLC, a consulting firm offering CFO services to public and private companies since 2007. From February 2010 to May 2020, Mr. Natan served as CEO of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on LED lighting products. From February 2002 to November 2007, Mr. Natan served as CFO of PharmaNet Development Group, Inc., a drug development company, and, from June 1995 to February 2002, as CFO and VP of Global Technovations, Inc., a manufacturer and marketer of speaker components. Prior to that, Mr. Natan served in various roles with Deloitte & Touche LLP. From April 2020 through June 2023, Mr. Natan was Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., Spokane, WA, a privately-held aerospace transportation company. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of NetBrands, Inc. (OTC: NBND), a distributor of snack products, since February 2021; and serves as a member of the Board of Directors and Chair of the Audit Committee of Titan Pharmaceuticals Inc. (NASDAQ: TTNP) a pharmaceutical company, since August 2022. Additionally, in November 2023, Mr. Natan was appointed to the board of Directors and Audit Committee Chair of Minim Inc. (NASDAQ: MINM). Mr. Natan holds a B.A. in Economics from Boston University.

 

Dr. Andrew M. Keller has served as a director of our Company since February 2022. From 2016 through November 2019, Dr. Keller was the Chief Medical Officer at the Western Connecticut Medical Group, Bethel CT, a multispecialty organization. He was employed by this group beginning in 1989, and in 2003 became Chief – Section of Cardiovascular Diseases. In 2014 he was appointed Chief Medical Informatics Officer. Previously, Dr. Keller was an Assistant Professor of Medicine/Radiology at Columbia University, The College of Physicians and Surgeons, NY, NY. Dr. Keller retired as a practicing physician in 2019. Upon his retirement as a practicing physician Dr. Keller enrolled as a full time student at Quinnipiac University College of Law, where he graduated with a Juris Doctor degree in 2023. In July 2023, Dr. Keller passed the Bar exam and was admitted to practice law in the State of Connecticut in November 2023. Since November 2023 he has been employed at the Law Office of Robin P. Keller LLC, Norwalk, CT advocating for the educational needs of disabled children with medically complex diagnoses. Dr. Keller received a Doctor of Medicine degree in 1979 from The Ohio State University and a Bachelor of Arts degree in Physics, Magna Cum Laude from Ithaca College in 1975.

 

 

 

 43 

 

 

Mr. Malek Chamoun was appointed as our Chief Development Officer in January 2024. In addition, he is President of Nora Pharma Inc., our wholly owned subsidiary that we acquired in October 2022. In 2017 he founded Nora Pharma, where he has been the President since inception. Mr. Chamoun received a bachelor’s degree in business administration from Hautes Études Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012. He devotes all of his business time to Nora Pharma’s affairs. 

 

Mr. Marc Beaudoin was appointed as our Chief Operating Officer in January 2024. Mr. Beaudoin was the sole owner of M.A. Beaudoin Consulting Group Inc., a privately held business strategy consulting company in the Canadian pharmaceutical and biopharmaceutical sectors since 2016. From January 2018 through February 2019, he was employed by the KDA Group, Inc., a publicly held Canadian healthcare company, as the COO of KDA Group and CEO of its Canadian generic pharmaceutical division, Pharmapar. From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and Communications, Strategic Planning, Business Development & Portfolio Management. As an executive and an entrepreneur, he combines expertise in strategic planning with operational and commercial execution. Mr. Beaudoin obtained his MBA from Sherbrooke University in 2018. He also holds multiple certifications (including a fellowship) from the Association for Supply Chain Management. 

 

Corporate Governance

 

Board of Directors Term of Office

 

Directors are elected at our annual meeting of shareholders and serve for one year until the next annual meeting of shareholders or until their successors are elected and qualified.

  

Committees of our Board of Directors

 

We have established an audit committee, a compensation committee, and a corporate governance and nominating committee of our board of directors. Each committee is comprised of each of our independent directors. David Natan is our audit committee financial expert.

   

No Family Relationships

 

There is no family relationship between any director and executive officer or among any directors or executive officers.

  

Involvement in Certain Legal Proceedings

 

Our directors and executive officers have not been involved in any of the following events during the past ten years:

 

  1. any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
     
  2. any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
     
  3. being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
     
  4. being found by a court of competent jurisdiction in a civil action, the SEC or the CFTC to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
     
  5. being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  6. being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

 

 44 

 

 

Board Diversity

 

Our Board seeks members from diverse professional backgrounds who combine a solid professional reputation and knowledge of our business and industry with a reputation for integrity. Our Board does not have a formal policy concerning diversity and inclusion but is in the process of establishing a policy on diversity. Diversity of experience, expertise, and viewpoints is one of many factors the Nominating and Corporate Governance Committee considers when recommending director nominees to our Board. Further, our Board is committed to actively seeking highly qualified women and individuals from minority groups and the LGBTQ+ community to include in the pool from which new candidates are selected. Our Board also seeks members that have experience in positions with a high degree of responsibility or are, or have been, leaders in the companies or institutions with which they are, or were, affiliated, but may seek other members with different backgrounds, based upon the contributions they can make to our Company. While the Board has continued its efforts to identify candidates that have such experience, they have currently been unable to identify any such candidates which fulfill the diversity requirement with the requisite professional experience.

 

Code of Ethics

 

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, and principal accounting officer. Our Code of Ethics is available on our website at www.sunshinebiopharma.com.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The following table sets forth compensation information for services rendered by our executive officers in all capacities during the last two completed fiscal years.

 

Name and Principal Position   Year     Salary ($)     Bonus ($)     Stock Awards ($)     All Other Compen-
sation ($)		     Total ($)  
                                     
Dr. Steve N. Slilaty     2022       360,000 (1)     10,000       –       –       370,000  
Chief Executive Officer and Director     2023          378,000       182,000               –          560,000  
                                                 
Camille Sebaaly     2022       300,000       630,000       –       –       930,000  
Chief Financial Officer     2023          315,000       380,000               –          695,000  
                                                 
Dr. Abderrazzak Merzouki     2022       240,000       245,000       –       –       485,000  
Chief Operating Officer and Director     2023          252,000       8,000               –          260,000  

  (1) Of this amount, $60,000 was paid to Advanomics Corporation, a company controlled by Dr. Slilaty.

 

Employment Agreements

 

On April 8, 2022, we entered into an employment agreement with Dr. Steve N. Slilaty, our Chief Executive Officer. Pursuant to the employment agreement, Dr. Slilaty will continue to serve as our CEO and will be paid a base annual salary of $360,000 (which will increase annually at the rate of the Consumer Price Index or 5%, whichever is higher). The employment agreement has a term of four years and will renew automatically for a term of an additional three years. In the event the employment agreement is terminated by us without cause, we will pay Dr. Slilaty $10 million. Upon expiration of the employment agreement, we will pay Dr. Slilaty $2 million.

 

Outstanding Equity Awards at 2023 Fiscal Year-End

 

We did not have any outstanding equity awards as of December 31, 2023.

 

 

 

 45 

 

 

Director Compensation

 

The following table sets forth compensation we paid to our directors during the year ended December 31, 2023.

 

Name   Fees Paid in Cash ($)     Stock Awards     Option Awards     All Other Compensation     Total ($)  
Dr. Rabi Kiderchah     80,000       –       –       –       80,000  
Mr. David Natan     80,000       –       –       –       80,000  
Dr. Abderrazzak Merzouki     80,000       –       –       –       80,000  
Dr. Andrew Keller     80,000       –       –       –       80,000  
Dr. Steve N. Slilaty     80,000       –       –       –       80,000  

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information, as of March 28, 2024, with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five (5%) percent; (ii) each of our executive officers and directors; and (iii) our directors and executive officers as a group.

 

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. The table lists applicable percentage ownership based on 99,452,865 shares of common stock outstanding as of March 28, 2024. In addition, under SEC rules, beneficial ownership of common stock includes shares of our common stock issuable pursuant to the conversion or exercise of securities that are either immediately exercisable or convertible into common stock or exercisable or convertible into common stock within 60 days of March 28, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

 

 

 

 

 46 

 

 

Title of Class  Name and Address of Beneficial Owner  Amount   Percent of Class  
            
Common 

Dr. Steve N. Slilaty(1)

c/o Sunshine Biopharma, Inc.

1177 Avenue of the Americas, 5th Floor

       
   New York, NY 10036   3,821,024(3)    3.8% 
Series B Preferred      130,000(2)    100% 
              
Common 

Camille Sebaaly(1)

c/o Sunshine Biopharma, Inc.

1177 Avenue of the Americas, 5th Floor

New York, NY 10036

    174,465    * 
              
Common  Dr. Abderrazzak Merzouki(1)

c/o Sunshine Biopharma, Inc.

1177 Avenue of the Americas, 5th Floor

New York, NY 10036

   116,720    * 
              
Common 

Dr. Andrew Keller(1)

c/o Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York, NY 10036

   0    * 
              
Common  David Natan(1)
c/o Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York, NY 10036		   0    * 
              
Common  Dr. Rabi Kiderchah(1)
c/o Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York, NY 10036		   1,625    * 
              
Common 

Malek Chamoun(1)

c/o Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor

       
   New York, NY 10036   3,700,000(3)    3.7% 
              
Common 

Marc Beaudoin(1)

c/o Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York, NY 10036		   0    * 
              
   All Officers and Directors as Group (8 persons)   4,113,834    4.1% 

* Less than 1%.

(1) Officer and/or director of our Company.
(2) Each share of Series B Preferred Stock gives the holder the right to 1,000 votes per share.
(3)

Includes 3,700,000 common shares owned by Malek Chamoun, the President of Nora Pharma Inc., a company acquired by the Company in October 2022. Dr. Slilaty controls the voting of Mr. Chamoun’s shares through a voting agreement between Mr. Chamoun and Dr. Slilaty dated October 20, 2022.

 

 

 

 47 

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Related Transactions

 

On February 22, 2022, we redeemed 990,000 shares of Series B Preferred Stock held by Dr. Steve Slilaty, our CEO, at a redemption price equal to the stated value of $0.10 per share.

 

On February 8, 2024, we sold 20,000 shares of Series B Preferred Stock to Dr. Slilaty for a purchase price equal to the stated value of $0.10 per share.

 

On March 4, 2024, we sold 100,000 shares of Series B Preferred Stock to Dr. Slilaty for a purchase price equal to the stated value of $0.10 per share.

 

Director Independence

 

Our independent directors consist of Dr. Kiderchah, Mr. Natan and Dr. Keller.

  

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

  

The following table presents fees for professional audit services rendered by B F Borgers CPA PC, our independent auditors, during our fiscal years ended December 31, 2023 and 2022:

  

  

December 31,

2023

  

December 31,

2022

 
Audit Fees  $170,500   $137,500 
Audit-related Fees   –    – 
Tax Fees   –    – 
All Other Fees   –    – 
Total  $170,500   $137,500 

 

Audit Fees. Audit fees consist of amounts billed for professional services rendered for the audit of our annual financial statements included in our Annual Reports on Forms 10-K for our fiscal years ended December 31, 2023 and 2022 and for reviews of our interim financial statements included in our Quarterly Reports on Form 10-Q.

  

Audit-related Fees. Audit-related fees represent fees for assurance and related services performed that are reasonably related to the performance of the audit or review of our financial statements.

 

Tax Fees. B F Borgers CPA PC did not perform any tax compliance services for us during the years ended December 31, 2023 or 2022.

 

All Other Fees. B F Borgers CPA PC did not receive any other fees from us for the years ended December 31, 2023 or 2022.

 

As of December 31, 2023, the Board of Directors appointed our three independent directors as the members of our audit committee. Our audit committee charter is available is available on our website at www.sunshinebiopharma.com.

 

 

 

 48 

 

 

PART IV

 

ITEM 15           EXHIBITS

 

1.1   Underwriting Agreement, dated February 13, 2024 (1)
3.1   Articles of Incorporation (3)
3.2   Certificate of Amendment to Articles of Incorporation filed November 2, 2009 (5)
3.3   Statement of Share and Equity Capital Exchange (5)
3.4   Articles of Amendment to Articles of Incorporation filed July 13, 2010 (5)
3.5   Articles of Amendment to Articles of Incorporation filed May 27, 2015 (6)
3.6   Articles of Amendment to Articles of Incorporation (7)
3.7   Articles of Amendment to Articles of Incorporation (8)
3.8   Bylaws (15)
4.1   Description of Registrant’s Securities (17)
10.1   Patent Purchase Agreement with Advanomics Corporation (9)
10.2   Second Patent Purchase Agreement with Advanomics Corporation (10)
10.3   Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note (11)
10.4   Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note (11)
10.5   Form of Warrant, dated February 17, 2022 (2)
10.6   Warrant Agent Agreement between the Company and Equiniti, dated February 17, 2022 (2)
10.7   Sponsored Research Agreement, dated October 6, 2020, between the Company and the University of Georgia Research Foundation, Inc. (12) *
10.8   Research Agreement between the Company and Arizona Board of Regents on behalf of the University of Arizona (13)
10.9   Form of Warrant, dated March 14, 2022 (16)
10.10   Form of Amendment to Warrant, dated March 24, 2022 (18)
10.11   Employment Agreement between Sunshine Biopharma, Inc. and Dr. Steve Slilaty (19)
10.12   Form of Warrant, dated April 28, 2022 (20)
10.13   Share Purchase Agreement between Sunshine Biopharma, Inc., Malek Chamoun and Nora Pharma Inc. (21)
10.14   Employment Agreement between Sunshine Biopharma, Inc., Nora Pharma Inc. and Malek Chamoun (21)
10.15   License Agreement between the Company and the University of Arizona (22) *
10.16   Form of Warrant, dated May 16, 2023 (23)
10.17   Amendment No. 1 to Warrant Agent Agreement, dated October 18, 2023 (24)
10.18   2023 Equity Incentive Plan (25)
10.19   Form of Warrant Agency Agreement (26)
10.20   Form of Pre-Funded Warrant (26)
10.21   Form of Series A Warrant (1)
10.22   Form of Series B Warrant (1)
14.1   Code of Ethics (14)
21.1   Subsidiaries (filed herewith)
23.1   Consent of BF Borgers CPA PC (filed herewith)
31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act (filed herewith)
31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act (filed herewith)
32.1   Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
97.1   Clawback policy (filed herewith)

 

 

 49 

 

 

EX-101   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
EX-104   Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

 _______________________

  * Portions of the exhibit have been omitted.

 

(1) Incorporated by reference to 8-K filed with the SEC on February 15, 2024.
(2) Incorporated by reference to 8-K filed with the SEC on February 17, 2022.
(3) Incorporated by reference to SB-2 filed with the SEC on October 19, 2007.
(4) Incorporated by reference to 8-K filed with the SEC on November 6, 2009.
(5) Incorporated by reference to 10-Q filed with the SEC on August 4, 2010.
(6) Incorporated by reference to 8-K filed with the SEC on June 1, 2015.
(7) Incorporated by reference to 8-K filed with the SEC on June 24, 2020.
(8) Incorporated by reference to 8-K filed February 9, 2022.
(9) Incorporated by reference to 8-K filed with the SEC on October 9, 2015.
(10) Incorporated by reference to 8-K filed with the SEC on December 28, 2015.
(11) Incorporated by reference to 8-K filed with the SEC on March 14, 2016.
(12) Incorporated by reference to S-1/A filed with the SEC on January 24, 2022.
(13) Incorporated by reference to 8-K filed with the SEC on February 25, 2022.
(14) Incorporated by reference to 10-K filed with the SEC on May 1, 2020.
(15) Incorporated by reference to 8-K filed with the SEC on April 19, 2023.
(16) Incorporated by reference to 8-K filed with the SEC on March 15, 2022.
(17) Incorporated by reference to 10-K filed with the SEC on March 21, 2022.
(18) Incorporated by reference to 8-K filed with the SEC on March 24, 2022.
(19) Incorporated by reference to 8-K filed with the SEC on April 8, 2022.
(20) Incorporated by reference to 8-K filed with the SEC on April 28, 2022.
(21) Incorporated by reference to 8-K filed with the SEC on October 20, 2022.
(22) Incorporated by reference to 8-K filed with the SEC on February 28, 2023.
(23) Incorporated by reference to 8-K filed with the SEC on May 16, 2023.
(24) Incorporated by reference to 8-K filed with the SEC on October 20, 2023.
(25) Incorporated by reference to S-8 filed with the SEC on January 8, 2024.
(26) Incorporated by reference to S-1/A filed with the SEC on February 9, 2024.

 

 

 

 

 

 50 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 

  SUNSHINE BIOPHARMA, INC.  
       
Dated: March 28, 2024 By: /s/ Dr. Steve N. Slilaty  
    Dr. Steve N. Slilaty, Chief Executive Officer (principal executive officer)  
       
    /s/ Camille Sebaaly  
    Camille Sebaaly, Chief Financial Officer (principal financial and accounting officer)  
       

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Dr. Steve N. Slilaty   Chief Executive Officer and Director   March 28, 2024
Dr. Steve N. Slilaty   (Principal Executive Officer)    
         
/s/ Camille Sebaaly   Chief Financial Officer   March 28, 2024
Camille Sebaaly   (Principal Financial and Accounting Officer)    
         
/s/ Dr. Abderrazzak Merzouki   Director   March 28, 2024
Dr. Abderrazzak Merzouki        
         
/s/ David Natan   Director   March 28, 2024
David Natan        
         
/s/ Dr. Andrew Keller   Director   March 28, 2024
Dr. Andrew Keller        
         
/s/ Dr. Rabi Kiderchah   Director   March 28, 2024
Dr. Rabi Kiderchah        

 

 

 51 

 

 EX-21.1 2 sunshine_ex2101.htm LIST OF SUBSIDIARIES

EXHIBIT 21.1

 

SUNSHINE BIOPHARMA, INC.

 

LIST OF SUBSIDIARIES

 

 

Sunshine Biopharma Canada Inc.

 

Nora Pharma Inc.

 EX-23.1 3 sunshine_ex2301.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-264830, 333-263998, and 333-272197) and Form S-8 (No. 333-276417) of our report dated March 28, 2024, relating to the consolidated financial of Sunshine Biopharma, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.

 

 

A picture containing text Description automatically generated 

Certified Public Accountants

Lakewood, CO

March 28, 2024

 EX-31.1 4 sunshine_ex3101.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

 

I, Steve N. Slilaty, certify that:

 

1.            I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

 

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.           Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.           Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

 

d.           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

March 28, 2024 /s/ Steve N. Slilaty
  Steve N. Slilaty, Chief Executive Officer

 

 EX-31.2 5 sunshine_ex3102.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

 

I, Camille Sebaaly, certify that:

 

1.            I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

 

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.           Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.           Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

 

d.           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: March 28, 2024 /s/ Camille Sebaaly
  Camille Sebaaly, Chief Financial Officer

 

 EX-32.1 6 sunshine_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this annual report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1. The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: March 28, 2024

 /s/ Steve N. Slilaty
  Steve N. Slilaty, Chief Executive Officer
   
Dated: March 28, 2024 /s/ Camille Sebaaly
  Camille Sebaaly, Chief Financial Officer

 

 EX-97.1 7 sunshine_ex9701.htm CLAWBACK POLICY

Exhibit 97.1

 

SUNSHINE BIOPHARMA, INC.

CLAWBACK POLICY

EFFECTIVE NOVEMBER 17, 2023

 

1.Purpose. The purpose of this Sunshine Biopharma, Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”) and Listing Rule 5608 of the corporate governance rules of The Nasdaq Stock Market (“Nasdaq”) (the “Listing Standards”). Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 2.

 

2.Definitions. As used in this Policy, the following capitalized terms shall have the meanings set forth below.

 

a.“Accounting Restatement” means an accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a “Big R” restatement), or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a “little r” restatement).

 

b.“Accounting Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board’s action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.

 

c.“Applicable Period” means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).

 

d.“Board” means the board of directors of the Company.

 

e.“Code” means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.

 

f.“Covered Executive Officer” means an individual who is currently or previously served as the Company’s principal executive officer, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller), vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), an officer who performs (or performed) a policy-making function, or any other person who performs (or performed) similar policy-making functions for the Company or is otherwise determined to be an executive officer of the Company pursuant to Item 401(b) of Regulation S-K. An executive officer of the Company’s parent or subsidiary is deemed a “Covered Executive Officer” if the executive officer performs (or performed) such policy- making functions for the Company.

 

 

 

 1 

 

 

g.“Erroneously Awarded Compensation” means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.

 

h.“Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure is not required to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a “Financial Reporting Measure.”

 

i.“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is deemed “received” for purposes of this Policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.

 

3.Administration. This Policy shall be administered by the Board, the Compensation Committee of the Board (the “Compensation Committee”), the Audit Committee of the Board (the “Audit Committee”) or a special committee comprised of members of the Compensation Committee and Audit Committee. For purposes of this Policy, the body charged with administering this Policy shall be referred to herein as the “Administrator.” The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Administrator pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this Policy.
   
  

In the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to any limitation at applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). Any action or inaction by the Administrator with respect to a Covered Executive Officer under this Policy in no way limits the Administrator’s decision to act or not to act with respect to any other Covered Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this Policy.

 

 

 

 2 

 

 

4.Application of this Policy. This Policy applies to all Incentive-Based Compensation received by a person: (a) after beginning service as a Covered Executive Officer; (b) who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a listed class of securities on a national securities exchange; and (d) during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.

 

5.Recovery Erroneously Awarded Compensation. In the event of an Accounting Restatement, the Company must recover Erroneously Awarded Compensation reasonably promptly, in amounts determined pursuant to this Policy. The Company’s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this Policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Administrator in its sole and absolute discretion, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.
   
  

Recovery may include, without limitation, (i) reimbursement of all or a portion of any incentive compensation award, (ii) cancellation of incentive compensation awards and (iii) any other method authorized by applicable law or contract.

 

The Company is authorized and directed pursuant to this Policy to recover Erroneously Awarded Compensation in compliance with this Policy unless the Compensation Committee has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:

 

a.The direct expenses paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before reaching such conclusion, the Administrator must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq;

 

b.Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching such conclusion, the Administrator must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation, and must provide such opinion to Nasdaq; or

 

c.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.

 

6.Prohibition on Indemnification and Insurance Reimbursement. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this Policy would not apply or fail to be enforced against a Covered Executive Officer.

 

 

 

 3 

 

 

7.Required Policy-Related Disclosure and Filings. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. A copy of this Policy and any amendments hereto shall be posted on the Company’s website and filed as an exhibit to the Company’s annual report on Form 10-K.

 

8.Acknowledgement. Each Covered Executive Officer shall sign and return to the Company within thirty (30) calendar days following the later of (i) the effective date of this Policy set forth below or (ii) the date such individual becomes a Covered Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the Covered Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.

 

9.Amendment; Termination. The Board may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this Policy at any time; provided, that the termination of this Policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S. Securities and Exchange Commission or the Listing Standards.

 

10.Other Recovery Obligations; General Rights. The Board intends that this Policy shall be applied to the fullest extent of the law. To the extent that the application of this Policy would provide for recovery of Incentive- Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this Policy in respect of such Covered Executive Officer.

 

11.Effective Date. This Policy shall be effective as of November 17, 2023. The terms of this Policy shall apply to any Incentive- Based Compensation that is received by Covered Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to such date.

 

This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.

 

This Policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.

 

 

 

 4 

 

 

EXHIBIT A

SUNSHINE BIOPHARMA, INC. CLAWBACK POLICY

ACKNOWLEDGEMENT FORM

 

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Sunshine Biopharma, Inc. (the “Company”) Clawback Policy (the “Policy”).

 

By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment or service with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.

 

 

EXECUTIVE OFFICER

 

 

______________________________________

Signature

 

 

______________________________________

Print Name

 

 

______________________________________

Date

 

 

 

 5 

 

 GRAPHIC 8 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBO//B# M\2$\-[M+TO9+JA7YW/*VX/3([MCH/Q/H;A!S=D1.<8*\CK=<\3:1X<@$NJ7L M<&X92/J[_11R?KTKSB^^,EU>W8M/#FBF61SA&N269O\ @"]/^^J\K1=2\1ZR MJM)+=WUR_+R-DGW)[ ?H*]Q\,^$]%\.605)GDNW4>=/Y?+'T'H/:N7,\90R^ MG9M.H]DY**]7Y?F8T/:XF7NZ1[VN/TB3Q-78?\ />7_ +XH\NP_Y[R_]\5\!6S''5I\\IP7I.R^ MY/\ S/;A1IP5DG\U/N/JJ$?UJW;7MO=Y$,@+#DJ>&'X5B>78?\ M/>7_ +XICP6+89+J>.1>4=5P5->E@U;N/HPX$H]1[^U;5?9III2B[IZI]T<*=PHHHIC"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/&_B5?"WAF>^7:; ME_W5LI[R'O\ 0#)_"OF6>>6YN))YY&DED8N[L@%>KAH*,+]SR,54^%>A6-OIGJOI<&D:?I5I9B"0^1"D9.3R0,$]:M^ M;I/_ #PD_,_XU^88[$+%8B564Z+N]+\S=NGX'TE"G[*FH)2_X(S;I?\ >GHV MZ7_>GI_FZ3_SPD_,_P"-'FZ3_P \)/S/^-<7+3_FH?=(VN_[PS;I?]Z>C;I? M]Z>G^;I/_/"3\S_C1YND_P#/"3\S_C1RT_YJ'W2"[_O&-KL=M'#%>V$DJW$# M@Y/I_P#K_K73Z1J*ZIIL5RN Q^5U'9AU_P ^]9MQ_9,UO+$(9 74J#D\9'UK M(\%79COI[-C\LB[P/]H?_6/Z5]IDM7VN%E3YH-P>G)>R3]?.YY6(7LZZ=G:7 M?NCJ-&9&CD4_Q*1@C\J\.U3PUXI^&NH3:IH<\ MDVF$Y9U&X!>PE3\_F'YC->Y1LTXIV9A6NI*35T>G^$=%U#0)-5L;BXN+BP$Z MO8RSR[VV%1E>N1@C'09Z]ZZ>N2\'>*;;QWX>F\^$1SI^ZNH48@?< M8/UKA/AY:K>?$35[>XFN98;!I&MXVN'(4K* I//.!ZYJ7!R-D6X<"39'E0!G .%(XQDGFE&FFTK[E2J.*;ML>IT5YAX3\4V_C#0+C MP_KAECU6VC;H[1M+M'WLC!##N/Q]<:G@ZWFT_P"&1U&S\V?4Y[.2<,[M(7D M8H "2/08'6E*DX[[A&JI:K8[NBO"_"%QX;\1:?=6GB'4;F+7IY#Y=W/<..OW M=ISM&#V/7/Y=]XNTV2#X9N+R9Y+^PLUQ/%*ZYD +<$9S[U4J7++E;%&MS1< MDCMJ*\J^&>IZ%#X6EDU;6;=+VY=XY5NK_:VSH 6X[\CFLOP+!;W_P 4M3MU MO)[G3[,2SV@6Z=D^650ASGY@ W?.:'1MS:["5>_+9;^9[317CGQH1M.O=+N[ M.:>":[$HF*3. VP1A>,X'!/2NP\8Z!9V_@&[CMFN(C80/- ZW#[@PY.3GYL^ M^>M+V:M%WW*]J[R5MCLZ*\8\%>*[[PKJA\.^*&D%K= 207$C$[-PX.[^X?7L M?QQU7A?1+6W\?>(BCW#1V+0"U1[AV6/S(MS<$\]>,YQ1*ERWNQ1K MT5X?K=O:P?&$:7<7L]MI4C*TBF[=%!,>[[Q;C+>_>NX\,Z9I,?BRYGT'4YY[ M>UM_)N8VN#-&S.0RE6)/(VG/U'O1*DHJ]^EPC5"P[ M5M_$.-HO'^L*XP3,&_ J"/T-8>E7"VFL65R^-D-Q'(V?0,#7L*_LM.WZ'AR_ MB._?]3Z>^V:9_P ^W_C@H^V:9_S[?^."IO[1L_\ G@__ '[%']HV?_/!_P#O MV*_-?:0_Y_TO_!9]59_RO[R'[9IG_/M_XX*/MFF?\^W_ (X*F_M&S_YX/_W[ M%']HV?\ SP?_ +]BCVD/^?\ 2_\ !86?\K^\A^V:9_S[?^."C[9IG_/M_P". M"IO[1L_^>#_]^Q1_:-G_ ,\'_P"_8H]I#_G_ $O_ 6%G_*_O(?MFF?\^W_C M@KD-%D6+Q9$8_N&9E';@Y%=HVI62J6,+ 9/[L5PNAYG\1VK$1 MVDJK4X25E\,>7OOW/+QSM*"LUKU?H=7XXFU.U\+3WFD&3[7;21S!(\DNJN-R MD#J,9R/2J-O\2/"U[HAN[B^BB)C/FVD@S(#CE=O\7IQP:Z>^U"STRV-S?74- MM #@R2N%&?3)K/LM5\.:E?K]CN].GO"-Z[&0R$>H[FO4C;EU0Y7YM&<;\'M! MO-,T[4=0NH'MX[YT\B*0$-L7=\Q'H=W'TSWK"T6]B\$?%K6%U@&VM+XR^5,X M.W#.'4Y],<'T/T->KR:]I,.I+ITFH6ZWK$!8"XWG/3BC5=0TFT5(M4GME\S[ MD4N&+X]%ZG\!5^T;DVUN9^R2BE%_".U5?&7B'3++QKX9@N+V*/[-/))< G_5!H\*6],[J['2]1TO4("-+ MN;>6.([66$CY#Z$#I]#5:3Q7X?BGD@DUJQ62,X=3.HVGWYXJ4]=MBFO=WW.( M^(7@=[X#Q/XV:ZJ\UO2]/MHKF[U"VA@E_P!7*\@"M]#T-+)JFFV6FI>R74$-D0-L MI(5.>G-'/)Q46K_UL'LXJ3DG:Z_IGC_CE_!>OZ NKZ0\46MRNF+:$$22,3AE M=!W')W=R.IS74:U-+I?P86UUJ817TEF(520_,S=E^H4<_0UW-C)IU\@O['[/ M,LG2>( [OQ[U/;WEM>>:;:>.812&*0HP.UQU4^XS5.KHE;9B5+5N^Z/,/A4O MAVZ\)2QWD.GRWEN\DLWG1*76/CYB2.GO6-X$U;2+;XLZO+'/#!9W0FAM2,*C M$RH5"]AD XKU>?Q5H%M=2VT^L64<\1Q(C3+E#WSZ5=DU*QCT_P"WM=P_8]N[ MSPX*8])-*E^'=[3&X491N^/4?C6;\)K:_L+CQ#::KO6\MW@1Q(V2%56" M\^FT#!]*]'N+RVM/*%Q/'$9I!%&'8#>YZ*/4U*$4,S!0&;&2!R:7M'RN/1E> MR7,I=4>#ZUK>A7'QCCU*>>"YTE2@DDV>9&?W>.F#G!Q^5=SI/B/PK;>(8[3P MLL<]SJLR+-#!&8HHD16)<#:!G&>._M77SZ]I-MJ*Z?/J%O'>-@+ S@.<],"I M+?6-.N[^6P@O8)+N$9D@5QO4=,D=>X_.JE.Z6CV(C3LV[KQX5\:-(:U\26VJ*O[J\A"LW^VG' M_H)7\C7F=?4/C/PW'XI\-W&GG:LX_>6[G^&0=/P/(/L:^8[FVFL[J6VN(VBF MB^W_].EU_W[_^O7A/PM\8+X>U=]/O"?L-Z0 ?^>GKJ>KAJD:E-.VJWU&?;_^G2Z_[]__ M %Z/M_\ TZ77_?O_ .O3_M;?\^MQ_P!\C_&C[6W_ #ZW'_?(_P :X_:S_P"? M_P#Y3_X!TV7\OXC/M_\ TZ77_?O_ .O1]O\ ^G2Z_P"_?_UZ?]K;_GUN/^^1 M_C3)M16WA:6:"9(T&69@,#]:/:S_ .?_ /Y3_P" *R_E_$R?$>L"'298A#-' M)./+4NN.._Z?SK#\&6IFU=K@CY8$)S[G@?IFL_6]5?5]0,H!$2_+$A[#_$UV M_AS3#IFE*LBXGE^>3V]!^ _K7T<(3H8?EJ2YI/R2_!=CRN95J_-%:(@\;?\ M(CZW_P!>I&3EIV_4CO_P#DL>D_]@N3_P!":J_P]G.J MZSXFU6[RU]]M-N-_6*)?NH/0=?KBMNY\-WD_C2V\0KJ4"K!"8!;FU)RA))RV M_KSUQCV--;PM+8Z_8^UV\T7F0S'^]@%2K'';7DUS5;L7=]%&8K=8X_+B@4]=JDDECT))_ 5#9>& M[VT\87VO'4K=Q>(L;P"T(VJN,8;S.O')Q^ I\ZM;R_4.25[^=_P."U?1K_1/ M@SJ%OJ">2\EZ)H[??N\A&=<)D<=B>/6NO\7ZEJ,G@[5TDT*YA1K20-(T\)"C M'7 ;/Y5J>+_#LOBG0GTM+U+2.1E9W,/F$X(( ^88Y'O4VLZ3>ZQX;GTM[Z". M:XC,4LXMB5VG(.U-_!^I-'M$[-]_\A>S:NEV_P S/T_4?[*^&>F7BJ6E33;= M8D"EB\C(JH,#DY8@<")XM(\9ZKH49NOLMW$E[;M=021.S@!9#B0 G)R< M_P"S716_AO4(;/0[1]4MGM]**';]C8&;8A1 MSV5S=0)I*&5($#$+D9)!(XJYX1L?[*^&-]<":.:.ZBGO(TB8E8E9.$!/ICGC MJ36S!X8ND\87>NS:A;RQW4'V9[7[(0/+'3YMYYXYXQ[51M/!-[IFF:IHUAK" M)I-ZDBQ136YD>VWC#!6#C(Y/7O\ CFG*+5K]B5"2=[=_Q,GP?J47A"6^T/4) M"EF+8:G9.W>-ERZ#W#9P.IYJ7PS;W$/Q,O9[P%;R[TI+F="?N,TG"?\ 5"K M_P !K>N_!T&HOH,U_*DL^DOG>D6P2J!PI!)QR%/4]#ZU(/#EXOC*?Q"NHP9D MM/LBP&U. N[<"3OY.1Z#\*3G%W?5H:A)671,Y;XBS_;_ +7]G%W]HT98YK=H M;:5T$V0[;F52HVH%^\1]XUWVCZC'J^C6>HQ8V7,*R ]"1R/P/'X55TK1Y[' M3+JUN[J&[EN)997E\@H&+DG#+N.0,XZC@ >]5_"/AZY\,:.-,EU%+R"-B83Y M!C9 221]YLC)]JF3BXV[%Q4E._X'^>M;M_P"&[R\\86.O)J4$:V<;1I;FU+;E88;+ M;QSSQQQ[U=M=,O8/$%[J,E]#)!UFGT%R-W M377]#G](\2VOB?4M%N$C\F\@,\=S;/\ ?@?8,CUQQP?Z@U4^'S_VOKOB36;W MY[];PVR!^3!$O11Z#M[XKH3X3LT\91>)+9#.1T8J"I#<]0?PY.3FC9I=?ZL+EG=-ZV?Z;FZ;& MV.HK?^4!="(P^8.I0D'!]>1^I]:L5AC2=5FFGNKO5D%P;9X+86]OL2 MCY\% MB6;('7 ZCN:=:Z5J\-I#%-KKRRI&JO)]G7YB!R?QK*R[FJ;[&U7G7Q(^'@\0 MQMJVEHJZI&OSQ\ 7"C_V8#H>_3TKT6BG";@[H)P4X\LCY!EBD@F>&:-HY$8J MZ,,%2.H(KV7X;?$=;B&'0M9E)N5PEK.Q \P= C$G[WH>_P!>O4>,OAYIGBQ# M<#%IJ0&%N$7A_0.._P!>H_2O"/$/A?5O"][]GU*W* _ZN5#E)!Z@_P!#S7>Y M0Q$.6]F>;RSP\N9:H^I/-?\ YX2?FO\ C1YK_P#/"3\U_P :\/\ "GQ;OM-L MUT_54%TJX$5RY.Y!Z-_>'OU^O;J9O%FI:C$&BNE2)QD?9^ ?H>OZUQ?4JU[< M_P"".MXRG:]CN;_6[735S<[E;L@*EC^&:X?6M?N-7?9CR[93E8@>ON?4T67A MW5-2?S#$T:,/]!78445SU*CF[LZZ=.-.-D%%%%9F@4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8^O7EPL< M5A8\WEUD C^!>[9[548\SL3*7*KF?K_BD6CM:6&UIQP\G4(?0>IKGD\.:IKN MY[J' MH_D>3:E\%(9H&DL-2$-SU\MT)B/MG.1]>?I7*VVG>-OAQ?&Z2P,EN#\[*GG0 ML/4D#7T'126)GM+5#>%AO'1G"^&?BGH>NA(+MQIMZ>/+F;Y&/^R_3\#C M\:[D$$ @Y!Z$5BZIX0\/:T2U_I%K*YZR!=CG_@2X/ZU5TWP7 MC#+9$,9]%4<_FQ/Y5?J&U4+$P'_/1S_X^:I.R9+5VB:BBBI*"BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH %HH __]D! end EX-101.SCH 9 sbfm-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Acquisition of Nora Pharma Inc. link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Plant, Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Reverse Stock Splits link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Management and Director Compensation link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Acquisition of Nora Pharma Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Plant, Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives) link:presentationLink link:calculationLink link:definitionLink 995539 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets) link:presentationLink link:calculationLink link:definitionLink 995540 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995541 - Disclosure - Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price) link:presentationLink link:calculationLink link:definitionLink 995542 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995543 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 995544 - Disclosure - Intangible Assets (Details - Intangible assets) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Intangible Assets (Details - Amortization expense) link:presentationLink link:calculationLink link:definitionLink 995546 - Disclosure - Goodwill (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Plant, Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995548 - Disclosure - Plant, Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995549 - Disclosure - Reverse Stock Splits (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995550 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995551 - Disclosure - Warrants (Details - Warrants issued with financing) link:presentationLink link:calculationLink link:definitionLink 995552 - Disclosure - Warrants (Details - Warrants outstanding) link:presentationLink link:calculationLink link:definitionLink 995553 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995554 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Income Taxes (Details - Provision for income taxes) link:presentationLink link:calculationLink link:definitionLink 995556 - Disclosure - Income Taxes (Details - Reconcilation of tax rate) link:presentationLink link:calculationLink link:definitionLink 995557 - Disclosure - INCOME TAXES (Details - Deferred taxes) link:presentationLink link:calculationLink link:definitionLink 995558 - Disclosure - Lease (Details - Lease information) link:presentationLink link:calculationLink link:definitionLink 995559 - Disclosure - Lease (Details - Maturities of lease payments) link:presentationLink link:calculationLink link:definitionLink 995560 - Disclosure - Management and Director Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 sbfm-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 sbfm-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 12 sbfm-20231231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Warrant [Member] Class of Stock [Axis] Series B Preferred Stock [Member] Additional Paid-in Capital [Member] Preferred Stock [Member] Comprehensive Income [Member] Retained Earnings [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Product and Service [Axis] Generic Pharmaceuticals [Member] O T C Products [Member] Long-Lived Tangible Asset [Axis] Office Equipment [Member] Computer Equipment [Member] Equipment [Member] Vehicles [Member] Finite-Lived Intangible Assets by Major Class [Axis] Licenses [Member] Website [Member] Business Acquisition [Axis] Nora Pharma [Member] Counterparty Name [Axis] Malek Chamoun [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Transaction Type [Axis] First Reverse Stock Split [Member] Title of Individual [Axis] Director [Member] Chief Executive Officer [Member] Sale of Stock [Axis] Public Offering [Member] Award Type [Axis] Tradeable Warrants [Member] Securities Financing Transaction [Axis] Private Placement [Member] Common Stock Member And Investor Warrants [Member] Common Stock Member And April Warrants [Member] Nora Pharma Inc [Member] Single Institutional Investor [Member] May Pre Funded Warrants [Member] May Investor Warrants [Member] Warrants Exercised [Member] Exercise Of May Pre Funded Warrants [Member] Pre Funded Warrants [Member] Investor Warrants [Member] April Warrants [Member] All Warrants [Member] Tradeable Warrants [Member] Related Party, Type [Axis] Advanomics Corporation [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Name Auditor Firm ID Auditor Location Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable Inventory Prepaid expenses Total Current Assets Property and equipment Intangible assets Right-of-use-asset TOTAL ASSETS LIABILITIES Current Liabilities: Accounts payable and accrued expenses Earnout payable Income tax payable Right-of-use-liability Total Current Liabilities Long-Term Liabilities: Deferred tax liability Right-of-use-liability Total Long-Term Liabilities TOTAL LIABILITIES SHAREHOLDERS' EQUITY Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 10,000 shares issued and outstanding Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 28,024,290 and 22,585,632 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively Capital paid in excess of par value Accumulated comprehensive income Accumulated (Deficit) TOTAL SHAREHOLDERS' EQUITY TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales Cost of sales Gross profit General and Administrative Expenses: Accounting Consulting Director fees Goodwill impairment Legal Marketing Office Patent fees R&D Salaries Taxes Depreciation & amortization Total General and Administrative Expenses (Loss) From Operations Other Income (Expense): Foreign exchange (loss) Interest income Interest expense Debt release Total Other Income (Expense) Net (loss) before income taxes Provision for income taxes Net (Loss Foreign exchange translation Comprehensive Income (Loss) Basic (Loss) per common share Diluted (Loss) per common share Weighted average common shares outstanding (Basic) Weighted average common shares outstanding (Diluted) Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Foreign exchange Debt release Accounts receivable Inventory Prepaid expenses Accounts payable and accrued expenses Deferred tax liability Income tax payable Interest payable Net Cash Flows (Used In) Operating Activities Cash Flows From Investing Activities: Reduction in Right-of-use asset Nora Pharma acquisition Cash from Nora Pharma acquisition Purchase of intangible assets Purchase of equipment Net Cash Flows (Used In) Investing Activities Cash Flows From Financing Activities: Sale of common stock in private placements Exercise of warrants Purchase of treasury stock Lease liability Advances to Nora Pharma - pre acquisition Payments of notes payable Net Cash Flows Provided by Financing Activities Cash and Cash Equivalents at Beginning of Period Net increase (decrease) in cash and cash equivalents Effect of exchange rate changes on cash Foreign currency translation adjustment Cash and Cash Equivalents at End of Period Supplementary Disclosure of Cash Flow Information: Cash paid for interest Stock issued for acquisition of Nora Pharma Beginning balance, value Beginning balance, shares Repurchase of treasury stock Fractional shares issued for reverse stock split Fractional shares issued for reverse stock split, shares Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs, shares Exercise of warrants Excersise of warrants, shares Preferred stock purchased from related party Preferred stock purchased from related party, shares Common stock issued as part of Nora Pharma acquisition Common stock issued as part of Nora Pharma acquisition, shares Net (loss) [custom:RepurchaseOfTreasuryStock] Repurchase of treasury stock, shares [custom:RepurchaseOfTreasuryStockShares] Common stock and pre-funded warrants issued in a private offering net of expenses Common stock and pre-funded warrants issued in a private offering net of expenses, shares Ending balance, value Ending balance, shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance [Table Text Block] Company Selected Measure Name Named Executive Officers, Footnote [Text Block] Peer Group Issuers, Footnote [Text Block] Changed Peer Group, Footnote [Text Block] PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Equity Valuation Assumption Difference, Footnote [Text Block] Compensation Actually Paid vs. Total Shareholder Return [Text Block] Compensation Actually Paid vs. Net Income [Text Block] Compensation Actually Paid vs. Company Selected Measure [Text Block] Total Shareholder Return Vs Peer Group [Text Block] Compensation Actually Paid vs. Other Measure [Text Block] Tabular List [Table Text Block] Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Attributable to Parent Company Selected Measure Amount Other Performance Measure Amount Adjustment to Compensation Amount PEO Name Measure Name Non-GAAP Measure Description [Text Block] Additional 402(v) Disclosure [Text Block] Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis [Text Block] Stock Price or TSR Estimation Method [Text Block] Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined [Text Block] Forgone Recovery, Individual Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability [Text Block] Outstanding Recovery, Individual Name Outstanding Recovery Compensation Amount Restatement Does Not Require Recovery [Text Block] Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure [Text Block] Award Timing Method [Text Block] Award Timing Predetermined [Flag] Award Timing MNPI Considered [Flag] Award Timing, How MNPI Considered [Text Block] MNPI Disclosure Timed for Compensation Value [Flag] Awards Close in Time to MNPI Disclosures [Table Text Block] Awards Close in Time to MNPI Disclosures, Individual Name Award Underlying Securities Amount Award Exercise Price Award Grant Date Fair Value Underlying Security Market Price Change, Percent Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted [Flag] Insider Trading Policies and Procedures Not Adopted [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Acquisition of Nora Pharma Inc. Goodwill and Intangible Assets Disclosure [Abstract] Goodwill Intangible Assets Property, Plant and Equipment [Abstract] Plant, Property and Equipment Reverse Stock Splits Reverse Stock Splits Equity [Abstract] Capital Stock Warrants Warrants Earnings Per Share [Abstract] Earnings Per Share Income Tax Disclosure [Abstract] Income Taxes Leases Leases Management And Director Compensation Management and Director Compensation Subsequent Events [Abstract] Subsequent Events PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS INVENTORY VALUATION CASH AND CASH EQUIVALENTS PROPERTY AND EQUIPMENT INTANGIBLE ASSETS INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES BASIC AND DILUTED NET GAIN (LOSS) PER SHARE INCOME TAXES FUNCTIONAL CURRENCY CONCENTRATION OF CREDIT RISKS FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS NOTES PAYABLE REVENUE RECOGNITION LEASES RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Schedule of estimated useful lives Schedule of intangible assets estimated useful lives Schedule of allocation of purchase price Schedule of goodwill Schedule of intangible assets Schedule of estimated amortization expense Schedule of property and equipment Schedule of warrants issued with financing Schedule of warrants outstanding Schedule of earnings per share computation Schedule of provision for income taxes Schedule of income tax expense Schedule of components of net deferred tax assets Schedule of lease information Schedule of maturities of lease liabilities Schedule of Product Information [Table] Product Information [Line Items] Concentration risk, percentage Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment estimated useful lives Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible asset estimated useful lives Anti dilutive securities shares Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business combination, account receivable Business combination, inventory Business combination, intangible assets Business combination, equipment and furniture Business combination, other assets Business combination, total assets Business combination, liabilities assumed Business combination, net assets Business combination, goodwill Business combination, total consideration Purchase price of shares Payments to acquire shares Stock issued for acquisition Stock issued for acquisition, value Payment of earnout liability Gooodwill Goodwill acquired during the period Goodwill impairment Goodwill additions Finite-Lived Intangible Assets, Gross Intangible assets acquired Intangible assets additions Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net 2024 2025 2026 2027 2028 Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Goodwill Total Less: Accumulated depreciation Plant, property and equipment, net Depreciation Offsetting Assets [Table] Offsetting Assets [Line Items] Reverse stock split Schedule of Stock by Class [Table] Class of Stock [Line Items] Net proceeds issuance of private placement Stock issued new, shares Warrants issued, shares Number of shares redeemed Nominal exercise price Stock issued for acquisition, shares Stock repurchase program amount Stock repurchased, shares Payment for stock repurchased Gross proceeds from sale of stock Net proceeds from sale of stock Warrants issued, shares Stock issued for conversion of securities Proceeds from warrant exercises Warrants exercised Dividends Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of warrants Exercise price Expiry date Number of warrants outstanding Warrants exercised Net gain (loss) attributable to common stock Basic weighted average outstanding shares of common stock Dilutive common share equivalents Dilutive weighted average outstanding shares of common stock Net gain (loss) per share attributable to common stock Current: Federal State Foreign Deferred: Federal State Foreign Total Pre-Tax Book Income Pre-Tax Book Income State Taxes State Taxes Permanent Adjustments Permanent Adjustments Change in Valuation Allowance Change in Valuation Allowance Foreign Tax Rate Differential Foreign Tax Rate Differential Rate Change Rate Change Provision to Return Adjustments Provision to Return Adjustments Other Adjustments Other Adjustments Income Tax Expense (Benefit) Total effective income tax rate Deferred Tax Assets: Net Operating Loss, Credits and Carryforwards Fixed Assets Intangibles Research and Development Other DTA Lease Liability Valuation Allowance Deferred Tax Assets Deferred Tax Liabilities: Fixed Assets Intangibles Right-of-Use Asset Deferred Tax Liabilities Net Deferred Tax Liability Lease Operating lease ROU asset Operating Lease, Liability, Current Operating lease liability - Long-term Remaining lease term Discount rate 2024 2025 2026 2027 2028 Thereafter Schedule of Defined Benefit Plans Disclosures [Table] Related Party Transaction [Line Items] Officers compensation Directors compensation Tradeable Warrants [Member] [Default Label] Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit General and Administrative Expense Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Deferred Liabilities Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities CashFromNoraPharmaAcquisition Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PurchaseOfTreasuryStock PaymentForLeaseLiability AdvancesToNoraPharmaPreAcquisitio Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Shares, Outstanding Stock Repurchased During Period, Value Stock Issued During Period, Value, Conversion of Convertible Securities ReverseStockSplitTextBlock WarrantsDisclosureTextBlock Lessee, Operating Leases [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment WarrantsIssuedDuringPeriodSharesNewIssues Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Deferred Tax Assets, Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Intangible Assets Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Liabilities, Net Deferred Tax Assets, Net Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five EX-101.PRE 13 sbfm-20231231_pre.xml XBRL PRESENTATION FILE GRAPHIC 14 image_002.jpg GRAPHIC begin 644 image_002.jpg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htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 28, 2024
Jun. 30, 2023
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41282    
Entity Registrant Name SUNSHINE BIOPHARMA, INC.    
Entity Central Index Key 0001402328    
Entity Tax Identification Number 20-5566275    
Entity Incorporation, State or Country Code CO    
Entity Address, Address Line One 1177 Avenue of the Americas    
Entity Address, Address Line Two 5th Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10036    
City Area Code (332)    
Local Phone Number 216-1147    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 10,708,072
Entity Common Stock, Shares Outstanding   99,452,865  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Name BF Borgers CPA    
Auditor Firm ID 5041    
Auditor Location Lakewood, CO    
Common Stock [Member]      
Title of 12(b) Security Common Stock, par value $0.001    
Trading Symbol SBFM    
Security Exchange Name NASDAQ    
Warrant [Member]      
Title of 12(b) Security Warrants    
Trading Symbol SBFMW    
Security Exchange Name NASDAQ    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current Assets:    
Cash and cash equivalents $ 16,292,347 $ 21,826,437
Accounts receivable 2,552,362 1,912,153
Inventory 5,734,755 3,289,945
Prepaid expenses 310,591 283,799
Total Current Assets 24,890,055 27,312,334
Property and equipment 365,868 394,249
Intangible assets 1,444,259 776,856
Right-of-use-asset 646,779 760,409
TOTAL ASSETS 27,346,961 29,243,848
Current Liabilities:    
Accounts payable and accrued expenses 2,585,466 2,802,797
Earnout payable 2,547,831 3,632,000
Income tax payable 299,869 373,191
Right-of-use-liability 118,670 123,026
Total Current Liabilities 5,551,836 6,931,014
Long-Term Liabilities:    
Deferred tax liability 48,729 43,032
Right-of-use-liability 539,035 642,232
Total Long-Term Liabilities 587,764 685,264
TOTAL LIABILITIES 6,139,600 7,616,278
SHAREHOLDERS' EQUITY    
Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 10,000 shares issued and outstanding 1,000 1,000
Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 28,024,290 and 22,585,632 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively 28,024 22,585
Capital paid in excess of par value 84,387,890 80,841,752
Accumulated comprehensive income 696,105 161,847
Accumulated (Deficit) (63,905,658) (59,399,614)
TOTAL SHAREHOLDERS' EQUITY 21,207,361 21,627,570
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 27,346,961 $ 29,243,848
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 3,000,000,000 3,000,000,000
Common stock, shares issued 28,024,290 22,585,632
Common stock, shares outstanding 28,024,290 22,585,632
Series B Preferred Stock [Member]    
Preferred stock, par value $ 0.10 $ 0.10
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 10,000 10,000
Preferred stock, shares outstanding 10,000 10,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Sales $ 24,092,787 $ 4,345,603
Cost of sales 15,753,616 2,649,028
Gross profit 8,339,171 1,696,575
General and Administrative Expenses:    
Accounting 463,705 341,139
Consulting 850,173 842,894
Director fees 400,000 300,000
Goodwill impairment 0 18,326,719
Legal 512,199 550,117
Marketing 734,248 578,085
Office 2,142,355 796,007
Patent fees 14,108 15,148
R&D 1,855,830 811,858
Salaries 5,712,968 6,054,962
Taxes 289,737 55,233
Depreciation & amortization 149,147 25,163
Total General and Administrative Expenses 13,124,470 28,697,325
(Loss) From Operations (4,785,299) (27,000,750)
Other Income (Expense):    
Foreign exchange (loss) (245) (476)
Interest income 811,974 518,650
Interest expense (137,308) (39,412)
Debt release 0 10,852
Total Other Income (Expense) 674,421 489,614
Net (loss) before income taxes (4,110,878) (26,511,136)
Provision for income taxes 395,166 233,304
Net (Loss (4,506,044) (26,744,440)
Foreign exchange translation 534,258 184,986
Comprehensive Income (Loss) $ (3,971,786) $ (26,559,454)
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Basic (Loss) per common share $ (0.19) $ (1.76)
Diluted (Loss) per common share $ (0.19) $ (1.76)
Weighted average common shares outstanding (Basic) 24,331,908 15,180,868
Weighted average common shares outstanding (Diluted) 24,331,908 15,180,868
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash Flows From Operating Activities:    
Net (Loss) $ (4,506,044) $ (26,744,440)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 149,147 25,163
Goodwill impairment 0 18,326,719
Foreign exchange 0 548
Debt release 0 (10,852)
Accounts receivable (594,141) (524,486)
Inventory (2,365,549) 42,983
Prepaid expenses (21,143) 82,846
Accounts payable and accrued expenses (1,364,134) 3,359,141
Deferred tax liability 0 3,628
Income tax payable (73,247) 238,679
Interest payable 0 (48,287)
Net Cash Flows (Used In) Operating Activities (8,775,111) (5,248,358)
Cash Flows From Investing Activities:    
Reduction in Right-of-use asset 131,949 33,379
Nora Pharma acquisition 0 (14,346,637)
Cash from Nora Pharma acquisition 0 (1,135)
Purchase of intangible assets (705,848) (111,015)
Purchase of equipment (82,251) (193,982)
Net Cash Flows (Used In) Investing Activities (656,150) (14,619,390)
Cash Flows From Financing Activities:    
Sale of common stock in private placements 4,089,218 30,367,185
Exercise of warrants 3,502 13,193,177
Purchase of treasury stock (541,143) (99,000)
Lease liability (125,990) (31,924)
Advances to Nora Pharma - pre acquisition 0 (2,064,331)
Payments of notes payable 0 (1,900,000)
Net Cash Flows Provided by Financing Activities 3,425,587 39,465,107
Cash and Cash Equivalents at Beginning of Period 21,826,437 2,045,167
Net increase (decrease) in cash and cash equivalents (6,005,674) 19,597,359
Effect of exchange rate changes on cash (62,674) (1,075)
Foreign currency translation adjustment 534,258 184,986
Cash and Cash Equivalents at End of Period 16,292,347 21,826,437
Supplementary Disclosure of Cash Flow Information:    
Cash paid for interest 0 48,287
Stock issued for acquisition of Nora Pharma $ 0 $ 4,514,000
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statement of Shareholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Preferred Stock [Member]
Comprehensive Income [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 2,591 $ 32,787,384 $ 100,000 $ (23,139) $ (32,655,174) $ 211,662
Beginning balance, shares at Dec. 31, 2021 2,591,240   1,000,000      
Fractional shares issued for reverse stock split $ 4 (4)
Fractional shares issued for reverse stock split, shares 4,380          
Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs $ 6,657 30,360,528 30,367,185
Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs, shares 6,656,526          
Exercise of warrants $ 9,633 13,183,544 13,193,177
Excersise of warrants, shares 9,633,486          
Preferred stock purchased from related party $ (99,000) (99,000)
Preferred stock purchased from related party, shares     (990,000)      
Common stock issued as part of Nora Pharma acquisition $ 3,700 4,510,300 4,514,000
Common stock issued as part of Nora Pharma acquisition, shares 3,700,000          
Net (loss) 184,986 (26,744,440) (26,559,454)
Ending balance, value at Dec. 31, 2022 $ 22,585 80,841,752 $ 1,000 161,847 (59,399,614) 21,627,570
Ending balance, shares at Dec. 31, 2022 22,585,632   10,000      
Beginning balance, value at Dec. 31, 2021 $ 2,591 32,787,384 $ 100,000 (23,139) (32,655,174) 211,662
Beginning balance, shares at Dec. 31, 2021 2,591,240   1,000,000      
Ending balance, value at Dec. 31, 2023 $ 28,024 84,387,890 $ 1,000 696,105 (63,905,658) 21,207,361
Ending balance, shares at Dec. 31, 2023 28,024,290   10,000      
Beginning balance, value at Dec. 31, 2022 $ 22,585 80,841,752 $ 1,000 161,847 (59,399,614) 21,627,570
Beginning balance, shares at Dec. 31, 2022 22,585,632   10,000      
Repurchase of treasury stock $ (514) (540,629) (541,143)
Exercise of warrants $ 3,502 3,502
Excersise of warrants, shares 3,502,381          
Net (loss) 534,258 (4,506,044) (3,971,786)
Repurchase of treasury stock, shares (513,723)          
Common stock and pre-funded warrants issued in a private offering net of expenses $ 2,451 4,086,767 4,089,218
Common stock and pre-funded warrants issued in a private offering net of expenses, shares 2,450,000          
Ending balance, value at Dec. 31, 2023 $ 28,024 $ 84,387,890 $ 1,000 $ 696,105 $ (63,905,658) $ 21,207,361
Ending balance, shares at Dec. 31, 2023 28,024,290   10,000      
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure [Table]    
Net Income (Loss) Attributable to Parent $ (4,506,044) $ (26,744,440)
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual [Table]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Description of Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

Note 1 – Description of Business

 

The Company was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company.

 

Sunshine Biopharma operates two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio of pharmaceutical products consisting of 52 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells nonprescription over-the-counter (“OTC”) products.

 

The Company has determined that it has two reportable segments:

 

•Prescription Generic Pharmaceuticals (“Generic Pharmaceuticals”)
•Nonprescription Over-The-Counter Products (“OTC Products”)

 

Through December 31, 2023, sales from the Generic Pharmaceuticals segment represented approximately 97% of total revenues of the Company while the remaining approximately 3% was generated from the sale of OTC Products. Based on these results, the Company deems segmentation reporting to be immaterial at December 31, 2023.

 

The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, in Canada Provincial governments reimburse patients for their prescription drugs expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on governmental policies which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance (“pCPA”) and the Canadian Generic Pharmaceutical Association have resulted in updated generic pricing for certain products which took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February 29, 2024, the Canadian federal government tabled new drug reimbursement legislation, a bill known as PharmaCare which, if passed, would result in a single-payer program whereby the Canadian federal government would pay for the drugs sold in Canada rather than the Provinces.

 

In addition, the Company is engaged in the development of the following proprietary drugs:

 

•Adva-27a, a small chemotherapy molecule for treatment of pancreatic cancer (IND-enabling studies were paused in November 2023 due to unfavorable results. See “Products in Development,” above.
•K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer
•SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections

 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.

 

PRINCIPLES OF CONSOLIDATION

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

 

USE OF ESTIMATES

 

The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

  

TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

 

Trade accounts receivable are stated at net realizable value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis, management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts or if any accounts should be written off based on a past history of write-offs, collections and current credit conditions. A receivable is considered past due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral to support its receivables.

 

INVENTORY VALUATION

 

Inventory is valued at the lower of cost and net realizable value. Cost is determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business, less the costs of completion and costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to the acquisition of finished goods.

 

CASH AND CASH EQUIVALENTS

 

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $16,292,347 and $21,826,437 as of December 31, 2023 and December 31, 2022, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 in the U.S. or the equivalent in Canada.

 

PROPERTY AND EQUIPMENT

 

Property and equipment are reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2023 and 2022, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

 

Property and equipment are stated at cost. Depreciation is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows: 

   
Office Equipment: Straight-line and Declining balance method 5-7 Years / 20%
Computer Equipment: Declining balance method 55%
Laboratory Equipment: Straight-line method 5 Years
Vehicles: Straight-line and Declining balance method 5 Years / 30%

 

INTANGIBLE ASSETS

 

Intangible assets are amortized over their estimated useful lives according to the following methods at the following annual rates and period: 

   
Licenses: Straight-line method 5 Years
Website: Declining balance method 55%

 

Intangible assets are tested for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal. In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over its fair value.

 

INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES

 

The cost of patents and licenses acquired is capitalized and is amortized over the remaining life of the patents or licenses.

 

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future cash flows associated with it.

 

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

 

The Company computes gain or loss per share in accordance with ASC 260 – Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

 

Basic net income (loss) per share is calculated by dividing net gain (loss) by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2023, no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

 

INCOME TAXES

 

In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

 

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2023 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

 

For Canadian and US tax purposes, the Company’s 2020 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

 

FUNCTIONAL CURRENCY

 

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

 

The Company translates its Canadian subsidiaries' financial statements into U.S. dollars as follows:

 

  · Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.
  · Income statement accounts are translated using the weighted average exchange rate for the period.

 

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.

 

CONCENTRATION OF CREDIT RISKS

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

 

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company applies the provisions of accounting guidance, ASC 825 – Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023 and 2022, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

 

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

 

  · Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
     
  · Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.
     
  · Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

  

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

 

NOTES PAYABLE

 

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company had no notes payable as of December 31, 2023 and 2022.

 

REVENUE RECOGNITION

 

Over 97% of the Company’s revenues are derived from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies, purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company’s products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion) accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the Company.

 

No significant judgments are made in connection with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine the price of its products.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed at the Company’s current price list on the date of shipping and known in advance by the customer and does not vary.

 

The Company is involved in a singular activity which is to sell pharmaceutical finished goods. The Company fulfills its performance obligation when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured and the transfer of ownership to the customer takes place when the customer receives goods. At this point, the Company issues an invoice for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. It is when the invoice is issued that the revenue is recognized. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days of the date of the invoice. The collection is reasonably assured because of the nature of the Company’s customers. The Company is conducting sales only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.

 

In the event of any breach by the Company of any product warranty (whether by reason of defective materials, production faults or otherwise), the Company’s liability shall be limited to, at Company’s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company carries product insurance and is not liable for products’ failure to comply with the warranty of products if the failure or damage arises because of the customer’s negligence, deliberate damage, misuse or failure to store the products in conditions per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These conditions also apply to any replacement products supplied by the Company.

 

The Company warrants to the customer that, at the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements. In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable laws to purchase, store, distribute, sell and use the Company’s products. Visible defects or damages must be reported to the Company in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company shall not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters, terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts, shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not within the Company’s control.

 

LEASES

 

The Company recognizes and measures its leases in accordance with FASB ASC 842, Leases. The Company is a lessee in a non-cancellable operating lease for office space. The Company determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases. The Company’s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured throughout the lease term at the remaining amount (i.e., present value of the remaining lease payments), plus unamortized initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.

 

The Company has elected, for all underlying classes of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.

 

Under the available practical expedient, we account for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further, we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less).

 

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

  

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Acquisition of Nora Pharma Inc.
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisition of Nora Pharma Inc.

Note 3 – Acquisition of Nora Pharma Inc.

 

On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (“Nora Pharma), a Canadian privately held pharmaceutical company. The purchase price for the shares was $18,860,637 which was paid in cash ($14,346,637) and by the issuance of 3,700,000 shares of the Company’s common stock valued at $4,514,000 or $1.22 per share on the acquisition date. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma’s operations are authorized by a Drug Establishment License issued by Health Canada.

 

The following table summarizes the allocation of the purchase price as of October 20, 2022, the acquisition date using Nora Pharma’s balance sheet assets and liabilities: 

     
Accounts receivable  $1,358,121 
Inventory   3,181,916 
Intangible assets   659,571 
Equipment & furniture   210,503 
Other assets   1,105,093 
Total assets   6,515,204 
Liabilities assumed   (5,981,286)
Net assets   533,918 
Goodwill   18,326,719 
Total Consideration  $18,860,637 

 

The value of the 3,700,000 common shares issued as part of the consideration paid for Nora Pharma was determined based on the closing market price of the Company’s common shares on the acquisition date, October 20, 2022 ($1.22 per share).

 

As part of the consideration paid for Nora Pharma, the Company agreed to a $5,000,000 CAD ($3,632,000 USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During the twelve-month period ended December 31, 2023, the Company paid an earn-out amount of $1,084,169 leaving a balance earn-out to be paid of $2,547,831 at December 31, 2023.

 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Goodwill
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill

Note 4 – Goodwill

 

The Company acquired Nora Pharma on October 20, 2022. Allocation of the purchase price per ASC 805-20-25-1 yielded a goodwill amount of $18,326,719. The Company’s used a discounted cash flow model which requires estimating future cash flows expected to be generated from the acquired entity, discounted to their present value using a risk-adjusted discount rate and terminal values.

 

Assessing the recoverability of goodwill requires the Company to make estimates and assumptions about sales, operating margins, growth rates and discount rates based on its budgets, business plans, economic projections, anticipated future cash flows and marketplace data. Management determined that there are inherent uncertainties related to these factors as well as significant risks to cash flows due to ongoing geopolitical and geo-economics conflicts, making the discounted cash flow model unreliable.

The following table presents the changes in the carrying amount of goodwill of the Company as of December 31, 2022 and 2023. The provisions of ASC 350-20-50-1 require the disclosure of cumulative impairment. As a result of the acquisition, a new basis in goodwill was recorded in accordance with ASC 805-10. All impairments shown in the table below have been recorded subsequent to the acquisition. The Company had no goodwill on its balance sheet prior to the acquisition:

Schedule of goodwill     
Balance as of December 31, 2021  $– 
Acquisition of Nora Pharma (October 20, 2022)   18,326,719 
Impairment   (18,326,719)
Balance as of December 31, 2022   – 
Additions in 2023   – 
Balance as of December 31, 2023  $– 

 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 5 – Intangible Assets

 

Intangible assets, net, consisted of the following at December 31, 2022 and 2023:

Schedule of intangible assets     
Balance as of December 31, 2021  $– 
Finite-Lived intangible assets   659,571 
Dossier fee additions   121,807 
Balance at December 31, 2022   781,378 
Less accumulated amortization   (4,522)
Finite-lived intangible assets, net at December 31, 2022  $776,856 
      
Balance as of December 31, 2022  $776,856 
Dossier fee additions   710,372 
Balance at December 31, 2023   1,487,228 
Less accumulated amortization   (42,969)
Finite-lived intangible assets, net at December 31, 2023  $1,444,259 

 

As of December 31, 2023, the estimated amortization expense of the Company’s intangible assets for each of the next five years is as follows:

     
2024  $59,745 
2025   59,745 
2026   58,541 
2027   19,041 
2028   9,985 

 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Plant, Property and Equipment
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Plant, Property and Equipment

Note 6 – Plant, Property and Equipment

 

Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:

Schedule of property and equipment          
   Year Ended December 31, 
   2023   2022 
Equipment  $171,859   $162,534 
Computer equipment   7,368    16,418 
Furniture and fixtures   34,132    33,329 
Leasehold improvements   17,664    – 
Vehicles   324,841    265,774 
Total   555,864    478,055 
Less: Accumulated depreciation   (189,996)   (83,806)
Plant, property and equipment, net  $365,868   $394,249 

 

Depreciation expense for the years ended December 31, 2023 and 2022 amounted to $110,701 and $20,641, respectively.

 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Reverse Stock Splits
 12 Months Ended
Dec. 31, 2023
Reverse Stock Splits  
Reverse Stock Splits

Note 7 – Reverse Stock Splits

 

Effective February 9, 2022, the Company completed a 1 for 200 reverse split of its common stock. The Company had previously completed two 20 to 1 reverse stock splits, one in 2019 and the other in 2020. The Company’s financial statements reflect all three reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

 
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Capital Stock
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Capital Stock

Note 8 – Capital Stock

 

The Company’s authorized capital is comprised of 3,000,000,000 shares of common stock, par value $0.001, and 30,000,000 shares of preferred stock, $0.10 par value. As of December 31, 2023, the Company had authorized 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible and non-redeemable. It has a liquidation preference to the common stock equal to the stated value of $0.10, relative to the rights to the common stock, and gives the holder the right to 1,000 votes per share. As of December 31, 2023, 10,000 shares of Series B Preferred Stock were outstanding and held by the Company’s Chief Executive Officer.

 

On February 17, 2022, the Company completed a public offering and received net proceeds of $6,833,071 from the offering. Pursuant to the public offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 warrants to purchase shares of common stock (the “Tradeable Warrants”).

 

On February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share. The remaining 10,000 shares of Series B Preferred Stock could not be voted pursuant to a warrant agent agreement relating to the Tradeable Warrants (the “Warrant Agent Agreement”). On October 12, 2023, the Company held a special meeting of the holders of the outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to the Warrant Agent Agreement to eliminate the provision that prohibited the Company’s CEO from exercising his voting rights under the Series B Preferred Stock, as well as to lower the exercise price of the Tradeable Warrants to $0.11. The Company entered into the amendment to the Warrant Agent Agreement on October 18, 2023.

 

On March 14, 2022, the Company completed a private placement and received net proceeds of $6,781,199. In connection with this private placement, the Company issued (i) 2,301,353 shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant was sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On October 20, 2022, the Company issued 3,700,000 shares of common stock as part of the acquisition of Nora Pharma. These shares were valued at $4,514,000, or $1.22 per share.

 

On January 19, 2023, the Company announced a stock repurchase program of up to $2 million (“Stock Repurchase Program”). During the six months ended June 30, 2023, the Company repurchased a total of 445,711 shares of common stock at an average price of $1.1371 per share for a total cost of $506,822. The 445,711 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 22,585,632 to 22,139,921.

 

On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with an institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were $4,089,218. In connection with the private placement, the Company issued (i) 2,450,000 shares of common stock, (ii) 3,502,381 pre-funded warrants (the “May Pre-Funded Warrants”), and (iii) investor warrants (the “May Warrants”) to purchase up to 11,904,762 shares of common stock at $0.59 per share. Each share of common stock and accompanying two May Warrants were sold together at a combined offering price of $0.84 and each May Pre-Funded Warrant and accompanying two May Warrants were sold together at a combined offering price of $0.839. The May Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Warrants have an exercise price of $0.59 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance.

 

In 2022 and 2023, the Company issued a total of 10,793,369 shares of common stock in connection with warrant exercises for aggregate net proceeds of $13,196,681.

 

In July 2023, the Company repurchased a total of 68,012 shares of common stock on the open market under the Stock Repurchase Program announced on January 19, 2023, at an average price of $0.5046 per share for a total cost of $34,321. In October 2023, the 68,012 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 25,746,302 to 25,678,290.

 

On November 16, 2023, the Company issued 2,346,000 shares of common stock and received net proceeds of $2,346 in connection with the exercise of all 2,346,000 remaining May Pre-Funded Warrants at the nominal exercise price of $0.001 per share.

 

As of December 31, 2023 and December 31, 2022, the Company has a total of 28,024,290 and 22,585,632 shares of common stock issued and outstanding, respectively.

 

The Company has declared no dividends since inception.

 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Warrants
 12 Months Ended
Dec. 31, 2023
Warrants  
Warrants

Note 9 – Warrants

 

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

 

In 2022 and 2023, the Company completed four financing events, and in connection therewith, it issued warrants as follows: 

           
Type   Number   Exercise Price   Expiry Date
Pre-Funded Warrants   3,692,276   $0.001   Unlimited
Tradeable Warrants   4,102,200   $2.22*   February 2027
Investor Warrants   3,603,604   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Pre-Funded Warrants   3,502,381   $0.001   Unlimited
May Warrants   11,904,762   $0.59   November 2028

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.

 

As of December 31, 2023, all of the Pre-Funded Warrants and a total of 3,138,507 Tradeable Warrants, 2,802,703 Investor Warrants, and all of the May Pre-Funded Warrants were exercised resulting in aggregate proceeds of $13,196,681 received by the Company.

 

The Company’s outstanding warrants at December 31, 2023 consisted of the following: 

           
Type   Number   Exercise Price   Expiry Date
Tradeable Warrants   963,693   $0.11*   February 2027
Investor Warrants   800,901   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Warrants   11,904,762   $0.59   November 2028

* On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.

 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings Per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share

Note 10 – Earnings Per Share

 

The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

        
   2023   2022 
Net gain (loss) attributable to common stock  $(4,506,044)  $(26,744,440)
Basic weighted average outstanding shares of common stock   24,331,908    15,180,868 
Dilutive common share equivalents   –    – 
Dilutive weighted average outstanding shares of common stock   24,331,908    15,180,868 
Net gain (loss) per share attributable to common stock  $(0.19)  $(1.76)

 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 11 – Income Taxes

 

The components of the provision for income taxes were as follows:

    
Current:     
Federal  $– 
State   50 
Foreign   379,246 
    

379,296

 
Deferred:     
Federal   – 
State   – 
Foreign   15,870 
    15,870 
Total  $395,166 

The Company’s effective tax rate differs from the federal statutory rate as follows:

Schedule of income tax expense          
Pre-Tax Book Income  $(826,953)  $20.14% 
State Taxes   50    0.00% 
Permanent Adjustments   56,812    -1.38% 
Change in Valuation Allowance   860,705    -20.96% 
Foreign Tax Rate Differential   –    0.00% 
Rate Change   167,676    -4.08% 
Provision to Return Adjustments   67,144    -1.63% 
Other   69,732    -1.70% 
Total  $395,166   $-9.62% 

 

The components of the net deferred tax assets and liabilitie were as follows:

    
Deferred Tax Assets:    
Net Operating Loss, Credits and Carryforwards  $5,277,829 
Fixed Assets   – 
Intangibles   641,800 
Research and Development   25,327 
Other DTA   454,890 
Lease Liability   174,292 
Valuation Allowance   (6,397,374)
Deferred Tax Assets   176,764 
Deferred Tax Liabilities:     
Fixed Assets   

(54,095

)
Intangibles   – 
Right-of-Use Asset   (171,396)
Deferred Tax Liabilities   (225,491)
Net Deferred Tax Liability  $(48,727)

 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases  
Leases

Note 12 – Leases

 

The Company has obligations as a lessee for office space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company’s lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable Payment. The Company’s office space lease requires it to make variable payments for the Company’s proportionate share of building’s property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred.

 

Amounts reported on the balance sheet as of December 31, 2023 were as follows: 

   
Operating lease ROU asset $646,779
Operating Lease liability - Short-term $118,670
Operating lease liability - Long-term $539,035
Remaining lease term 6 years
Discount rate 6%

  

Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.

 

Maturities of lease liabilities under non-cancellable operating leases at December 31, 2023 are as follows:

 
2024 $118,670
2025 $118,862
2026 $112,582
2027 $106,042
2028 $99,881
Thereafter $101,667

  
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Management and Director Compensation
 12 Months Ended
Dec. 31, 2023
Management And Director Compensation  
Management and Director Compensation

Note 13 – Management and Director Compensation

 

The Company paid its officers cash compensation totaling $1,515,000 and $1,785,000 for the years ended December 31, 2023 and 2022, respectively. Of these amounts attributable to the Company’s CEO, $0 and $60,000, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

 

The Company paid its directors cash compensation totaling $400,000 and $300,000 for the years ended December 31, 2023 and 2022, respectively.

 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Events
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 14 – Subsequent Events

 

On February 15, 2024, the Company closed a firm commitment underwritten public offering with gross proceeds to the Company of approximately $10.0 million. The offering consisted of 71,428,571 Units, consisting of (a) 26,428,571 Common Units, with each Common Unit consisting of one share of our common stock, one-tenth (1/10) of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths (2/10) of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (b) 45,000,000 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock, one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The Pre-Funded Warrants are immediately exercisable at $0.001 per share and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant is $2.10 per share of common stock or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant is $2.38 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date.

 

On February 11, 2024, the Company bought back the 11,904,762 May Warrants from the holder, a single entity, for an aggregate purchase price of $2,361,596. Upon the closing of the transaction, the May Warrants were deemed cancelled and terminated in all respects.

 

On February 11, 2024, the Company entered into securities purchase agreements (the “April Warrants Purchase Agreements”) with the holders of warrants, dated April 28, 2022 (the “April Warrants”) to purchase an aggregate of 9,725,690 shares of common stock of the Company. Pursuant to the April Warrant Purchase Agreements, the Company bought back from the holders the April Warrants for a purchase price of $0.08 per April Warrant, for an aggregate purchase price of $778,055. Upon the closing of the April Warrant Purchase Agreements, which occurred on February 12, 2024, the Company paid the purchase price to the holders, and the April Warrants were deemed cancelled and terminated in all respects.

 

On February 8, 2024, the Company sold 20,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.

 

On March 4, 2024, the Company sold 100,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.

 

On March 4, 2024, the Company’s board of directors, and Company’s chief executive officer, as the holder of the majority of the voting power of the Company’s stockholders, approved an up to 1-for-200 reverse split of the Company’s common stock in order for the Company to become compliant with Nasdaq’s $1.00 minimum bid price for the listed common shares.

 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
PRINCIPLES OF CONSOLIDATION

PRINCIPLES OF CONSOLIDATION

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

 
USE OF ESTIMATES

USE OF ESTIMATES

 

The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

  
TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

 

Trade accounts receivable are stated at net realizable value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis, management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts or if any accounts should be written off based on a past history of write-offs, collections and current credit conditions. A receivable is considered past due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral to support its receivables.

 
INVENTORY VALUATION

INVENTORY VALUATION

 

Inventory is valued at the lower of cost and net realizable value. Cost is determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business, less the costs of completion and costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to the acquisition of finished goods.

 
CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

 

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $16,292,347 and $21,826,437 as of December 31, 2023 and December 31, 2022, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 in the U.S. or the equivalent in Canada.

 
PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

 

Property and equipment are reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2023 and 2022, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

 

Property and equipment are stated at cost. Depreciation is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows: 

   
Office Equipment: Straight-line and Declining balance method 5-7 Years / 20%
Computer Equipment: Declining balance method 55%
Laboratory Equipment: Straight-line method 5 Years
Vehicles: Straight-line and Declining balance method 5 Years / 30%

 
INTANGIBLE ASSETS

INTANGIBLE ASSETS

 

Intangible assets are amortized over their estimated useful lives according to the following methods at the following annual rates and period: 

   
Licenses: Straight-line method 5 Years
Website: Declining balance method 55%

 

Intangible assets are tested for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal. In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over its fair value.

 
INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES

INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES

 

The cost of patents and licenses acquired is capitalized and is amortized over the remaining life of the patents or licenses.

 

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future cash flows associated with it.

 
BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

 

The Company computes gain or loss per share in accordance with ASC 260 – Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

 

Basic net income (loss) per share is calculated by dividing net gain (loss) by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2023, no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

 
INCOME TAXES

INCOME TAXES

 

In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

 

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2023 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

 

For Canadian and US tax purposes, the Company’s 2020 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

 
FUNCTIONAL CURRENCY

FUNCTIONAL CURRENCY

 

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

 

The Company translates its Canadian subsidiaries' financial statements into U.S. dollars as follows:

 

  · Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.
  · Income statement accounts are translated using the weighted average exchange rate for the period.

 

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.

 
CONCENTRATION OF CREDIT RISKS

CONCENTRATION OF CREDIT RISKS

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

 
FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company applies the provisions of accounting guidance, ASC 825 – Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023 and 2022, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

 

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

 

  · Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
     
  · Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.
     
  · Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

  

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

 
NOTES PAYABLE

NOTES PAYABLE

 

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company had no notes payable as of December 31, 2023 and 2022.

 
REVENUE RECOGNITION

REVENUE RECOGNITION

 

Over 97% of the Company’s revenues are derived from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies, purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company’s products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion) accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the Company.

 

No significant judgments are made in connection with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine the price of its products.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed at the Company’s current price list on the date of shipping and known in advance by the customer and does not vary.

 

The Company is involved in a singular activity which is to sell pharmaceutical finished goods. The Company fulfills its performance obligation when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured and the transfer of ownership to the customer takes place when the customer receives goods. At this point, the Company issues an invoice for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. It is when the invoice is issued that the revenue is recognized. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days of the date of the invoice. The collection is reasonably assured because of the nature of the Company’s customers. The Company is conducting sales only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.

 

In the event of any breach by the Company of any product warranty (whether by reason of defective materials, production faults or otherwise), the Company’s liability shall be limited to, at Company’s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company carries product insurance and is not liable for products’ failure to comply with the warranty of products if the failure or damage arises because of the customer’s negligence, deliberate damage, misuse or failure to store the products in conditions per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These conditions also apply to any replacement products supplied by the Company.

 

The Company warrants to the customer that, at the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements. In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable laws to purchase, store, distribute, sell and use the Company’s products. Visible defects or damages must be reported to the Company in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company shall not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters, terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts, shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not within the Company’s control.

 
LEASES

LEASES

 

The Company recognizes and measures its leases in accordance with FASB ASC 842, Leases. The Company is a lessee in a non-cancellable operating lease for office space. The Company determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases. The Company’s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured throughout the lease term at the remaining amount (i.e., present value of the remaining lease payments), plus unamortized initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.

 

The Company has elected, for all underlying classes of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.

 

Under the available practical expedient, we account for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further, we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less).

 
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

  

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of estimated useful lives
   
Office Equipment: Straight-line and Declining balance method 5-7 Years / 20%
Computer Equipment: Declining balance method 55%
Laboratory Equipment: Straight-line method 5 Years
Vehicles: Straight-line and Declining balance method 5 Years / 30%
Schedule of intangible assets estimated useful lives
   
Licenses: Straight-line method 5 Years
Website: Declining balance method 55%
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Acquisition of Nora Pharma Inc. (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of allocation of purchase price
     
Accounts receivable  $1,358,121 
Inventory   3,181,916 
Intangible assets   659,571 
Equipment & furniture   210,503 
Other assets   1,105,093 
Total assets   6,515,204 
Liabilities assumed   (5,981,286)
Net assets   533,918 
Goodwill   18,326,719 
Total Consideration  $18,860,637 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Goodwill (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill
Schedule of goodwill     
Balance as of December 31, 2021  $– 
Acquisition of Nora Pharma (October 20, 2022)   18,326,719 
Impairment   (18,326,719)
Balance as of December 31, 2022   – 
Additions in 2023   – 
Balance as of December 31, 2023  $– 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
Schedule of intangible assets     
Balance as of December 31, 2021  $– 
Finite-Lived intangible assets   659,571 
Dossier fee additions   121,807 
Balance at December 31, 2022   781,378 
Less accumulated amortization   (4,522)
Finite-lived intangible assets, net at December 31, 2022  $776,856 
      
Balance as of December 31, 2022  $776,856 
Dossier fee additions   710,372 
Balance at December 31, 2023   1,487,228 
Less accumulated amortization   (42,969)
Finite-lived intangible assets, net at December 31, 2023  $1,444,259 
Schedule of estimated amortization expense
     
2024  $59,745 
2025   59,745 
2026   58,541 
2027   19,041 
2028   9,985 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Plant, Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
Schedule of property and equipment          
   Year Ended December 31, 
   2023   2022 
Equipment  $171,859   $162,534 
Computer equipment   7,368    16,418 
Furniture and fixtures   34,132    33,329 
Leasehold improvements   17,664    – 
Vehicles   324,841    265,774 
Total   555,864    478,055 
Less: Accumulated depreciation   (189,996)   (83,806)
Plant, property and equipment, net  $365,868   $394,249 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Warrants (Tables)
 12 Months Ended
Dec. 31, 2023
Warrants  
Schedule of warrants issued with financing
           
Type   Number   Exercise Price   Expiry Date
Pre-Funded Warrants   3,692,276   $0.001   Unlimited
Tradeable Warrants   4,102,200   $2.22*   February 2027
Investor Warrants   3,603,604   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Pre-Funded Warrants   3,502,381   $0.001   Unlimited
May Warrants   11,904,762   $0.59   November 2028

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
Schedule of warrants outstanding
           
Type   Number   Exercise Price   Expiry Date
Tradeable Warrants   963,693   $0.11*   February 2027
Investor Warrants   800,901   $2.22   March 2027
April Warrants   9,725,690   $3.76   April 2027
May Warrants   11,904,762   $0.59   November 2028

* On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of earnings per share computation
        
   2023   2022 
Net gain (loss) attributable to common stock  $(4,506,044)  $(26,744,440)
Basic weighted average outstanding shares of common stock   24,331,908    15,180,868 
Dilutive common share equivalents   –    – 
Dilutive weighted average outstanding shares of common stock   24,331,908    15,180,868 
Net gain (loss) per share attributable to common stock  $(0.19)  $(1.76)
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of provision for income taxes
    
Current:     
Federal  $– 
State   50 
Foreign   379,246 
    

379,296

 
Deferred:     
Federal   – 
State   – 
Foreign   15,870 
    15,870 
Total  $395,166 
Schedule of income tax expense
Schedule of income tax expense          
Pre-Tax Book Income  $(826,953)  $20.14% 
State Taxes   50    0.00% 
Permanent Adjustments   56,812    -1.38% 
Change in Valuation Allowance   860,705    -20.96% 
Foreign Tax Rate Differential   –    0.00% 
Rate Change   167,676    -4.08% 
Provision to Return Adjustments   67,144    -1.63% 
Other   69,732    -1.70% 
Total  $395,166   $-9.62% 
Schedule of components of net deferred tax assets
    
Deferred Tax Assets:    
Net Operating Loss, Credits and Carryforwards  $5,277,829 
Fixed Assets   – 
Intangibles   641,800 
Research and Development   25,327 
Other DTA   454,890 
Lease Liability   174,292 
Valuation Allowance   (6,397,374)
Deferred Tax Assets   176,764 
Deferred Tax Liabilities:     
Fixed Assets   

(54,095

)
Intangibles   – 
Right-of-Use Asset   (171,396)
Deferred Tax Liabilities   (225,491)
Net Deferred Tax Liability  $(48,727)
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases  
Schedule of lease information
   
Operating lease ROU asset $646,779
Operating Lease liability - Short-term $118,670
Operating lease liability - Long-term $539,035
Remaining lease term 6 years
Discount rate 6%
Schedule of maturities of lease liabilities
 
2024 $118,670
2025 $118,862
2026 $112,582
2027 $106,042
2028 $99,881
Thereafter $101,667
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Description of Business (Details Narrative) - Revenue Benchmark [Member] - Product Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2023
Generic Pharmaceuticals [Member]  
Product Information [Line Items]  
Concentration risk, percentage 97.00%
O T C Products [Member]  
Product Information [Line Items]  
Concentration risk, percentage 3.00%
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details - Estimated lives)
 12 Months Ended
Dec. 31, 2023
Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment estimated useful lives 5-7 Years / 20%
Computer Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment estimated useful lives 55%
Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment estimated useful lives 5 Years
Vehicles [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment estimated useful lives 5 Years / 30%
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details - Intangible assets)
 12 Months Ended
Dec. 31, 2023
Licenses [Member]  
Finite-Lived Intangible Assets [Line Items]  
Intangible asset estimated useful lives 5 Years
Website [Member]  
Finite-Lived Intangible Assets [Line Items]  
Intangible asset estimated useful lives 55%
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details Narrative)
 12 Months Ended
Dec. 31, 2023
shares
Accounting Policies [Abstract]  
Anti dilutive securities shares 0
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Oct. 20, 2022
Dec. 31, 2021
Business Acquisition [Line Items]        
Business combination, goodwill $ 0 $ 0   $ 0
Nora Pharma [Member]        
Business Acquisition [Line Items]        
Business combination, account receivable     $ 1,358,121  
Business combination, inventory     3,181,916  
Business combination, intangible assets     659,571  
Business combination, equipment and furniture     210,503  
Business combination, other assets     1,105,093  
Business combination, total assets     6,515,204  
Business combination, liabilities assumed     (5,981,286)  
Business combination, net assets     533,918  
Business combination, goodwill     18,326,719  
Business combination, total consideration     $ 18,860,637  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Acquisition of Nora Pharma Inc. (Details Narrative)
 12 Months Ended
Oct. 20, 2022
USD ($)
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Oct. 20, 2022
CAD ($)
Business Acquisition [Line Items]        
Payments to acquire shares   $ (0) $ 14,346,637  
Stock issued for acquisition, value     4,514,000  
Earnout payable   2,547,831 $ 3,632,000  
Nora Pharma [Member]        
Business Acquisition [Line Items]        
Purchase price of shares $ 18,860,637      
Payments to acquire shares $ 14,346,637      
Stock issued for acquisition | shares 3,700,000      
Stock issued for acquisition, value $ 4,514,000      
Nora Pharma [Member] | Malek Chamoun [Member]        
Business Acquisition [Line Items]        
Earnout payable $ 3,632,000 2,547,831   $ 5,000,000
Payment of earnout liability   $ 1,084,169    
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Goodwill (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]      
Gooodwill $ 0 $ 0 $ 0
Goodwill acquired during the period   18,326,719  
Goodwill impairment 0 $ (18,326,719)  
Goodwill additions    
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets (Details - Intangible assets) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]      
Finite-Lived Intangible Assets, Gross $ 1,487,228 $ 781,378 $ 0
Intangible assets acquired   659,571  
Intangible assets additions 710,372 121,807  
Finite-Lived Intangible Assets, Accumulated Amortization (42,969) (4,522)  
Finite-Lived Intangible Assets, Net $ 1,444,259 $ 776,856  
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets (Details - Amortization expense)
Dec. 31, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2024 $ 59,745
2025 59,745
2026 58,541
2027 19,041
2028 $ 9,985
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Goodwill (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Oct. 20, 2022
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]        
Goodwill $ 0 $ 0   $ 0
Nora Pharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Goodwill     $ 18,326,719  
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Plant, Property and Equipment (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total $ 555,864 $ 478,055
Less: Accumulated depreciation (189,996) (83,806)
Plant, property and equipment, net 365,868 394,249
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 171,859 162,534
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 7,368 16,418
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total 34,132 33,329
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Total 17,664 0
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 324,841 $ 265,774
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Plant, Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 110,701 $ 20,641
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Reverse Stock Splits (Details Narrative)
Feb. 09, 2022
First Reverse Stock Split [Member]  
Offsetting Assets [Line Items]  
Reverse stock split 1 for 200 reverse split
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Capital Stock (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended
Nov. 16, 2023
May 16, 2023
Oct. 20, 2022
Apr. 28, 2022
Mar. 14, 2022
Feb. 22, 2022
Feb. 17, 2022
Jul. 31, 2023
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Jan. 19, 2023
Class of Stock [Line Items]                          
Common stock, shares authorized                   3,000,000,000 3,000,000,000 3,000,000,000  
Common stock, par value                   $ 0.001 $ 0.001 $ 0.001  
Stock issued for acquisition, value                     $ 4,514,000    
Stock repurchase program amount                         $ 2,000,000
Proceeds from warrant exercises                   $ 3,502 $ 13,193,177    
Common stock, shares issued                   28,024,290 22,585,632 28,024,290  
Common stock, shares outstanding                   28,024,290 22,585,632 28,024,290  
Dividends                   $ 0      
Warrants Exercised [Member]                          
Class of Stock [Line Items]                          
Stock issued for conversion of securities                       10,793,369  
Proceeds from warrant exercises                       $ 13,196,681  
Exercise Of May Pre Funded Warrants [Member]                          
Class of Stock [Line Items]                          
Stock issued for conversion of securities 2,346,000                        
Proceeds from warrant exercises $ 2,346                        
Nora Pharma Inc [Member]                          
Class of Stock [Line Items]                          
Stock issued for acquisition, shares     3,700,000                    
Stock issued for acquisition, value     $ 4,514,000                    
Private Placement [Member]                          
Class of Stock [Line Items]                          
Net proceeds issuance of private placement       $ 16,752,915 $ 6,781,199                
Single Institutional Investor [Member]                          
Class of Stock [Line Items]                          
Gross proceeds from sale of stock   $ 5,000,000                      
Net proceeds from sale of stock   $ 4,089,218                      
Tradeable Warrants [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares                   4,102,200      
Nominal exercise price [1]                   $ 2.22   $ 2.22  
Common Stock Member And Investor Warrants [Member] | Private Placement [Member]                          
Class of Stock [Line Items]                          
Stock issued new, shares         2,301,353                
Common Stock Member And April Warrants [Member] | Private Placement [Member]                          
Class of Stock [Line Items]                          
Stock issued new, shares       2,472,820                  
May Pre Funded Warrants [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares                   3,502,381      
Nominal exercise price $ 0.001                 $ 0.001   0.001  
Warrants exercised 2,346,000                        
May Pre Funded Warrants [Member] | Single Institutional Investor [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares   3,502,381                      
May Investor Warrants [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares                   11,904,762      
Nominal exercise price                   $ 0.59   $ 0.59  
May Investor Warrants [Member] | Single Institutional Investor [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares   11,904,762                      
Common Stock [Member]                          
Class of Stock [Line Items]                          
Stock issued new, shares                   2,450,000      
Stock issued for acquisition, shares                     3,700,000    
Stock issued for acquisition, value                     $ 3,700    
Stock repurchased, shares               68,012 445,711 513,723      
Payment for stock repurchased               $ 34,321 $ 506,822        
Stock issued for conversion of securities                   3,502,381 9,633,486    
Common stock, shares issued                   28,024,290 22,585,632 28,024,290  
Common stock, shares outstanding                   28,024,290 22,585,632 28,024,290  
Common Stock [Member] | Single Institutional Investor [Member]                          
Class of Stock [Line Items]                          
Stock issued new, shares   2,450,000                      
Public Offering [Member]                          
Class of Stock [Line Items]                          
Net proceeds issuance of private placement             $ 6,833,071            
Public Offering [Member] | Tradeable Warrants [Member]                          
Class of Stock [Line Items]                          
Warrants issued, shares             4,102,200            
Nominal exercise price           $ 0.11              
Public Offering [Member] | Common Stock [Member]                          
Class of Stock [Line Items]                          
Stock issued new, shares             1,882,353            
Series B Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock, shares authorized                   1,000,000 1,000,000 1,000,000  
Preferred stock, par value                   $ 0.10 $ 0.10 $ 0.10  
Preferred stock, shares outstanding                   10,000 10,000 10,000  
Number of shares redeemed           990,000              
Director [Member]                          
Class of Stock [Line Items]                          
Preferred stock, shares authorized                   30,000,000   30,000,000  
Preferred stock, par value                   $ 0.10   $ 0.10  
Chief Executive Officer [Member] | Series B Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock, shares outstanding                   10,000   10,000  
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Warrants (Details - Warrants issued with financing) - $ / shares
 12 Months Ended
Dec. 31, 2023
Nov. 16, 2023
Pre Funded Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 3,692,276  
Exercise price $ 0.001  
Expiry date Unlimited  
Tradeable Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 4,102,200  
Exercise price [1] $ 2.22  
Expiry date February 2027  
Investor Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 3,603,604  
Exercise price $ 2.22  
Expiry date March 2027  
April Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 9,725,690  
Exercise price $ 3.76  
Expiry date April 2027  
May Pre Funded Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 3,502,381  
Exercise price $ 0.001 $ 0.001
Expiry date Unlimited  
May Investor Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of warrants 11,904,762  
Exercise price $ 0.59  
Expiry date November 2028  
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Warrants (Details - Warrants outstanding)
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Tradeable Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of warrants outstanding | shares 963,693
Exercise price $ 2.22 [1]
Expiry date February 2027
Tradeable Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Exercise price $ 0.11 [2]
Investor Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of warrants outstanding | shares 800,901
Exercise price $ 2.22
Expiry date March 2027
April Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of warrants outstanding | shares 9,725,690
Exercise price $ 3.76
Expiry date April 2027
May Investor Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of warrants outstanding | shares 11,904,762
Exercise price $ 0.59
Expiry date November 2028
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
[2] On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Warrants (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Proceeds from warrant exercises $ 3,502 $ 13,193,177
Tradeable Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants exercised 3,138,507  
Investor Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants exercised 2,802,703  
All Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Proceeds from warrant exercises $ 13,196,681  
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings Per Share (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Net gain (loss) attributable to common stock $ (4,506,044) $ (26,744,440)
Basic weighted average outstanding shares of common stock 24,331,908 15,180,868
Dilutive common share equivalents $ 0 $ 0
Dilutive weighted average outstanding shares of common stock 24,331,908 15,180,868
Net gain (loss) per share attributable to common stock $ (0.19) $ (1.76)
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details - Provision for income taxes) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Current:    
Federal $ 0  
State 50  
Foreign 379,246  
Deferred:    
Federal 0  
State 0  
Foreign 15,870  
Total $ 395,166 $ 233,304
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details - Reconcilation of tax rate) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Pre-Tax Book Income $ (826,953)  
Pre-Tax Book Income 20.14%  
State Taxes $ 50  
State Taxes 0.00%  
Permanent Adjustments $ 56,812  
Permanent Adjustments (1.38%)  
Change in Valuation Allowance $ 860,705  
Change in Valuation Allowance (20.96%)  
Foreign Tax Rate Differential $ 0  
Foreign Tax Rate Differential 0.00%  
Rate Change $ 167,676  
Rate Change (4.08%)  
Provision to Return Adjustments $ 67,144  
Provision to Return Adjustments (1.63%)  
Other Adjustments $ 69,732  
Other Adjustments (1.70%)  
Income Tax Expense (Benefit) $ 395,166 $ 233,304
Total effective income tax rate (9.62%)  
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.1
INCOME TAXES (Details - Deferred taxes)
Dec. 31, 2023
USD ($)
Deferred Tax Assets:  
Net Operating Loss, Credits and Carryforwards $ 5,277,829
Fixed Assets
Intangibles 641,800
Research and Development 25,327
Other DTA 454,890
Lease Liability 174,292
Valuation Allowance (6,397,374)
Deferred Tax Assets 176,764
Deferred Tax Liabilities:  
Fixed Assets (54,095)
Intangibles
Right-of-Use Asset (171,396)
Deferred Tax Liabilities (225,491)
Net Deferred Tax Liability $ (48,727)
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Lease (Details - Lease information) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Leases    
Operating lease ROU asset $ 646,779 $ 760,409
Operating Lease, Liability, Current 118,670 123,026
Operating lease liability - Long-term $ 539,035 $ 642,232
Remaining lease term 6 years  
Discount rate 6.00%  
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Lease (Details - Maturities of lease payments)
Dec. 31, 2022
USD ($)
Leases  
2024 $ 118,670
2025 118,862
2026 112,582
2027 106,042
2028 99,881
Thereafter $ 101,667
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Management and Director Compensation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Officers compensation $ 1,515,000 $ 1,785,000
Directors compensation 400,000 300,000
Advanomics Corporation [Member]    
Related Party Transaction [Line Items]    
Officers compensation $ 0 $ 60,000
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

E,QK;WGX.F=]EEE?>N8_EYO?'!@ MR#_/Y:&SLGS>BG3-A6]4QE<)VL*S>^!D]?+%XFS^]D ,)T,,)X?0#];GH.;S M?GVT@>F$7KXX3Q>+MS1DZ/>2Z<;6C3*/:)3/K7:TKBJ;J=A==DL!&$WKLA)-0HW3&9X07]_=T/G\]#B='Z>GQPMZ MU%R!+Z2H&.I3V]8$P?B!%N='R_3LZ,WBQU@G[[4I(K3CS#ZP4QM=Z? HPH.^ MX^BQGX11&,&B3^Z9V >-[F4?:: \QD\C+N-]@RE%7E7LCPACSB$4&,-P*K3! M5H%:A9+JLS)1%J?^]%>N15WK+L6%-8R5/!MK&H!12Z%L/&\3Y:3UAL*YU)2E"'OHJ3 M?0KARH!,M]G!K.%:V-S/FS1&((.G,XYB/6@?:0)IX?#R="XH3^%&#F$JU8,LV3Q! M^W;C$9/PIF/(V+WI5^.A5#D9.TIOSW]51;>ZJP3:WSI 3?X'=3&YP[4B;^'+ MJ$23ZU[Y^=HL,!;ZB359/V&)Z'A$O1H-J%C2UZ-A,GD_9(9>C6;,Z^_83I\L MY[GNY@92*D09OAQ&6#YY3\\="+/1X5VS*^(51=H'/.[.\6%WN 6MN\/_2;R[ M0GWH)A=5O(7J?/KF-$$CQVM)]Q)L$Z\"&QMPL8C+$C%CXQ%=KZQ;B^73#5OB(]O?-@Z99W*,TO$5I MN)*@<3D+;]*KV]S9>X,_..[,T1BZ=B4'+9?=E3_MS.'*HDA,.V=XA\[R[0)[E/;-L/M5J M!]I9$YH;>*G>F\AQZ2[ET6K:Y>1GY^^E97+%%P+AQABT9AI;@G6;<;V'N.T@ MLA,0:08?E;1K S_+!INO 6+BTY/*#J1NL[.(]UA?PBB-($NRT1F\42]RY/'& M)_!^4:K9<2& R09>*89[;FJAS%8C_'6S,%93JOP]= Y=E-%P%/=\KLR&U3@+ MZ7T8U%\PG+]]DXZ3ZS,:\EY#?@[]_UW468AA@K\IBU# VS=5EJ;7 Z=SM,+\ M2@02;02UHI=I+#:@EF#7"$LEZ(ESN0)F@:X0VP7JPS5F_NS=?5X%CU19FBWA MD2/_%CVX98+)VDW=_KY@+(<1U4Q_H[ZK+<;%E6F"?'-SHD:01KE51EEV?=E M9=%D/#FM*SBAZR74A0N6YU%63"B=AA2-(I\[:"QO7U/ )VH^!O<9%MRI=L/D ML[__\MH,W#EU*4!6KP\Y*?')PI)XPS,R31[&G6R7J>;K3!RF$.PI!,0U)SV4 M4V5>N%EQ-!Y#445%GKIQ">DD2KIQ!9-H4A4P]/[CHZ+=HE[YUF3H66VE[>IW MO]IWOYNNZ+^8=ZWS(],K3M&PO=V]R:W-H965TR(=\2)',V4>NE'$S+!6X4Z*'KF'JZQE;N5W[L/Q]\X;O&V(-PO>S9#N_1_-%O M%.W"":7B'0K-I0"%]WS+#U4LD]*"M-:';AJ#IM01$EZ!B^="*<.+W^+\($I<;;47Q.&OZ^VVBAZ*O^1;?E< MZIZ5N/*I/C2J!_37[]_%>?3QC-_9Y'=V#OW_)^HLW&EG?Y,&O1S>ORN2./X( M9TU.QX'73X'$Z98I!&V8P0J8@5)J0#IT<(@^9BY]1L;FV9_F3# M 1V:1E9 G0UJ+I@@UUIJ-+U4QBKT@^JE1FT)*&*B7?E7($<74!O>.8*#QGIH MH:7VHCWB-3FH+^#NI!3AB1U"K61'T@H1C 2S)]I/\(1,D>+F;'!*26U1&SA8 MJV5+W9648!?*WM_D07/U2>EI,1NB\I6F&( MYW%0S!9VE2?!+,V\&]GU@T'EO?@S#]*\(($@BPOOTZ $-X-"S]JM^:-=:TBS M($X32-,@31;>KTC!;&1;>;RSF4*+H\E:D.?9\Q/TOF+#R]8J)UE09#$D^2R8 MSS/O=VDH6;/9+"A(/)L7032;$:C6E]Y560[=T+JH5\=O[D-<+(+%(H/&1]I2&IT3\GFP^40\#\A=DW, M67!A9IT$1XU^@[5SHTS3:^!8,:>/YU.$_-J M'!0OXN.X_&ULI91-;]LP#(;O^Q6$"_14Q!])TZRU#31IB^W0 M(4BP[:S8=&Q$ECQ)3MI_/TIVO Q(@P&[6*)$/GPIBXH/4NUTB6C@K>9")UYI M3'/O^SHKL69Z)!L4M%-(53-#IMKZNE'(S6EBJ-96MX M)7"I0+=US=3['+D\)%[H'1=6U;8T=L%/XX9M<8WF>[-49/D#):]J%+J2 A06 MB?<8WL\GUM\Y_*CPH$_F8"O92+FSQM<\\0(K"#EFQA(8#7M<(.<61#)^]4QO M2&D#3^='^HNKG6K9,(T+R7]6N2D3;^9!C@5KN5G)PQ?LZ[FUO$QR[;YPZ'PC MRIBUVLBZ#R:[KD0WLK?^'$X"9L$' 5$?$#G=72*G\HD9EL9*'D!9;Z+9B2O5 M19.X2MB?LC:*=BN*,^D*]Z@TPMK(; ?KAE=&Q[XALMWWLYXR[RC1!Y0P@E28_PWP2=*@*SKJFD<7B4^8C6 NGU53@-'BYHG P:)Y?H_ZSQ(N6\QF_2(-S!]=4L"L,' M.)<)GHL"78_ "VY42RT*G]WY1S=@2H2%K!LFWB&CD:/!_!.#$.A=()^ &K1# M:@N#]>RM>F=I60@/'@D*#T=VM M!ZKKO\XPLG%W?B,-=9";EO1DH;(.M%](.I#>L F&1S#]#5!+ P04 " "M M@'Q88W\I0A,$ !R"0 &0 'AL+W=O&S++3;"GN@6%;U9 M:],(1U.S&=O6H*B"4U./>9),QHV0*EK.P]JE6?JD64>$%88^D\@J#'#5Y@77L@DO%CP(SVE-[Q<'R/_C'$ M3K&LA,4+7?\M*[==1$4$%:Y%5[OO>O<[#O'D'J_4M0W_L.MM&1F7G76Z&9Q) M02-5_Q2W0QX.'(KD&0<^./"@NR<**M\+)Y9SHW=@O#6A^4$(-7B3.*E\4:Z< MH;>2_-SR0K32B1JNG"ZOYV-'D/[%N!SU\$%56#T&&).6 MO2!^+^BP?OPHY/N#OXY6UEGJ ?^/19D M#Y$>A_#[XIUM18F+B!K?HKG!:/GV#9LDIR\(S/8"LY?07Z_ B^['Q7W5#J& MMV\*SM@I/** /[8(%[IIA;H+!M-3"Z)S6VWD3ZR@'(RE'95D9:2E1;V&-$Z2 MY/X'R4F2,$@/%U@";#]E_>.;@H^X,AWM=V#34%0>@WM0 )ZC1D<< MIN5GZ#25RDI&K*B+)SF*60Q2WC, M?Z'VI$^I#5:(#4'/9OL8F/?[(DRY!9:]JM?(&^%PU-:4?SJIW.N*IP6+V6P& MI#9A03'QG1%0#;QXA4]I>F%& RO\;U9&M#F/9RPGVFS*XX*']'PKG5ZA(=)C MQ-+:CN#2>#J4-(MS2LE0U<]"]46=]3OUL:]02G>J#$FRONE&!MN.DDKGIQ>W M,:+QVKH6G":%'+(LCZ>4_3RAJG+>5^'.2S\"_W(-B,AV@@8$3?18=D8ZB1;V M"L3&8&^[DVY+:D$JZZ3K_$7A6U_=(,DV0)<>;(RV]E%&14NS6TE7 M9WI#ZG MU"3%+.:L\ G.^W2E<4Z=F!;4G2R>)5D\G7#XI$*F0\6>QC6D7)!ROP/U>D3; M:#I+XW0R Y92XTSB"0$2RN>.J)\B/*3Y$Q7R6^+V: M%WD\2?GA214<*BQK87R/:SAV\HX/[L$&S2;<]I;:I5.NOQ+WJ_L/BK/^'GTP M[[]&Z C84%- C6MR34ZF>02FO^'[B=-MN%57VM$='89;^BA"XPWH_5K3&3Q, M/,'^,VOY'U!+ P04 " "M@'Q8:^W@$6,& #?#P &0 'AL+W=OVNRO7;+B]G-G_4W8._8REXXNC?ZB,I^?]F=]D=%"UMI_-*O? MJ=W/(=M+C7;AKU@ULO&X+]+:>5.TRD!0J++YE7=M'+849M$C"DFKD 39% MHYD\HADGXITI?>[$59E1MFM@!!AK+$F'Y2)YTN)K2H=B' ]$$B7C)^R-UWL; M!WO3_["W1G.\7Y,KX:6K9$JG?5#=D;VE_MF+9_$T>O4$KLD:U^0IZT_B>E)S M/Z[WQI,X%B^>S9(X?B4ZZ^)33N+2%)4L[T'^U-2\B#(6RKF:,K'J!$GYG&Q/ M.B&%5G*NM/+W H+TO>8G509]F\DR)?#3Y^+\YE),9M%!'+$ M$<^< FC66:-QN:EU)N8(6(N LCT)PDJ3H^VX-TX&#,=;=#V&([$SN3=T3 B. M752T"T\#,4? M'>2#S69V65&0='7@! !)99$T7<-B&2PR7P/U0(N&!Q#C#U1FC(-DF@-M9:QG MKQ6,!&>E#4QQ(B1KB5.1\Z2-VT^W+B&;K#[*N"ZMP2(O@D6 DNHZ>T".3%NP M5:6Q8Z[2W\[/KSFJZ $62;P*JH\2I^UK6&8>/\F>7LAGZ%ZE:8GA.)I;*ISJ M9:G^XICM)P2R6/+YE(3]\T'U8P\H*DT-H-J*A2JA"E;V0BV@JEB-VY4IRW8P MX0@0XT)N_8/F++EG:\Q.[F7O!B-95NO WK5 I\ ;V[C[=%^1>-]TO*L[LJER M)*ZMPC:N[BIE[P7&!>I=6SIXPWG)-N?&># ]3@;)T50\CX91%*.U:%4H[*GW MR]M>4O@B]TQ'_'_B7@>Y-]) MB_(-PN<5FOY&\GAPE!P"#$R/AX#3? Z2[]#,]F,_!)KQ+'Z(G5765;J0:,)43P) MDU'2$.ZA:U[= WDEN85E==K4<0CZ8-^9'IHW#B77,-(LT$)#Z\=P)Z_&4ZV0,UD?#./Y' MUL^B"(R+_R_G?Y[ '\K>A]0;7HF3P9Y.E9/F)+F*4J8R#SY;C,R-#I,,7M5N MS/9Q#&Q:Y0I;DA@SOF)TX_%DT=LVA!9O 3&4CP2QLS!]@) LU!H2YTL*?RU1 M][FA[K^C_,*:HHETCQD?$H23N:/ ,#!N X(K!+;3FMLVRFT=MUD3MZ'8-_2/ MMBY=!=EEN%KR&8GSJ+E_K5?7M]?SYM*V$6^NOJ##4F%FT+2 :C0\.NP+VUPG MFQ=OJG"%FQN/"V%XS'$#)\L"^+XPN .T+^Q@?:<_^QM02P,$% @ K8!\ M6*>R;>/X @ XP8 !D !X;"]W;W)K&ULK55- M3^,P$+WW5XS""H$4-1]-2X&V$@56NP<0@OTXK/;@)M/&(K&#[;3P[W?LM*&L M2I?#7AI_S'M^,_:\CE92/>H"R:AB"WQ \[VZ4S0+6I:,ER@TEP(4SL?>170V36R\"_C!<:6WQF S MF4GY:"=?L[$76D%88&HL Z//$B^Q*"P1R7A:@;#2QV8%+U:%)'!?V4AZ,HEU..#.Y M9DIPL=!PAPH>TL0D*!65;Q1 M-8WW,EYAVH5>Y$,ZHCY[8E> I,9)#QHC:8@2 K MX8+"$"HBUHZ8\ []@DQI0/M.@&X9RQF%]**SS@/935;3<<2)&V&O^.U3[:.P M+R/NW-)1"W(>."JDUL? C%%\5C>ZC;2HDEJ?NBA]A$]PE/C]<."'20+'=AH/ M_),D\9,DA./.U"6RC@IVBI\0QPG?H\>ZVDXA*CO M1\/0'PZ&G2M;#G*<-M;E@4\U7[("!=5TJ>#&BTZV4'6\93HEHX>]7$50O3>%"[VCKX16-!"0X%S@H;= MD[X'JK'49F)DY6QL)@V9HAOF]"^$R@;0_ES2\UY/[ 'M_]KD#U!+ P04 M" "M@'Q8SWPM*E$$ "&"0 &0 'AL+W=O.&3CICP+\-E#!#X#*7F;1EDK3W<',/ B_@JVUQD@CA MO[^5;!SH0/IB6])^WWZ[JY4\W''Q4ZX1%;P6>2EO[+52FT&W*Q=K+)CL\ V6 MM++DHF"*AF+5E1N!+#6@(N_ZKAMW"Y:5]FAHYF9B-.1;E6+SC!/-=$).._FM-N7&K@\?>! M_<[$3K',F<0)S__*4K6^L7LVI+ADVUP]\MV?6,<3:;X%SZ5YPJZR#0(;%ENI M>%&1E=6;O=9Y. +TW L OP;X1G?ER*B<,L5&0\%W(+0UL>D/$ZI!D[BL MU$5Y4H)6,\*IT7VYX 7",WM%.>PJ8M3SW46-OJW0_@6TY\,77JJUA#_*%--3 M@BY):?3X!SVW_KN,4UQT(/ <\%T_>([Z+/ M:_O*%8+GP<(]!PPTLLE02^!$4S&\%?,M-WU/:050!E #ND M_#%)"SDUM!Q83W1.I-L<-?8RSIILA2 7 ^L.4Q0LAZN#(.M),5(8N1;U&751 M"4'2=_PPMLR['UM37"*ATS?P*?0P.N"]R.DEKE6_GKDR[H)^Y'AQK$.V)A0R M*_<&F'R6@,LEFO-!JP6A2=.,Y@0%*GAADK*L?4ORN55<["N[2[EXBQ[PE)^BUK,F:E2LDY_"#Y5MF3KZQ5L?*!4(O=IW$C:!- M;OIQJTF8%O6H/4Y-T,2;O26Y]F[6:WHO3IPXB:$==EQR.FO*KC@\HMJ*\D0B M67MAJ"7&0=)#"R$R+_M497T.YW8K]U87^6=%NE]:8P&692(BVS M,H4\8_,LSU2&9J]:E^ISRGJ!L=EZ)D5C,S>POI+QMPUM!I65*WC@4CHP(:.L MEC!A0NRI W9,I))BB1P_29R>W[?NLE?BJGB:;7M?*LIJ-L^IV''H.3W7M1ZI M>YE8K W?%%_H]MSH9((?.8&?U$FM!Z3+"1[JZ/?@)2$UCV^= MVP?7L1/T$R=(0OAT+D0"QTX2AZ=K#TUF*0Q[9*,3?M9NK_LG[#F)GU#[G#M_NT=W8X%B M9?X )%5_6ZKJFFQFFY^,<76WOIE7?RA?F%AEI80DHK@?:0?/K-?H?4$L#!!0 ( *V ?%@1;[E) MY@0 (8+ 9 >&PO=V]R:W-H965T5"JJ_%L,LG&M5 Z79V'NUN[.C>MKY3&6PNNK6MAGZ^P,MN+=)KV%W=J4WJ^ M&*_.&['!>_3?FUM+I_& DJL:M5-&@\7B(KV3K+C[W*/_'GPG7];"X;6I_E&Y M+R_290HY%J*M_)W9?L;.GQ/&DZ9RX1>V478Z3T&VSINZ4R8&M=+Q7SQU<=A1 M6$Y^H3#K%&:!=S046-X(+U;GUFS!LC2A\4-P-6@3.:4Y*??>TEM%>G[U!_2H1K4S="/T,I')AUI3:"F\ ! M'054Z!PB4$N#*0HE,0G05'J^!*655Z(";?1'*;2DAA'K"L&CK1V]!7R2I$^: M8#3",PI[M&=25L(Y52C,P=-UQ:2"70TT2RP1T9MX&_6B@*1JHAGB$D&]KG%+ M#$P3&I=I"B!-97*V6E ;![/N"*Y0BI:T_8Y]Y4"B93#PAMBBE:H3V4<>A;OX M3)>=!<5.RJJEJDX((D=VG()"I%_9238\Y()3QYVXAG&E?>04LM8=\P M",+B ,ZA? 'L=?="&?*Z^.22*),;2JXVOH> R"QDMK/@0K20\D@$&F'],\?@ MQ0R]I.KQ5H5A2*'4E&'.-I="4)+F$>F2F=SV_N0M1I\2OY, !+!FLL+?^#<#&FL;8 MD%AJ$5=RX*ETUJVJC;#'Y"717X8O1FU[^9'XZFLQ/DCODO+S(A]=9X(I<10M%L9CQ2; M'1RJ6-H'F$]A3?U*[F>LOGG$D#B29W:LS)F3PMIG@DNBQ&%KM(T@%P*/'>JT MK\*WEH8Y[ACOX\F7<4R]FO/)JQE-_OJA5H;O.O[ M/-[9C6JTF[ !TA>"HQG7I.%V6#(OXV[U(AXWU*_";FA D$<%J4Z.%B2UJ4T;( O2\,?;"[ QL85N_5?U!+ P04 " "M@'Q8 MLVC(1T\" "I!0 &0 'AL+W=O[CK-IT+-26/$EIVG\_2G:]#$A2 M;!>+DLF'+R60BZTV3[9"=/#2U,HN6>5<.X\BFU?8"#O2+2KZ4VK3"$=;LXYL M:U 4(:BIHX3S:=0(J5BV"&=W)EOHC:NEPCL#=M,TPKRNL-;;)8O9V\&]7%?. M'T39HA5K?$#WO;TSM(L&2B$;5%9J!0;+);N*YZNQ]P\./R1N[8X-OI)'K9_\ MYDNQ9-P+PAISYPF"EF>\QKKV()+QJV>R(:4/W+7?Z)]"[53+H[!XK>N?LG#5 MDLT8%%B*3>WN]?8S]O5,/"_7M0U?V':^Z06#?&.=;OI@4M!(U:WBI;^'G8 9 M/Q"0] %)T-TE"BIOA!/9PN@M&.]--&^$4D,TB9/*/\J#,_174IS+;H6BNZ=; M=B!4 3?2T'5I ]>ZH7>WPE_=(G*4R?M'>4]===3D #5.X%8K5UGXJ HL_@9$ M)''0F;SI7"5'B3>8CR"-SR'A27J$EPYUIX$W?;_NJW^INZ.F^ZF^@^:V%3DN M&;6(1?.,+#L[C:?\\HCF\:!Y?(S^WV]UE+I?\U?M$.(4SDYG21Q?PH'4)[NI MX5N%08M0K] *68!T%G19RAR-A5S8"O(=_Q.GG2 U:_@ \?DDGIQSSLFZF'46 MARD/QEYNT4MX!SSF'2/MUWW/$.VT3X-F'88$@5P"!@ 2Q !D !X;"]W;W)K&ULM5A+<]LV$+[S5^PHGHP]0TLD];+CQXSE)-,>DGCBICET M>H#(E8@&)!@ E.Q_WP7X$"5+:M).#Y8$8/'MMXO=Q<+7:ZF^Z131P%,F^3(V=&-Q>%VR)CVB^% ^*1H,6)>$9 MYIK+'!0N;GIWX9O9R,H[@=\YKG7G-UA+YE)^LX-?DYM>8 FAP-A8!$9?*[Q' M(2P0T?A>8_9:E79C]W>#_M[93K;,F<9[*;[RQ*0WO8L>)+A@I3"?Y?H7K.T9 M6[Q8"NT^85W)1I<]B$MM9%9O)@89SZMO]E3[H;/A(CBP(:HW1(YWI%,=;N)',_MH3P:1:N<]IG;QW*N\7N)N8%W*_K4UP-#L'9Q M$-<0LPHB.@ 11O!!YB;5\"Y/,-D&&!"?EE34D)I%1Q'?8MR'8>A#%$3#(WC# MULBAPYO\J)'PQ]U<&T4A\><^>RNTX7XTFR9O=,%BO.E1'FA4*^S=OGX53H*K M(UQ'+=?1,?0?.Y"C$/L)?I0&(1S!ZU<741A>P4N??,KA/+&8.X5Y5SP&.1B@8KG2PIH MD\)22:VA4#)&3#08N04L%\ *6GSBE&^ V 5 MR!Q!ITRA&Y3*F4VBE)GQ-]\NGY/1)O5.PT$8G#E3X)&8HH8[6#.E&#F(["U* M%:=4/[81NVAP:@\G"J[:[5^K[6XZO#H#EB=@UK+2J.$TVE7IS?Z;RMFN2M_I M/)V?P6CL!T%@_^!!X?E[>^;)2T]NUKP#WJ28/%]4NW^*:\?9.UZN.>^Z9]LO MM5 53!T+ZGD-5B7/,DQX%8/XA"KFFLT% C-P0A$9A%"@JNE9;1E[ACDVHC8W M+(MG,'1Q4588+CIK//<6I1 5 T[.X6RS3&[AL;/9N?&%;5S#2=0/@PZ!W;.4 MRGI1E[5'&=UYPJ#*F;WX(&8Z%4A)V&CT9&':[-K55[FCZX*N:ZSI^%1P$AE2 MFE;5GRU(F4OKQC:N+1FR*J%MQ\SV=LR>[9@]O#AL]A;_V4_SGVSS]X[P_Y1[ MFP(9[BN0IRV#D3R=T15*DM-P62F9.()6"*B9*@0-H1M%J&B9H,9%[441H(:,%U0)Z5_Q UD!"'; MK12&&N.2;@9[.JT-C*S"S-TZIW9C783NR#:QH??0B-^UXFTEM 7'VWC0)7M= M3:@<)8YY!4>5WU*,CFAJ4;MU:,O[A'[I3Z.Q/[D,JC#4FSCTZO1;=)W0M_3; M7+0+6SKW&7'PXP/8; MY76-6J><,EO&% 8V*&2WS8CVA4_!>.(F=@C5?JQ]4-U,+QW1C6KOWT7UQ3Y6 MFM32M+L -Q'0UAVZ4:@_L08^NF@@LG0SPOV[3\[1%DD;IWK%1-F<3+>>.PX? M&)D,HX,$PN!_9@"'&;C6<7JE*329LMV7EU %C8UL#F-7+DXY+FP1CDMW!5$+ M1^=HRYWNG&032AG[2U*A>&[&*^FZAD*N-S*[&ESF-0'AN1YRY0X;RL(Z(#PG MT\_IA4HGO2(9NNUL^U+^:YZ(&[$JV^2YQH$+FAKT)^.>Z"JIVLU,+)PS\6Y-/3X=#]3 M>NVCL@*TOI#TDJ@'5D'[_X/;OP%02P,$% @ K8!\6'_EV6).' -E, M !D !X;"]W;W)K&ULO5Q;<]NXDG[GKT!Y9LZQ MJV3'EB>7N:5*4>1$=3QRCB5G=FIK'R 2DC"F2 U!6M'\^NT+ ((2Q4RRI_8E ML22BT6CTY>M&@S]O\^+1K)0JQ:=UFIE?3E9EN?GQV3,3K]1:FHM\HS+X99$7 M:UG"QV+YS&P*)1,:M$Z?]2\O7SQ;2YV=O/Z9OOM0O/XYK\I49^I#(4RU7LMB M]T:E^?:7DZL3]\6]7JY*_.+9ZY\W32^1(I2HND82$_Y[44*4I4@(^ M_K1$3_R<.##\VU&_H<7#8N;2J&&>_J:3 MG*>&_A5;?O9%_T3$E2GSM1T,'*QUQO_+3U80P8!7ET<&].V /O'-$Q&7;V4I M7_]K^.OOY60E3(X%GL9WF#4_3/S+-55_\FF?ERHA1EJBD M2> 9\.P9[SO&W_0[*;Y5\86XONJ)_F7_NH/>M1?$-=%[<81>VXK_>S W90&* M\S]M*V9ZU^WTT)I^-!L9JU].P%R,*I[4R>M_?'/UXO*G#FZ_]]Q^WT7]]8?[ M\60X_G [FHJ[&S&\FTSO;L=O![/QW:2-U4YB[:QVS"!F*P7F%.?KC$+,.'21#J+TRI1HK1#0=0&E0X_#YF0D%DB-'QM MJKG1B98%[$%/R!1L8I6G*2CI-E/)A1C -SHK51&[@8X@4H -RXPDFS=B)9^4 MF"N5"95J,!]D$'@)&(;'+D3'CCSW._*\IB,4U&@Z&_\ZF(VF;=O02:%] M&_;)DNSAYXTLB'>489O !2\2W;8N=]%6EROQ,!7O5*8*B;($?5<;W*Y0\0O8 M)KU)0?4+]6>E@0OP-1EX9Z0IRAP^/2JA3*G!'RJ6MS3@T3YJ0J%RP+VD2N<^=@8G@75 MSNE2JRQ(+0)V(LL.#BK4D\HJRX#Z!-'.P(>D*E @]2#\M%&%SD'_< O6.3!I M H]Y7"AK"7H_WX62E##X2:85;2$*!:5=[F#3P-]4Q'0/8@OL,RS%;?.F@%A< ME&PG.&"##_98$-\T6F(L_O!VY$8#(=W#Y/95-R/AJ/QQ\&; M6_AN\E8,;F_O?AM,AB-Q8-/!0Z_ )"[$': J:Q6@' ". MM.E%@9HKUD$< ^LHCR^+-!@<.GAH>'B[4L@.,@$/Y04L-L,PD&_!M!7QD^35 MO%Q4:1!+"J'!N031( (N4='G2FQA(;!F$,>",%PB0M#'5H/+@5/) > MW+&OJME#8TK.JPW\C:(QO+6.PM)[\B17CACY;!*"43'O'L@%EP*[ $]'(%)3 M;="AT98$V]II>R^][;WLM+WQY.-H,KN[_UU\'-P^'(4CG43:+:J%LAAGX+II M[T#HI/V)"PF@*Z! %$0,*S@82U0;B[#&,L2?8;37OD14QGG^A2[PUZQG_X*D M1JQ!-3$&3!JVQ^20$(YS_BV!74A3BAR%!L5E!QB!0D.0 JY!30M#_G*.DRH# M:@<[87TO<&9X!6N(R)S"H![2]QELG#%(Q 5E'&-D:AT +1L&ZUI$#,"8^*8J M8E!!%3%C2#N6UZ%6G%@T'T_?D*.F/T;\?P'?>CHYXYTY2[;ITE+Z 1(_6^$:FY&JFF%>Q M_4]K. &K'DJS$C>@9>#P$*"N(/D#>:4:9).0U$W)#Q/R\KX4AOYP"8!E1PZ+ M-AN]Y>6E-0'Q<#&]$%;6]2KQ MUR%$CT1VJM$/7HU^^$R.=/=A=#_[G;8:=_G#K[#);3K42>=8>M1&'!!T&T:C M/0:@J=46\R..I_D3>&2"L@#/5YBA/"D;R, V ?KZ2Q9*5'.4D M.;S2ZL$_581@85P$] J03XW>(?2JK4RMM\=%YND2/>P"_8X_MDH_Y!9AFA:H]D&0G1_M9I2) ^5,4F M-P[U0OJ5H@0@&W$SX$#$[^Y!,GI=!/&D,@I!3PJ&R:*0QC)D?HRF,;CA*J6 MTCXDNELLT-^/G)A^!+=62"Q.#GW\7W7WW5YDJO+ MNDIV^1E@,QM,WHT)P4^GH_90U$WC&*[9(PRH!HQ]J0D7V[07-WJ-6O070L,G M18XS5(RHJ1C_.65N:I4^8*V=@^@6M SSZ,_L[F]J#D!"=:O-$8$ G^5_TIFR M1+T[Y0H!^5-T>G-5S^(QUMZS6-L X)DMSU$(2<1IN/9 WXVV_JZTCIH1&>3 MKH1QZ+')7U-Q(B[9>W(JS\D[A@&0/CM 7#9N)) 'R+3BVB["D<_%A,"-2Y1YHKRI">^,H& 4ZR MD!_%J3X#70Q+=(GB:I5#H6M9/-I"&0D.JPS(5@_&'@R6"3 #&1,OU9&@4DJ) M(EB#!P69P/=;"%DK3PRW#:PSZ>%#0!<)XV$4K 2QA\VB2"F"Z=)=#:G=GCH3 M*_02T 5D_I'W" N+I?=R,\=#<^O7((.JL)E@BP&SM[">=BFQ)KF7UC8\%./, M*'!4,#9'F 4_4O:CRVYK[]?6WN^T]C>#*605:%%OQ["). M;^^FTS,!1BBF[P?WHU8K[Z3>;N5?,&5#R#&#(R-0@&2&Z&@AJ JS0FW56<1A MFJ(=B6DP'8K^BTOQCV]>]:^N?A(C6:!=\Z@IC7HCC8ZI[@?:GZ^5.$6R9R'= M$-9&\QT$@B=-6 !'$3-V#/R&N[JE@F19M M]]A,R8\!RU3.3W!Y$+8H,PI3'Y^;X!*0=66\R>T R0@NIQZDUSUP2IV:7Q]. M7G6>)D*P&=[]"AHV^*\C >PK#B-#F@"R1)L^OOR^UL[,BP^+4JJ2'%IQ&][D<]=K.+C M)C[SJ&!7J<2RI:*O 4@CK9-V9/'@3Z)7E7022$AHRZF9YT6;8"5M M10.N)!V6"HYL[AX0\;3QC!@V7-EZ[49!C"OI!)CK^EB58J=2'B6-^; MC'.6 MG:RQ/%EBI>%)^>.])@>VLI^ZJGRT4 E1 "&2.&B.0&OPH8+/OTJNQ0&5@T&- M >"DL !,Y[)X[DJZ-\OIZ'*_S,*;Y7Q.Q [(2L;MJQ,.;S45S;3D O'#M%%$ M:% G4W[YD\$ZSR7J0%XM5U3KH3$[2IL946*!)B,O%RS$>>Q0W? @%@"!A:,9 MMLJDI%[JG'PC2J/B UJ"9_+S1WU7=1O$57BS>6X#]-O>MAOX1CR?_(G#8UGEHD4G\PUTKHG]&1M@*POD $ MIE&"^LI?ZX:0YI0U6'"80SC,T63#23L\\@_0@#U)L83I:";YHW(E?\S*([]QGK#K M0K#KPRI=8TZ71.59L[NET=!2)]AX8!6<-(A,4KT7Q :)"_>' "H'&GFF++!' M/(4^'Q(9ZPELXP$ML+ U6N\.P85_T=P]\HMT.(E9@T.]X-FI3I'EV3EICA=- M2+W;(=1=.%?=;3C#NPGDVK-[/B'$SJ7[T=OQ#/+RZ;_:D=-7-.5T3B)NO+H& M[1R,538YIHN:CFW!V/X /8A"YP^V!7@'\O72U<8Q-^03YT*;1T9#$ ,BUPB5J.81;ZC&FU3&U@'@\"@<3K@"S[3;5+L#UR)_TL9;D6^YBI:5)LC=([C]JO_N=-Q0B):2RX MCK1AMS"RW&)_G2VF@-\I-6HF:2%[>%MPP 5$Y+>/BJFN1P=K6FGPT$6\VMF< M#5='P.,O.TIGD&ISE86.PWFZD 1%+<(D(H64+S544,-6"U<%*=42:/[%SAS5 MWT9G/SEC;]=; "9(A+@J#M/; A>L^4GJU'>UA!4D5XROV0H$$QR"OQQO8,%_5CG^1SM.!3CN<[;[P7DJ%_1B!,45OJ5PWJ?@@[>9P^NT^V]$8>IIK.:U7>?:5 M"W.5_> 4#@>4#+,I8W.I9$Y'>SV/U8"]>7]IRI>J/L":5I!M^N@1+)W*<+,5X<&4FK!Y0 228?Y)YB MKR4V.H.;/Z-NHQ[\WEB9/R38XPTQ8RE=4&,T#,Z%$$)^C($]85[O"?,Z%&:; MJAT72EV I8XVM$CX&O+E.HVTGHK4R?6W'2%V3!>:YS^^@%Q'Q_:&U8C;V1C[ MAN[)N"EL8UJ!W5M4\@!V #?5GZG)[B((#D=:8YOT$'IY&A'18&B,?9^UVGFG M M80L$?G5E$9%H=TR47C:'FP<\+JWW*YNW"^7Q3YQ6'CT M]^2@)*H5MD?*UIP$B'%G-M9)NA!1W4YWU=U/-[G#EN\/@]^Q=[05X7Q%*UV# MJ'B3%P6%7&.[5(*BE;96W=#6'A5RT;0#%,!]8ZYF<;%/%9T$X$M.*^S6(]7Z M/ L)_$2Y _BN*6X-K##:IS>SQK]F9HM M+5OW-:_74N>/G,1!/*JK5JXUL,4:LAQS[8W<,3#H:,;"6DRW\M1==%?=;73W MHX^C"8#5^]'P[MUD?*P9LYM*NPJUD!9W*+T?7GZW=ZO#E9R"1GLLM8.$\8S< M=I]SZR*=BD*.NH;9*@[KL.M)%6/_VX?V'T";;+D80I.!W)8BN0MML>]^]OC, MQDST TO(I+#G+K*34@ -?Z![)PI9VR^@^&YI1-*&&<#DS?=:AT0PF7JO9 K_ M<7M;KUFBJ3.ONGMN@+VI').MQ JYS0"$-HRBYJ^^Y.!XQ+ FZ:8,(P(2,0AR MG%G(RZVGX8^X!"L+++Q&KDV4@;\-QX8L"-8F$W=+@[C$/NCF@![RH&"BD@X_ M&0ZY5FS.C6UE >=U0Y'W=A6*_*93[IJX:J3?8\R.*2FE'A:AP1<]Y3'97$Z7 M'8)Y; QW0\E#F VFUP[9J,RXN&-Q +5ATQT6U_A&Z[0MG-2FJUQW5U5XH-"4 M"A4!45\2!6['E?BENXY#P3;/1)H5W,+YD 8E-?)M.<@T1XW47/'+L0D!]=;:.GW MMZ2K'W7;/ EMKOE8+V\NNZ"5O&>;=1V%P58B:3),U"Y M'5UL*? IVTY%5VA)X/-4+Z4; 1)>:"#!6Q\UUF5S=N;$-E@W2I&-QG_V?9!. M[UA!G0_TJ^^Y,WS< ++)QN6MO%Y;5"\=,UPT.>^)^0 0L98Q;(02> -5HWM! M",/\61Q5(&BC\Y*Z1'-WN8$ZV3-WJ8+%7W-L8\4Y3THV6$?[7@W4K.QK5^"= M'\85Z079(Y2G/MFTBWZU5YE2((* MR/4A95GD*2,(Z61%:19=/G0U%0PV%)]JS2W\E1C;QT&IF54*@B7^"@.GEG8- M.O.=1"ZR6LOF,TB=/>4ZMC0)N3JN4.?T)\3>96N@=IO"VY]BN=':I[MH9T*) M/6;Y-J/\/'DB]=[WRN2,W!T5< J[ QU&7M,G7A3F&=FRPM,5EZ%%_O#$E:[V M4,+^'820O)4D%SJ/6*'WN>V&A^9%W891;02_K6IV7L M&1^I 5V^L;6@,/SHC),4%\=]'0X$CA=?"Y0Z#&QZB%(^*AL/NY9A!8.=_"M, M4W*--P<;/0[@"6S89,VIST#<"KD1>ZTYYD14N./H:M$#.8;3=],9/?KOZ>S, M7QK9X.U%C =JSUPFR!51.,/#47OOBD,[69BMR5R[:QJ+ANH'S+F;-H'[CP[=/SB 6%;& M#[;'-$= L@>0!S:"D1/A$E@=2YLP1'!CX@/7EM#1HT= [JN_!W9(?O! M/%/81/]$)]2PY3-P4YJ:M$ET%K6Q4-Q<> /;JP6A[CW_2US(N:*X1KYK0QW] M[(X(['MRMMO#.C@^^[87%/GXF2P&NX!THOCR#7-AD:RM13"*F1?DZ_;8X1^= M^:)9@G%!?#IU5PWG.QNY"1(KF]OAO1U(5&2*BL)C<9_IE0_&0UK4MK/68_:@ MDF16DML\;(LBA '"4OLC\@V'..Q>+!39]=HN+[#%4T,547)+]#CW%N(0O9[C MK;+&((?LR*,W-"OB9-S4P0&]$-_7X)93;JOTY3ZWZ^[\<"%UBOI,)U=KA!Z^ M)\5+F>\NL[+8>Y!N&%[EE&MP H 2-%;C]ZS%V8.73Z:6X+85G9@@PIW3'0I+ MI"?6VM#H(F0,[W>JIBMC].>@*':O<8(6695T2,0U*[2 +BL4KT),DL!CCTH, MI+6ACG!X)TA_YM.R'L_%G2.8P'"=!)N$J&702ZC>9/Z>A+K00 "=.W81]?P] M0D%=\>PG,7\@FZ",SW%KT[Z@8GQ&J]S#Z*G)(T:4Y QV#9VL/4!%9SC[7J I M-JL.YB#VH6='6Z# 1N4ULD'*7G:]O1#D,BTM/6P$NX*(GO#%$G=021V#LDA, M#8[G]JR)0Q8DZ-BCB&.H7JB6(''[[)JOW(WQO3/@K;/>0; .$;==F%M772.@ M*UH"#]P-<5FH5#WADQL$V3:@LF,$04>>)G?3!+RF M,1]Y+-"!GCX_JY62XBD#9@(FFWVW9BZB]SI) ,XSOZ?V FW-P(7E.-M1[F5 M'*@IT[<<-76:O;IM6&_D\\"8#45VB0PP0G_@/$A0-W(>(@+UE[2Z!F*ELX#S MQE>7 0/X=]LHN4L2/ MH&_4,$:)) "H%1@;HD]?VR%LPY=/)!:_L/D,T 3D@IC!E*6,'^$K$"O%4_\. M$S[/@:\Q30,11OCB$M!]G">&#"#EAF#;$ '*HW-B80-X8*UCP_6)C#_096U$ M=F@9C_A'FL>/B!YZ_-H"23TV"Q_;Z60";Z;U:,<>$TQG\B)BB^#[U3& 'U50 M?3!\\48]<6:WZCE+Y*7_ @V?:T1(06OA\E=3RE=F<&2 M.1^/A(575(!@57PNN<3EA%X#?@- 5)!"CUE+1;2ED] "D4%]%-5:"# M(,:LJN%T>^*@"T&\<1M\1]F.Q/.9B7L6;E"0K A'H"Y85+?R1WY4!PT!$$]B/)T^ MC-ZZ5^>,)^_P$N $_AZ.CG:%==,^=N#U-R<\< MY94U5O<"K:+1!YO9X@>F[7AS,^:;_T??=.5K;9!^:_54WV^U#9Z4$'.\!EZ: M#$2UPZ'"95A\65/!TSHC'STM1WFVQU1]EZ/P+Y["2I:_]M^N"L^"5QD"(%K2 M"QOIE559R6\U]-_ZET(.^%6(]>/\1LE?9;'$-M14+6#HY<7+YR< '>@EC?RA MS#?T8D0P2T!?].=*23 ?? !^7^1YZ3[@!/Y5F:__%U!+ P04 " "M@'Q8 MH%9C';," "!P &0 'AL+W=O MH#OPHW'%SH9-O!&X$+.W&FCE/8JWO MW.9C.O$"1P@D).@0./T>X!RD=$!$XWZ%Z74FG>+F>HW^OO&=?(FYA7,M;T6* MQ<0[\U@*&:\E7NOE!UCYTQ!,M+3-ERU;V>' 8TEM49,J#AL* M9\$.A7"E$#:\6T,-RPN./!H;O63&21.:6S2N-MI$3BB7E 4:NA6DA]&B30;3 M&5N(7(E,)%PAFR:)KA4*E;.YEB(18-FKSSR68%^/?23#3MU/5D9FK9%PAY%^ MR*ZTPL*R=RJ%]"F 3XP[VN&:]BS_ &71@&#=[)#KQM M_GZ;QA8-E(/M>*Z51K;B"4P\ZA4+Y@&\Z.6+_DGP=@_;XX[M\3[T M:$&MF=827-; HJ#BA)35%K):,DE5;K,J@/8N_M:5-27.&($P%W9 M'SHTQE7**#&T=G&,N>2*Q$O 0J=L>'C*O@(WEOF4M(/>N2ZK&L%LPNU6'A[T M+GFL#4=-Q;J3P5J\M=2[@4(D5++/(]K1' 0'>Y(U[)(U_.O "H5TSTO=?K/2>)/22TJGLG_'Y+8RW$%N!L#\_VR+E;\RE$DS>3%_+FE9K1U1W MV@WX:3O7?HFWK\,5-[E0EDG(2#4X.J5PF';BMAO453/E8HTT,YME08\4&"= M]YG6N-XX ]VS%_T$4$L#!!0 ( *V ?%C(,#--ZP( !D& 9 >&PO M=V]R:W-H965T*/THRD!+/E; M"6DF?FEM?1F&)B^A8N9CD?./_6X2>'C=E;$Y?)4JE'M[DJ)G[D!(& W#H&AI]G6( 0 MC@AE/&TY_3ZD ^ZO=^R?V]PQER4SL%#B%R]L.?&'/BE@Q1IA[]3F*VSS21U? MKH1I?\FF\TT'/LD;8U6U!:."BLONR_YN[V$/,(R. .(M(&YU=X%:E1^99=.Q M5ANBG3>RN46;:HM&<5RZHMQ;C:<<<78ZRY\:;GA[0VI%;I1FY+9DF"^YDODY M>?? E@+,^W%H,9K#A/F6>=XQQT>8:4RNE;2E(9]D <5K@A!E]EKCG=9Y?)+Q M(Z"@A 8DCN+D!%_2YYZT?-D1OGECT&(,6:AJR27KGHDLR,P8;(?]J_D]6QJK M\0G].70179CDF9CE,?.P; _H9_.G9&YI%'TXD,>B3&)QBG]YCFQ:- M %<])H3*V:Z6=:/S$A\LJ37/X9#ND\R'=1\-Y[T.Y\WR7#72&NS<'/BS>T7D M+:%!D@X#&E/O2CZ#M$J_D"2@0QJ,:(8VR^2:.U?F2F!(EHZ"]()ZG[ 4-)HX'WC M;,D%UA:,.VPJ*,B[-!BAD'B8D??>#3Z +2I-$E0W]+XH56RX$(0.@R3.@@LZ MVM(O% ZI G1W%V^=PS"+@BRY((,[WFTA !*X1&YQ>I3W0WB+J-577;_$ME<92TRQ)G-VCG@.QNXP+T M_P;3?U!+ P04 " "M@'Q8S131C8$" "Z!0 &0 'AL+W=O6R+9I;>*F^ MVI)CPEW*HU'VE-DZDWZ2,F\9YW#\C2XYZI-):"RL.PRS'F+>09!7(&("]U*8 M4L,'D6/^/T!H^0RDR)K4G.Q%O,7L#)+X%$A$DCUXR2 R\7BCMT12D<.=,%04 MS(J%F=9H--PRG7&I&X7P:[;41ME?Y?>N[]!U279WH^%\T'"^#SU]M';,&TM:KJ#H]>SBN!=E-\==T =SRJG($*AV87LC M6"U1K6\EAG=P=#@F<7Q],,O^-$PS;S*;^D4J"HN26LO \=?,2%=&(E]&3B > MGR9D='H9OS^XJVK*E'6X@>--&$[>Z$TVG?/RZFG#+ M3Q6JPD\-#9ELA.FL-42'P33K_+A)[Z;:/54%LP0YKFQI='9Y$8#J)D6W,;+V M[EQ*8[WNEZ4=KJA<@CU?26G6&]=@&-?I/U!+ P04 " "M@'Q8GAF@D1(# M #A!P &0 'AL+W=OA68C096 MU$&E"&@8CH*2<>G-)O7>K9Y-5&4%EW"KB:G*DNG? .[)?-K48K:%$*7H(T7$FB83GU+J.+>>+\:X>O'+;F8$VP(DH^*FG7AKR1!13_ @1(K&5' M]^SFM!?Q&O)S,HQ\0D,Z[,$;MFJ'-=[H"-Y;I8HM%X(P69"GTJ^YR84RE0;R M_7)AK,::^=%U#TV687<6UT<79L-RF'K8* ;T+_!FIR^B4?BZ1T/<:HC[T&=W MV)=%A:35DO!'":R6T$6V%ZZ;;&^.P9P))G-GNG/\1E N0.^_4T1.R.F+C$;1 MZ\$-E]S"JP_8>,53(#)*QGZ21H-K90Q'A"7@45%PUZ^&1#3RLS!]3&>?Y*(D MS2)_F&:##V ,MGA>E95@%K.Q4FG+_["Z]\]B/T'GEWM"HIN03R0^@P=Y!FV> M$Y*F(S]+1L^HIZU?MZ@T"I$O[1,U))$?9ZE/Z?.RJ#\>C8_K&AS1]9CJQ"6+ M8Y\F8])3G$E;G,E_%R<8R\NGI.$!!XJ!KDKMQ7Z^4KL3#G8)!Z@W1KU8D5Q_(0L,30\#S%J]#-0&D,JS;U([Y0%D="O5SC# ;M'/!\ MJ93=&RY!.]5G?P%02P,$% @ K8!\6+>7HC?O @ / 8 !D !X;"]W M;W)K&UL?57;;MLP#'WW5PC>4'2 4-OR)4Z;!&B[ M%ANP <&Z"X9A#XK-Q,)DRY7DIOO[47;B94.:EYB2R<-S2).9;97^92H 2YYK MV9BY7UG;7@:!*2JHN;E0+33X9JUTS2T>]28PK09>]D&U#%@89D'-1>,O9OW= M4B]FJK-2-+#4Q'1US?7O&Y!J._+\>X>O K;FP"9.R4JI7^[POIS[H2,$$@KK$#@^GN 6 MI'1 2.-QA^F/*5W@H;U'O^^UHY85-W"KY#=1VFKNYSXI8:]$,3_Z\J\-!0!Z^$,!V :SG/23J6;[EEB]F M6FV)=MZ(YHQ>:A^-Y$3CFO)@-;X5&&<72\D;2\E28YNU_4UX4Y*[QTZT6'A+ MSC_SE03S9A98S.4B@F*'>S/@LA=P(T8^JL96AMPU)93_ @1()_)>3.1]!ZZ]OL$$VP/U"K1KD>=:Y/K$O+\5?4VB243S=.JLC-$T3KQ; M5;>=!>V-D&1"XRQ'!YI$N7??Z4;83H/G\J[%L[,-B1,:Q8S$,8W9U/L .)65 MDJ4G:N3Y! ['8#::90DY>Y6S*+KROD(E"NF"64+S)"(L2^EDDGB?E>62I&E* MTSQ$RQMF MR3M>*TH:<$6(,Y#QOA MK_NP5S]RO1&-(1+6&!I>3%*?Z&%7#0>KVGX_K)3%;=.;%:YWT,X!WZ^5LON# M2S#^82S^ %!+ P04 " "M@'Q8):][-N,# #>"0 &0 'AL+W=O@FZIB:GN%I=Q,O=C;#WSDJ\+8@7 VJ=D*[] \U'-%O;!#R7F%0G,I M0.%RZEW&%U<#:^\,_N6XT0=ML)$LI/QL.^_RJ1=90EAB9BP"H[\U7F-96B"B M\66'Z75+6L?#]A[]QL5.L2R8QFM9?N*Y*:;>V(,Y^0=W\3B"F2RU M^\*FM>VG'F2--K+:.1.#BHOVGSWM\G#@,(Y><4AV#HGCW2[D6+YAALTF2FY M66M"LPT7JO,F2QV%K/]+BG+8D+7;,,IQYI7J-:HS?[]9=X&/U]@E>_X]4_A3Z[HQ++FQ)! M+F&SWPBN=8,YR< 4L.2"B8R+U3'F_Q=V[WY;([QOJ@4J>/N$*N,:8:YXAM2M MN=H"20M[H/SQ,_&0WA+ JB*(8'(E)Q@WGO7K$K?M^ M')%U%,$9)$&2P TN5$-G@=WH4>^=6",)7KV C^RO#V?._I:IK&B-+VO%RV?+ M4MV\)Q[@-BDX[CK[E;E\XNCOWSJ.^/AHDU')S#>[E& MERR"'_?^A/L"CT5;L!R8 "ZXX:P$W&>V=IFE;3GK!\29SL/%(YU18"2P_)%* MGLX\$\!#38>6*1"R4FK:)NMAN]>RJIG8_J8MT)HV!NJ2!&J=>N31IBCNN^)) M?.?R]=)V] CE#=-TTN9-1GDB.B[I/D5 AV59T@QRHK)!ECDK;+G^9LV.Z(85L M"DXA,;J;'J7B9DN>O4,@5M>**+J28"36W K6BLP:[8#@!P%;L 0FK>L+.&BI]H!+J\C9N\W94V^'!G5NA6KF7 MA89,-L*TUV\WVCU>+ML[^]F\??F0&E9<:"AQ2:Y1,")1J_8UT7:,K-T-OI"& MW@.N6= ##)4UH/FEE&;?L0MT3[K9?U!+ P04 " "M@'Q8/+J^([4" !1 M!@ &0 'AL+W=O"/5HRX #'DNN= 3KS"FN@P"G1504MV3%0B\64I54H.F6@6Z4D!S%U3R M( [#85!2)KQT[,YF*AW+VG F8*:(KLN2JM]3X'(S\2)O=_# 5H6Q!T$ZKN@* MYF"^53.%5M"BY*P$H9D41,%RXEU'E]/$^CN'[PPV>F]/;"8+*1^M\3F?>*$E M!!PR8Q$H+FNX 0_6&Z*B3?R2 Y+ M6G/S(#>?8)O/P.)EDFOW2S:-;]+W2%9K(\MM,#(HF6A6^KRMPU[ *'PC(-X& MQ(YW\Y!C>4L-3<=*;HBRWHAF-RY5%XWDF+!_RMPHO&489]([J@03*TUFH,B\ MH K(V5>ZX*"[X\#@ ]8MR+9@TP8L?@,LBLF]%*;0Y$[DD+\&")!92R_>T9O& M1Q%O(>N1?N23.(S[1_#Z;;I]AS?\_W1_7B^T4=@=OPXEW,#U#\/9B;G4%(7'MB&>RK&I#;7,? M8OY>V!U;>EO_N/,%16*%@T[.N-2Z2Z@QBBW0#_N%&&FC2IPT;-KLD7P@9XD_ M"(=^F"2D:\UXZ)\GB9\D(>EVIE2SC&SMGIYW^< CJA&PQC"R&ULK5;?<]HX$'[W7[%#2X?,&/!/&5)@AL!E+C/IE4G2 MWL/-/0B\@*_&HI((R7]_*]DXI$=I'N[%LJ3=;[_=U:XTV OY3:T1-3QM\D(- M&VNMMY?=KEJL<<-51VRQH)VED!NN:2I77;65R%.KM,F[@>>Q[H9G16,TL&LS M.1J(G:Y 2(:WRO,1FW2*![_']"OK>_DRYPKG(C\SRS5ZV&CUX 4EWR7ZSNQ_QTK M?V*#MQ"YLE_8E[*QUX#%3FFQJ92)P28KRI$_57$X4NC]3"&H% ++NS1D64ZY MYJ.!%'N01IK0S(]UU6H3N:PP2;G7DG8STM.CFV(A-@@/_ D5M![X/$=U,>AJ M@C8"W44%. \?WO4"W__HW&NN$6+/H5JA2B@@3/IN$#'' MCGWF3'&)I)V^*+]6/#XS0%^\1+P MB?J=PE.!/8OWZ\#^UX@SD]@V)_**NA94)_0]M'H!<_MQ"!K)",PU>>[[AM MA>.<>C$O%@@]YKF)%T.;S/19LXZ^(75G+$ZS)>6-<+.7C%76[7X%[[/$90F# M=M3QR.BL/D-:P!WJG2Q>421I/XH,118VG<]ZC1)8WTU"2SLA\!\3_A[:_0X+ MFNK['\V4=>'#?W8KETZ?Y#P MYRU5B\Z*%=P*I5R8D%!&6+Q(8<*E?*8RW7.9*HI1[ 9)XO:"OG.=/1%6B5/7 MUDVA*5N9Z?' (M_M>9YS1T>5R\7:XDWQD:[IK4D2!+$;!DF5G.G#&*(X.*?.5XNY83]QPR2"BU,NDC)S$Q:]WCM@9T@Q M>.5)BSAX_9C CGTY^&>?%&VQ;'\A@E8#6G[B$P7VH_DC$] *R->H[Y.,"?A) MN6=3EU'/38($+DZ=P>[1';Q!N;(O#47)WQ6ZO([KU?HQ,R[O\!?Q\B7TBAQB/+UT4YT6)K;_2YT/0^L+]K>I"A- *TOQ1"'R;&0/W$&_T+ M4$L#!!0 ( *V ?%AD^//!I0( &X& 9 >&PO=V]R:W-H965T>J4Q]7D0Z+R$ MBNHS68/ S$JJBAH,U3K0M0):.%#%@S@,DZ"B3'C9Q.W=J6PB&\.9@#M%=%-5 M5+W,@,O-U(N\W<:ZO M=^Q?7._8RY)JN)3\!RM,.?52CQ2PH@TW<[GY"MM^G,!< N(G>[V14[E%34TFRBY(\$ :KI),4[2;/X*.,5Y&>D'_DD#N/^$;Y^UV+?\25'6SS468OK'\;9ZW"N M:YK#U,/SKD$]@9>]?QC3.,<$:7C#/S0D[)HI3*G!I0 M%0*B*/634?@'Z3[@6HKUKG[8'_MA?]B;@QT2K_4NG?2NF,YE(PQ!,B#)$6N' MG;7#O_8"#6@4,PS/>.?,3B@[?"K^&WD/#_" G.S\PFC81FD2VRBQ4>P/4Q>- M, H3/QRX*"4GX[&?IE'OO@2)R7X!4$L#!!0 ( *V ?%@T := G0( 'L' 9 >&PO M=V]R:W-H965T7"BR.W M-E=Q)$N3<0%S1729YU3]F4 F=V.OZ^T7%GR=&KO@QU%!UW 'YGLQ5SCS&Y6$ MYR TEX(H6(V]J^[E9&3MG<$/#CM],"8VDJ64&SNY2<9>8($@ V:L L6_+4PA MRZP08ORN-;WF2.MX.-ZK?W2Q8RQ+JF$JLY\\,>G8&WDD@14M,[.0NT]0QW-N M]9C,M/LEN]HV\ @KM9%Y[8P$.1?5/WVH\W#@T!V<< AKA]!Q5PN S)%9F4&@VT)F]F8"C/-/E" ME:(V*+K@^M$J M\@TRVY-]5O--*K[P!%\W)+=2F%23#R*!Y*F C\$V$8?[B"=AJ^(,6(?TNFBUZOR6#/Z?5.Z%V# ,49F:<4;PF#TG!&,7%M,;\X3UO MS>_3ZZ3P.IV1 I1=PZYQC+;2NW!ZMBEMXZ!S,8S\[1&*04,Q:*7X2KZ1Z?Z* MMQ>W5>@_DS5L,(?/7MSA"_".&M[1,Q=W=*2X0>^?XOH'#3$'M79M7Q,F2V&J MWMBL-B_+5=50'\VK9^F6JC47FF2P0M>@,\3;I:I67TV,+%Q[74J#S=H-4WP= M05D#W%]):?83>T#SWL9_ 5!+ P04 " "M@'Q8C&B]@!NI'/15Z M%CJ4G%3 ).$,"2C&P5E\>A[WC8$]<4=@*;?&R(0RY_S>3*[S<1 91D A4P8" MZ]%B!!LZG,=P>K]&_V.!U,',LX8+3GR17Y3@X#E .!6ZHNN7+ MK[ **#5X&:?2/M&R/3O4'K-&*EZMC/6\(JQ]XZ=5(K8,XL$>@V1ED%C>K2/+ M\A(K/!D)OD3"G-9H9F!#M=::'&'FJ\R4T+M$VZG)K/T:B!=H1A:,%"3#3*&S M+.,-4X0MT)13DA&0Z.,E*$RH1(?H2BJB,P(YHCJG\M,H5)J+00RSE=_SUF^R MQV^)%_$2LB/4BP]0$B4]#U[/9:9G\7I[ M\+X7.A> KAX:4FL9*O3[!JHYB#^[@O5"F9MU*FN">(1@\N%=/(@^ M>XCV'=&^11_L(3H5^HX*]7R IM1\.\SR;=;?]'%TK:"2.YGW.V">.N:I-\5K MYI8R.,K@U-5(*!K:BFP7>3]\>CA$OP +B4(MBO<>P@-'>.!%O.!5W2@0+U2% M%^R5N1TZJL,.53'L@/FQ8W[)<*O#JD L;!\ID6V2VF;+K;I>]:SMT#;' MVT;W!HL%81)1*+1I=#3414RTO6,[4;RV_=J<*]W]V6&I^VT0YH#>+SA7ZXEQ MX#KXR5]02P,$% @ K8!\6(]MZ"Z% @ BP< !D !X;"]W;W)K&ULM55M:]LP$/XKA\?&!FN=.,T+76)(VI456@@-6QEE M'Q3[;(O*DB?)3??O=Y(3+QN)/PSRQ=9)=\\]CTXZ33=*/YL"T<)K*:29!86U MU648FJ3 DIES5:&DE4SIDEDR=1Z:2B-+?5 IPJC7&X4EXS*(IWYNJ>.IJJW@ M$I<:3%V63/]:H%";6= /=A,//"^LFPCC:<5R7*']6BTU66&+DO(2I>%*@L9L M%LS[EXN)\_<.WSANS-X8G)*U4L_.N$UG0<\10H&)=0B,?B]XA4(X(*+Q!! 4ANKRFTP,2BY;/[L=;L/>P']T9& :!L0>=Y-(L_RFED63[7:@';>A.8& M7JJ/)G)29SQATL(\250M+99%DSDZDKD?P;V2MC#P6::8_@T0 MDHQ62[33LH@Z$:\Q.8=!_R-$O6C0@3=H]V;@\09'\.YX0J>/E#_=8[E&_>.0 MR$X(=Z4N3<42G 5T9PSJ%PSB=V_ZH]ZG#H(7+<$+CSXZ0O"&2V[Q[([.=;I? MD[FO"3S=D3_<6BS-0>H7)Z ^;*D/._?VWQ,$:"RG2T9":H-9+4"0*G.(=C?P M$+XCTZ:#XJBE..I$>L2UH>WMK'XGPG]NX;CE-SYE]<&PO=V]R:W-H965TD&P*#GE@N=X\:8;A5%FC;0$CV3'0A[4DG5$F--54>Z4T!* M#VIYE,;Q,FH)$[C(_-Y.%9GL#6<"=@KIOFV)>MD ET..$WS:>&1U8]Q&5&0= MJ6$/YGNW4]:*)I:2M2 TDP(IJ'*\3E:;A?/W#C\8#/ILC5PF!RF?G/&US''L M! $':AP#L;\CW /GCLC*^#-RXBFD YZO3^R??>XVEP/1<"_Y3U::)L95;8DB1*3D@Y;PMFUOX5#W:BF/"7*'O*+,X4^W 92%9HSVK!*D:) M,&A-J>R%8:)&.\D99:#1FRT8PKA&WXA2Q!7S;189J\$Q172,MPGQTBOQDA0] M2&$:C3Z)$LK_"2(K?LH@/66P26\R;H'.T#QYA](XG2/=$ 7Z!NU\*LSX(A1S;Z=&@CH"+UZ^29?SQAMK%I'9Q MB[U86Z6H9+QWUX(TT%XQXR1?JD>0&PCO/*$;W6,19]'Q7$-TUE8MJ-H/CT:^ M+J'#IMUI/M>A+?^YA^%^(*IF0B,.E87&L_&PO=V]R:W-H965TVR#F051F4)K;K M.(&=$II9\VEY[(G/IZR0"@100*QU BB/G;P $FB26H?4@6_$U7-0?_F<(9W7PAU M1 C4+,N7W]4Q]"@A%?]T^3T@O6ZD7FAN14YBF%EJ)1' =V#-?_D)!\ZO7;9- MPB*3L(4A6*LN7ET7KX]^K$O,TB7-RG^"=VC#V&I/DZ2K* ?>J.3IQ7HW=Z;V MKFGZ/Z^(>LUDU.NDN51\^0CI$GCG].RE#)V>)F&12=C"$*Q5 M"K\NA6]^V?!-UL4D+#()6QB"M>H2U'4)KE@V2!RS(I/J:U8,=$>6"725IY<\ MM#PF85'P:B7!GA]B_0!L+E\+0TE;YL>U^?$5YFFV@TPR_J-+>"]PJ'"3L.@ M\QO"/1SB"0Y.A!M*VA(>UL+#JX1+DFVHFN*(" %2=(GO!0\5;Q(6A:_$!_[$ M'Y].=$,Y6]XGM??)%=Y!/09RUM,+WZH?9.P:/+*OHL= MW_%.[!O*V;*/G6/[Y%SAG\DM\)XIWP\=:MTH+:IH3>]8>Y^5MFV^T;CB M*\Q+)DG29[X7.MB\25I4T=KK#?9=9W1JWE#:MOECDXI[>ZTSYA-*EC11WSU! M:/]%"JO. AAM5XW2HHK6+,![?Z*^VH2GCUI3>=L5.+:C^)I^- /9-_--MI,/ M1FE116N*]SUO@L-3[8:RMK4?.U[M=Z6.6";H"7A[LK(#1/MV MQYB#[VF2L;FQY_QP;YHLVN,4L3MRP)EXLB4T15S=S,#4MZ MA!,<<8E XN>(?9PDDB3\^%9!C;I/:=B\/M-_*P8O!K-&#/LD^2O>\/W+&24G0.7;@B8O"O4+ M:Z%7G,F)\LRI>!H+.[YXB+[E,8N+H)$M^$0H JL]$B$ CUET!]X%F*,X8> 3 MHA3)H+Z?F5QT+,W-J.K$+SNQ;W0";?!$,KYG(,PV>-,&F,+CVFW[[/;25A+_ MB/@=L*T/XL^VP9?G +S[^3U@PG',^OQ3TP(L1NK @N:<:3V8X.T86X$)AXS- M?^C!M#1SZE [!=>[P5WF3+0P!IHQ__J[: ./'*?L[QY7ER72Z4?*5>R>'5"$ MYX98IABF1VPL?OD)>M:O?5'0"0MTPD)-L%9FRIWWX"NXWJ>,VZ_&&KRJZ7@J%9PI%3P MF9/H!<2,Y7@#1/(L92QG^ =P1$F.^Z140H=*J1,6E+!10W5W!%W+NHI.J*G3 MENA>+;JG%#U$-!,[#W! KVB=] JL! P5V.MH8H_<\<2!5S/6Z\Q8QW/LKG:: MG&MI-ZZU&RNU:Z;9KT\X76/:N_HJ*4,%U D+=,)"3;!6*"9U*";ZL^)$9UQT MP@*=L% 3K!67:1V7J3HKYC3:BPH '&@<8;DWO9T3I]TD-9EX5B=)^Q;PCTI]V$F$ MSMBR.@G.5SLP6'R=M% 7K2V^?1'?_C\VC!6U.?%[]V6^NOO!TNNDA;IH;>DO M12A4UE*]6Q\QWY]0@E^ OT\;RB_*L(/2R$?=NO-_MI*[=-@!;O^C:QV)FN+ M(*YV2&*WC).:OO4IIK51AMP2%UL2%WO1:3IW=AKIHI>9F MXTPYQ717'.8S$(GEF9?GM'5K_<'@H3@FOVKWX7U0'OM?,.57B"=$=W'&0(*W M FG=C<5\H.7!?GG#R:$XN5X3SDE:7.XQVF J7Q#/MX3P\XWLH/Z\LO@74$L# M!!0 ( *V ?%@[$W4@T0( +T) 9 >&PO=V]R:W-H965TKV,.W!)!=BU;%3 MVX'NW\]V0@8T4%;Q0OQQS_$]Q\;7PQ47CS(#4.@YITR.G$RI8N"Z,LD@Q_*2 M%\#TS)R+'"O=%0M7%@)P:D$Y=?U.)W1S3)@3#>W8K8B&O%24,+@52)9YCL6? M"5"^&CF>LQZX(XM,F0$W&A9X ?>@'HI;H7MNPY*2')@DG"$!\Y$S]@9QW\3; M@!\$5G*CC8R2&>>/IG.=CIR.20@H),HP8/U9PA0H-40ZC:>:TVF6-,#-]IK] MJ]6NM)Y M#=89Y(157_Q<^[ !\,(] +\&^+N [AY 4 ."8P'=&M"USE12K \Q5C@:"KY" MPD1K-M.P9EJTED^8V?9[)?0LT3@5?>,\71%*T5D,"A,JS]$%>KB/T=G[\Z&K M] HFSDUJMDG%YN]A\WQTPYG*)/K"4DBW"5R=6I.?O\YOXA]DC"&Y1('W$?D= M/VA):'H\W&^!Q\?#O0-J@L;MP/*%K[F-68JNF<)L0684T%A*4!+%1":4RU( M^C6>227TO^)WVRY4JP3MJYB;8B +G,#(T5>!!+$$)_KPS@L[G]L[C;O=0^S&W-LLJ:-="S5VXC#I#=[GIPZL1\:&(K8Q[3<:]US*NST/R M5!(!*4I+0=@"J0Q0 8+PM$W+0=+_W?Z*K+8&)T'5'M1D3OM"RN\GABRV\V"/W8$)OE-MOY/://!=I2DQ]E&UJ#W*T M9XC:3L ;>/9? "MC<8+$@3"(*SKTR.JQT+54;RPY7/&E2[&MIGI]Q4($Z#GYYRK M=<&ULK59K3]LP%/TK5C9-( %)G">LC53(8$AC0B"V M#],^N,EM:^'$Q79:ME\_.RE924/%ZTOCQSWGWG/<.'>PY.)6S@ 4NB]8*8?6 M3*GYD6W+; 8%D0=\#J7>F7!1$*6G8FK+N0"2UZ""V=AQ0KL@M+220;UV*9(! MKQ2C)5P*)*NB(.+/,3"^'%JN];!P1:68PH"!IDR#$0_%G "C!DB M7<;=BM-J4QK@^OB!_;36KK6,B803SG[27,V&5FRA'":D8NJ*+[_"2D]@^#+. M9/V+EDULH(.S2BI>K,"Z@H*6S9/+-=8IV/NX.;*73&Q([6Z4Z;E+A)U*Y&%WP4LTD M^E+FD#\FL'7=;?'XH?ACO)4QA>P >>X>P@[V>@HZ>3X<]\#3Y\/=+6J\]BB\ MFB]\@N^,\WQ)&4.DS-'FN:149HS+2@#Z-1I+)?0K\[OO%)HL7G\6T*"6("5?/K@AL[G/@??DRQ])[)'[OJMN_XV]N24EE3!_C=]R_2XNX?. M!)>RS\Z&UJ]IS26Z2%P_CC".!_9BW:G-N"AVO:@3EFZ&.6W$(V%!*RS8*FSC M)=5WZ5U%1?<-:]1LY7KIGZ,A"]:TA,%A$+D=R>^4\Y$[8>M.^%)W\IR:3T[O M88<;BB+7\2+<.>O-,!>[L1-UA&\M[97"HU9X]*;_^RC+JJ)B1.GM4<&%HG^) ML:7/E6A#[KZ/#\/#CBM]80'N>)=N+?N5IL2M*?&;3/D.JD]_W',%^#X.N@9L MQD51& =AQX&M-;[4 7OMVU^ F-8]E$09KTK5?$G;U;9-&]7=26?]V#TZ:;JM M_S1-[W=!Q)26$C&8:$KG(-)'+)I^JIDH/J\[C#%7NE^IAS/=@H(P 7I_PKEZ MF)@$;5.;_ -02P,$% @ K8!\6%:UOA!, @ VP4 !D !X;"]W;W)K M&ULC93;CMHP$(9?Q4JK:BNUY$ .0)-(L*CM7E1" MB[:]J'IADH%8Z\2I;0CMT]=V0H26L/0F/O[S_>/8$S>,/XL"0*)C22N16(64 M]VJ#G@W(A*:GN.$]HE)I65QF9NQ=.8[24E M%:PX$ONRQ/S/ BAK$LNU3A./9%=(/6&G<8UWL ;Y5*^X&ME]E)R44 G"*L1A MFUAS=[:(]'ZSX3N!1ISUD5H0T ADSH"5LT![H%2'4C9^-W% MM'JD%I[W3]$_F]Q5+ALLX)[1'R2716)-+)3#%N^I?&3-5^CR"72\C%%AOJAI M]P9C"V5[(5G9B96#DE1MBX_=.9P)/.^*P.L$GO'=@HS+)98XC3EK$->[533= M,:D:M3)'*OU3UI*K5:)T,GVH)*YV9$,!S84 *=#=$B0F5*"/:%XR+LE?;,X/ MCNHB"'@?VU)QM=K..L:B97A7&$O(1FCL?D">XXW1TWJ)[MZ^"&,KV[UWK_?N MF;CAE;A?&,L;0BG"58XN$UD2D5$F]AS0S_E&2*YNP*\A]RUE/$S1KV(F:IQ! M8JEK+X ?P$K?O7%#Y],K.8S[',:O14_5D?A#GEJ5;U3Z81W28!KY06P?!F!^ M#_-OP8(A6*L*_@\6]+#@%BP<@@67L$G@N\.PL(>%MV#1$"R\@+E3YQHLZF'1 M+=AD"!9=_+/I=/+R%.VSMZK+WC?,=Z02B,)6R9Q1I,SRMI2T \EJ\WPW3*IB M8+J%JK[ ]0:UOF5,G@:Z(O3U//T'4$L#!!0 ( *V ?%A\TQ8$H ( %L+ M 9 >&PO=V]R:W-H965TVPGBUJ1A@Z%F\9V_#[V>4]Z M=***\0>1 TCT6-!23*QL.-HC5=P M"_)N/>=J9K>4C!10"L)*Q&$YL3ZXY[-0[S<;OA&HQ,X8Z4@6C#WHR64VL1Q] M(:"02DW ZK&%*5"J0>H:/QNFU1ZIA;OC)_I'$[N*98$%3!G]3C*93ZPS"V6P MQ!LJ;UCU&9IXQIJ7,BK,+ZKJO4%@H70C)"L:L;I!0O(UNJL[3"3AON1+G7(4_ZY5]3.5+2@_+9\:>[^W);^=N:[+4F>X87 M'N#=@)!\D\H-)^4*39F0")<94LO MX#NOZC]Z%)"(7YT.5W#_6ZX+B3G8HU3 MF%BJ4ABB%;]ZX8;.^R[?AX0E0\)F \'V,N2W&?+[Z.W?H,O^6AD8I2Z[V]B) M[.VNIW_=D?2>_ERC^H[;BSYHHP]ZH[]F'*-YCE7A1?=74"R =WZ(O93G?HA# MPI(A8;.!8'NI&+>I&/_/4C$>,D-#PI(A8;.!8'L9"ML,A?]<*GJ5S[5_2%@2 M_E$SW#/?"T_==_N5:C;0J;6U]DYCHMO.*\Q7I!2(PE+AG=&I2B2O6[EZ(MG: M]"H+)E7G8X:YZGZ!ZPWJ_9(Q^331[4_;3\>_ 5!+ P04 " "M@'Q8]IVI M9=<# !>$P &0 'AL+W=O#V^7,L&1%D$+,)001?QN80YI*)%''CP;4:.\I$_O'S^@W-7E! MYH&4,*?IO\F2KV=&:* EK$B5\B]T^PD:0I[$BVE:UK]HNXOU+ /%55U;2N"2?1E-$M8C):H,F#NC=U MMF"3Y'(:[SD35Q.1QZ-%2G)^@19,"(/QGXCD2_3Q1Y448JHX>G,-G"1I^1:] M0U_OK]&;UV^G)A>WEGV\-T4Y!M M&=LM8[O&\X\Q;J@*TI+['N/_[D0XNN60E?^KJ.ZP'36V7'-794%BF!EB497 M-F!$?[W"OO6WBOA(8(,V.&T;'!UZ] _E)%4QW*6Y=9I\"&PBS_-"WYV:FW[M MAV%N$%J>UX8-JG+;JEQM57=0EE?H?1Q76942#DNQ) 7Y."%RT:O*W>%YO3K> MX7 RF?A[]2KB0B>T?'6]7ENOIZVW63Y%?_G LY@N4 Y<5;-W4(OCBQ:'>R4K MPB:N[4[4)?MMR;ZVY)[6/T/V $RIIDHM6"GSL9( M8 />V.I>N]899=F C]2)L="&K>@Y$/QGTFSR^J(+G(.GI"(*^RX.U5QJ]:E'/'E:SF$/<.-!(-%"]X_\#.*\*L(_+L M+ ?6>XYOL$[B]'?/3"W&R;,P$MJ0<6=G\.2<@AS5WXR%-OS([@R.K74-QP79 MY/6_'!W;#5V\ITA%G.U[0;!O.YH?<>?I,V&.2ERB%E4BT+@.A:;;;S-D- M."WJ_9 'RCG-ZL,UD"4P&2"NKRCESP.YQ=)NJ46_ %!+ P04 " "M@'Q8 M[M.OAUL" "N!0 &0 'AL+W=OB!UI:6T0H4B%I._G[+BE9<5P[ MZ*$7\;4SG!UQ-]LH_6 J $N>:B'-D%;6-E=!8(H*:F;.50,23Q9*U\SB4B\# MTVA@I0?5(HC#, UJQB7-,[\WU7FF5E9P"5--S*JNF7X>@5";(8WH=N..+ROK M-H(\:]@29F#OFZG&5="SE+P&:;B21,-B2*^CJ_' Q?N 'QPV9F=.7"9SI1[< MXELYI*$3! (*ZQ@8#FL8@Q"."&4\=IRTO](!=^=;]B\^=\QES@R,E?C)2UL- MZ2=*2EBPE;!W:O,5NGPN'%^AA/%?LFECTY"28F6LJCLP*JBY;$?VU/FP XC2 M(X"X \3[@,$10-(!$I]HJ\RG-6&6Y9E6&Z)=-+*YB??&HS$;+MU?G%F-IQQQ M-I\*)NT9F6I\%]H^$R9+1625L9OR$GZ=U,/%]ZS,W.1C34^;KGYJ_KN;$:'^[O0]:US,EA9E?, M5Z9A!0PI5JL!O0::?W@7I>'G0VG_)[)7)@QZ$P9OL:.I2%IPYLKT4*(M>N#1 MKLFL\R@*+\,H"]:[*?P=%H?IX"6JU1;L//T:]-)W!$,*M9*V?4;];M]TKGVM M[>V/L!FUO>.%INUDMTPON31$P (IP_/+"TITVQW:A56-+["YLEBN?EIA0P7M M O!\H93=+MP%?8O._P!02P,$% @ K8!\6+4$S"D3 @ Y 0 !D !X M;"]W;W)K&ULM511;],P$/XKEI$02*A)TZ[ 2"*M MFR8F;5"U AXF'MSTTEJUX^"[-N/?8SMI5$3;-U[B._N^[[Z[^)PVQFYQ T#L M1:L*,[XAJJ^C"(L-:($#4T/E3DICM2#GVG6$M06Q"B"MHB2.)Y$6LN)Y&O9F M-D_-CI2L8&89[K06]O<4E&DR/N2'C;E<;\AO1'E:BS4L@+[5,^N\J&=920T5 M2E,Q"V7&;X;7T[&/#P'?)31X9#-?R=*8K7<>5AF/O2!04)!G$&[9PRTHY8F< MC%\=)^]3>N"Q?6"_#[6[6I8"X=:H'W)%FXQ_X&P%I=@IFIOF,W3U7'F^PB@, M7]:TL6.7L=@A&=V!G:]EU:[BI>O#$2 9GP$D'2 )NMM$0>6=()&GUC3,^FC' MYHU0:D [<;+R/V5!UIU*AZ-\#GNP"&Q!IMBR1:TD(7MS!R2D0O9%6"M\V]ZF M$;EL'A,5'?.T94[.,-_#R5)KW2)/"-SO%)B\1.Z&7/ M3Z"78'^>TGB1T]_X:ZQ% 1EW5QK![H'GKU\-)_&G"XI'O>)18)^<4?RU+!&( M9+5F-^@L9,^/+H0]$&@\J7;T']2.>[7CB_T]=!9#9]%W]I3$RR1#YMX)]\=C M-[ =W;]$K;SHZ-+Z^7\2=BTK9 I*1QT/WE]Q9MN9:ATR=;C'2T-N*H*Y<<\0 M6!_@SDMCZ.#XT>@?MOP/4$L#!!0 ( *V ?%CV-3);IQ8 "2# 0 9 M>&PO=V]R:W-H965TF*BL1 MX+?7=E5BX:.!!MHU278N4G,!4Y#%"4DP "@G4_GQ"U"4H":A%N&\FXL92T(_ M38KN8P(\;+[]DA>_E'=95EF_K5>;\MW%755MWUQ=E8N[;)V6E_DVV]0_N[6 MZ[3X_?MLE7]Y=V%?/'[C[\O/=U7SC:OW;[?IY^R'K/II^[&HO[IZ4FZ6ZVQ3 M+O.-562W[RZ^L]^H^; 9L#_B?Y?9E_+9GZWFKGS*\U^:+\3-NXM!?C_ M]+?#+^+9 'OXP@#G,, Y'C!Z8<#P,&!X[@RCPX#1N3.,#P/&YPZ8' 9,SATP M/0R8GCM@=A@P.W? _#!@?CQ@_-(#-WA\Y 9G#WEZL$\>['W+[[,?9U6Z7)56DA9%VBS< MOUG_;?WTP[7UUV_^]O:JJB=LAETM#GCX@#LOX+85YYOJKK3OC*_\QJ0F %G9 "NZE_UT^_;>?Q]?W",8I+?7UKVY%O+&3C#CAMT;1X> MI[^;1KOFT6I17=9#]\.=CN&>>?AWVZ(>/GMQN/_:;:^'VZ,7AP?FX5[VJ9[= M>7&X.&.X/7UQ>&@>'NY6E];0?O$W'[TV?%,/'[PX7)J'7V<+X^SQ^<.[[GOR MYV97K]SWM+[O]KQKN+:$AD^1-=Q[DY?;UIMRFB^S=1?WTJLR*^^SB_7_^Q9X,_J=K=9*82V(>B?DD%I"8 M(+&0Q"(2DR06DUA"8@K"M!@9/<7(R*2__Y"OU_7Y2=F$R+=6>9?64UCIKKK+ MB^6_.Y\L?#""?:.$Q%P2\TC,)[& Q 2)A206D9A\P,9[K+E8LH!=U\;35/GE;SQ+B:'Y[P+\MR ME]U8MWEAI8M?=\MRV5QH_/;EE6U$^ZYL$G-)S",QG\0"$A,D%I)81&*2Q.(' M;/1L:8_&]NCT7W5R4@5A6E),GY)B>D92%-EV5RSNTC*SMD7^N4C75KK.=YNJ M*R6,8-^4(#&7Q#P2\TDL(#%!8B&)120F22PFL83$U/0DOYRC4PTM)69/*3$S MIL3'(E]DV4UIW1;YVOK2O.:QJ:SLMZQ8+,NL[$H)(]@W)4C,)3&/Q'P2"TA, MD%A(8A&)R=G)\AF.!\[12<+I0?;0G@_MZ?3H20)YTQ2$:]#V&@;]%W>^J\HJW=PL-Y^[5KB9[+O$4\GFD6>Z<& MVGM$-0_5?%0+4$V@6HAJ$:I)5(M1+3EHQR^H3B:SXTHE-:^>&FVITC:W*A\O MC%CJUFK>7_BQR"QOU[S?T7JZ>&*\9(+V*U'-134/U7Q4"U!-H%J(:A&J252+ M42U!-45I>LRTC4Q[BEXR0?N8J.:BFH=J/JH%J"90+42U"-4DJL6HEJ":HC0] M5=H&IVVNWAZ/)22_^VGPC>L<'6M5$-1_5 E03J!:B6H1J$M5B M5$M035&:'A]M ]0V5T"_YHK)_.2\K@F-X\1 "YZHYJ&:CVH!J@E4"U$M0C6) M:C&J):BF*$W?OJGME3KF7FF2%ZGU\2XMUJDE-@OCE1$SU?<U M -4$JH6H%J&:1+48U1)44Y2F1TK;775L\LJ(@[994$-,9+V@#%M7<@Z9M.S3MV'/(0Z?U M42U -8%J(:I%J"91+4:U!-44I>G)T99;'6/-[6NWV3&KO8.#U-R#]NH.*!XZ MK8]J :H)5 M1+4(UB6HQJB6HIBA-#XZVO^J8^ZL?B^5]6F76QU4]QSK;5.:K M(VAA%=5<5/-0S4>U -4$JH6H%J&:1+48U1)44Y2FATI;:G7&Z-41M-"*:BZJ M>:CFHUJ :@+50E2+4$VB6HQJ":HI2M-3I2V].N;2:Y)5S9Z #R_^-JI-$ M@-Y @6HAJD6H)E$M1K4$U12EZ=G0-E6=5S8/76X^K^KG&)NR6E:[YJI'NJJ_ MNL_**B_,IS1H:1757%3S4,U'M0#5!*J%J!:AFD2U&-425%.4I@=,6UIU9N@I M#;KI**JYJ.:AFH]J :H)5 M1+4(UB6HQJB6HIBA-3Y6VR^J8NZQ^D=>ILM4: MK66ZVI_5[+=![,P6=%=3Y[0;.^[Z3!@7G=9#-1_5 E03J!:B6H1J$M5B5$M0 M35&:_F&*;:%U^$JA]?F5D/-"PRSV#8V#IKTV.YC-'7MV%!KHM!ZJ^:@6H)I MM1#5(E23J!:C6H)JBM+TT&@KJT/S=JL_%NE-EGZJ<^*L+0+,6N_ 0"NKJ.:A MFH]J :H)5 M1+4(UB6HQJB6HIBA-3Q6G316'O"XR1)NJJ.:BFH=J/JH%J"90 M+42U"-4DJL6HEJ":HC0]59Y]7+RQ]=;N /W0:#5UW\U2[T0A-1?5/%3S42U M-8%J(:I%J"8/VO-W1XSL@>.QRT MFC[(HJON_OTKT,]V]W,6M/2*:BZJ>:CFHUJ :@+50E2+4$T>M-FSA'$NG>-/ MDD/G3,Z:4U%SZK'1EE2'9WW._,-YR\.%$.N[S4W;&CFY3&+]8?6KRYMO0>_D M0(NMJ.:AFH]J :H)5 M1+4(UB6HQJB6HIBA-3Z*VV#JCH='!7IT6H%J(:I%J"91+4:U!-44I>EIT?9;A^9-65\Z&_IN M6RQ7Q*D06HA%-1?5/%3S42U -8%J(:I%J"91+4:U!-44I>DQU!9BAW/T5 BM MPJ*:BVH>JOFH%J":0+40U2)4DZ@6HUJ":HK2M%09M7W9D;DOV^=4R$SUC114 M?73: -4$JH6H%J&:1+48U1)44Y2FIT5;E!V9B[)? M\X%:9K)W:J!M653S4,U'M0#5!*J%J!:AFD2U&-425%.4ID>+TT8+VI8=H6U9 M5'-1S4,U']4"5!.H%J):A&H2U6)42U!-49J>*FU;=F0LV/5IRYJEWHE":BZJ M>:CFHUJ :@+50E2+4$T>-&TO\?' &1Y_/&^,3IN@FJ(T/2S:MNP(:LM^.$#3 M9[_MP>5@VFCC%-5\5 M03:!:B&H1 MJDE4BU$M035%:7I.M(W3D7DKU=JOFH%J":0+40U2)4 MDP?M^69C@\OQ_#@HT/KH67,J:DX] -I:Z-C8)'OEZL:?>HG7/'/OQ" U%]4\ M5/-1+4 U@6HAJD6H)E$M1K4$U12EZ0G4=DW'(_0R"+K1*JJYJ.:AFH]J :H) M5 M1+4(UB6HQJB6HIBA-3Y6VY#H^L^1ZQF40= /6\6EOMONTU$7G]5#-1[4 MU02JA:@6H9I$M1C5$E13E*:G15MU'9NKKMK&9L9S&K2VBFHNJGFHYJ-:@&H" MU4)4BU!-HEJ,:@FJ*4K3\Z2MK8[1VNH8K:VBFHMJ'JKYJ!:@FD"U$-4B5).H M%J-:@FJ*TO14:6NK8W-MM<\.96:J=Z2@6ZFBFH=J/JH%J"90+42U"-7D^+0G M[8S&IY\W'Z/3)JBF*$U/B[:W.C;W5K6TN,T+*UW\NEN6R^8E'&-RH.U55'-1 MS4,U']4"5!.H%J):A&H2U>*#IKU?8SHXS:$$G591FI8*#-CH*CJ/40.=4E*:G1EL\ MG9B+IP^I463;7;&X2TOS:RYFJW=6H-535/-0S4>U -4$JH63TWKG9#:PCUY$ MBSH.&XW&4_OH#96RX[BQ/9PZ1Y_!$Z-W(D$U16GZ G?:!6[NBGY,?]]_@DOS MC* \7NR=BQRMC**:BVH>JOFH%J":0+7PH&G_3(Z&CGV\R$\/&P\FL^,/BY7H MC8M1+4$U16EZ%+2MT8FQ$W9ZAK#(-_=94=8G",VK'F6VV!7UZ<(+__:3[;5K M5'-1S4,U']4"5!.H%J):A&KRH+V^O6C'@?/)<#B:38[/ LC;IRA-3X:VS3DQ M[QQZ:%+LGQ\\G@ <@J(S"] V)ZJYJ.:AFH]J :H)5 M1+4(U>="TEREF V?D MS(]?I^@ZTAG/QI.A>[JJS2SX+R[WCR!>6^[FFHNZ+OMS;BN3D*RJ2 M?^K]8>8)>X7 M7=/-(FM29ELL[],JL[:K>O*FQM49,F@K$]5<5/-0S4>U -7$07O>G9K,AL/! M]*BO$*+31J@F42U&M035%*7I^>&T^?%*Q_.%$QWK#^O'(KW)TD^K[+P/03!/ MU#M+T/(GJGFHYJ-:@&H"U4)4BU!-HEJ,:@FJ*4K3 Z=MDDZ'Z&D0V96[1C47 MU3Q4\U$M0#6!:B&J1:@F42U&M035%*7IJ=*V4*?F%FJ/W?_,4N]$01NHJ.:A MFH]J :J)Z6F':CFHUIPT/1]]8_?\"G0.4-4BU!-HEJ,:@FJ*4K3@Z*MP$[-%5C# MQ9&S-Q U3]$[0M#2*ZIYJ.:C6H!J M5"5(M03:):C&H)JBE*TZ.F+;U.T=+K M%"V]HIJ+:AZJ^:@6H)I M1#5(E23J!:C6H)JBM+T5&E+KU.N]&JF>D<*NH$H MJGFHYJ-:@&IB>EH]MF'E\704NOJ"91+4:U!-44I>EIT99>IZ]L(%J? MY62E];WUL;'\=_<>1&:T=[B@K5=4\U#-1[4 U02JA:@6H9JOZ+/GC'0?/.2@YYR!%W7A]9;>ET)FQ'O;BO^.O["YF5GLO M<5)S4:S;/W"\W2TJ8EJ+JIYJ.:C6C [[5;.YZ=_LP0Z:XAJ$:I) M5(M1+4$U16EZ6K1%S9FYJ'F]+++%:[L*FHW>*8%V-%'-0S4?U0)4$Z@6HEJ$ M:A+58E1+4$U1FIXE;9=S-D%?@$!KFZCFHIJ':CZJ!:@F4"U$M0C5)*K%J):@ MFJ(T/57:VN;,6.#ZVA<@T/8FJKFHYJ&:CVH!J@E4"U$M0C5YT+0/1!ETOP*! M-C//GE=1\^JAT+8N9^;69<_7*=#>):JYJ.:AFH]J :H)5 M1+4(U>=!>>9T" M[5R>,Z6BIM0CH*U2SLQ5R@]WR^S69\U;R%;+K)"^QR%KVE;FJ?M M'19HVQ+5/%3S42U -8%J(:I%J"91+4:U!-44I6GQ,V_;EG.T;3E'VY:HYJ*: MAVH^J@6H)E M1+4(U22JQ:B6H)JB-#U5VK;E_.O:EJ^T-,QJ[W1!ZY:HYJ&: MCVH!J@E4"U$M0C4Y?Z$<>72*@TZ:G#>IHB;5\Z#I8^K?:7M< M9?]AU?]U[!YZE]Y8Z<9:;I;5\F3[G>;9RC>C2V=_&M7 M5LWVQ9?63]M\8U5WF;58Y66S'4<]HOGR0[[>IIO?_ZL\W?-X?TOJ47%:+.XL M>_2MY0P_JBRK?O+NJ_<)_RJLK7^S_>9?4OJV@. MJ']^F^?5XQ?-!%_RXI?]77W_?U!+ P04 " "M@'Q8E..J:WH% !G(0 M&0 'AL+W=O!&< 9VTF:?[\V4!Q2XK0)5:NJ <-Y M[?> 3Q]PABO&?X@00**')$[%>2N4:0JB-3QA,JU2Z?.6+. M@0994!([Q'5[3D*CM#4:9FVW?#1D"QE'*=QR)!9)0OGZ$F*V.F_AUF/#YV@6 M2MW@C(9S.H,[D/?S6Z[VG%(EB!)(1<12Q&%ZWKK 9U=>1P=D9_P;P4IL;"-M M9<+8#[WS,3AON7I$$(,OM015'TL80QQK)36.GX5HJ^Q3!VYN/ZI?9^:5F0D5 M,&;QURB0X7GKM(4"F-)%+#^SU=]0&.IJ/9_%(ON+5L6Y;@OY"R%94@2K$211 MFG_2AR(1&P'8VQ% B@"R'=#;$> 5 =YV0&='0*<(R%+MY%:R/%Q124=#SE:( MZ[.5FM[(DIE%*_M1JJ_[G>3J:*3BY.@KY9RF4J _KD#2*!;H/2K;(B$6$*@1 MR1!-HY2F?I3._E1GO$,.$B'E((:.5*/06HY?]#C.>R0[>L0$W;!4A@)]2 ,( MJ@*.&G[I@3QZ&!.KXA7X;>3A$T1_HDMVPCWZL(KP_'*E'J9GK=# M[Y8#NEYH;R:3WVX@F0#_KRY=5C4][\_$G/IPWE(36P!?0FOTVZ^XY_Y59[4A ML8KQ3FF\DZGW=AB_TW?$^TLU"P,T9HDJ38)FD_M"9V$&JEQ(-%FCS?-NZ3IK MOEA1'J!O_RA)]%%"(FI3U6DR50V)55+5+5/5M=XCGQ;Z=D!LBE;%+5)G-]?H M9AJZ@"]'7F] 2+\W=):;3JQ]'>BD5SKI69U\> #N1P+0G$<^U+G(X_L;+MRV MZ^(M#]9>#O30+SWT]WB81WR- BIK#=B#[U5+$LGM2I:[LH8>Z.JT='5J'=@7 M3@.@DQB>5X:L8B^=6PV)57P/2M^#-RY#@R93U9!8)578-?_^W08*42&R68DZ MV"4*+K=FL;VW0]ULP P^KAA=[A'XAFLO>!%UNN&?M G9-F_5/M0\,>;),55L M3_0U3/A"D;^FH'[=?6J//]2=@2ILIZJ/Z1(4#?/G%3.[V$NG:%-J5>L&J_!; MJWLSVK7X.NL,$K?"Q?%0+[BM-K !8VA(6/ M0JP]T3>4^^'NRO0:E(4-9F$[9UVH*Q,_LRPU"EE-J55]&\S";\U9N%'0:DJM M^H["D!9I@K3(4](:]$FW-]@F+7MOA[HQI$6.)*TQ>&IM(H]C4 ME%HU70:;2!/81&JPJ>L2[W3[?8Z]MT/=&&PBQV(3>=Y[J;VG50=H@(@RQAZ;>\!"Q\Y N/"][6K,+OG@>O086$8-%Y*VQB#2*14VI5==*#!9Y M36"1]Q2+,!ZXG7YO^SG'WMVA=@P7><=RD?>4B]QV=[!MXS6XR#-[TL(OR#U4_/:/*0!HBF*TDA& M-$90N<;ZUGW7:9/N"1*+R7?P)9(,T>#[0D@]J=OH?JYFOPP!^3$343K3$7I7 M5P>:KG\76FBI4HWFL3*M@[*1J*C\P1=WLL5)U>M]8,>T4%XA L?%5A MU)#>Z;<")\H%HK[/>$!3%9VM[>IX"3P1>HL#F[;KTNQLK#(GP&?9:KU /END M,E\=+5O+;P1<9NO@V^V>=S;VO-HC'74D7]DV7>1?05"IF$6I0#%,57=NNZ^* M <]7]?,=R>;9.O>$2&PO=V]R:W-H965T@-02Z7O6,>"X+3; I@V:=OL0](&6QI9:251)VJZ! M_?@=4HKD)#*=)@V2AUBB.&?.#&=X)(XW0GY5$8 FW],D4R>M2.O\V/-4$$'* M55ODD.&3A9 IUW@KEY[*)?#0&J6)QWR_[Z4\SEJ3L1V[D).Q6.DDSN!"$K5* M4RZWIY"(S4F+MJX'WL?+2)L!;S+.^1(N07_,+R3>>15*&*>0J5AD1,+BI#6E MQS,V, 9VQK\Q;-3.-3&AS(7X:F[.PI.6;QA! H$V$!Q_UC"#)#%(R.-;"=JJ M?!K#W>MK]# QFSA7,1/(I#G5TTAJV2 @+ODKT>['Y&\J >@8O$(FR_\FF MG.NW2+!26J2E,3)(XZSXY=_+1.P8=-@> U8:L%L&M+/'H%,:=&R@!3,;UBNN M^60LQ89(,QO1S(7-C;7&:.+,+..EEO@T1CL]^<2EY)E6Y(]7H'F<*/*25&.X M[$KS+(RSY9]C3Z,[8^0%)?1I 9R&$-P$\Y%F19==D3YD3 M\14$;=*A1X3YK$->$(^HB$M0Y8_#0Z=*1\=ZZ.SQ\$'R$/@\@3H)5^>0SD%^ M;DJ $\QTX+'*>0 G+6PQ!7(-K#:K>BVK7H_3U4+TW,+T^QA$,R M$RGVM>*V,Z:&^!*PUS29;\GNO N^MFM&C[@YHJYBICN*!-UXIQE:T#]D_L#[G,H@. M[:^T%B;J%HTI1I_]!O=LQJO6&'],;9)0>LB[(^T"6L5A/F5I-S MOB4_IBANP ?6$JL5A3VWHK"G4!16*PI[,D5A=Q6%TI'?'?3W;.VLUA3V6$UA M=S7%;_=&>QS7FL(>I2D'K-^*M:UDTS!#U_(86;DY4F_?S/UI@%\G'R+XA>!? MPUM]Q$/",Q)GL8YY0N!&'LTJO^BV6>^(J-7\"P2::$%X^&6EM*G8-OF88VGK M"$B0"&76'RW,K2E]GFU_5P9HC8(U:8PL$[0J])1V[;D .[)F=]V;T0;: M&ZZ(A' 58/L@I1?F]> (HR \"(0,>8;6FUA'UEZ#3)6YDB 6;7S1?9=9$N\" M+4SR*2O.)HYVJ9,($DP-43D$)C,I@-X),!))"%*9V_A6"S3016*;*,9P.4GY M%R%CO45+2V(7C.>YQ(JP*\(Q5Z'=%C ^,ZD$(].EW2N6$N#Z<9&)'\O@0HJT MR%M! Y-H/AI(C@DI.[M-L'!VB)BD(WZPTD@15[#*W[#(7[NI@KV=4ZX4Y-(> M_BD2B%6FBX.%:K0Z8)S:8[5;XZ?T>$:;QMGQK&G^E/7Q0;_QR>#Z#-.K*14G MH%B5RSA3)($%TO/; VQ@61PJ%C=:Y/9<;BZT%JF]C "S*\T$?+X00E_?& ?5 MT>[D?U!+ P04 " "M@'Q8 Y$LN4@# "R#@ &0 'AL+W=O1\ M?:7KS \AP>R2K"$5;Y:$)IB+(5WI;$T!!RHHB77+,!P]P5&J>0,U-Z/>@&QX M'*4PHXAMD@33YS'$)!MJIK:;N(U6(9<3NC=8XQ7,@=^M9U2,]!(EB!)(6412 M1&$YU$;FU<2T98!:\3N"C%6>D:2R(.11#JZ#H6;(C" >L(++ZV,($XED@B MC[\%J%;N*0.KSSOT;XJ\(+/ #"8DOH\"'@ZUGH8"6.)-S&])]AT*0EV)YY.8 MJ4^4Y6O=OH;\#>,D*8)%!DF4YM_XJ1"B$F Z)P*L(L Z#.B<"+"+ *6F M:$TQQ]Z D@Q1N5J@R0>EC8H6;*)4'N.<4_$V$G'4XI0S=#8%CJ.8H9]R M1FI[CB[0W7R*SCZ>#W0N]I(1NE_@CG-/[R^O]Q5; M8Q^&FKB_#.@6-._3!],QOAP3IR6PFE2=4JI.$[HWH\0'"!A:4I*@+'<<@B>@ M?L2 '>.> W84H/PEVGIVUQ#'MJUR^G^1:9M]VW3=O2<&L%>>TXM@=5X.R5OYYTM[;0I54M@-:G<4BJWT2*E,78N M#H[1S3&Z51>;=J]KN =&;MSKC4QZ)9->(Y/K= OB7X:^S.N-6*\]P); :K3[ M)>W^.WN]WZ94+8'5I#*-?8U@M.#V J1J=ZMG6*YA']B]>;>WLJE4/&8CFU$< MO\SLS3BO/<*VT.JLK3UKZYT-7R30EEPMH=7EVE=W9F-%])::I4 \K$< M7H!6JS&]4OTG0%>J*6+()YN4Y^5U.5LV7B/5;AS,CV5#IKJ*/4S>S=U@NHI2 MAF)8"DCCTA67G.8-4C[@9*UZC 7AHF-1CZ%H*H'*!>+]DA"^&\@-RC;5^P=0 M2P,$% @ K8!\6(ED^+/W @ P @ !D !X;"]W;W)K&ULK5;?;]HP$/Y7K&R:.FDE/PEI!Y%*Z;0]=$)%W1ZF/9CD(%:3 M.+4=Z/[[G1W(@*:,2N6!V,[=Y^\[^^XR7'/Q(#, 19Z*O)0C*U.JNK1MF610 M4-GC%93X9L%%015.Q=*6E0":&JV"LM**AV9M*N(AKU7.2I@*(NNB MH.+/&'*^'EFNM5VX8\M,Z04['E9T"3-0]]54X,QN45)60"D9+XF QD MEHH7&V><%ZQLGO1I$X<=!S=\P<';.'B'#L$+#O[&P3="&V9&UH0J&@\%7Q.A MK1%-#TQLC#>J8:4^Q9D2^):AGXIOJ"A9N91D"H+,,BJ G$U 49;+C^2T<1)Y#T MB.]^(I[C^1V$KD]W]X[0\=O ^08O/#UPOZ[F4@F\F+^[XM7 ^=UP.EDO9443 M&%F8C1+$"JSXPSLW=#YW:7TCL#WE0:L\.(8>?\?:LL3Z0,YR+O&64*4$F]>* MSG,@BI.$%P4F*%[=Y*$K$ UZ8-!UD5G%YT'?"9T@&-JK79$=AEXX"/#GM)9[ M"OJM@OY1!6,J64+6)L4A)70% BL6P2(G%2U3/%8B]8E*PA?_E=-LU=]AZ06^ M[UXXT8&SQ'+0\!Z?Q?*/ #TX-_'/#XX&/6D'1JQ*APDK0!/^U*='L$^W>=*?G M7ASHZ+!R>X/P0(2]TPP*$$O3(R52J$O55-MVM6W#5Z;['*R/L3TWW?0?3-/; M;ZE8LE*2'!8(Z?0&&%O1],MFHGAE6LZ<*VQ@9ICA)P8(;8#O%YRK[41OT'ZT MQ'\!4$L#!!0 ( *V ?%A)[<*ZX ( -4* 9 >&PO=V]R:W-H965T M:7M B9[:4Y5C(+MN9O&" 8PW*,].Q+-_,<4J,,-!C:Q8&="^RE,":(;[/ M<\S^+""CQ[EA&Z>!NW27"#5@AD&!=[ !\5"LF>R9-4N:3T275NXKEA*4600204!9:O RPARQ23U/&[(C7J-16P MV3ZQ7VOSTLPCYK"DV:\T%LG9^*.'G] 9\: B%G7UI1( MMQNI\G7&"QS!W) )R8$=P @_?;!]ZUN7K7V5R5)L<];&'UQ #PUF7QQ(X MTD#U"3F$5F >FL)[J0<*]VKA7J_PC< "NF27,*\AVVOK[F4>J-NO=?O]&TZ9 M_!Z1+N7^&^7N>.J,_);Z7OZ!ZL>U^G%O3JQ@"S(KXLZD&+]G4KP3V2N7D]KE M9&A23-Z<4?MR]5(/%#ZMA4^')<7TG[)[B0?*MJV77Y>[;>SNB/.<5W7&M5QI3*S42#DP':Z;N(H MHGLBRE]M/5K79E>Z(FF-+U3-I@N/%YJRX+O%;)<2CC+82DKK&ULM9AKD]HV M%(;_BL9M.F2FBRT9#&R &2[I-!\R97:3]$,G'[3F &YLB4KBTG]?60;;:XQ( MG=W9F<6W\Y[S2);T6L,#%]_D!D"A8Q(S.7(V2FWO75>&&TBH;/,M,'UGQ45" ME3X5:U=N!="E"4IBEWA>X"8T8LYX:*XMQ'C(=RJ.&"P$DKLDH>+?*<3\,'*P M<[[P$*TW*KW@CH=;NH9'4)^W"Z'/W%QE&27 9,09$K :.1-\/R,FP#SQ)8*# M+!VC%.6)\V_IR8?ER/'2BB"&4*425/_L809QG"KI.OXYB3IYSC2P?'Q6_\W M:Y@G*F'&XS^CI=J,G+Z#EK"BNU@]\,/O< +JIGHACZ7YCP[9LX'.&.ZDXLDI M6)\G$ MF+8QT9HF8FDW/BJA[T8Z3HT_L) G@#[1(TC4FH.B42S1'7J D+,PBJEI;+Y" MBAZ1H K>ZIN?'^>H]?/;H:MT!:F.&YZR3;-LY$HV3-!'SM1&HO=L"G;_2"F\V)YI$,8RYW M!? MDR>IA'YCO]8U6:;HURNFP_A>;FD((T>/4PEB#\[XEY]PX+VKPWTAL6?PG1R^ M8U,?+P313/6A1UA)UO)E(QXBDL\Q^?-QFX[2U^+[XQ:8!-2: H-5I&H_KLFEY_ '71Q4)\>:YXCO M^UXQ)I\77+@)8E_]/W%%8P1Z#3*[+]I6&(#SWD!MS3?\Q* =D/K.L4?^W\YQ M2WLD"8BUV3J2*.0[IK+MAOQJOCTU,9LRE>M3?#_+-ID*F6S/ZR,5ZXA)%,-* M2WKMGI[+1;:-E)THOC4[,4]<*9Z8PPW0)8CT 7U_Q;DZGZ0)\LV\\7]02P,$ M% @ K8!\6/""RE95 P [ H !D !X;"]W;W)K&ULK59KCYLX%/TK%KM:=:5FP.859A.D3-*J(TT[HWET]ZM#;A*K@%G; M>?<:WRXDP,7W^060*%CD9=RZFR5JJY=5V9;**B\ MXA64^LV:BX(J/14;5U8"Z*H.*G*7>%[D%I253CJIGSV(=,)W*FL-Y/PP=;#S]N"1;;;*/'#3244W\ 3JI7H0>N9V*"M60"D9+Y& ]=29X>L; M')F >L57!@=Y-D8FE27GW\SD=C5U/*,(MDEE3"G.=_LI7:3IVQ@U:PIKMQG-97]&A61M$ M#LIV4O&B#=8*"E8V=WIL"W$60$A/ &D#2*V[(:I5+JBBZ43P Q)FM48S@SK5 M.EJ+8Z79E2I[]]>$)O5N HBR7:(06L 8A8(44/8+\ M?>(J369"W*P%OFF 20_P K(KY./WB'C$1R]/"_3NUQ]@7*VU$TPZP:3&C7IQ M6V'/](AF4H*2US9U#8IO1S'?^K6L: 931W_,$L0>G/2W7W#D_3&@T>\T^D/H MZ1=]FNXK$%2QO1911QH-DC[J#*C(MO6&+&"O_:G2;J-L"J(+!23T26P7$'<" MXD$!]VH+ BV>9S;&^((Q"(-QTI/SN*,<#U+>@?8O=,?HDN5,O=J(QQ?$. Y( M0NS$24><#!)_I?F.UBX\R_5_@)89V,B3"_)1Y">Q'P=V>NR=7,X;%&!Q#:NE M>9;THSCJXS]S6?SO7>MM QC8K:O%^G^]"Y\,%@]ZXT]=H@W_;IO"P$O"GB*= M7!,/V^9/?& X^K_;$S[9)A[VS;I7&?'UZ$4?G[HP5GW!95UPC/TDZBG,R1_Q ML$'V?3U6%9=V.2(D#!+1NOJW/=5 MOH&2JI&H@)N5E9 EU68HU[ZJ)-"E Y6%CX. ^"5EW,M2-W86+.UAMM)_PLK>@:;D#?5M?2C/R69#O>KTD76R$.+.#GXL)UY@!4$!N;8,U#0[F$)16"(CXT_#Z;5; M6F"W?V#_YKP;+PNJ8"J*WVRI-Q/OU$-+6-%MH>=B_QT:/['ERT6AW!?MZ]B( M>"C?*BW*!FP4E(S7+;UO\M !C*-7 +@!X+<"P@80.J.U,F=K1C7-4BGV2-IH MPV8[+C<.;=PP;JMXHZ5990:GLTLP.4!',]"4%0J=H'J"\?H',9G^;"9O;V;H MZ./GU-=F2POT\X;^HJ;'K]#/(!^A<'R,<(##'OCT[7#\%.X;HZU;W+K%CH\, MN55]-FIYS75-%CLJ>]UU&(I(D9ZF_Z_IY&9:0( H>PYXHC5JE MT1N5NK(:>\)P&KSEN-J:#P'_\X9/67#(H:\94+K9<(U,8Z'-5P\\Z.0U& 7F6^,$] MWNO []S']BW\2>6:<66ROS+TP2@Q99;U^U(/M*C<%;T0VESXKKLQ3S)(&V#6 M5T+HP\#>^NTCG_T%4$L#!!0 ( *V ?%C*U,*:2 ( "(& 9 >&PO M=V]R:W-H965T\@5JO%%Q41.FIV+JR$4 V5E0Q%WM>Y%:$UDZ6VGM+D:5\ MIQBM82F0W%45$:]WP'@[=WSG<..1;DME;KA9VI MK$ ]-4NA9^[@LJ$5U)+R M&@DHYLY7?W:7F/UVPV\*K3P:(U/)FO-G,_FQF3N>"00,TQF01G@\/KA_L[7K6M9$PCUG?^A&E7,G<= &"K)CZI&WWZ&O)S1^.6?2 M_J*VVQO$#LIW4O&J%^L$%:V[*WGI_X(F%V M:SHHB 1+Q"SRPUY MU<]!R8^IJS33*-V\][_K_/$9_P7D$S3U/R'L88R>5@MT\_Z-C:LC#[GQD!M; MW^A2;CF6I]--QW7F'9_)AN0P=_1++$'LPZ:+#,8R M=:K JLPQV6>^GT2QE[K[$5HPT()KM'",UJG"_VE)A,=IX4 +K]&B,5HX0L-A MHT6G-"_R@C.T>*#%UVC)&"T^H=W>)HD_#DL&6'(1]JL$W3X+ M!6(,F9R^*IX?1?$;IGMTY$WW?"!B2VNI#VRAA=XDUJ%%UY&ZB>*-[0)KKG1/ ML<-2-W$09H->+SA7AXEI+,-G(?L'4$L#!!0 ( *V ?%AZ5-DOT ( 4) M 9 >&PO=V]R:W-H965TP&MN9;:#]][,=R$@);)/8E\0O=X^?YW*7 M<[SFXE$N !1ZH@63 V>A5'GINC)= ,7R@I? ]$[.!<5*3\7COK&W!M\(K.7.&!DE,\X?S>0F&SB>(00% MI,H@8/U:P0B*P@!I&C\WF$Y]I''<'6_1/UKM6LL,2QCQXCO)U&+@]!V408Z7 MA;KEZVO8Z.D:O)07TC[1NK*->@Y*EU)QNG'6#"AAU1L_;>*PX^!'!QR"C4/P MTJ%SP"'<.(16:,7,RAICA9-8\#42QEJCF8&-C?76:@@S7_%.";U+M)]*)ICI MCZ4_BT*896A,A(XO%VC$J4X4B6VLS\:@,"DD^HR%P";NY^@=NK\;H[/7Y[&K M- ^#YJ:;,X?5F<&!,_T 33A3"XD^L RR)H"K!=0J@JV*87 4<0SI!0K]MRCP M@K"%T.COW8,C=,(ZJ*'%BP[@W4*!%61HBH5Z1E\%UH&LLO;ADS9%-PJH_-$6 MN HW;,O/(C[WV;Z!.!-4+0J4/0.8:>?,ESDH*0 M*-U)I#;%%4S'PIA?SBKQNW[7\[S87>V*:;'K]1MV#9[=FF?W*,]MPO^9:(73 MW2'0\;Q]GOMF8=.L03.J:49':5YE*\PX):G4E2E*+JK"?)@ G8%H3:6C@/^: M2B<":VCOU=I[_ZF:>J<,P8G &B'HUR'HGZ::^GM5\C(_]RVBEO1T=SH*!3&W MC=8UPH>\I((R!WL\Y5]N).:"^^22_ %!+ P04 " "M@'Q8 MK\SH*3H# L$P #0 'AL+W-T>6QE#NZX'Q>9Y2BZ5;F*[".[OQ _? M ]8]$,B%: 7VB#.,!A4UAFEY93O-X,;X (I\^W95684S35?=WCG9.#0O&V2B M=,YT&Z9+UJ;10+ "Y&@^F\/;J"H&T!A5VD;.Z4Q)VFA8>_B&I9TR(6Y@)WXM M=KB7Q5;>.I UV3:M(-]T-*X#_-MLCGN;MO=;O%'%[Y7YL+#3D4T?JIM=:U;P M9=-?%JT C+V+L].J$JOW@L]DR=SDGQUP-*!KOVBN-/]AHT&I3*V!:1+=,VWX M=-OR7=/JEBW-NIR6!:ZY]U_S$YIG3#)-Q;9H6_O/4.P/@I?0W&S2?<5!D^-^=YSN2#JX*E-W1B_Q78X;?C!UA.'ZL0;*9X)6(S MQ=<:D/"Z@4>6A;.-Q0$/+ M8[4#\-8?20$3;8T.P6BP^0"X99K>] M9!:GUV )C%BH]O;0$NT340B M59)RFO[ZDM*\D+5[L9=K/SFB(O*(E.ZY)/7^2:K'M92/Y%M="3V.=L8TUX.! M+G:LIOJU;)BP9S92U=380[4=Z$8Q6NH=8Z:N!LEP.!K4E(OHP_M#70LU\ ^D M887A4MA"5_"%LR?]^,&5X<52\=) KNM9=B:'K!VI!QM%H:"O<<*5-]Q]= M_=0R[IG]Y_ZH-?(/7AFF9M2P3TJV#1=;5XV]BX%W&UT_''[[3KQ6_Z<;Y6;# M"S:315LS8?I^5*QR@$+O>*,C(FC-QM%4[IER]V,;N"G[>S,6RNLI=V]9)\I!45!2-=%VH/, $ DXL!DJL%]2!3 #(](^320;@+-)$; MN=!C@#(T24@'>-R1Q7S(-\ D&]P(1?T MF>PU63#57>Y>FQG7125U&R"^!1#?XB+>",U+ILA*T=+&8C)1BHIM/^(>X3N M\!TNX8SI0O'&E;OA_=AJ+ICVX>(A%+R'N'C+MJZI>NZ>/+X5W%Y&[8,X*0K9 M"L-]3- QR)*9%%];V^BA%^^DHF1AWY2:DAM1O/8Q(=/$R*KY)&7YQ*O*YX&D M$B-;Y<:F16+K&B43K4,CQY!(8F23+*R%S6_$YH%6;N:94%&2N1WBQEWG0T(B MB9%-\L!LDJ5MKF!D\4B6C4U%@PZ$_!%C"X0VW*:\/9L/!?DB1A;&7]2%W["3 M(#G$R':84R6L%3J%'8DUAJ00(UO!!BU9,[*BWUB0)4,J2)!5\)E1'=) $3]! MCOBW5-!>Y%UPF'%E)XQ2D:FL;:T!)CBW0([XRW:MV=?68<[W/V4="13Z$^30 M#XH]R-432 0)L@A@S-3'A%20(*L S#_"WH2LD"!;X9!_D*L5M2WK5SX89(8$ MV0Q'BQ(14DJ*K!1? MNB?A()&DR"+I[7L2"UR60M;(+Z:OY&K&#.7^1">%-))>5".9CPEI)$76"(R9 M^YB01E)DC<"8(Q\3DDJ*+!58RG[ND$)F29'- F,&SR9DEA39+"^Y0_]J!S$H M@]22(:OE1/+P+R+YW7:ACPGI)4/7"X YJ7U,2#39F=:H7NCN7$[A-KJ"$8>L MDR%;!TS&@G0[ [=#+KF*%02@#+).=H%U+&_T?4S(.MDYE[2.GTX?$[).=J9% M+O_M_J^,^_/_#+).AFP=$%.V/B9DG>QL\QDP&N60?_(+3&U..#*'Y).?=6[S M,N0V-CD8'Q.23XXLGU]A/K!"BB+ A/R38^^;W$WO;^=D-?E[OO0Q9VS#5+"* MG$/^R9']T\T9?;Z^@(N^-A\3W)!']L\1YBTUK;(),>MVY7U,R#\YLG_ %>?P MZP;(/WGGG\'A&Z"2;>R,N;RS36A;7M"J6"CB?OK=RBQW&Q&;MJJFMNQ>?):T M/'Q2=/@&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X D_N8\%!"14.+V( 5 M)@^1Q)9G$,GNB4(1CD5!@^94UMCR]5]]LL:>OZ1=6[;=(6^V?9X<][M#7C2; M4OJ'$/)RD_9MONGZ=#A?677#OBWGY; .?;M\;]NI M3W^9V*U6VV5ZZI8?^W0HOPP.G]WPGCBGHK@=Z*>BN!WCIZV2;06U%O)=!;46\ET%M1;R706U%O M)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;1ILE!'H;ZFT$>AOJ M;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OMH MLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.^(>D<"O2/J'0GTCJAW)- [ MHMZ10.^(>D<"O>/H8R6!WA'UC@1Z1]0[_J?>N9QV*5][OM?X_/^DNISO3=?' M7Y;?)T?L7' .\ O(XQ=02P,$% @ K8!\6+)H2=C5 0 OR$ !, !; M0V]N=&5N=%]4>7!E&ULS=I=3X,P% ;@O[)P:T;7K_D1YXUZJU[X!RJ< M#3*@3=O-^>\M3$TT2EQFXGL#@;;G/;3)<\7EXXNC,-FU31<6616CNV L%!6U M)N3649=&EM:W)J9'OV+.%&NS(B9FLSDK;!>IB]/8U\BN+F]H:39-G-SNTNM0 MVVZ1>6I"-KG>3^RS%IEQKJD+$],XVW;EEY3I6T*>5@YS0E6[<)(F9.S;A'[D MYX"W=?=;\KXN:?)@?+PS;9K%=@T+\:6AD(^7^*9'NUS6!96VV+1I21Z<)U.& MBBBV3;XO>C*>'-,.T_[*C\X?RHP%IID/WKJ03LS3X7'O1]*OGKI4B'RLQS_Q M(S&5/OK[J#_MDLI?9J?M?;9^/9Q'8,/M^#W^?,8?]0_L0X#T(4'Z4"!]:) ^ MYB!]G(+T<0;2QSE('WR&T@B*J!R%5(YB*D=!E:.HRE%8Y2BNN3M>N__J6@O^>MJ;OW?#;\MW'U"E!+ 0(4 Q0 M ( *V ?%@'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ K8!\6 $C V_O *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ K8!\6)E< MG",0!@ G"< !, ( !S0$ 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " "M@'Q8$Z?OS0X( #J-P & @($. M" >&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6$,M M[3,Q!@ Z!@ !@ ("!4A 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ K8!\6&/>H"+9 @ #0@ !@ M ("! " 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ K8!\6 _UV3E: @ N04 !@ ("!8C, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6 [K]X@\! 4@D !D M ("!0UL 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ K8!\6+F\?6_- P 4P@ !D ("!'V@ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\ M6&OMX!%C!@ WP\ !D ("!T'( 'AL+W=O0 >&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6!%ON4GF! A@L M !D ("!(8$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6'_EV6).' -E, !D M ("!_8X 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ K8!\6,T4T8V! @ N@4 !D ("!CK$ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6"6O M>S;C P W@D !D ("!M;H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6&3X\\&E @ ;@8 !D M ("!&\8 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ K8!\6(]MZ"Z% @ BP< !D ("! MZLX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ K8!\6/X<*2M.! :AD !D ("!;=@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6%:UOA!, M @ VP4 !D ("!4>, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6.[3KX=; @ K@4 !D M ("!N>P 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ K8!\6)3CJFMZ!0 9R$ !D ("!&PO=V]R:W-H965T&UL4$L! A0#% @ MK8!\6(ED^+/W @ P @ !D ("!]A8! 'AL+W=OW"NN " #5"@ &0 M @($D&@$ >&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6/""RE95 P M[ H !D ("!K"$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ K8!\6'I4V2_0 @ !0D !D M ("!CRH! 'AL+W=O&PO0Q 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "M M@'Q8\R"+>>D! 2(@ &@ @ &D-@$ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "M@'Q8LFA)V-4! "_(0 $P M @ '%. $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 00!! + +X1 #+.@$ ! end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 99 286 1 true 41 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://sunshinebiopharma.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://sunshinebiopharma.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statement of Shareholders' Equity Sheet http://sunshinebiopharma.com/role/StatementOfShareholdersEquity Consolidated Statement of Shareholders' Equity Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995513 - Disclosure - Description of Business Sheet http://sunshinebiopharma.com/role/DescriptionOfBusiness Description of Business Notes 10 false false R11.htm 995514 - Disclosure - Summary of Significant Accounting Policies Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995515 - Disclosure - Acquisition of Nora Pharma Inc. Sheet http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc. Acquisition of Nora Pharma Inc. Notes 12 false false R13.htm 995516 - Disclosure - Goodwill Sheet http://sunshinebiopharma.com/role/Goodwill Goodwill Notes 13 false false R14.htm 995517 - Disclosure - Intangible Assets Sheet http://sunshinebiopharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 995518 - Disclosure - Plant, Property and Equipment Sheet http://sunshinebiopharma.com/role/PlantPropertyAndEquipment Plant, Property and Equipment Notes 15 false false R16.htm 995519 - Disclosure - Reverse Stock Splits Sheet http://sunshinebiopharma.com/role/ReverseStockSplits Reverse Stock Splits Notes 16 false false R17.htm 995520 - Disclosure - Capital Stock Sheet http://sunshinebiopharma.com/role/CapitalStock Capital Stock Notes 17 false false R18.htm 995521 - Disclosure - Warrants Sheet http://sunshinebiopharma.com/role/Warrants Warrants Notes 18 false false R19.htm 995522 - Disclosure - Earnings Per Share Sheet http://sunshinebiopharma.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 995523 - Disclosure - Income Taxes Sheet http://sunshinebiopharma.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 995524 - Disclosure - Leases Sheet http://sunshinebiopharma.com/role/Leases Leases Notes 21 false false R22.htm 995525 - Disclosure - Management and Director Compensation Sheet http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation Management and Director Compensation Notes 22 false false R23.htm 995526 - Disclosure - Subsequent Events Sheet http://sunshinebiopharma.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 995527 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 995528 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 995529 - Disclosure - Acquisition of Nora Pharma Inc. (Tables) Sheet http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Tables Acquisition of Nora Pharma Inc. (Tables) Tables http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc. 26 false false R27.htm 995530 - Disclosure - Goodwill (Tables) Sheet http://sunshinebiopharma.com/role/GoodwillTables Goodwill (Tables) Tables http://sunshinebiopharma.com/role/Goodwill 27 false false R28.htm 995531 - Disclosure - Intangible Assets (Tables) Sheet http://sunshinebiopharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://sunshinebiopharma.com/role/IntangibleAssets 28 false false R29.htm 995532 - Disclosure - Plant, Property and Equipment (Tables) Sheet http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables Plant, Property and Equipment (Tables) Tables http://sunshinebiopharma.com/role/PlantPropertyAndEquipment 29 false false R30.htm 995533 - Disclosure - Warrants (Tables) Sheet http://sunshinebiopharma.com/role/WarrantsTables Warrants (Tables) Tables http://sunshinebiopharma.com/role/Warrants 30 false false R31.htm 995534 - Disclosure - Earnings Per Share (Tables) Sheet http://sunshinebiopharma.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://sunshinebiopharma.com/role/EarningsPerShare 31 false false R32.htm 995535 - Disclosure - Income Taxes (Tables) Sheet http://sunshinebiopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://sunshinebiopharma.com/role/IncomeTaxes 32 false false R33.htm 995536 - Disclosure - Leases (Tables) Sheet http://sunshinebiopharma.com/role/LeasesTables Leases (Tables) Tables http://sunshinebiopharma.com/role/Leases 33 false false R34.htm 995537 - Disclosure - Description of Business (Details Narrative) Sheet http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative Description of Business (Details Narrative) Details http://sunshinebiopharma.com/role/DescriptionOfBusiness 34 false false R35.htm 995538 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives Summary of Significant Accounting Policies (Details - Estimated lives) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 995539 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets Summary of Significant Accounting Policies (Details - Intangible assets) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 995540 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 37 false false R38.htm 995541 - Disclosure - Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price) Sheet http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price) Details http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Tables 38 false false R39.htm 995542 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative) Sheet http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative Acquisition of Nora Pharma Inc. (Details Narrative) Details http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Tables 39 false false R40.htm 995543 - Disclosure - Goodwill (Details) Sheet http://sunshinebiopharma.com/role/GoodwillDetails Goodwill (Details) Details http://sunshinebiopharma.com/role/GoodwillTables 40 false false R41.htm 995544 - Disclosure - Intangible Assets (Details - Intangible assets) Sheet http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets Intangible Assets (Details - Intangible assets) Details http://sunshinebiopharma.com/role/IntangibleAssetsTables 41 false false R42.htm 995545 - Disclosure - Intangible Assets (Details - Amortization expense) Sheet http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense Intangible Assets (Details - Amortization expense) Details http://sunshinebiopharma.com/role/IntangibleAssetsTables 42 false false R43.htm 995546 - Disclosure - Goodwill (Details Narrative) Sheet http://sunshinebiopharma.com/role/GoodwillDetailsNarrative Goodwill (Details Narrative) Details http://sunshinebiopharma.com/role/GoodwillTables 43 false false R44.htm 995547 - Disclosure - Plant, Property and Equipment (Details) Sheet http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails Plant, Property and Equipment (Details) Details http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables 44 false false R45.htm 995548 - Disclosure - Plant, Property and Equipment (Details Narrative) Sheet http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative Plant, Property and Equipment (Details Narrative) Details http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables 45 false false R46.htm 995549 - Disclosure - Reverse Stock Splits (Details Narrative) Sheet http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative Reverse Stock Splits (Details Narrative) Details http://sunshinebiopharma.com/role/ReverseStockSplits 46 false false R47.htm 995550 - Disclosure - Capital Stock (Details Narrative) Sheet http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://sunshinebiopharma.com/role/CapitalStock 47 false false R48.htm 995551 - Disclosure - Warrants (Details - Warrants issued with financing) Sheet http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing Warrants (Details - Warrants issued with financing) Details http://sunshinebiopharma.com/role/WarrantsTables 48 false false R49.htm 995552 - Disclosure - Warrants (Details - Warrants outstanding) Sheet http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding Warrants (Details - Warrants outstanding) Details http://sunshinebiopharma.com/role/WarrantsTables 49 false false R50.htm 995553 - Disclosure - Warrants (Details Narrative) Sheet http://sunshinebiopharma.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://sunshinebiopharma.com/role/WarrantsTables 50 false false R51.htm 995554 - Disclosure - Earnings Per Share (Details) Sheet http://sunshinebiopharma.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://sunshinebiopharma.com/role/EarningsPerShareTables 51 false false R52.htm 995555 - Disclosure - Income Taxes (Details - Provision for income taxes) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes Income Taxes (Details - Provision for income taxes) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 52 false false R53.htm 995556 - Disclosure - Income Taxes (Details - Reconcilation of tax rate) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate Income Taxes (Details - Reconcilation of tax rate) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 53 false false R54.htm 995557 - Disclosure - INCOME TAXES (Details - Deferred taxes) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes INCOME TAXES (Details - Deferred taxes) Details 54 false false R55.htm 995558 - Disclosure - Lease (Details - Lease information) Sheet http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation Lease (Details - Lease information) Details http://sunshinebiopharma.com/role/LeasesTables 55 false false R56.htm 995559 - Disclosure - Lease (Details - Maturities of lease payments) Sheet http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments Lease (Details - Maturities of lease payments) Details http://sunshinebiopharma.com/role/LeasesTables 56 false false R57.htm 995560 - Disclosure - Management and Director Compensation (Details Narrative) Sheet http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative Management and Director Compensation (Details Narrative) Details http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation 57 false false All Reports Book All Reports sbfm-20231231.xsd sbfm-20231231_cal.xml sbfm-20231231_def.xml sbfm-20231231_lab.xml sbfm-20231231_pre.xml sunshine_i10k-123123.htm image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_i10k-123123.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20231231", "dts": { "schema": { "local": [ "sbfm-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "sbfm-20231231_cal.xml" ] }, "definitionLink": { "local": [ "sbfm-20231231_def.xml" ] }, "labelLink": { "local": [ "sbfm-20231231_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20231231_pre.xml" ] }, "inline": { "local": [ "sunshine_i10k-123123.htm" ] } }, "keyStandard": 253, "keyCustom": 33, "axisStandard": 15, "axisCustom": 0, "memberStandard": 18, "memberCustom": 23, "hidden": { "total": 40, "http://fasb.org/us-gaap/2023": 25, "http://sunshinebiopharma.com/20231231": 11, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 99, "entityCount": 1, "segmentCount": 41, "elementCount": 520, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 455, "http://xbrl.sec.gov/dei/2023": 41, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R2": { "role": "http://sunshinebiopharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R3": { "role": "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R4": { "role": "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R5": { "role": "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical", "longName": "00000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareDiluted", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:EarningsPerShareBasic", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R6": { "role": "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R7": { "role": "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "longName": "00000007 - Statement - Consolidated Statement of Shareholders' Equity", "shortName": "Consolidated Statement of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_CommonStockMember", "name": "SBFM:StockIssuedDuringPeriodValueReverseStockSplits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R10": { "role": "http://sunshinebiopharma.com/role/DescriptionOfBusiness", "longName": "995513 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R11": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995514 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R12": { "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.", "longName": "995515 - Disclosure - Acquisition of Nora Pharma Inc.", "shortName": "Acquisition of Nora Pharma Inc.", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R13": { "role": "http://sunshinebiopharma.com/role/Goodwill", "longName": "995516 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R14": { "role": "http://sunshinebiopharma.com/role/IntangibleAssets", "longName": "995517 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R15": { "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment", "longName": "995518 - Disclosure - Plant, Property and Equipment", "shortName": "Plant, Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R16": { "role": "http://sunshinebiopharma.com/role/ReverseStockSplits", "longName": "995519 - Disclosure - Reverse Stock Splits", "shortName": "Reverse Stock Splits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:ReverseStockSplitTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:ReverseStockSplitTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R17": { "role": "http://sunshinebiopharma.com/role/CapitalStock", "longName": "995520 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R18": { "role": "http://sunshinebiopharma.com/role/Warrants", "longName": "995521 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:WarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:WarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R19": { "role": "http://sunshinebiopharma.com/role/EarningsPerShare", "longName": "995522 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R20": { "role": "http://sunshinebiopharma.com/role/IncomeTaxes", "longName": "995523 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R21": { "role": "http://sunshinebiopharma.com/role/Leases", "longName": "995524 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R22": { "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation", "longName": "995525 - Disclosure - Management and Director Compensation", "shortName": "Management and Director Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:ManagementAndDirectorCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:ManagementAndDirectorCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R23": { "role": "http://sunshinebiopharma.com/role/SubsequentEvents", "longName": "995526 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R24": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995527 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R25": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995528 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R26": { "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Tables", "longName": "995529 - Disclosure - Acquisition of Nora Pharma Inc. (Tables)", "shortName": "Acquisition of Nora Pharma Inc. (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R27": { "role": "http://sunshinebiopharma.com/role/GoodwillTables", "longName": "995530 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R28": { "role": "http://sunshinebiopharma.com/role/IntangibleAssetsTables", "longName": "995531 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R29": { "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables", "longName": "995532 - Disclosure - Plant, Property and Equipment (Tables)", "shortName": "Plant, Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R30": { "role": "http://sunshinebiopharma.com/role/WarrantsTables", "longName": "995533 - Disclosure - Warrants (Tables)", "shortName": "Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R31": { "role": "http://sunshinebiopharma.com/role/EarningsPerShareTables", "longName": "995534 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R32": { "role": "http://sunshinebiopharma.com/role/IncomeTaxesTables", "longName": "995535 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R33": { "role": "http://sunshinebiopharma.com/role/LeasesTables", "longName": "995536 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R34": { "role": "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative", "longName": "995537 - Disclosure - Description of Business (Details Narrative)", "shortName": "Description of Business (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_GenericPharmaceuticalsMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_GenericPharmaceuticalsMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R35": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives", "longName": "995538 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)", "shortName": "Summary of Significant Accounting Policies (Details - Estimated lives)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_OfficeEquipmentMember", "name": "SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_OfficeEquipmentMember", "name": "SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R36": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets", "longName": "995539 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)", "shortName": "Summary of Significant Accounting Policies (Details - Intangible assets)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_LicensesMember", "name": "SBFM:IntangibleAssetsEstimatedUsefulLives", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_LicensesMember", "name": "SBFM:IntangibleAssetsEstimatedUsefulLives", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R37": { "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995540 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "SBFM:BasicAndDilutedNetGainLossPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "SBFM:BasicAndDilutedNetGainLossPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R38": { "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "longName": "995541 - Disclosure - Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price)", "shortName": "Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-10-20_custom_NoraPharmaMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R39": { "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "longName": "995542 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)", "shortName": "Acquisition of Nora Pharma Inc. (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-192022-10-20_custom_NoraPharmaMember", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R40": { "role": "http://sunshinebiopharma.com/role/GoodwillDetails", "longName": "995543 - Disclosure - Goodwill (Details)", "shortName": "Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R41": { "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets", "longName": "995544 - Disclosure - Intangible Assets (Details - Intangible assets)", "shortName": "Intangible Assets (Details - Intangible assets)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R42": { "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense", "longName": "995545 - Disclosure - Intangible Assets (Details - Amortization expense)", "shortName": "Intangible Assets (Details - Amortization expense)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R43": { "role": "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative", "longName": "995546 - Disclosure - Goodwill (Details Narrative)", "shortName": "Goodwill (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "longName": "995547 - Disclosure - Plant, Property and Equipment (Details)", "shortName": "Plant, Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R45": { "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative", "longName": "995548 - Disclosure - Plant, Property and Equipment (Details Narrative)", "shortName": "Plant, Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R46": { "role": "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative", "longName": "995549 - Disclosure - Reverse Stock Splits (Details Narrative)", "shortName": "Reverse Stock Splits (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "From2022-02-082022-02-09_custom_FirstReverseStockSplitMember", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "SBFM:ReverseStockSplitTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-02-082022-02-09_custom_FirstReverseStockSplitMember", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "SBFM:ReverseStockSplitTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R47": { "role": "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "longName": "995550 - Disclosure - Capital Stock (Details Narrative)", "shortName": "Capital Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-01-19", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R48": { "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "longName": "995551 - Disclosure - Warrants (Details - Warrants issued with financing)", "shortName": "Warrants (Details - Warrants issued with financing)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_PreFundedWarrantsMember", "name": "SBFM:WarrantsIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_PreFundedWarrantsMember", "name": "SBFM:WarrantsIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R49": { "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "longName": "995552 - Disclosure - Warrants (Details - Warrants outstanding)", "shortName": "Warrants (Details - Warrants outstanding)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_TradeableWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_TradeableWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R50": { "role": "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative", "longName": "995553 - Disclosure - Warrants (Details Narrative)", "shortName": "Warrants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_TradeableWarrantsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R51": { "role": "http://sunshinebiopharma.com/role/EarningsPerShareDetails", "longName": "995554 - Disclosure - Earnings Per Share (Details)", "shortName": "Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R52": { "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes", "longName": "995555 - Disclosure - Income Taxes (Details - Provision for income taxes)", "shortName": "Income Taxes (Details - Provision for income taxes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R53": { "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate", "longName": "995556 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)", "shortName": "Income Taxes (Details - Reconcilation of tax rate)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R54": { "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes", "longName": "995557 - Disclosure - INCOME TAXES (Details - Deferred taxes)", "shortName": "INCOME TAXES (Details - Deferred taxes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R55": { "role": "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation", "longName": "995558 - Disclosure - Lease (Details - Lease information)", "shortName": "Lease (Details - Lease information)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "unique": true } }, "R56": { "role": "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments", "longName": "995559 - Disclosure - Lease (Details - Maturities of lease payments)", "shortName": "Lease (Details - Maturities of lease payments)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } }, "R57": { "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative", "longName": "995560 - Disclosure - Management and Director Compensation (Details Narrative)", "shortName": "Management and Director Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SalariesWagesAndOfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "SBFM:ManagementAndDirectorCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SalariesWagesAndOfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "SBFM:ManagementAndDirectorCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_i10k-123123.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r534" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r222", "r223" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r76", "r118" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r42", "r142", "r409" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r87", "r149", "r405", "r426", "r427" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r595" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Capital paid in excess of par value", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r80", "r534", "r698" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r311", "r312", "r313", "r439", "r650", "r651", "r652", "r684", "r702" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r601" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r601" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r601" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r601" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "SBFM_AdvancesToNoraPharmaPreAcquisitio": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "AdvancesToNoraPharmaPreAcquisitio", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Advances to Nora Pharma - pre acquisition", "label": "AdvancesToNoraPharmaPreAcquisitio" } } }, "auth_ref": [] }, "SBFM_AdvanomicsCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "AdvanomicsCorporationMember", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advanomics Corporation [Member]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r565", "r577", "r587", "r613" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r568", "r580", "r590", "r616" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r601" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r608" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r572", "r581", "r591", "r608", "r617", "r621", "r629" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r627" ] }, "SBFM_AllWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "AllWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "All Warrants [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r573" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Anti dilutive securities shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r199" ] }, "SBFM_AprilWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "AprilWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "April Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r117", "r145", "r173", "r206", "r213", "r217", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r338", "r340", "r352", "r402", "r470", "r534", "r546", "r674", "r675", "r692" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r138", "r153", "r173", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r338", "r340", "r352", "r534", "r674", "r675", "r692" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r573" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r558", "r560", "r573" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r558", "r560", "r573" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r558", "r560", "r573" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r625" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r620" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r620" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r620" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r620" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r620" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r620" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r623" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r621" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r621" ] }, "SBFM_BasicAndDilutedNetGainLossPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "BasicAndDilutedNetGainLossPerSharePolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "BASIC AND DILUTED NET GAIN (LOSS) PER SHARE" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r336", "r531", "r532" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r59", "r61", "r336", "r531", "r532" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r336" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase price of shares", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r13" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, total assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, account receivable", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, intangible assets", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "negatedLabel": "Business combination, liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, net assets", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, other assets", "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, equipment and furniture", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice" ], "lang": { "en-us": { "role": { "label": "Business combination, total consideration", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Tables" ], "lang": { "en-us": { "role": { "label": "Schedule of allocation of purchase price", "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "CASH AND CASH EQUIVALENTS", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period", "periodEndLabel": "Cash and Cash Equivalents at End of Period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r29", "r96", "r170" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r96" ] }, "SBFM_CashFromNoraPharmaAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "CashFromNoraPharmaAcquisition", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash from Nora Pharma acquisition", "label": "CashFromNoraPharmaAcquisition" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r599" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r655" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r173", "r193", "r194", "r196", "r198", "r204", "r205", "r224", "r253", "r255", "r256", "r257", "r260", "r261", "r265", "r266", "r269", "r272", "r279", "r352", "r433", "r434", "r435", "r436", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r458", "r479", "r501", "r507", "r508", "r509", "r510", "r511", "r638", "r647", "r653" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r147", "r148", "r204", "r265", "r266", "r267", "r269", "r272", "r277", "r279", "r433", "r434", "r435", "r436", "r529", "r638", "r647" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Nominal exercise price", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r280" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Number of warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r600" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r600" ] }, "SBFM_CommonStockAndPrefundedWarrantsIssuedInPublicAndPrivateOfferingsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "CommonStockAndPrefundedWarrantsIssuedInPublicAndPrivateOfferingsNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs" } } }, "auth_ref": [] }, "SBFM_CommonStockAndPrefundedWarrantsIssuedInPublicAndPrivateOfferingsNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "CommonStockAndPrefundedWarrantsIssuedInPublicAndPrivateOfferingsNetOfIssuanceCostsShares", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs, shares" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r536", "r537", "r538", "r540", "r541", "r542", "r543", "r650", "r651", "r684", "r696", "r702" ] }, "SBFM_CommonStockMemberAndAprilWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "CommonStockMemberAndAprilWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Member And April Warrants [Member]" } } }, "auth_ref": [] }, "SBFM_CommonStockMemberAndInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "CommonStockMemberAndInvestorWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Member And Investor Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r79", "r458" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r79", "r458", "r476", "r702", "r703" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 28,024,290 and 22,585,632 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r79", "r404", "r534" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r605" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r604" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r606" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r603" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Current:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeMember", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income [Member]", "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss)", "verboseLabel": "Net (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r155", "r157", "r164", "r398", "r413" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r31", "r33", "r66", "r67", "r221", "r513" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r31", "r33", "r66", "r67", "r221", "r428", "r513" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r31", "r33", "r66", "r67", "r221", "r513", "r640" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "CONCENTRATION OF CREDIT RISKS", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r69", "r128" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r31", "r33", "r66", "r67", "r221" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r31", "r33", "r66", "r67", "r221", "r513" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "PRINCIPLES OF CONSOLIDATION", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r64", "r521" ] }, "SBFM_ConsultingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ConsultingExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Consulting" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r91", "r173", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r352", "r674" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r175", "r176", "r262", "r267", "r375", "r518", "r520" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r642", "r649", "r682" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r642", "r649" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r642", "r649", "r682" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r649", "r681", "r682" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r113", "r649", "r681" ] }, "us-gaap_DeferredIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r649", "r681", "r682" ] }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Intangibles", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Net Deferred Tax Liability", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r679" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r679" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Net Operating Loss, Credits and Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Other DTA", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Fixed Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "SBFM_DeferredTaxAssetsResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "DeferredTaxAssetsResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Research and Development" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Lease Liability", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation Allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r324" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred Tax Liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r57", "r679" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Intangibles", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-Use Asset", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" ], "lang": { "en-us": { "role": { "negatedLabel": "Fixed Assets", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r58", "r680" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r41" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Depreciation & amortization", "verboseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r41" ] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive common share equivalents", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r655", "r697" ] }, "SBFM_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Lease" } } }, "auth_ref": [] }, "SBFM_DisclosureManagementAndDirectorCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "DisclosureManagementAndDirectorCompensationAbstract", "lang": { "en-us": { "role": { "label": "Management And Director Compensation" } } }, "auth_ref": [] }, "SBFM_DisclosureReverseStockSplitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "DisclosureReverseStockSplitsAbstract", "lang": { "en-us": { "role": { "label": "Reverse Stock Splits" } } }, "auth_ref": [] }, "SBFM_DisclosureWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "DisclosureWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r6", "r108" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r560" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r558", "r560", "r573" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r558", "r560", "r573", "r609" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r559" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r547" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r560" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r560" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r594" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r550" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareDetails", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Basic (Loss) per common share", "verboseLabel": "Net gain (loss) per share attributable to common stock", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r165", "r182", "r183", "r184", "r185", "r186", "r191", "r193", "r196", "r197", "r198", "r202", "r350", "r351", "r399", "r414", "r525" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Diluted (Loss) per common share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r165", "r182", "r183", "r184", "r185", "r186", "r193", "r196", "r197", "r198", "r202", "r350", "r351", "r399", "r414", "r525" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r190", "r199", "r200", "r201" ] }, "SBFM_EarnoutPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "EarnoutPayable", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Earnout payable" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r358" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r686" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Total effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r320" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Pre-Tax Book Income", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r174", "r320", "r332" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in Valuation Allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r678", "r683" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Rate Change", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r332", "r678" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign Tax Rate Differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r678", "r683" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Permanent Adjustments", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r678", "r683" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Adjustments", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r678", "r683" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision to Return Adjustments", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense." } } }, "auth_ref": [ "r678", "r683" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "verboseLabel": "State Taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r678", "r683" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r553" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r549" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r549" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r637" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r549" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r634" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r573" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r549" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r549" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r549" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r549" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r635" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r136", "r159", "r160", "r161", "r177", "r178", "r179", "r181", "r187", "r189", "r203", "r225", "r226", "r281", "r311", "r312", "r313", "r328", "r329", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r359", "r360", "r361", "r362", "r363", "r364", "r372", "r422", "r423", "r424", "r439", "r501" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r602" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r565", "r577", "r587", "r613" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r562", "r574", "r584", "r610" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r608" ] }, "SBFM_ExerciseOfMayPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ExerciseOfMayPreFundedWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise Of May Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r11", "r16" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r144", "r244" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of estimated amortization expense", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r241", "r243", "r244", "r245", "r383", "r384" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r101", "r384" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r383" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r38", "r40" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r101", "r383" ] }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible assets additions", "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible assets acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r242" ] }, "SBFM_FirstReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "FirstReverseStockSplitMember", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "First Reverse Stock Split [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign exchange (loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r498" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "FUNCTIONAL CURRENCY", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r353" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Debt release", "negatedLabel": "Debt release", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r8", "r43", "r44" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total General and Administrative Expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r93", "r481" ] }, "us-gaap_GeneralAndAdministrativeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses:" } } }, "auth_ref": [] }, "SBFM_GenericPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "GenericPharmaceuticalsMember", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Generic Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/GoodwillDetails", "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business combination, goodwill", "verboseLabel": "Gooodwill", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r143", "r233", "r397", "r528", "r534", "r662", "r669" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill acquired during the period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r236", "r528" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Goodwill" ], "lang": { "en-us": { "role": { "label": "Goodwill", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r232", "r235", "r238", "r528" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/GoodwillDetails", "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Goodwill impairment", "negatedLabel": "Goodwill impairment", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r8", "r234", "r237", "r239", "r528" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://sunshinebiopharma.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill additions", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r661" ] }, "SBFM_GrossProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "GrossProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from sale of stock" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r90", "r173", "r206", "r212", "r216", "r218", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r352", "r527", "r674" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r558", "r560", "r573" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r88", "r120", "r206", "r212", "r216", "r218", "r400", "r411", "r527" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r174", "r315", "r321", "r322", "r326", "r330", "r333", "r334", "r335", "r438" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes", "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "verboseLabel": "Total", "terseLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r124", "r134", "r188", "r189", "r210", "r319", "r331", "r415" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r158", "r317", "r318", "r322", "r323", "r325", "r327", "r432" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Change in Valuation Allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Rate Change", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r316", "r320" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Rate Differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Pre-Tax Book Income", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r320" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Permanent Adjustments", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Other Adjustments", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "Provision to Return Adjustments", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" ], "lang": { "en-us": { "role": { "label": "State Taxes", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liability", "label": "Increase (Decrease) in Deferred Liabilities", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest payable", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r7" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r572", "r581", "r591", "r608", "r617", "r621", "r629" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r627" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r561", "r633" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r561", "r633" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r561", "r633" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r240" ] }, "SBFM_IntangibleAssetsEstimatedUsefulLives": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "IntangibleAssetsEstimatedUsefulLives", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible asset estimated useful lives" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r40", "r379", "r380", "r381", "r383", "r522" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r37", "r39" ] }, "SBFM_IntellectualPropertyRightsPatentsAndLicensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "IntellectualPropertyRightsPatentsAndLicensesPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r68", "r123", "r162", "r209", "r365", "r485", "r544", "r699" ] }, "us-gaap_InterestIncomeDebtSecuritiesOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeDebtSecuritiesOperating", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r166", "r168", "r169" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r151", "r516", "r534" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INVENTORY VALUATION", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r125", "r140", "r150", "r227", "r228", "r229", "r378", "r523" ] }, "SBFM_InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "InvestorWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investor Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease information", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r688" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r104" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Legal", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r92" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "LEASES", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r369" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of maturities of lease liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r689" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-MaturitiesOfLeasePayments" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation" ], "lang": { "en-us": { "role": { "label": "Remaining lease term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r687" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r366" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r19", "r173", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r339", "r340", "r341", "r352", "r457", "r526", "r546", "r674", "r692", "r693" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r84", "r119", "r407", "r534", "r648", "r660", "r685" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r139", "r173", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r339", "r340", "r341", "r352", "r534", "r674", "r692", "r693" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Long-Term Liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r17", "r73", "r74", "r75", "r77", "r173", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r339", "r340", "r341", "r352", "r674", "r692", "r693" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Liabilities:" } } }, "auth_ref": [] }, "SBFM_LicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "LicensesMember", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Licenses [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "SBFM_MalekChamounMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "MalekChamounMember", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Malek Chamoun [Member]" } } }, "auth_ref": [] }, "SBFM_ManagementAndDirectorCompensationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ManagementAndDirectorCompensationTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" ], "lang": { "en-us": { "role": { "label": "Management and Director Compensation" } } }, "auth_ref": [] }, "us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Marketing", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": [ "r93" ] }, "SBFM_MayInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "MayInvestorWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "May Investor Warrants [Member]" } } }, "auth_ref": [] }, "SBFM_MayPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "MayPreFundedWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" ], "lang": { "en-us": { "role": { "label": "May Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r600" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name" } } }, "auth_ref": [ "r600" ] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." ], "lang": { "en-us": { "role": { "label": "Acquisition of Nora Pharma Inc.", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r72", "r114" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r620" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r628" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r601" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Provided by Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows (Used In) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows (Used In) Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareDetails", "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (Loss", "label": "Net (Loss)", "verboseLabel": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net gain (loss) attributable to common stock", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r98", "r121", "r137", "r154", "r156", "r161", "r173", "r180", "r182", "r183", "r184", "r185", "r188", "r189", "r195", "r206", "r212", "r216", "r218", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r351", "r352", "r412", "r478", "r499", "r500", "r527", "r544", "r674" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r600" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r598" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r597" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r628" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r628" ] }, "us-gaap_NoninterestExpenseDirectorsFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestExpenseDirectorsFees", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Director fees", "verboseLabel": "Directors compensation", "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits." } } }, "auth_ref": [ "r122" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total Other Income (Expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Income (Expense):" } } }, "auth_ref": [] }, "SBFM_NoraPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "NoraPharmaIncMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nora Pharma Inc [Member]" } } }, "auth_ref": [] }, "SBFM_NoraPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "NoraPharmaMember", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nora Pharma [Member]" } } }, "auth_ref": [] }, "SBFM_OTCProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "OTCProductsMember", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "O T C Products [Member]" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "SBFM_OfficeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "OfficeExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Office" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsLineItems", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTable", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) From Operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r206", "r212", "r216", "r218", "r527" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation" ], "lang": { "en-us": { "role": { "label": "Right-of-use-liability", "verboseLabel": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r368" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use-liability", "label": "Operating lease liability - Long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r368" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation" ], "lang": { "en-us": { "role": { "label": "Right-of-use-asset", "verboseLabel": "Operating lease ROU asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r367" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://sunshinebiopharma.com/role/LeaseDetails-LeaseInformation" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r370", "r533" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Description of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r71", "r115", "r429", "r430" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign exchange translation", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r87" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure Amount" } } }, "auth_ref": [ "r600" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r560" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r567", "r579", "r589", "r615" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r570", "r582", "r592", "r618" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r570", "r582", "r592", "r618" ] }, "SBFM_PatentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PatentFees", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Patent fees" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r596" ] }, "SBFM_PaymentForLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PaymentForLeaseLiability", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease liability", "label": "PaymentForLeaseLiability" } } }, "auth_ref": [] }, "SBFM_PaymentOfEarnoutLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PaymentOfEarnoutLiability", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment of earnout liability" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfEquity", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment for stock repurchased", "documentation": "The cash outflow to reacquire common and preferred stock." } } }, "auth_ref": [ "r27", "r436" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Nora Pharma acquisition", "label": "Payments to acquire shares", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r26", "r337" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r95" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r95" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r599" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r599" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r598" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r601" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r597" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r554" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r555" ] }, "SBFM_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" ], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r536", "r537", "r540", "r541", "r542", "r543", "r696", "r702" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r78", "r265" ] }, "SBFM_PreferredStockPurchasedFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PreferredStockPurchasedFromRelatedParty", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred stock purchased from related party" } } }, "auth_ref": [] }, "SBFM_PreferredStockPurchasedFromRelatedPartyShares": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PreferredStockPurchasedFromRelatedPartyShares", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred stock purchased from related party, shares" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r458" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r78", "r265" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r78", "r458", "r476", "r702", "r703" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 10,000 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r78", "r403", "r534" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r152", "r230", "r231", "r517" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Sale of common stock in private placements", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds from sale of stock", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds issuance of private placement", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r5", "r433" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "verboseLabel": "Proceeds from warrant exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r646" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r219", "r382", "r416", "r417", "r418", "r419", "r420", "r421", "r515", "r530", "r535", "r641", "r672", "r673", "r677", "r695" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "auth_ref": [ "r219", "r382", "r416", "r417", "r418", "r419", "r420", "r421", "r515", "r530", "r535", "r641", "r672", "r673", "r677", "r695" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Accounting", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r544", "r700", "r701" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Plant, Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r103", "r129", "r132", "r133" ] }, "SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives1", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Property and equipment estimated useful lives" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r104", "r141", "r410" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment", "verboseLabel": "Plant, property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r401", "r410", "r534" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r129", "r132", "r408" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r104" ] }, "SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of estimated useful lives" } } }, "auth_ref": [] }, "SBFM_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PublicOfferingMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Public Offering [Member]" } } }, "auth_ref": [] }, "SBFM_PurchaseOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "PurchaseOfTreasuryStock", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury stock", "label": "PurchaseOfTreasuryStock" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r596" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r596" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r656", "r657", "r658", "r659" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r562", "r574", "r584", "r610" ] }, "SBFM_ReductionInRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ReductionInRightOfUseAsset", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reduction in Right-of-use asset" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r282", "r373", "r374", "r452", "r453", "r454", "r455", "r456", "r475", "r477", "r506" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r482", "r483", "r484" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r282", "r373", "r374", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r452", "r453", "r454", "r455", "r456", "r475", "r477", "r506", "r691" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r28" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "auth_ref": [ "r175", "r176", "r262", "r267", "r375", "r519", "r520" ] }, "SBFM_RepurchaseOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "RepurchaseOfTreasuryStock", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "[custom:RepurchaseOfTreasuryStock]" } } }, "auth_ref": [] }, "SBFM_RepurchaseOfTreasuryStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "RepurchaseOfTreasuryStockShares", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "[custom:RepurchaseOfTreasuryStockShares]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "R&D", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r70", "r314", "r694" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r563", "r575", "r585", "r611" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r564", "r576", "r586", "r612" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r571", "r583", "r593", "r619" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated (Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r81", "r108", "r406", "r425", "r427", "r437", "r459", "r534" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r177", "r178", "r179", "r181", "r187", "r189", "r225", "r226", "r311", "r312", "r313", "r328", "r329", "r342", "r344", "r345", "r347", "r349", "r422", "r424", "r439", "r702" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "REVENUE RECOGNITION", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r480", "r514", "r524" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Sales", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r163", "r173", "r207", "r208", "r211", "r214", "r215", "r219", "r220", "r221", "r224", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r352", "r400", "r674" ] }, "SBFM_ReverseStockSplitTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ReverseStockSplitTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplits" ], "lang": { "en-us": { "role": { "verboseLabel": "Reverse Stock Splits", "label": "ReverseStockSplitTextBlock" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r628" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r628" ] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Salaries", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r645" ] }, "us-gaap_SalariesWagesAndOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesWagesAndOfficersCompensation", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officers compensation", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r221", "r639" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.Details-AllocationPurcahsePrice", "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r59", "r61", "r336" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of provision for income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r112" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of components of net deferred tax assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r111" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r12", "r52", "r53", "r54", "r55" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of earnings per share computation", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r654" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of income tax expense", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r38", "r40", "r383" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r38", "r40" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/GoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r528", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ] }, "SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets estimated useful lives" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://sunshinebiopharma.com/role/GoodwillDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r106", "r107", "r108", "r146", "r147", "r148", "r204", "r265", "r266", "r267", "r269", "r272", "r277", "r279", "r433", "r434", "r435", "r436", "r529", "r638", "r647" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r56" ] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesFinancingTransactionAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": [ "r116" ] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": [ "r116" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r548" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r552" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r551" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r556" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r643", "r644", "r676" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r99", "r171" ] }, "SBFM_SingleInstitutionalInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "SingleInstitutionalInvestorMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Single Institutional Investor [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r557" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r173", "r193", "r194", "r196", "r198", "r204", "r205", "r224", "r253", "r255", "r256", "r257", "r260", "r261", "r265", "r266", "r269", "r272", "r279", "r352", "r433", "r434", "r435", "r436", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r458", "r479", "r501", "r507", "r508", "r509", "r510", "r511", "r638", "r647", "r653" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r22", "r136", "r159", "r160", "r161", "r177", "r178", "r179", "r181", "r187", "r189", "r203", "r225", "r226", "r281", "r311", "r312", "r313", "r328", "r329", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r359", "r360", "r361", "r362", "r363", "r364", "r372", "r422", "r423", "r424", "r439", "r501" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r177", "r178", "r179", "r203", "r382", "r431", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r473", "r474", "r475", "r477", "r480", "r481", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r501", "r539" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r177", "r178", "r179", "r203", "r382", "r431", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r473", "r474", "r475", "r477", "r480", "r481", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r501", "r539" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r566", "r578", "r588", "r614" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued as part of Nora Pharma acquisition, shares", "verboseLabel": "Stock issued for acquisition", "terseLabel": "Stock issued for acquisition, shares", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r78", "r79", "r108" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Excersise of warrants, shares", "verboseLabel": "Stock issued for conversion of securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r21", "r48", "r108", "r263" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants issued in a private offering net of expenses, shares", "verboseLabel": "Stock issued new, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r78", "r79", "r108", "r433", "r501", "r508" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Fractional shares issued for reverse stock split, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative", "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued as part of Nora Pharma acquisition", "verboseLabel": "Stock issued for acquisition, value", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r14", "r22", "r108" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of warrants", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r22", "r108" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants issued in a private offering net of expenses", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r78", "r79", "r108", "r439", "r501", "r508", "r545" ] }, "SBFM_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Fractional shares issued for reverse stock split" } } }, "auth_ref": [] }, "SBFM_StockIssuedForAcquisitionOfNormaPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "StockIssuedForAcquisitionOfNormaPharma", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock issued for acquisition of Nora Pharma" } } }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares redeemed", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock repurchase program amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of treasury stock, shares", "label": "Stock repurchased, shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r78", "r79", "r108", "r436", "r501", "r510" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of treasury stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r78", "r79", "r108", "r439", "r501", "r510", "r545" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL SHAREHOLDERS' EQUITY", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r82", "r83", "r100", "r460", "r476", "r502", "r503", "r534", "r546", "r648", "r660", "r685", "r702" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "label": "Capital Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r105", "r172", "r264", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r281", "r348", "r504", "r505", "r512" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r109" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r376", "r377" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplementary Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r607" ] }, "SBFM_Taxes": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "Taxes", "crdr": "debit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Taxes" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r655", "r690" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r599" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r606" ] }, "SBFM_TradeableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "TradeableWarrantMember", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "verboseLabel": "Tradeable Warrants [Member]", "label": "Tradeable Warrants [Member] [Default Label]" } } }, "auth_ref": [] }, "SBFM_TradeableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "TradeableWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants [Member]" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r627" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r629" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionDomain", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r520" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionTypeAxis", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r520" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r630" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r631" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r629" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r629" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Aggregate Available" } } }, "auth_ref": [ "r632" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r630" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r626" ] }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "crdr": "credit", "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange", "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax", "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective." } } }, "auth_ref": [ "r65" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "USE OF ESTIMATES", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r34", "r35", "r36", "r126", "r127", "r130", "r131" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails", "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" ], "lang": { "en-us": { "role": { "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "SBFM_WarrantExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantExpirationDate", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Expiry date" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r536", "r537", "r540", "r541", "r542", "r543" ] }, "SBFM_WarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsDisclosureTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Warrants" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants", "label": "WarrantsDisclosureTextBlock" } } }, "auth_ref": [] }, "SBFM_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsExercised", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "auth_ref": [] }, "SBFM_WarrantsExercisedMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsExercisedMember", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Exercised [Member]" } } }, "auth_ref": [] }, "SBFM_WarrantsIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants issued, shares", "label": "WarrantsIssuedDuringPeriodSharesNewIssues" } } }, "auth_ref": [] }, "SBFM_WarrantsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsIssuedShares", "presentation": [ "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" ], "lang": { "en-us": { "role": { "label": "Warrants issued, shares", "verboseLabel": "Number of warrants" } } }, "auth_ref": [] }, "SBFM_WarrantsIssuedWithFinancingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WarrantsIssuedWithFinancingTableTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants issued with financing" } } }, "auth_ref": [] }, "SBFM_WebsiteMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231231", "localname": "WebsiteMember", "presentation": [ "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Website [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareDetails", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding (Diluted)", "verboseLabel": "Dilutive weighted average outstanding shares of common stock", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r192", "r198" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://sunshinebiopharma.com/role/EarningsPerShareDetails", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding (Basic)", "verboseLabel": "Basic weighted average outstanding shares of common stock", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r191", "r198" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r636" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r638": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 80 0001683168-24-001818-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001818-xbrl.zip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sunshine_i10k-123123_htm.xml IDEA: XBRL DOCUMENT 0001402328 2023-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001402328 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001402328 2023-06-30 0001402328 2024-03-28 0001402328 2023-12-31 0001402328 2022-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001402328 2022-01-01 2022-12-31 0001402328 2021-12-31 0001402328 us-gaap:CommonStockMember 2021-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001402328 us-gaap:PreferredStockMember 2021-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2021-12-31 0001402328 us-gaap:RetainedEarningsMember 2021-12-31 0001402328 us-gaap:CommonStockMember 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001402328 us-gaap:PreferredStockMember 2022-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2022-12-31 0001402328 us-gaap:RetainedEarningsMember 2022-12-31 0001402328 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001402328 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2022-01-01 2022-12-31 0001402328 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001402328 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2023-01-01 2023-12-31 0001402328 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001402328 us-gaap:PreferredStockMember 2023-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2023-12-31 0001402328 us-gaap:RetainedEarningsMember 2023-12-31 0001402328 SBFM:GenericPharmaceuticalsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001402328 SBFM:OTCProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001402328 us-gaap:OfficeEquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:ComputerEquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:EquipmentMember 2023-01-01 2023-12-31 0001402328 us-gaap:VehiclesMember 2023-01-01 2023-12-31 0001402328 SBFM:LicensesMember 2023-01-01 2023-12-31 0001402328 SBFM:WebsiteMember 2023-01-01 2023-12-31 0001402328 SBFM:NoraPharmaMember 2022-10-19 2022-10-20 0001402328 SBFM:MalekChamounMember SBFM:NoraPharmaMember 2022-10-20 0001402328 SBFM:MalekChamounMember SBFM:NoraPharmaMember 2023-01-01 2023-12-31 0001402328 SBFM:MalekChamounMember SBFM:NoraPharmaMember 2023-12-31 0001402328 SBFM:NoraPharmaMember 2022-10-20 0001402328 us-gaap:EquipmentMember 2023-12-31 0001402328 us-gaap:EquipmentMember 2022-12-31 0001402328 us-gaap:ComputerEquipmentMember 2023-12-31 0001402328 us-gaap:ComputerEquipmentMember 2022-12-31 0001402328 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001402328 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001402328 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001402328 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001402328 us-gaap:VehiclesMember 2023-12-31 0001402328 us-gaap:VehiclesMember 2022-12-31 0001402328 SBFM:FirstReverseStockSplitMember 2022-02-08 2022-02-09 0001402328 srt:DirectorMember 2023-12-31 0001402328 srt:ChiefExecutiveOfficerMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001402328 SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 us-gaap:CommonStockMember SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 SBFM:TradeableWarrantsMember SBFM:PublicOfferingMember 2022-02-16 2022-02-17 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-21 2022-02-22 0001402328 SBFM:TradeableWarrantsMember SBFM:PublicOfferingMember 2022-02-22 0001402328 us-gaap:PrivatePlacementMember 2022-03-13 2022-03-14 0001402328 SBFM:CommonStockMemberAndInvestorWarrantsMember us-gaap:PrivatePlacementMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-04-27 2022-04-28 0001402328 SBFM:CommonStockMemberAndAprilWarrantsMember us-gaap:PrivatePlacementMember 2022-04-27 2022-04-28 0001402328 SBFM:NoraPharmaIncMember 2022-10-19 2022-10-20 0001402328 2023-01-19 0001402328 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001402328 SBFM:SingleInstitutionalInvestorMember 2023-05-15 2023-05-16 0001402328 SBFM:SingleInstitutionalInvestorMember us-gaap:CommonStockMember 2023-05-15 2023-05-16 0001402328 SBFM:MayPreFundedWarrantsMember SBFM:SingleInstitutionalInvestorMember 2023-05-15 2023-05-16 0001402328 SBFM:MayInvestorWarrantsMember SBFM:SingleInstitutionalInvestorMember 2023-05-15 2023-05-16 0001402328 SBFM:WarrantsExercisedMember 2022-01-01 2023-12-31 0001402328 us-gaap:CommonStockMember 2023-07-01 2023-07-31 0001402328 SBFM:ExerciseOfMayPreFundedWarrantsMember 2023-11-15 2023-11-16 0001402328 SBFM:MayPreFundedWarrantsMember 2023-11-15 2023-11-16 0001402328 SBFM:MayPreFundedWarrantsMember 2023-11-16 0001402328 SBFM:PreFundedWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:PreFundedWarrantsMember 2023-12-31 0001402328 SBFM:TradeableWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:TradeableWarrantsMember 2023-12-31 0001402328 SBFM:InvestorWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:InvestorWarrantsMember 2023-12-31 0001402328 SBFM:AprilWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:AprilWarrantsMember 2023-12-31 0001402328 SBFM:MayPreFundedWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:MayPreFundedWarrantsMember 2023-12-31 0001402328 SBFM:MayInvestorWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:MayInvestorWarrantsMember 2023-12-31 0001402328 SBFM:AllWarrantsMember 2023-01-01 2023-12-31 0001402328 SBFM:TradeableWarrantMember 2023-12-31 0001402328 SBFM:AdvanomicsCorporationMember 2023-01-01 2023-12-31 0001402328 SBFM:AdvanomicsCorporationMember 2022-01-01 2022-12-31 0001402328 2023-10-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure iso4217:CAD false 2023 FY 0001402328 10-K true 2023-12-31 --12-31 false 001-41282 SUNSHINE BIOPHARMA, INC. CO 20-5566275 1177 Avenue of the Americas 5th Floor New York NY 10036 (332) 216-1147 Common Stock, par value $0.001 Warrants SBFM SBFMW NASDAQ NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 10708072 99452865 BF Borgers CPA 5041 Lakewood, CO 16292347 21826437 2552362 1912153 5734755 3289945 310591 283799 24890055 27312334 365868 394249 1444259 776856 646779 760409 27346961 29243848 2585466 2802797 2547831 3632000 299869 373191 118670 123026 5551836 6931014 48729 43032 539035 642232 587764 685264 6139600 7616278 0.10 0.10 1000000 1000000 10000 10000 10000 10000 1000 1000 0.001 0.001 3000000000 3000000000 28024290 28024290 22585632 22585632 28024 22585 84387890 80841752 696105 161847 -63905658 -59399614 21207361 21627570 27346961 29243848 24092787 4345603 15753616 2649028 8339171 1696575 463705 341139 850173 842894 400000 300000 0 18326719 512199 550117 734248 578085 2142355 796007 14108 15148 1855830 811858 5712968 6054962 289737 55233 149147 25163 13124470 28697325 -4785299 -27000750 -245 -476 811974 518650 137308 39412 0 10852 674421 489614 -4110878 -26511136 395166 233304 -4506044 -26744440 534258 184986 -3971786 -26559454 -0.19 -0.19 -1.76 -1.76 24331908 24331908 15180868 15180868 -4506044 -26744440 149147 25163 0 18326719 -0 -548 -0 10852 594141 524486 2365549 -42983 21143 -82846 -1364134 3359141 0 3628 -73247 238679 0 -48287 -8775111 -5248358 131949 33379 -0 14346637 -0 1135 705848 111015 82251 193982 -656150 -14619390 4089218 30367185 3502 13193177 541143 99000 125990 31924 -0 2064331 -0 1900000 3425587 39465107 21826437 2045167 -6005674 19597359 -62674 -1075 534258 184986 16292347 21826437 0 48287 0 4514000 2591240 2591 32787384 1000000 100000 -23139 -32655174 211662 4380 4 -4 6656526 6657 30360528 30367185 9633486 9633 13183544 13193177 -990000 -99000 -99000 3700000 3700 4510300 4514000 184986 -26744440 -26559454 22585632 22585 80841752 10000 1000 161847 -59399614 21627570 513723 514 540629 541143 2450000 2451 4086767 4089218 3502381 3502 3502 534258 -4506044 -3971786 28024290 28024 84387890 10000 1000 696105 -63905658 21207361 <p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z8B4dQk4EL91" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 1 – <span id="xdx_827_zXGn3YjOdNsj">Description of Business</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma operates two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio of pharmaceutical products consisting of 52 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells nonprescription over-the-counter (“OTC”) products.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has determined that it has two reportable segments:</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"> <td style="width: 24px"></td><td style="width: 24px; text-align: left">•</td><td>Prescription Generic Pharmaceuticals (“Generic Pharmaceuticals”)</td> </tr> <tr style="vertical-align: top"> <td></td><td style="text-align: left">•</td><td>Nonprescription Over-The-Counter Products (“OTC Products”)</td> </tr></table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Through December 31, 2023, sales from the Generic Pharmaceuticals segment represented approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--GenericPharmaceuticalsMember_zajgWXtWxMK6" title="Concentration risk, percentage">97</span>% of total revenues of the Company while the remaining approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OTCProductsMember_zXLc2Yt7UNOb" title="Concentration risk, percentage">3</span>% was generated from the sale of OTC Products. Based on these results, the Company deems segmentation reporting to be immaterial at December 31, 2023.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, in Canada Provincial governments reimburse patients for their prescription drugs expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on governmental policies which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance (“pCPA”) and the Canadian Generic Pharmaceutical Association have resulted in updated generic pricing for certain products which took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February 29, 2024, the Canadian federal government tabled new drug reimbursement legislation, a bill known as PharmaCare which, if passed, would result in a single-payer program whereby the Canadian federal government would pay for the drugs sold in Canada rather than the Provinces.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, the Company is engaged in the development of the following proprietary drugs:</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td><td style="width: 24px; text-align: justify">•</td><td style="text-align: justify">Adva-27a, a small chemotherapy molecule for treatment of pancreatic cancer (IND-enabling studies were paused in November 2023 due to unfavorable results. See <i>“Products in Development,”</i> above.</td> </tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td><td style="text-align: justify">•</td><td style="text-align: justify">K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer</td> </tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td><td style="text-align: justify">•</td><td style="text-align: justify">SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections</td> </tr></table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> 0.97 0.03 <p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zb9lugoWzUo5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 2 – <span id="xdx_829_z0Wjn5JcUt7j">Summary of Significant Accounting Policies</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zw9bSTlmjQS4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_860_z9l3uLLIM8Xe">PRINCIPLES OF CONSOLIDATION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--UseOfEstimates_zAWnXusq7tul" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zNhIdI5J17ph">USE OF ESTIMATES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zf6ttZLIUV1l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86D_zPGw8UtJLae8">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are stated at net realizable value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis, management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts or if any accounts should be written off based on a past history of write-offs, collections and current credit conditions. A receivable is considered past due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral to support its receivables.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zR3A0yq6E3Cd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_868_zwRstsdFWAdd">INVENTORY VALUATION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Inventory is valued at the lower of cost and net realizable value. Cost is determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business, less the costs of completion and costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to the acquisition of finished goods.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zfsyKSeo2Z52" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zhwarKKZrcV6">CASH AND CASH EQUIVALENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $16,292,347 and $21,826,437 as of December 31, 2023 and December 31, 2022, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 in the U.S. or the equivalent in Canada.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmh6Yq6O2V58" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86A_znpLTTpuTHW6">PROPERTY AND EQUIPMENT</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2023 and 2022, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zgOXr7zoUny3" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8BC_zq8TycgUlmyk" style="display: none">Schedule of estimated useful lives</span></td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td> <td style="width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSMXDC9sVyG5" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zoxtX4m8ZM99" title="Property and equipment estimated useful lives">55%</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQvWOiM7zuDk" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zCcyWdrs08Bi" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr> </table> <p id="xdx_8AA_zdFHQGYRIwvj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zfNaLOZkquJk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86F_zzLPksvNOekd">INTANGIBLE ASSETS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are amortized over their estimated useful lives according to the following methods at the following annual rates and period:<i> </i></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_ziv2s7X7M33b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"> <tr style="vertical-align: top"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BF_zBGFIC5G4YR" style="display: none">Schedule of intangible assets estimated useful lives</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td> <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z9JqXBt3jw5e" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zxdXdEAzJ1f1" title="Intangible asset estimated useful lives">55%</span></span></td></tr> </table> <p id="xdx_8AC_zuxSD87Wgjf4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are tested for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal. In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over its fair value.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_ecustom--IntellectualPropertyRightsPatentsAndLicensesPolicyTextBlock_zkckdEhdcve" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i>INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES</i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The cost of patents and licenses acquired is capitalized and is amortized over the remaining life of the patents or licenses.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future cash flows associated with it.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_ecustom--BasicAndDilutedNetGainLossPerSharePolicyTextBlock_zCrizoBMHeJk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_863_zEgDAyU5bwJ5">BASIC AND DILUTED NET GAIN (LOSS) PER SHARE</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company computes gain or loss per share in accordance with <i>ASC 260 – Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is calculated by dividing net gain (loss) by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2023, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20230101__20231231_ztszjuJ20X3e" title="Anti dilutive securities shares">no</span> potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_za6kpU47mwV7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_866_zn3vntTHP776">INCOME TAXES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASC 740 – Income Taxes</i>, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2023 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For Canadian and US tax purposes, the Company’s 2020 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zBKzVJ3qphc8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_866_ze7PXsdpgvV1">FUNCTIONAL CURRENCY</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiaries' financial statements into U.S. dollars as follows:</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 24px"> </td> <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income statement accounts are translated using the weighted average exchange rate for the period.</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z2rfVTEl0q4b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zxzJlioUWff6">CONCENTRATION OF CREDIT RISKS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zplH8pT8A6K5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_z7TlJhaMaqB">FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting guidance, <i>ASC 825 – Financial Instruments</i>. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023 and 2022, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 24px"> </td> <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"> </td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"> </td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--DebtPolicyTextBlock_zUj5zqN0lWAa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_863_zXNM78fZ962a">NOTES PAYABLE</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company had no notes payable as of December 31, 2023 and 2022.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zc4iHcWks9D1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_861_zECyAxl3CkF3">REVENUE RECOGNITION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Over 97% of the Company’s revenues are derived from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies, purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company’s products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion) accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the Company.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No significant judgments are made in connection with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine the price of its products.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed at the Company’s current price list on the date of shipping and known in advance by the customer and does not vary.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company is involved in a singular activity which is to sell pharmaceutical finished goods. The Company fulfills its performance obligation when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured and the transfer of ownership to the customer takes place when the customer receives goods. At this point, the Company issues an invoice for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. It is when the invoice is issued that the revenue is recognized. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days of the date of the invoice. The collection is reasonably assured because of the nature of the Company’s customers. The Company is conducting sales only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the event of any breach by the Company of any product warranty (whether by reason of defective materials, production faults or otherwise), the Company’s liability shall be limited to, at Company’s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company carries product insurance and is not liable for products’ failure to comply with the warranty of products if the failure or damage arises because of the customer’s negligence, deliberate damage, misuse or failure to store the products in conditions per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These conditions also apply to any replacement products supplied by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company warrants to the customer that, at the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements. In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable laws to purchase, store, distribute, sell and use the Company’s products. Visible defects or damages must be reported to the Company in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company shall not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters, terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts, shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not within the Company’s control.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_zzmLkQYB6wM6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86C_zSB6htSvtOHk">LEASES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company recognizes and measures its leases in accordance with <i>FASB ASC 842, Leases</i>. The Company is a lessee in a non-cancellable operating lease for office space. The Company determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases. The Company’s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured throughout the lease term at the remaining amount (i.e., present value of the remaining lease payments), plus unamortized initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has elected, for all underlying classes of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the available practical expedient, we account for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further, we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zipTsnaxBtXl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86A_zuB8UZbXAc8a">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zw9bSTlmjQS4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_860_z9l3uLLIM8Xe">PRINCIPLES OF CONSOLIDATION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--UseOfEstimates_zAWnXusq7tul" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zNhIdI5J17ph">USE OF ESTIMATES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zf6ttZLIUV1l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86D_zPGw8UtJLae8">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are stated at net realizable value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis, management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts or if any accounts should be written off based on a past history of write-offs, collections and current credit conditions. A receivable is considered past due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral to support its receivables.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zR3A0yq6E3Cd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_868_zwRstsdFWAdd">INVENTORY VALUATION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Inventory is valued at the lower of cost and net realizable value. Cost is determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business, less the costs of completion and costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to the acquisition of finished goods.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zfsyKSeo2Z52" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zhwarKKZrcV6">CASH AND CASH EQUIVALENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $16,292,347 and $21,826,437 as of December 31, 2023 and December 31, 2022, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 in the U.S. or the equivalent in Canada.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmh6Yq6O2V58" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86A_znpLTTpuTHW6">PROPERTY AND EQUIPMENT</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2023 and 2022, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zgOXr7zoUny3" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8BC_zq8TycgUlmyk" style="display: none">Schedule of estimated useful lives</span></td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td> <td style="width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSMXDC9sVyG5" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zoxtX4m8ZM99" title="Property and equipment estimated useful lives">55%</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQvWOiM7zuDk" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zCcyWdrs08Bi" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr> </table> <p id="xdx_8AA_zdFHQGYRIwvj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zgOXr7zoUny3" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8BC_zq8TycgUlmyk" style="display: none">Schedule of estimated useful lives</span></td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td> <td style="width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSMXDC9sVyG5" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zoxtX4m8ZM99" title="Property and equipment estimated useful lives">55%</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQvWOiM7zuDk" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zCcyWdrs08Bi" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr> </table> 5-7 Years / 20% 55% 5 Years 5 Years / 30% <p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zfNaLOZkquJk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86F_zzLPksvNOekd">INTANGIBLE ASSETS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are amortized over their estimated useful lives according to the following methods at the following annual rates and period:<i> </i></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_ziv2s7X7M33b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"> <tr style="vertical-align: top"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BF_zBGFIC5G4YR" style="display: none">Schedule of intangible assets estimated useful lives</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td> <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z9JqXBt3jw5e" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zxdXdEAzJ1f1" title="Intangible asset estimated useful lives">55%</span></span></td></tr> </table> <p id="xdx_8AC_zuxSD87Wgjf4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are tested for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal. In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over its fair value.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_ziv2s7X7M33b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"> <tr style="vertical-align: top"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BF_zBGFIC5G4YR" style="display: none">Schedule of intangible assets estimated useful lives</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td> <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z9JqXBt3jw5e" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_ecustom--IntangibleAssetsEstimatedUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zxdXdEAzJ1f1" title="Intangible asset estimated useful lives">55%</span></span></td></tr> </table> 5 Years 55% <p id="xdx_840_ecustom--IntellectualPropertyRightsPatentsAndLicensesPolicyTextBlock_zkckdEhdcve" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i>INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES</i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The cost of patents and licenses acquired is capitalized and is amortized over the remaining life of the patents or licenses.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future cash flows associated with it.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_ecustom--BasicAndDilutedNetGainLossPerSharePolicyTextBlock_zCrizoBMHeJk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_863_zEgDAyU5bwJ5">BASIC AND DILUTED NET GAIN (LOSS) PER SHARE</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company computes gain or loss per share in accordance with <i>ASC 260 – Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is calculated by dividing net gain (loss) by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2023, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20230101__20231231_ztszjuJ20X3e" title="Anti dilutive securities shares">no</span> potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> 0 <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_za6kpU47mwV7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_866_zn3vntTHP776">INCOME TAXES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASC 740 – Income Taxes</i>, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2023 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For Canadian and US tax purposes, the Company’s 2020 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zBKzVJ3qphc8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_866_ze7PXsdpgvV1">FUNCTIONAL CURRENCY</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiaries' financial statements into U.S. dollars as follows:</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 24px"> </td> <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income statement accounts are translated using the weighted average exchange rate for the period.</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z2rfVTEl0q4b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zxzJlioUWff6">CONCENTRATION OF CREDIT RISKS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zplH8pT8A6K5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_z7TlJhaMaqB">FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting guidance, <i>ASC 825 – Financial Instruments</i>. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023 and 2022, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 24px"> </td> <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"> </td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></td></tr> <tr> <td> </td> <td style="vertical-align: top"> </td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--DebtPolicyTextBlock_zUj5zqN0lWAa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_863_zXNM78fZ962a">NOTES PAYABLE</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company had no notes payable as of December 31, 2023 and 2022.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zc4iHcWks9D1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_861_zECyAxl3CkF3">REVENUE RECOGNITION</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Over 97% of the Company’s revenues are derived from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies, purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company’s products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion) accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the Company.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No significant judgments are made in connection with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine the price of its products.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed at the Company’s current price list on the date of shipping and known in advance by the customer and does not vary.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company is involved in a singular activity which is to sell pharmaceutical finished goods. The Company fulfills its performance obligation when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured and the transfer of ownership to the customer takes place when the customer receives goods. At this point, the Company issues an invoice for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. It is when the invoice is issued that the revenue is recognized. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days of the date of the invoice. The collection is reasonably assured because of the nature of the Company’s customers. The Company is conducting sales only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the event of any breach by the Company of any product warranty (whether by reason of defective materials, production faults or otherwise), the Company’s liability shall be limited to, at Company’s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company carries product insurance and is not liable for products’ failure to comply with the warranty of products if the failure or damage arises because of the customer’s negligence, deliberate damage, misuse or failure to store the products in conditions per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These conditions also apply to any replacement products supplied by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company warrants to the customer that, at the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements. In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable laws to purchase, store, distribute, sell and use the Company’s products. Visible defects or damages must be reported to the Company in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company shall not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters, terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts, shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not within the Company’s control.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_zzmLkQYB6wM6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86C_zSB6htSvtOHk">LEASES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company recognizes and measures its leases in accordance with <i>FASB ASC 842, Leases</i>. The Company is a lessee in a non-cancellable operating lease for office space. The Company determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases. The Company’s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured throughout the lease term at the remaining amount (i.e., present value of the remaining lease payments), plus unamortized initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has elected, for all underlying classes of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the available practical expedient, we account for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further, we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zipTsnaxBtXl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86A_zuB8UZbXAc8a">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_808_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zyC4ITtNQva4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 3 – <span id="xdx_820_zXRRAosOF8U3">Acquisition of Nora Pharma Inc.</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (“Nora Pharma), a Canadian privately held pharmaceutical company. The purchase price for the shares was $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" title="Purchase price of shares">18,860,637</span> which was paid in cash ($<span id="xdx_907_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zmtaiLYIoNFh" title="Payments to acquire shares">14,346,637</span>) and by the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pdd" title="Stock issued for acquisition">3,700,000</span> shares of the Company’s common stock valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" title="Stock issued for acquisition, value">4,514,000</span> or $1.22 per share on the acquisition date. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma’s operations are authorized by a Drug Establishment License issued by Health Canada.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table summarizes the allocation of the purchase price as of October 20, 2022, the acquisition date using Nora Pharma’s balance sheet assets and liabilities: </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_z2Qrt0iqgq0h" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zgn2KZmzfLnc" style="display: none">Schedule of allocation of purchase price</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="width: 14%; text-align: right" title="Business combination, account receivable">1,358,121</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, inventory">3,181,916</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, intangible assets">659,571</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equipment &amp; furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, equipment and furniture">210,503</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, other assets">1,105,093</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, total assets">6,515,204</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pp0p0_di_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zEAvHnyvZu83" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, liabilities assumed">(5,981,286</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, net assets">533,918</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Goodwill_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, goodwill">18,326,719</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Business combination, total consideration">18,860,637</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The value of the 3,700,000 common shares issued as part of the consideration paid for Nora Pharma was determined based on the closing market price of the Company’s common shares on the acquisition date, October 20, 2022 ($1.22 per share).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As part of the consideration paid for Nora Pharma, the Company agreed to a $<span id="xdx_90C_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_z772dMTX5aNe" title="Earnout payable">5,000,000</span> CAD ($<span id="xdx_902_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_ziNbCs3thvA2" title="Earnout payable">3,632,000</span> USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During the twelve-month period ended December 31, 2023, the Company paid an earn-out amount of $<span id="xdx_900_ecustom--PaymentOfEarnoutLiability_pp0p0_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_z7pndLIGqA84" title="Payment of earnout liability">1,084,169</span> leaving a balance earn-out to be paid of $<span id="xdx_902_ecustom--EarnoutPayable_iI_pp0p0_uUSD_c20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_z9id1kVGuhQ3" title="Earnout payable">2,547,831</span> at December 31, 2023.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> 18860637 14346637 3700000 4514000 <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_z2Qrt0iqgq0h" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Acquisition of Nora Pharma Inc. (Details - Allocation purcahse price)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zgn2KZmzfLnc" style="display: none">Schedule of allocation of purchase price</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="width: 14%; text-align: right" title="Business combination, account receivable">1,358,121</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, inventory">3,181,916</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, intangible assets">659,571</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equipment &amp; furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, equipment and furniture">210,503</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, other assets">1,105,093</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, total assets">6,515,204</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pp0p0_di_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zEAvHnyvZu83" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, liabilities assumed">(5,981,286</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="text-align: right" title="Business combination, net assets">533,918</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Goodwill_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Business combination, goodwill">18,326,719</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Business combination, total consideration">18,860,637</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1358121 3181916 659571 210503 1105093 6515204 5981286 533918 18326719 18860637 5000000 3632000 1084169 2547831 <p id="xdx_805_eus-gaap--GoodwillDisclosureTextBlock_zRI0yooY6H04" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 4 – <span id="xdx_82F_z8PRjPEBH7Tc">Goodwill</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company acquired Nora Pharma on October 20, 2022. Allocation of the purchase price per ASC 805-20-25-1 yielded a goodwill amount of $<span id="xdx_902_eus-gaap--Goodwill_iI_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zJGmj5DGDUul">18,326,719</span>. The Company’s used a discounted cash flow model which requires estimating future cash flows expected to be generated from the acquired entity, discounted to their present value using a risk-adjusted discount rate and terminal values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Assessing the recoverability of goodwill requires the Company to make estimates and assumptions about sales, operating margins, growth rates and discount rates based on its budgets, business plans, economic projections, anticipated future cash flows and marketplace data. Management determined that there are inherent uncertainties related to these factors as well as significant risks to cash flows due to ongoing geopolitical and geo-economics conflicts, making the discounted cash flow model unreliable.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table presents the changes in the carrying amount of goodwill of the Company as of December 31, 2022 and 2023. The provisions of ASC 350-20-50-1 require the disclosure of cumulative impairment. As a result of the acquisition, a new basis in goodwill was recorded in accordance with ASC 805-10. All impairments shown in the table below have been recorded subsequent to the acquisition. The Company had no goodwill on its balance sheet prior to the acquisition:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfGoodwillTextBlock_z6N9Ind21vh6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Goodwill (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; width: 83%"><span id="xdx_8B3_zwFjlj3TI5i7"><b style="display: none">Schedule of goodwill</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iI_d0_c20211231_znXgwj4Oigy7" style="width: 13%; text-align: right" title="Gooodwill">–</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Acquisition of Nora Pharma (October 20, 2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GoodwillAcquiredDuringPeriod_c20220101__20221231_zLCbSjS9XxW" style="text-align: right" title="Goodwill acquired during the period">18,326,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zjojosHz0tY8" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(18,326,719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Balance as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Goodwill_iI_d0_c20221231_zCAtjFpOObwe" style="text-align: right" title="Gooodwill">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Additions in 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--GoodwillPeriodIncreaseDecrease_c20230101__20231231_z3C5Gx9yJCo5" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill additions"><span style="-sec-ix-hidden: xdx2ixbrl0652">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iI_d0_c20231231_z7kNIqwafrR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Gooodwill">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> 18326719 <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfGoodwillTextBlock_z6N9Ind21vh6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Goodwill (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; width: 83%"><span id="xdx_8B3_zwFjlj3TI5i7"><b style="display: none">Schedule of goodwill</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iI_d0_c20211231_znXgwj4Oigy7" style="width: 13%; text-align: right" title="Gooodwill">–</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Acquisition of Nora Pharma (October 20, 2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GoodwillAcquiredDuringPeriod_c20220101__20221231_zLCbSjS9XxW" style="text-align: right" title="Goodwill acquired during the period">18,326,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zjojosHz0tY8" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(18,326,719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Balance as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Goodwill_iI_d0_c20221231_zCAtjFpOObwe" style="text-align: right" title="Gooodwill">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Additions in 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--GoodwillPeriodIncreaseDecrease_c20230101__20231231_z3C5Gx9yJCo5" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill additions"><span style="-sec-ix-hidden: xdx2ixbrl0652">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iI_d0_c20231231_z7kNIqwafrR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Gooodwill">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 18326719 18326719 0 0 <p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zdOu86iWIw0g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 5 – <span id="xdx_822_zlJQAPP2Wgk3">Intangible Assets</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Intangible assets, net, consisted of the following at December 31, 2022 and 2023:</p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9m6zu1LWqof" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"> <tr style="vertical-align: bottom"> <td style="width: 83%"><span id="xdx_8B9_zXL0U0ClO4Wl"><b style="display: none">Schedule of intangible assets</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance as of December 31, 2021</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20211231_z2yE0bW4in5l" style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-Lived intangible assets</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98E_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20220101__20221231_zTSoILekRKJ9" style="text-align: right" title="Intangible assets acquired"><span style="font-family: Arial, Helvetica, Sans-Serif">659,571</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Dossier fee additions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20220101__20221231_zbmZgXCXaCQa" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets additions"><span style="font-family: Arial, Helvetica, Sans-Serif">121,807</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at December 31, 2022</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20221231_zrjRTAmGB4Nc" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">781,378</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less accumulated amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di0_c20221231_zozslabSXQNe" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(4,522</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-lived intangible assets, net at December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20221231_zEDSdhs15yX4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">776,856</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance as of December 31, 2022</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"></span>$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20221231_zyVZWggkzQM4" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">776,856</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Dossier fee additions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20230101__20231231_zLm67rLUWsn7" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets additions"><span style="font-family: Arial, Helvetica, Sans-Serif">710,372</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at December 31, 2023</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20231231_zml9ZkxTVX2h" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">1,487,228</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less accumulated amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di0_c20231231_zwVkzZpdfz52" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(42,969</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-lived intangible assets, net at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20231231_zII20OtMgZLk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">1,444,259</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the estimated amortization expense of the Company’s intangible assets for each of the next five years is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zDJVKhCLBs85" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_zfCb0vhpv381" style="display: none">Schedule of estimated amortization expense</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20231231_zKqlM858Bka4" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">59,745</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,745</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,541</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,041</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,985</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9m6zu1LWqof" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"> <tr style="vertical-align: bottom"> <td style="width: 83%"><span id="xdx_8B9_zXL0U0ClO4Wl"><b style="display: none">Schedule of intangible assets</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance as of December 31, 2021</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20211231_z2yE0bW4in5l" style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-Lived intangible assets</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98E_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20220101__20221231_zTSoILekRKJ9" style="text-align: right" title="Intangible assets acquired"><span style="font-family: Arial, Helvetica, Sans-Serif">659,571</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Dossier fee additions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20220101__20221231_zbmZgXCXaCQa" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets additions"><span style="font-family: Arial, Helvetica, Sans-Serif">121,807</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at December 31, 2022</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20221231_zrjRTAmGB4Nc" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">781,378</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less accumulated amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di0_c20221231_zozslabSXQNe" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(4,522</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-lived intangible assets, net at December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20221231_zEDSdhs15yX4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">776,856</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance as of December 31, 2022</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"></span>$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20221231_zyVZWggkzQM4" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">776,856</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Dossier fee additions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20230101__20231231_zLm67rLUWsn7" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets additions"><span style="font-family: Arial, Helvetica, Sans-Serif">710,372</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at December 31, 2023</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_d0_c20231231_zml9ZkxTVX2h" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">1,487,228</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less accumulated amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di0_c20231231_zwVkzZpdfz52" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(42,969</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Finite-lived intangible assets, net at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_c20231231_zII20OtMgZLk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">1,444,259</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> 0 659571 121807 781378 4522 776856 776856 710372 1487228 42969 1444259 <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zDJVKhCLBs85" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_zfCb0vhpv381" style="display: none">Schedule of estimated amortization expense</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20231231_zKqlM858Bka4" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">59,745</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,745</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,541</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,041</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,985</td><td style="text-align: left"> </td></tr> </table> 59745 59745 58541 19041 9985 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zgCEPLEjrxy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #00487F"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span style="text-decoration: underline">Note 6 – <span id="xdx_82B_z939UoYC4sZi">Plant, Property and Equipment</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:</span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_zUsdA7A1fXq" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; width: 66%"><span id="xdx_8B9_zrHSGPZsuWmi"><b style="display: none">Schedule of property and equipment</b></span></td><td style="color: Black; width: 2%"> </td> <td style="color: Black; text-align: left; width: 1%"> </td><td id="xdx_492_20231231_z7EIOpLMMYKe" style="text-align: right; width: 13%"> </td><td style="color: Black; text-align: left; width: 1%"> </td><td style="color: Black; width: 2%"> </td> <td style="color: Black; text-align: left; width: 1%"> </td><td id="xdx_49E_20221231_zmh9VgExV1yg" style="color: Black; text-align: right; width: 13%"> </td><td style="color: Black; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; font-weight: 700; font-style: normal; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; font-weight: 700; font-style: normal; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; color: Black; font-weight: 700; font-style: normal"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2023</span></td><td style="padding-bottom: 1pt; color: Black; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2022</b></span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znlGodAG7h7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Equipment</span></td><td style="width: 2%; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right; width: 13%"><span style="font-family: Arial, Helvetica, Sans-Serif">171,859</span></td><td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="width: 2%; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">162,534</span></td><td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zRngLJKart3c" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Computer equipment</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">7,368</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">16,418</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zWcTnRPvSC69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Furniture and fixtures</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">34,132</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">33,329</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8KIv2qWDaoc" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Leasehold improvements</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">17,664</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zFSCVZDBBO4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Vehicles</span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">324,841</span></td><td style="padding-bottom: 1pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">265,774</span></td><td style="padding-bottom: 1pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_zlgjhOSz4Ehc" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Total</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">555,864</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">478,055</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNaDzNJDLYL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less: Accumulated depreciation</span></td><td style="color: teal; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: teal; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: teal; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; color: Black">(189,996</span></td><td style="padding-bottom: 1pt; color: teal; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; color: Black">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(83,806</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhEhWjKdcFag" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Plant, property and equipment, net</span></td><td style="color: Black; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">365,868</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">394,249</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the years ended December 31, 2023 and 2022 amounted to $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_z3p6ule74Hyl">110,701</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20220101__20221231_zg08txGxbBHg">20,641</span>, respectively.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_zUsdA7A1fXq" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; width: 66%"><span id="xdx_8B9_zrHSGPZsuWmi"><b style="display: none">Schedule of property and equipment</b></span></td><td style="color: Black; width: 2%"> </td> <td style="color: Black; text-align: left; width: 1%"> </td><td id="xdx_492_20231231_z7EIOpLMMYKe" style="text-align: right; width: 13%"> </td><td style="color: Black; text-align: left; width: 1%"> </td><td style="color: Black; width: 2%"> </td> <td style="color: Black; text-align: left; width: 1%"> </td><td id="xdx_49E_20221231_zmh9VgExV1yg" style="color: Black; text-align: right; width: 13%"> </td><td style="color: Black; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; font-weight: 700; font-style: normal; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; font-weight: 700; font-style: normal; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; color: Black; font-weight: 700; font-style: normal"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2023</span></td><td style="padding-bottom: 1pt; color: Black; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2022</b></span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znlGodAG7h7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Equipment</span></td><td style="width: 2%; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right; width: 13%"><span style="font-family: Arial, Helvetica, Sans-Serif">171,859</span></td><td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="width: 2%; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">162,534</span></td><td style="width: 1%; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zRngLJKart3c" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Computer equipment</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">7,368</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">16,418</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zWcTnRPvSC69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Furniture and fixtures</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">34,132</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">33,329</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8KIv2qWDaoc" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Leasehold improvements</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">17,664</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zFSCVZDBBO4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Vehicles</span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">324,841</span></td><td style="padding-bottom: 1pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 1pt; color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">265,774</span></td><td style="padding-bottom: 1pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_zlgjhOSz4Ehc" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Total</span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">555,864</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">478,055</span></td><td style="color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNaDzNJDLYL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Less: Accumulated depreciation</span></td><td style="color: teal; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: teal; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: teal; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; color: Black">(189,996</span></td><td style="padding-bottom: 1pt; color: teal; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; color: Black">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(83,806</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhEhWjKdcFag" style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; color: Black; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Plant, property and equipment, net</span></td><td style="color: Black; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">365,868</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="color: Black; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">394,249</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> 171859 162534 7368 16418 34132 33329 17664 0 324841 265774 555864 478055 189996 83806 365868 394249 110701 20641 <p id="xdx_807_ecustom--ReverseStockSplitTextBlock_zAtyAnPd5zGl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 7 – <span id="xdx_828_zOXXMlU0ySC1">Reverse Stock Splits</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Effective February 9, 2022, the Company completed a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20220208__20220209__us-gaap--TransactionTypeAxis__custom--FirstReverseStockSplitMember_zTTzmyq0Yc3k" title="Reverse stock split">1 for 200 reverse split</span> of its common stock. The Company had previously completed two 20 to 1 reverse stock splits, one in 2019 and the other in 2020. The Company’s financial statements reflect all three reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> 1 for 200 reverse split <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyuvJVeQVJg2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 8 – <span id="xdx_82A_z1QEoJr3fNVj">Capital Stock</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company’s authorized capital is comprised of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zfGB5IHjuDW6" title="Common stock, shares authorized">3,000,000,000</span> shares of common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_znjlC6qOnZ4l" title="Common stock, par value">0.001</span>, and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zVOWMYkNiaQf" title="Preferred stock, shares authorized">30,000,000</span> shares of preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zMlj92pKx1u2" title="Preferred stock, par value">0.10</span> par value. As of December 31, 2023, the Company had authorized <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGFmNaLrNM1f" title="Preferred stock, shares authorized">1,000,000</span> shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible and non-redeemable. It has a liquidation preference to the common stock equal to the stated value of $0.10, relative to the rights to the common stock, and gives the holder the right to 1,000 votes per share. As of December 31, 2023, <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zb5yDcycaOR8" title="Preferred stock, shares outstanding">10,000</span> shares of Series B Preferred Stock were outstanding and held by the Company’s Chief Executive Officer.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 17, 2022, the Company completed a public offering and received net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220216__20220217__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zQdG2d6d4ygk" title="Net proceeds from public offering">6,833,071</span> from the offering. Pursuant to the public offering, the Company issued and sold an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220216__20220217__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zx7BmurkXCZd" title="Stock issued new, shares">1,882,353</span> shares of common stock and <span id="xdx_905_ecustom--WarrantsIssuedShares_c20220216__20220217__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zvO4dtvL0s35" title="Warrants issued, shares">4,102,200</span> warrants to purchase shares of common stock (the “Tradeable Warrants”).</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 22, 2022, the Company redeemed <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220221__20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znUcrgX8jxY1" title="Number of shares redeemed">990,000</span> shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share. The remaining 10,000 shares of Series B Preferred Stock could not be voted pursuant to a warrant agent agreement relating to the Tradeable Warrants (the “Warrant Agent Agreement”). On October 12, 2023, the Company held a special meeting of the holders of the outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to the Warrant Agent Agreement to eliminate the provision that prohibited the Company’s CEO from exercising his voting rights under the Series B Preferred Stock, as well as to lower the exercise price of the Tradeable Warrants to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220222__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zL38dL7syGcj" title="Exercise price of warrants">0.11</span>. The Company entered into the amendment to the Warrant Agent Agreement on October 18, 2023.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, the Company completed a private placement and received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_z8xVldLIp4Fl" title="Net proceeds issuance of private placement">6,781,199</span>. In connection with this private placement, the Company issued (i) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--CommonStockMemberAndInvestorWarrantsMember_zuq1iDzgoPHi" title="Stock issued new, shares">2,301,353</span> shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant was sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 28, 2022, the Company completed another private placement and received net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220427__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zXTOGomJnTAh" title="Net proceeds issuance of private placement">16,752,915</span>. In connection with this private placement, the Company issued (i) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220427__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--CommonStockMemberAndAprilWarrantsMember_zLwY4iRgzNu8" title="Stock issued new, shares">2,472,820</span> shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 20, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaIncMember_zhyaTkd5sgpi" title="Stock issued for acquisition, shares">3,700,000</span> shares of common stock as part of the acquisition of Nora Pharma. These shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaIncMember_zAUWq3Dc3EX1" title="Stock issued for acquisition, value">4,514,000</span>, or $1.22 per share.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On January 19, 2023, the Company announced a stock repurchase program of up to $<span id="xdx_907_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn6n6_c20230119_zWD8S1KntKja" title="Stock repurchase program amount">2</span> million (“Stock Repurchase Program”). During the six months ended June 30, 2023, the Company repurchased a total of <span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOpj0vQ2ddVl" title="Stock repurchased, shares">445,711</span> shares of common stock at an average price of $1.1371 per share for a total cost of $<span id="xdx_90E_eus-gaap--PaymentsForRepurchaseOfEquity_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z70F5pbs1Epe" title="Payment for stock repurchased">506,822</span>. The 445,711 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 22,585,632 to 22,139,921.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with an institutional investor for gross proceeds of approximately $<span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20230515__20230516__us-gaap--SecuritiesFinancingTransactionAxis__custom--SingleInstitutionalInvestorMember_zxi9k9wD4Bkl" title="Gross proceeds from sale of stock">5</span> million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230515__20230516__us-gaap--SecuritiesFinancingTransactionAxis__custom--SingleInstitutionalInvestorMember_zXvRARo9Rs3h" title="Net proceeds from sale of stock">4,089,218</span>. In connection with the private placement, the Company issued (i) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230515__20230516__us-gaap--SecuritiesFinancingTransactionAxis__custom--SingleInstitutionalInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1wVtBZ6Jf7c" title="Stock issued new, shares">2,450,000</span> shares of common stock, (ii) <span id="xdx_902_ecustom--WarrantsIssuedDuringPeriodSharesNewIssues_c20230515__20230516__us-gaap--SecuritiesFinancingTransactionAxis__custom--SingleInstitutionalInvestorMember__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zu8Du8aGLYu4" title="Warrants issued, shares">3,502,381</span> pre-funded warrants (the “May Pre-Funded Warrants”), and (iii) investor warrants (the “May Warrants”) to purchase up to <span id="xdx_90B_ecustom--WarrantsIssuedDuringPeriodSharesNewIssues_c20230515__20230516__us-gaap--SecuritiesFinancingTransactionAxis__custom--SingleInstitutionalInvestorMember__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zagHoxnuC48b" title="Warrants issued, shares">11,904,762</span> shares of common stock at $0.59 per share. Each share of common stock and accompanying two May Warrants were sold together at a combined offering price of $0.84 and each May Pre-Funded Warrant and accompanying two May Warrants were sold together at a combined offering price of $0.839. The May Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Warrants have an exercise price of $0.59 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In 2022 and 2023, the Company issued a total of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20231231__us-gaap--TransactionTypeAxis__custom--WarrantsExercisedMember_zjH4lht6mmv8" title="Stock issued for warrant exercises">10,793,369</span> shares of common stock in connection with warrant exercises for aggregate net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_c20220101__20231231__us-gaap--TransactionTypeAxis__custom--WarrantsExercisedMember_z9yJoS5Mecoj" title="Proceeds from warrant exercises">13,196,681</span>.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In July 2023, the Company repurchased a total of <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3EGJRjYi1mg" title="Stock repurchased, shares">68,012</span> shares of common stock on the open market under the Stock Repurchase Program announced on January 19, 2023, at an average price of $0.5046 per share for a total cost of $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfEquity_pp0p0_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDQ1KcY61mm5" title="Payment for stock repurchased">34,321</span>. In October 2023, the 68,012 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 25,746,302 to 25,678,290.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On November 16, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20231115__20231116__us-gaap--TransactionTypeAxis__custom--ExerciseOfMayPreFundedWarrantsMember_zPKnl2k7Cp3j" title="Stock issued for conversion of securities">2,346,000</span> shares of common stock and received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20231115__20231116__us-gaap--TransactionTypeAxis__custom--ExerciseOfMayPreFundedWarrantsMember_zADjZfSVPhSi">2,346</span> in connection with the exercise of all <span id="xdx_90D_ecustom--WarrantsExercised_c20231115__20231116__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_ziZkW7ln8Q5j" title="Warrants exercised">2,346,000</span> remaining May Pre-Funded Warrants at the nominal exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231116__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z0LVe2Xf3IP" title="Nominal exercise price">0.001</span> per share.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023 and December 31, 2022, the Company has a total of <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1QLYjgtUNCc" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIjHICneGYX5" title="Common stock, shares outstanding">28,024,290</span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvmfXE6VBrk" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6VS4ChN5k89" title="Common stock, shares outstanding">22,585,632</span></span> shares of common stock issued and outstanding, respectively.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has declared <span id="xdx_909_eus-gaap--Dividends_pp0p0_do_c20230101__20231231_zb945swljZJc" title="Dividends">no</span> dividends since inception.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> 3000000000 0.001 30000000 0.10 1000000 10000 6833071 1882353 4102200 990000 0.11 6781199 2301353 16752915 2472820 3700000 4514000 2000000 445711 506822 5000000 4089218 2450000 3502381 11904762 10793369 13196681 68012 34321 2346000 2346 2346000 0.001 28024290 28024290 22585632 22585632 0 <p id="xdx_80A_ecustom--WarrantsDisclosureTextBlock_zIrhUTPibEb9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 9 – <span id="xdx_827_zcIhmskImXRf">Warrants</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In 2022 and 2023, the Company completed four financing events, and in connection therewith, it issued warrants as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zgpvShD2huF1" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"> <tr style="vertical-align: top"> <td><span id="xdx_8BB_zfrSmtmlxwde" style="display: none">Schedule of warrants issued with financing</span></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="border-top: Black 1pt solid; vertical-align: top"> <td style="border-bottom: Black 1pt solid; width: 31%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,692,276</span></td> <td> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_zq6JJGOD8sAj" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.001</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_z6boSMhCS9a9" title="Expiry date">Unlimited</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Tradeable Warrants</span></td> <td> </td> <td id="xdx_984_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4,102,200</span></td> <td> </td> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zEm685Glapmd" title="Exercise price">2.22</span>*</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zFWh3q5Xys7c" title="Expiry date">February 2027</span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investor Warrants</span></td> <td> </td> <td id="xdx_98C_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,603,604</span></td> <td> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$2.22</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember" title="Expiry date">March 2027</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">9,725,690</span></td> <td> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$3.76</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember" title="Expiry date">April 2027</span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Pre-Funded Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,502,381</span></td> <td> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.001</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember" title="Expiry date">Unlimited</span></span></td></tr> <tr style="border-bottom: Black 1pt solid; background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Warrants</span></td> <td> </td> <td id="xdx_986_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">11,904,762</span></td> <td> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.59</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember" title="Expiry date">November 2028</span></span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; font-size: 10pt"><span id="xdx_F0B_zuq2AsyfINXa" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td> <td style="width: 99%; font-size: 10pt; text-align: justify"><span id="xdx_F1C_z70pTNd4Qip9" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.</span></td></tr> </table> <p id="xdx_8AA_zJvOSyfea11l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, all of the Pre-Funded Warrants and a total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z6TFZDR1ehLc" title="Warrants exercised">3,138,507</span> Tradeable Warrants, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" title="Warrants exercised">2,802,703</span> Investor Warrants, and all of the May Pre-Funded Warrants were exercised resulting in aggregate proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AllWarrantsMember_zIL3ofgHG7X9" title="Proceeds from warrant exercises">13,196,681</span> received by the Company.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Company’s outstanding warrants at December 31, 2023 consisted of the following: </p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z0znESleoi7h" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"> <tr style="vertical-align: top"> <td><span id="xdx_8B3_zGC24CueMFtl" style="display: none">Schedule of warrants outstanding</span></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="border-top: Black 1pt solid; vertical-align: top"> <td style="border-bottom: Black 1pt solid; width: 31%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Tradeable Warrants</span></td> <td> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zqlqE0gOy4n7" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">963,693</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantMember_fKg_____zx7V5WbPWsSb" title="Exercise price">0.11</span>*</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z5h1iXHEPUR7" title="Expiry date">February 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investor Warrants</span></td> <td> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">800,901</span></td> <td> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zKxKZmN7w4se" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$2.22</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zBoTSF9NT0j4" title="Expiry date">March 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April Warrants</span></td> <td> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">9,725,690</span></td> <td> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zMKysqTpnUgd" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$3.76</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_905_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zssk81mLLFl4" title="Expiry date">April 2027</span></span></td></tr> <tr style="border-bottom: Black 1pt solid; vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Warrants</span></td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">11,904,762</span></td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zsB0khsiRs3i" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.59</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_ztdfKjqtOom1" title="Expiry date">November 2028</span></span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; font-size: 10pt; text-align: justify"><span id="xdx_F0B_z5vOvpDPKsv1" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td> <td style="width: 99%; font-size: 10pt; text-align: justify"><span id="xdx_F11_zf2CaFmVGNHc" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.</span></td></tr> </table> <p id="xdx_8AC_zWnUUJqwSXe9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zgpvShD2huF1" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"> <tr style="vertical-align: top"> <td><span id="xdx_8BB_zfrSmtmlxwde" style="display: none">Schedule of warrants issued with financing</span></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="border-top: Black 1pt solid; vertical-align: top"> <td style="border-bottom: Black 1pt solid; width: 31%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,692,276</span></td> <td> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_zq6JJGOD8sAj" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.001</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PreFundedWarrantsMember_z6boSMhCS9a9" title="Expiry date">Unlimited</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Tradeable Warrants</span></td> <td> </td> <td id="xdx_984_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4,102,200</span></td> <td> </td> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zEm685Glapmd" title="Exercise price">2.22</span>*</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zFWh3q5Xys7c" title="Expiry date">February 2027</span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investor Warrants</span></td> <td> </td> <td id="xdx_98C_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,603,604</span></td> <td> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$2.22</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember" title="Expiry date">March 2027</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">9,725,690</span></td> <td> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$3.76</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember" title="Expiry date">April 2027</span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Pre-Funded Warrants</span></td> <td> </td> <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,502,381</span></td> <td> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.001</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember" title="Expiry date">Unlimited</span></span></td></tr> <tr style="border-bottom: Black 1pt solid; background-color: White"> <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Warrants</span></td> <td> </td> <td id="xdx_986_ecustom--WarrantsIssuedShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of warrants"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">11,904,762</span></td> <td> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" style="vertical-align: top" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.59</span></td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember" title="Expiry date">November 2028</span></span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; font-size: 10pt"><span id="xdx_F0B_zuq2AsyfINXa" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td> <td style="width: 99%; font-size: 10pt; text-align: justify"><span id="xdx_F1C_z70pTNd4Qip9" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.</span></td></tr> </table> 3692276 0.001 Unlimited 4102200 2.22 February 2027 3603604 2.22 March 2027 9725690 3.76 April 2027 3502381 0.001 Unlimited 11904762 0.59 November 2028 3138507 2802703 13196681 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z0znESleoi7h" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"> <tr style="vertical-align: top"> <td><span id="xdx_8B3_zGC24CueMFtl" style="display: none">Schedule of warrants outstanding</span></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="border-top: Black 1pt solid; vertical-align: top"> <td style="border-bottom: Black 1pt solid; width: 31%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 22%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Tradeable Warrants</span></td> <td> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zqlqE0gOy4n7" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">963,693</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantMember_fKg_____zx7V5WbPWsSb" title="Exercise price">0.11</span>*</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z5h1iXHEPUR7" title="Expiry date">February 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investor Warrants</span></td> <td> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">800,901</span></td> <td> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zKxKZmN7w4se" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$2.22</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zBoTSF9NT0j4" title="Expiry date">March 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April Warrants</span></td> <td> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">9,725,690</span></td> <td> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zMKysqTpnUgd" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$3.76</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_905_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zssk81mLLFl4" title="Expiry date">April 2027</span></span></td></tr> <tr style="border-bottom: Black 1pt solid; vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May Warrants</span></td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_pdd" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">11,904,762</span></td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zsB0khsiRs3i" title="Exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$0.59</span></td> <td> </td> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_ztdfKjqtOom1" title="Expiry date">November 2028</span></span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; font-size: 10pt; text-align: justify"><span id="xdx_F0B_z5vOvpDPKsv1" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td> <td style="width: 99%; font-size: 10pt; text-align: justify"><span id="xdx_F11_zf2CaFmVGNHc" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.</span></td></tr> </table> 963693 0.11 February 2027 800901 2.22 March 2027 9725690 3.76 April 2027 11904762 0.59 November 2028 <p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_ztZHEx7vNYi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 10 – <span id="xdx_829_zgJzUt4QvrO7">Earnings Per Share</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:</p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zr5TmbxeCRbd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zGPfJAe6Tvy7" style="display: none">Schedule of earnings per share computation</span></td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zQ0jqfDom8yk" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zj2A1UrREhhc" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zC8u7cv9Gmvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Net gain (loss) attributable to common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(4,506,044</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(26,744,440</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zNiApVBQPnD4" style="vertical-align: bottom; background-color: White"> <td>Basic weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,331,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,868</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_d0_zt06bouvAcF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dilutive common share equivalents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zcEJVh4aw2Kh" style="vertical-align: bottom; background-color: White"> <td>Dilutive weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,331,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,868</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_z9pQA2KkfSD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net gain (loss) per share attributable to common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.76</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zr5TmbxeCRbd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zGPfJAe6Tvy7" style="display: none">Schedule of earnings per share computation</span></td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zQ0jqfDom8yk" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zj2A1UrREhhc" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zC8u7cv9Gmvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Net gain (loss) attributable to common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(4,506,044</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(26,744,440</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zNiApVBQPnD4" style="vertical-align: bottom; background-color: White"> <td>Basic weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,331,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,868</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_d0_zt06bouvAcF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dilutive common share equivalents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zcEJVh4aw2Kh" style="vertical-align: bottom; background-color: White"> <td>Dilutive weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,331,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,868</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_z9pQA2KkfSD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net gain (loss) per share attributable to common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.76</td><td style="text-align: left">)</td></tr> </table> -4506044 -26744440 24331908 15180868 0 0 24331908 15180868 -0.19 -1.76 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zn0yuoUdwO0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 11 – <span id="xdx_828_zBEpfCQKMkM">Income Taxes</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The components of the provision for income taxes were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ze4kiYnLv8f3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zbae13f4Vssb" style="display: none">Schedule of provision for income taxes</span></td><td> </td> <td colspan="2" id="xdx_493_20230101__20231231_zvGP328FgXGg" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zRDHIL4Xt54b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zWfIzzuWmwLl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zrGmpTXODx4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_zhqFu1PIW25a" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; width: 83%">Foreign</td><td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">379,246</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="text-align: right">379,296</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z1LtnWchFBNe" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zigmvCiFgQL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zIcscx6hW3xk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_z2qRyNsId21g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_zFJjsmN7PlEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">395,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Company’s effective tax rate differs from the federal statutory rate as follows:</span></p> <p style="margin-top: 0; margin-bottom: 0"></p><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zYYMyfgmy2F7" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left; width: 66%"><span id="xdx_8B3_ztNxghgUtMna"><b style="display: none">Schedule of income tax expense</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Pre-Tax Book Income</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_mataxrate2023_c20230101__20231231_zm3o0tid5bkh" style="width: 13%; text-align: right" title="Pre-Tax Book Income"><span style="font-family: Arial, Helvetica, Sans-Serif">(826,953</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_maratepercent2023_c20230101__20231231_z7o8Ys4Ewia6" style="width: 13%; text-align: right" title="Pre-Tax Book Income"><span style="font-family: Arial, Helvetica, Sans-Serif">20.14%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">State Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zN2PULlIcFMh" style="text-align: right" title="State Taxes"><span style="font-family: Arial, Helvetica, Sans-Serif">50</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zLAjvuauehH9" style="text-align: right" title="State Taxes"><span style="font-family: Arial, Helvetica, Sans-Serif">0.00%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Permanent Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_c20230101__20231231_zZiLvAAFaEc6" style="text-align: right" title="Permanent Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">56,812</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_c20230101__20231231_z25vNYsWdLp3" style="text-align: right" title="Permanent Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.38%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Change in Valuation Allowance</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zwCxfXHXMzTh" style="text-align: right" title="Change in Valuation Allowance"><span style="font-family: Arial, Helvetica, Sans-Serif">860,705</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zPuV4qQLWrMl" style="text-align: right" title="Change in Valuation Allowance"><span style="font-family: Arial, Helvetica, Sans-Serif">-20.96%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Foreign Tax Rate Differential</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d0_c20230101__20231231_zj0Z5x2hM6Ja" style="text-align: right" title="Foreign Tax Rate Differential"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20230101__20231231_z7ls9tmuiCk" style="text-align: right" title="Foreign Tax Rate Differential"><span style="font-family: Arial, Helvetica, Sans-Serif">0.00%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Rate Change</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_c20230101__20231231_z0lH6kLmrW55" style="text-align: right" title="Rate Change"><span style="font-family: Arial, Helvetica, Sans-Serif">167,676</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_c20230101__20231231_zdFYVkSk5x3l" style="text-align: right" title="Rate Change"><span style="font-family: Arial, Helvetica, Sans-Serif">-4.08%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Provision to Return Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_c20230101__20231231_zGwp1Ut24W0k" style="text-align: right" title="Provision to Return Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">67,144</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20230101__20231231_zGo5hiBKoNoe" style="text-align: right" title="Provision to Return Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.63%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zBSVmuAk9558" style="border-bottom: Black 1pt solid; text-align: right" title="Other Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">69,732</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230101__20231231_zEnKR8WCkZ03" style="border-bottom: Black 1pt solid; text-align: right" title="Other Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.70%</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_mttaxrate2023_c20230101__20231231_zJNz2lHcpZUe" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">395,166</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mtratepercent2023_c20230101__20231231_zGij0uN4s4kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total effective income tax rate"><span style="font-family: Arial, Helvetica, Sans-Serif">-9.62%</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The components of the net deferred tax assets and liabilitie were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zdcWQkVRzve" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details - Deferred taxes)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BD_zLXbJ3mxMzdk" style="display: none">Schedule of components of net deferred tax assets</span></td><td> </td> <td colspan="2" id="xdx_49D_20231231_zErpa4KQRDf3" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_zJajVP3oaRRh" style="vertical-align: bottom"> <td>Deferred Tax Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zn46dP9sBCKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 83%; text-align: left">Net Operating Loss, Credits and Carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,277,829</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zmxfNdNxk7Db" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fixed Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zO0mxzcSIVWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">641,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zcMB810XQake" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,327</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_zex78dFeDSBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other DTA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,890</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zs3g3jn8S9b8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lease Liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z0MSn2Z4bYbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,397,374</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_z1WQkkGNNnla" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">176,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zDZMocHC45sg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z4E4yDXXPjmj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fixed Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">(54,095</span></p></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_zw6eXADf6Yqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_zke7bGbuf3Q6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right-of-Use Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(171,396</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilities_iNI_di_zZgePvYAmyJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred Tax Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(225,491</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zKkI3y8L3Fh9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,727</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ze4kiYnLv8f3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zbae13f4Vssb" style="display: none">Schedule of provision for income taxes</span></td><td> </td> <td colspan="2" id="xdx_493_20230101__20231231_zvGP328FgXGg" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zRDHIL4Xt54b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zWfIzzuWmwLl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zrGmpTXODx4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_zhqFu1PIW25a" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; width: 83%">Foreign</td><td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">379,246</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="text-align: right">379,296</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z1LtnWchFBNe" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zigmvCiFgQL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zIcscx6hW3xk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_z2qRyNsId21g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_zFJjsmN7PlEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">395,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 50 379246 0 0 15870 395166 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zYYMyfgmy2F7" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left; width: 66%"><span id="xdx_8B3_ztNxghgUtMna"><b style="display: none">Schedule of income tax expense</b></span></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Pre-Tax Book Income</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_mataxrate2023_c20230101__20231231_zm3o0tid5bkh" style="width: 13%; text-align: right" title="Pre-Tax Book Income"><span style="font-family: Arial, Helvetica, Sans-Serif">(826,953</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_maratepercent2023_c20230101__20231231_z7o8Ys4Ewia6" style="width: 13%; text-align: right" title="Pre-Tax Book Income"><span style="font-family: Arial, Helvetica, Sans-Serif">20.14%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">State Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zN2PULlIcFMh" style="text-align: right" title="State Taxes"><span style="font-family: Arial, Helvetica, Sans-Serif">50</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zLAjvuauehH9" style="text-align: right" title="State Taxes"><span style="font-family: Arial, Helvetica, Sans-Serif">0.00%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Permanent Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_c20230101__20231231_zZiLvAAFaEc6" style="text-align: right" title="Permanent Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">56,812</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_c20230101__20231231_z25vNYsWdLp3" style="text-align: right" title="Permanent Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.38%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Change in Valuation Allowance</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zwCxfXHXMzTh" style="text-align: right" title="Change in Valuation Allowance"><span style="font-family: Arial, Helvetica, Sans-Serif">860,705</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zPuV4qQLWrMl" style="text-align: right" title="Change in Valuation Allowance"><span style="font-family: Arial, Helvetica, Sans-Serif">-20.96%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Foreign Tax Rate Differential</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d0_c20230101__20231231_zj0Z5x2hM6Ja" style="text-align: right" title="Foreign Tax Rate Differential"><span style="font-family: Arial, Helvetica, Sans-Serif">–</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20230101__20231231_z7ls9tmuiCk" style="text-align: right" title="Foreign Tax Rate Differential"><span style="font-family: Arial, Helvetica, Sans-Serif">0.00%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Rate Change</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_c20230101__20231231_z0lH6kLmrW55" style="text-align: right" title="Rate Change"><span style="font-family: Arial, Helvetica, Sans-Serif">167,676</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_c20230101__20231231_zdFYVkSk5x3l" style="text-align: right" title="Rate Change"><span style="font-family: Arial, Helvetica, Sans-Serif">-4.08%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Provision to Return Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_c20230101__20231231_zGwp1Ut24W0k" style="text-align: right" title="Provision to Return Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">67,144</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20230101__20231231_zGo5hiBKoNoe" style="text-align: right" title="Provision to Return Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.63%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zBSVmuAk9558" style="border-bottom: Black 1pt solid; text-align: right" title="Other Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">69,732</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230101__20231231_zEnKR8WCkZ03" style="border-bottom: Black 1pt solid; text-align: right" title="Other Adjustments"><span style="font-family: Arial, Helvetica, Sans-Serif">-1.70%</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_mttaxrate2023_c20230101__20231231_zJNz2lHcpZUe" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">395,166</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mtratepercent2023_c20230101__20231231_zGij0uN4s4kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total effective income tax rate"><span style="font-family: Arial, Helvetica, Sans-Serif">-9.62%</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></td></tr> </table> -826953 0.2014 50 0.0000 56812 -0.0138 860705 -0.2096 0 0.0000 167676 -0.0408 67144 -0.0163 69732 -0.0170 395166 -0.0962 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zdcWQkVRzve" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details - Deferred taxes)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BD_zLXbJ3mxMzdk" style="display: none">Schedule of components of net deferred tax assets</span></td><td> </td> <td colspan="2" id="xdx_49D_20231231_zErpa4KQRDf3" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_zJajVP3oaRRh" style="vertical-align: bottom"> <td>Deferred Tax Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zn46dP9sBCKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 83%; text-align: left">Net Operating Loss, Credits and Carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,277,829</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zmxfNdNxk7Db" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fixed Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zO0mxzcSIVWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">641,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zcMB810XQake" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,327</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_zex78dFeDSBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other DTA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,890</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zs3g3jn8S9b8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lease Liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z0MSn2Z4bYbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,397,374</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_z1WQkkGNNnla" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">176,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zDZMocHC45sg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z4E4yDXXPjmj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fixed Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">(54,095</span></p></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_zw6eXADf6Yqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_zke7bGbuf3Q6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right-of-Use Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(171,396</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilities_iNI_di_zZgePvYAmyJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred Tax Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(225,491</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zKkI3y8L3Fh9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,727</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 5277829 641800 25327 454890 174292 6397374 176764 54095 171396 225491 48727 <p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zXpvZ42Sa2Qg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 12 – <span id="xdx_823_zBeqp9VZC1m4">Leases</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has obligations as a lessee for office space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company’s lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable Payment. The Company’s office space lease requires it to make variable payments for the Company’s proportionate share of building’s property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts reported on the balance sheet as of December 31, 2023 were as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LeaseCostTableTextBlock_zlNj9DU65Jm" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Lease (Details - Lease information)"> <tr style="vertical-align: top"> <td style="width: 5%"><span id="xdx_8B4_zkHGj3sjngpl" style="display: none">Schedule of lease information</span></td> <td style="width: 42%"> </td> <td style="width: 53%"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating lease ROU asset</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zSwJsrPTORAk" title="Operating lease ROU asset">646,779</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating Lease liability - Short-term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_zAmhmLxA8tF7">118,670</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating lease liability - Long-term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_znpA0i3Zgs76" title="Operating lease liability - Long-term">539,035</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Remaining lease term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zYAanKNB4Ur6" title="Remaining lease term">6</span> years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Discount rate</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zRDoc8QOOOab" title="Discount rate">6</span>%</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Maturities of lease liabilities under non-cancellable operating leases at December 31, 2023 are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zXRho5gV3vv1" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Lease (Details - Maturities of lease payments)"> <tr style="vertical-align: top"> <td style="text-align: justify"><span id="xdx_8BB_z2xQ4bdJoLbh" style="display: none">Schedule of maturities of lease liabilities</span></td> <td id="xdx_499_20221231_zO5ZJ5B7zJxg" style="text-align: center"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zJC5Er684e8b" style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 43%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2024</span></td> <td style="text-align: right; width: 57%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$118,670</span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z8sEaIryv7Mj" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2025</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$118,862</span></td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zZHR3SCoqRr1" style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$112,582</span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zLETkgUL7hW5" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$106,042</span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zADUtCDbUrje" style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$99,881</span></td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zZBAPgybD8v" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Thereafter</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$101,667</span></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LeaseCostTableTextBlock_zlNj9DU65Jm" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Lease (Details - Lease information)"> <tr style="vertical-align: top"> <td style="width: 5%"><span id="xdx_8B4_zkHGj3sjngpl" style="display: none">Schedule of lease information</span></td> <td style="width: 42%"> </td> <td style="width: 53%"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating lease ROU asset</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zSwJsrPTORAk" title="Operating lease ROU asset">646,779</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating Lease liability - Short-term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_zAmhmLxA8tF7">118,670</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating lease liability - Long-term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$<span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_znpA0i3Zgs76" title="Operating lease liability - Long-term">539,035</span></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Remaining lease term</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zYAanKNB4Ur6" title="Remaining lease term">6</span> years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Discount rate</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zRDoc8QOOOab" title="Discount rate">6</span>%</span></td></tr> </table> 646779 118670 539035 P6Y 0.06 <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zXRho5gV3vv1" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Lease (Details - Maturities of lease payments)"> <tr style="vertical-align: top"> <td style="text-align: justify"><span id="xdx_8BB_z2xQ4bdJoLbh" style="display: none">Schedule of maturities of lease liabilities</span></td> <td id="xdx_499_20221231_zO5ZJ5B7zJxg" style="text-align: center"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zJC5Er684e8b" style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 43%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2024</span></td> <td style="text-align: right; width: 57%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$118,670</span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z8sEaIryv7Mj" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2025</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$118,862</span></td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zZHR3SCoqRr1" style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$112,582</span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zLETkgUL7hW5" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$106,042</span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zADUtCDbUrje" style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$99,881</span></td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zZBAPgybD8v" style="vertical-align: top; background-color: White"> <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Thereafter</span></td> <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$101,667</span></td></tr> </table> 118670 118862 112582 106042 99881 101667 <p id="xdx_802_ecustom--ManagementAndDirectorCompensationTextBlock_zzl5LLXQHM31" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 13 – <span id="xdx_828_z3ovctLd6Thd">Management and Director Compensation</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its officers cash compensation totaling $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20230101__20231231_zAEtqZV338fa" title="Officers compensation">1,515,000</span> and $<span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20221231_z7MztlbqTDk2" title="Officers compensation">1,785,000</span> for the years ended December 31, 2023 and 2022, respectively. Of these amounts attributable to the Company’s CEO, $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_z7LvU7bKBAua" title="Officers compensation">0</span> and $<span id="xdx_90F_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zpXJ4eDOHrFf" title="Officers compensation">60,000</span>, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its directors cash compensation totaling $<span id="xdx_90C_eus-gaap--NoninterestExpenseDirectorsFees_c20230101__20231231_zT7zFK48iw4j" title="Directors compensation">400,000</span> and $<span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20220101__20221231_z1DgBNcK2yx" title="Directors compensation">300,000</span> for the years ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> 1515000 1785000 0 60000 400000 300000 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zuaUBCgklA2k" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><b><span style="text-decoration: underline">Note 14 – <span id="xdx_82F_zth7XIUTnDPh">Subsequent Events</span></span></b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, the Company closed a firm commitment underwritten public offering with gross proceeds to the Company of approximately $10.0 million. The offering consisted of 71,428,571 Units, consisting of (a) 26,428,571 Common Units, with each Common Unit consisting of one share of our common stock, one-tenth (1/10) of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths (2/10) of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (b) 45,000,000 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock, one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The Pre-Funded Warrants are immediately exercisable at $0.001 per share and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant is $2.10 per share of common stock or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant is $2.38 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On February 11, 2024, the Company bought back the 11,904,762 May Warrants from the holder, a single entity, for an aggregate purchase price of $2,361,596. Upon the closing of the transaction, the May Warrants were deemed cancelled and terminated in all respects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On February 11, 2024, the Company entered into securities purchase agreements (the “April Warrants Purchase Agreements”) with the holders of warrants, dated April 28, 2022 (the “April Warrants”) to purchase an aggregate of 9,725,690 shares of common stock of the Company. Pursuant to the April Warrant Purchase Agreements, the Company bought back from the holders the April Warrants for a purchase price of $0.08 per April Warrant, for an aggregate purchase price of $778,055. Upon the closing of the April Warrant Purchase Agreements, which occurred on February 12, 2024, the Company paid the purchase price to the holders, and the April Warrants were deemed cancelled and terminated in all respects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On February 8, 2024, the Company sold 20,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On March 4, 2024, the Company sold 100,000 shares of Series B Preferred Stock to its CEO for the stated value of $0.10 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On March 4, 2024, the Company’s board of directors, and Company’s chief executive officer, as the holder of the majority of the voting power of the Company’s stockholders, approved an up to 1-for-200 reverse split of the Company’s common stock in order for the Company to become compliant with Nasdaq’s $1.00 minimum bid price for the listed common shares.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> false false false false The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof. On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants from $2.22 to $0.11 per warrant. The amendment was executed on October 18, 2023.